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General introduction
General introduction
Cancer metastasis is responsible for 90% of cancer-related deaths, and despite all efforts 
to target metastatic disease, a lack of mechanistic insight has hampered the development 
of effective anti-cancer drugs. Metastasis formation is a complicated multi-step process 
involving tumor cell proliferation, dissociation from the primary tumor, matrix invasion, 
entry into the circulatory system, extravasation through capillary endothelium, and finally 
the outgrowth of secondary tumors in distant organs (Fig. 1). In addition to genetic 
instability and environmental factors, physical interactions between tumor cells and the 
tumor microenvironment contribute to the malignant transformation of tumor cells, i.e. 
the transition from a benign to a malignant phenotype, and the actual metastatic process.
Multiprotein complexes, known as cell adhesions, structurally and functionally link a 
cell to its surroundings. Both cell-cell and cell-matrix adhesions comprise transmembrane 
receptors that link complementary receptors on neighboring cells or extracellular matrix 
(ECM) proteins to the intracellular actomyosin cytoskeleton via a complex of signaling and 
adaptor proteins. Both cell-cell and cell-matrix adhesions function as cellular anchors, as 
well as bidirectional signaling hubs that convey chemical and mechanical cues across the 
plasma membrane (1-7). Cell adhesions are essential in guiding tissue morphogenesis and 
maintaining tissue homeostasis by controlling key cellular processes such as proliferation, 
apoptosis, differentiation and motility (Fig. 2A). Consistent with this notion, perturbed 
adhesion signaling underlies the malignant behavior of cancer cells. Hence, the complex 
protein-protein interactions that take place at cell adhesion sites are considered potential 
therapeutic targets to restore tissue integrity and limit the metastatic potential of cancer 
cells (6-9).
Cell adhesions in the malignant transformation of tumor cells
Malignant transformation is a key hallmark of aggressive tumors and generally involves 
activation of a developmental program known as the ‘epithelial-mesenchymal transition’ 
(EMT). EMT plays an important role during embryonic development as well as during tissue 
remodeling and regeneration in the adult. When adopted by cancer cells, it confers a highly 
proliferative and invasive phenotype onto non-migratory, quiescent epithelial cells (6, 10). 
A prominent feature of EMT is the destabilization of cell-cell adhesions known as adherens 
junctions through transcriptional and posttranscriptional suppression of E-cadherin, a major 
intercellular adhesion molecule (11-18). Cell-cell adhesion signaling is crucial for contact 
inhibition of proliferation and, as a consequence, the loss of E-cadherin contributes to 
the uncontrolled proliferation of tumor cells. Moreover, destabilization of cadherin-based 
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adhesions facilitates the detachment of tumor cells from the primary tumor to allow their 
dissemination (Fig. 2B) (6, 10, 12, 19). 
In addition to perturbed cell-cell signaling, the EMT-associated transcriptional program 
contributes to the malignant transformation of tumor cells by affecting integrin-mediated cell-
matrix adhesions. Altered integrin signaling may induce anchorage independent growth and 
thereby contribute to uncontrolled proliferation of tumor cells (Fig. 2C) (20). Furthermore, 
differential regulation and expression of cell-matrix adhesion components activate the 
migratory and invasive machinery of tumor cells (21-36). For instance, EMT can induce 
the secretion of matrix metalloproteinases (MMPs) by specialized adhesion structures, 
invadosomes, that locally degrade the extracellular matrix to allow tissue invasion by tumor 
cells (Fig. 2D) (32, 37, 38). Interestingly, adhesive changes that occur during EMT appear 
to reinforce this process through a variety of signaling pathways, providing a feed-forward 
mechanism that drives the malignant transformation of tumor cells (12, 39-45).
The mechanical crosstalk between tumor cells and the ECM through cell-matrix adhesions 
has been recently put forward as major inducer of the malignant transformation of tumor 
Figure 1. Metastatic cascade. Schematic overview of events that lead to metastasis formation by epithelial 
tumors. Normal tissue architecture (A) is perturbed by the malignant transformation of tumor cells. Altered cell 
adhesion signaling enhances proliferation (B) and allows tumor cells to degrade (C) and invade (D) the surrounding 
tissue. Invasive tumor cells eventually enter the circulation (E) and are either trapped at ectopic sites by physical 
occlusion or arrested by specific ligand-receptor interactions between the tumor cell and endothelial cells (F). 
Captured tumor cells may subsequently extravasate and invade tissues (G). Depending on the presence of survival 
and proliferative signals, disseminated tumor cells may or may not succeed in colonizing other tissues (H).
Blood Flow
Proliferation
Secondary tumor
growth
Basal membrane
Extravascular space
Endothelial cells
Basal membrane
Vascular space
Endothelial cells
Basal membrane
Intra-
vasation
Capture by cell 
adhesion
Extravascular space
Invasion
Capture by physical 
occlusion
Extra-
vasation
A
B
C D
E
F G
Epithelial (tumor-) cells
H
13
General introduction
cells. Due to tumor intrinsic factors such as increased collagen deposition and cross-linking, 
expansive tumor growth and matrix stiffening caused by fibrosis, tumors are stiffer than 
normal tissues. Increased matrix stiffness activates cell-matrix adhesion signaling which 
increases cytoskeletal tension (see section ‘Mechanical crosstalk between tumor cells 
and the tumor microenvironment’) (7, 46, 47). Contractile cells, in turn, exert pulling 
forces on the ECM, leading to further stiffening of the matrix. The resulting cellular tension 
promotes disruption of E-cadherin-based adherens junctions, cell proliferation and tumor 
cell dissemination (48-52). Hence, reciprocal interactions between ECM and cytoskeletal 
tension, mediated by cell-matrix adhesions, can drive cancer progression (7, 47). 
Tumor cell migration and invasion
Malignant tumor cells invade the surrounding 
tissue to establish secondary tumors at 
distant sites. In the absence of active cell 
migration, growth of the primary tumors 
can lead to tissue invasion by the passive 
displacement of tumor cells. However, 
malignant transformation of solid tumors 
often activates a migratory program that 
allows more efficient tissue invasion (Fig. 
1). Depending on the cell intrinsic adhesive 
and matrix degrading properties as well 
as the mechanical features of the tumor 
microenvironment, transformed tumor 
cells adopt different migratory strategies to 
allow efficient cell movement in a structurally 
complex environment such as the ECM (53, 
54). When cell-cell adhesions are still intact, 
tumor cells can invade the surrounding tissue 
in collective strands. Repression of E-cadherin 
mediated cell-cell adhesions during EMT, leads 
to a loss of the multicellular coordination 
which allows the tumor cells to move 
individually, referred to as mesenchymal-
like or single cell invasion. Both migratory 
Integrin-based 
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E-cadherin-based
cell-cell adhesion
Matrix degradation
by MMPs
Malignant 
transformation
A
D
Proliferation
& motility
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C
Figure 2. Cell adhesions in malignant
transformation. Malignant transformation of tumor cells 
involves extensive modification of cell adhesions. Cell-
cell and cell-matrix adhesions control cell proliferation 
and motility in order to maintain tissue quiescence (A). 
Dissolution of cell-cell adhesions, through suppression of 
E-cadherin expression at the plasma membrane, promotes 
proliferation and facilitates detachment of tumor cells 
from the primary tumor (B). Moreover, growth control 
by integrin-based cell-matrix interactions is abolished and 
additional adhesive changes activate the migratory and 
matrix degrading machinery of tumor cells (C), allowing 
efficient tissue invasion (D).
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strategies depend on cell-matrix adhesions that generate the required tractions forces, as 
well as on proteolytic degradation of the extracellular matrix required for crossing tissue 
boundaries. Attempts to inhibit cancer metastasis using compounds that target cell-matrix 
adhesions and proteases, have thus far been unsuccessful. This may be due to the fact that 
tumor cells switch to an alternative, amoeboid-type of migration, which is independent of 
both adhesion to and proteolytic degradation of the ECM (54). 
In addition to cell intrinsic features, the physical properties of the ECM strongly affect cell 
migration. In low density or soft matrices, cell-matrix adhesions cannot provide sufficient 
traction forces to allow adhesion dependent migration and tumor cells tend to switch 
to an amoeboid type of migration. In contrast, cell-matrix adhesions can generate high 
traction forces on high density and stiff matrices allowing adhesion dependent migration 
(53). Moreover, increased matrix stiffness stabilizes cellular protrusions by favoring focal 
adhesion maturation, so that cells tend to migrate towards substrates with greater stiffness 
(i.e. durotaxis) (51, 53). 
Cell migration
Polarized cell movement is triggered and sustained by extracellular cues such as gradients 
of growth factors or chemokines (chemotaxis), specific extracellular matrix constituents 
(haptotaxis) and mechanical cues (durotaxis). The resultant signaling events converge on 
Rho-GTPases, e.g. RAC, CDC42 and Rho, that spatially control actin filament assembly and 
myosin II generated cytoskeletal tension (Box 1) (55). In turn, actin polymerization and 
cytoskeletal contractility drive cell protrusion and focal adhesion formation, maturation and 
turnover (56, 57). The dynamics of this migratory machinery has been thoroughly studied in a 
2D environment but it is likely that similar principles apply to migration in a 3D matrix (Fig. 3).
The first step in the migration cycle is the extension of the leading edge, i.e. the front of 
the cell, initiated by the local activation of the actin polymerizing machinery by the small 
GTPases RAC and CDC42. The extension of a branched actin network at the leading edge 
drives the formation of highly dynamic cell protrusions known as filopodia and lamellipodia 
which are attached to the substrate by nascent adhesions. As the leading edge of the cell 
progresses, these nascent adhesions either disassemble due to the inherent instability of the 
actin meshwork or mature into focal complexes within a more stable cellular region behind 
these cell protrusions, known as the lamellum. In the lamellum, Rho promotes adhesion 
maturation through the activation of myosin II motor proteins. Myosin II motor proteins 
stabilize actin filaments by their filament bundling properties. Moreover, activated myosin 
II motor proteins generate tension onto nascent cell-matrix adhesions which enforces 
15
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adhesion maturation by the mechanically induced recruitment of adhesion components (For 
details, refer to section ‘Mechanical crosstalk between tumor cells and the tumor 
microenvironment’). From the central region to the rear of the cell, Rho activity mediates 
the organization of actin filaments into thick parallel actin bundles that are anchored to the 
substrate at both ends by mature focal adhesions. Subsequent myosin II-mediated cytoskeletal 
contraction generates traction forces at these adhesion sites.  Whereas in the lamellum, 
myosin II-mediated contraction stabilizes and enforces adhesions, high contractility in the 
rear induces focal adhesion disassembly. Although not fully understood, the general concept 
is that high tension in the rear disrupts intergrin-substrate interactions that subsequently 
leads to adhesion disassembly and retraction of the cell rear. The resulting cycle of cell 
protrusion in the front, interaction with the extracellular matrix and retraction of the rear 
results in directional cell migration (3, 57).
Cell invasion
Migrating tumor cells encounter barriers such as the basal membrane in case of epithelial 
tumors, blood vessel walls and the dense meshwork of the ECM. Hence, tumor cells need 
to acquire the capacity to cross these tissue boundaries in order to metastasize. Malignant 
tumor cells therefore adopt the invasive machinery used by immune cells and osteoclasts 
to infiltrate tissues or resorb the bone matrix respectively. This invasive machinery involves 
a distinct type of integrin-based cell-matrix adhesions, named invadosomes, which locally 
degrade the extracellular matrix by the secretion of matrix degrading proteases (e.g. MMPs) 
(38). In non-malignant cells, invadosomes are usually referred to as podosomes, whereas 
the closely related structures present in invasive tumor cells are known as invadopodia. 
Both podosomes and invadopodia consist of a highly organized actin core surrounded by a 
ring of myosin II motor proteins and cytoskeletal linker proteins connected to the ECM by 
integrins. Although closely related, podosome and invadopodia show divergent architecture 
and dynamics. Whereas podosomes are short-lived and non-protrusive columnar structures 
that extend into the intracellular space, invadopodia are more stable spike-like plasma 
membrane protrusions (38). These differences are reflected by their matrix degrading 
properties; podosomes degrade the underlying matrix in a widespread and shallow manner, 
whereas invadopodia provide focal and deep degradation (38). Although the in vivo relevance 
of invadosomes in cancer metastasis has not been fully established, the formation of these 
invasive structures is typically associated with invasive properties of tumor cells in vitro. In 
agreement with these observations, the malignant behavior of tumor cells is often associated 
with increased expression of MMPs and invadosome specific constituents (22, 26-29, 32).
16
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Whereas focal adhesion formation and maturation are directly associated with Rho-
mediated actin assembly and myosin II-mediated contraction, the role of cytoskeletal tension 
in invadosome dynamics is considerably more complex. The current notion is that the levels 
of myosin II contraction in the invadosome ring are to be tightly balanced (38). Basal levels of 
myosin II contraction in the invadosome ring are required for their assembly and stability (58), 
but drastic increases in cytoskeletal tension cause invadosome disassembly (59). Consistent 
with these findings, we and others have shown that moderate inhibition of myosin II motor 
function promotes podosome formation (60, 61). Multiple studies report that the formation 
of invadosomes is, similar to that of focal adhesions, controlled by the mechanical properties 
of the underlying substrate. Matrix stiffness increases invadosome formation, proteolytic 
activity and life span (62, 63). Moreover, invadosomes are sensitive to the ECM architecture 
since the 3D topology of the 
substrate was shown to dictate 
the spatial organization of these 
invasive adhesion structures (64). 
Figure 3. Cell migration machinery 
on 2D substrates. Dynamic actin 
polymerization, depolymerization and 
crosslinking drives the formation of a 
branched actin network (A) that, when 
stabilized by nascent adhesions, leads 
to the formation of protrusive filopodia 
and lamelipodia (B). In the lamellum, 
nascent adhesions either disassemble 
(C) or mature through myosin II induced 
stabilization of actin f ilaments (D). 
High myosin II mediated cytoskeletal 
contractility in the cell body disrupts cell-
matrix adhesion at the rear of the cell (D)
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Box 1. Actomyosin cytoskeleton
The actomyosin cytoskeleton controls many cellular processes that require the generation 
of force, including cell motility, cell division, vesicle and organelle movement, and the 
establishment and maintenance of cell adhesion. It’s main components, actin, actin-binding 
proteins and myosin II motor proteins, are tightly regulated in space and time by a variety of 
signaling molecules, such as Rho-GTPases, which respond to intra- and extracellular cues.
Actin
Cytoskeletal architecture largely depends on the dynamic polymerization and 
depolymerization of actin filaments (F-actin). F-actin filament formation involves self-
assembly of actin monomers into polarized filaments. Filament length is depending on 
the balance between actin monomer association at the barbed end and dissociation at 
the pointed end. Many actin binding proteins control filament elongation: 
• Actin depolymerizing factors (cofilin) that favor actin monomer dissociation at    
 the pointed ends of actin filaments. 
• Actin nucleators (profilin) that favor actin monomer association at the barbed   
 ends of actin filaments. 
• Filament severing proteins (gelsolin).
• Filament stabilizing proteins (tropomyosins).
• Filament capping proteins that prevent actin monomer association (capz) and   
 dissociation (tropomodulins).
Branched actin network (Lamellipod) Stress fibers
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Box 1. Continued
Filament nucleating proteins at the leading edge of a cell, such as the ARP2/3 complex 
and formins, mediate branching of actin filaments into an actin meshwork that forms the 
lamellipodium (Left panel). Within the cell body, actin filaments assemble into stress 
fibers by the bundling activity of both myosin II motor proteins and actin crosslinkers 
such as a-actinins (Right panel) (122) . 
Myosin II
Myosin II is the major motor protein driving actomyosin contractility in both muscle and 
non-muscle cells by pulling together oppositely oriented actin filaments. Additionally, myosin 
II functions to bundle actin filaments into stable stress fibers. Myosin II is a hexameric 
protein that contains a pair of heavy chains, together forming the myosin II heavy chain 
(MHCII), a pair of essential light chains and a pair of regulatory light chains (MLC). The 
essential light chains provide structural integrity to the motor domain, and the regulatory 
light chains control myosin motor activity. The MHCII comprises a conserved motor 
domain, a neck domain and a helical coiled-coil tail domain. The motor domain, formed 
by the two amino-terminal parts of the heavy chains, drives the movement along actin 
filaments. The neck domain contains light chain binding sites and serves as a rigid lever 
to generate movement of the motor domain. Electrostatic interactions between the 
helical coiled-coil tail domains, formed by intertwining of the carboxy-terminal portions 
of the heavy chains, mediate self-assembly of myosin II into bipolar filaments, which is 
required for the generation of force (57).
Three non-muscle MHCII isoforms have been identified in mammalian cells, myosin IIA, 
IIB and IIC, and are encoded by the genes MYH9, MYH10 and MYH14 respectively. The 
three isoforms are well conserved and show overlapping functions. However, differences 
in mRNA expression patterns, intracellular localization and modes of regulation, indicate 
that MHCII isoforms are functionally distinct (57, 123-129). Note that originally, these 
myosin II isoforms were called non-muscle myosins because they were thought to be
exclusively expressed in non-muscle cells. mRNA expression profiling and functional 
characterization in smooth muscle and cardiac muscle cells has demonstrated this 
assumption to be wrong (57, 125).
In vertebrates, myosin II motor activity is predominantly controlled by MLC kinases 
and phosphatases. MLC phosphorylation (MLC-P) strengthens the association of myosin II 
with F-actin and activates the myosin motor domain to increase cytoskeletal contraction 
(Middle panel). In addition to MLC phosphorylation, MHCII phosphorylation (MHCII-P) 
19
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Box 1. Continued
regulates myosin II function in early eukaryotes, such as Dictyostelium discoideum. MHCII 
kinases, encoded by the Dictyostelium genome, belong to the a-kinase family which shows 
little sequence homology with other members of the protein kinase superfamily. a-Kinases 
are characterized by their propensity to phosphorylate serine and threonine residues 
in the context of a-helical structures, such as the myosin II heavy chain (Chapter 6). 
In Dictyostelium, MHCII phosphorylation interferes with the electrostatic interactions 
between MHCII coiled-coil domains. Thereby, it prevents the assembly of myosin II 
molecules into bipolar filaments, resulting in the release of cytoskeletal tension. Despite 
the notion that in higher eukaryotes actomyosin-based contraction is predominantly 
regulated by MLC phosphorylation, several studies, including our own, indicate a role for 
MHCII phosphorylation in the regulation of myosin filament assembly (Middle panel) 
(Chapter 6 - 8 & (130-132)). In this dissertation, we focus on the role of TRPM7 as 
MHCII kinase.
Rho-GTPases
Rho-GTPases are cellular switches that, in response to plasma membrane receptor 
signaling, spatially and temporally modulate cytoskeletal dynamics (133). Rho activation 
inhibits MLC phosphatase and consequently, increases myosin II-mediated cytoskeletal 
tension, actin stress fiber formation and adhesion maturation (Middle panel) (133, 
134). Rac and CDC42, in turn, have partially overlapping functions in promoting the 
formation of actin-rich protrusions such as lamellipodia and filopodia. At the leading edge 
of the cell, Rac and CDC42 inhibit cofilin and activate the ARP2/3 complex to increase 
actin polymerization and filament branching (133). Of interest, Rac-mediated signaling 
reduces cytoskeletal tension by antagonizing Rho activation, inhibiting MLC kinase and 
inducing MHCII phosphorylation (Middle panel) (133). The regulation of Rho-GTPases 
by extracellular cues, including growth factor signaling, integrin signaling and G-protein 
coupled receptor signaling, lies beyond the scope of this thesis.
Mechanical crosstalk between tumor cells and tumor microenvironment 
(Tumor-) cells are able to sense the physical characteristics of their surroundings and 
modulate the adhesive machinery in order to maximize migration and invasion through 
a complex environment (53). In addition to their role in maintaining tissue integrity and 
generating traction forces, cell adhesions themselves act as environmental sensors that 
through their physical interactions with the ECM, control actomyosin remodeling in response 
20
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to mechanical cues. This bifunctional nature of cell adhesions has been particularly well 
described for focal adhesions, although also adherens junctions and invadosomes appear to 
be intrinsically responsive to mechanical cues (65). Focal adhesion formation and maturation 
depend on myosin II-mediated pulling forces that adhesion sites undergo through their actin 
connections (56). The stiffer the underlying matrix, the larger the pulling forces exerted on 
focal adhesions by actomyosin contraction. Accordingly, cells grow more and larger focal 
adhesions on stiffer substrates (7, 53, 65, 66). In turn, focal adhesion formation is strongly 
reduced by inhibitors of myosin II and actin polymerization (56). The crosstalk between 
cell-matrix interactions and cytoskeletal dynamics provides a mechanism by which cells can 
sense the mechanical properties of their surroundings and distinguish between stable and 
unstable adhesions (65).
Perception and response to mechanical forces critically depend on the crosstalk between 
interdependent modules within the focal adhesion that structurally and functionally link 
the ECM to the intracellular actomyosin cytoskeleton (Fig. 4). Forces generated by actin 
polymerization, myosin II-based contractility and the ECM, converge on the adhesion module, 
comprising integrins that link the ECM to the actomyosin cytoskeleton via adaptor and 
signaling modules. The adhesion module serves as bidirectional conductor of mechanical 
information across the plasma membrane, either to transmit actomyosin-driven traction 
forces onto the substrate, or to initiate cytoskeletal remodeling in response to environmental 
mechanical cues. Within the cytoskeletal adaptor module, proteins such as zyxin, talin, 
vinculin and alpha-actinin provide the structural link between the adhesion module and the 
actomyosin cytoskeleton. In turn, the signaling module, comprising proteins such as focal 
adhesion-kinase (FAK), paxillin and p130CAS, bidirectionally modulates the cytoskeleton 
and integrin mediated substrate interactions via a variety of signaling cascades that control 
integrin activity and cytoskeletal remodelers such as Rho-GTPases and the actin nucleation 
machinery (65).
Pulling forces experienced by integrin-containing cell-matrix adhesions, for instance in 
response to increased actomyosin-based tension or changes in substrate rigidity, trigger 
conformational changes in mechanosensitive adaptor- and signaling proteins. These force-
induced unfolding responses can expose cryptic phosphorylation or protein binding sites and 
consequently trigger a variety of signaling responses and protein recruitment (67-69). Talin, for 
instance, is a force-bearing focal adhesion protein that directly links the cytoplasmic domains 
of integrins to actin filaments. Upon the application of mechanical stress onto cell adhesions, 
force induced stretch of talin reveals a vinculin-binding site. The subsequent binding of vinculin, 
a cytoskeletal adaptor protein, enforces the adhesion structure by recruiting additional 
21
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adhesion components (70, 71). Zyxin, 
another mechanically-regulated adhesion 
component, controls actin polymerization at 
force-bearing adhesions as it associates with 
focal adhesions in a force-dependent manner 
and locally recruits the actin polymerizing 
machinery (72).  Additionally, many focal 
adhesion signaling proteins, including paxillin 
and p130CAS, are regulated by mechanical 
cues (73). Moreover, there is an increasing 
body of evidence indicating that the 
mechanosensitive elements of adhesion sites 
also comprise force activated Ca2+ channels 
(68, 74-76).
Ca2+ signaling in cancer metastasis
Ca2+ ions are universal cellular messengers 
and Ca2+-dependent signaling cascades 
control virtually all cellular processes. As a 
consequence, Ca2+ signaling is considered to 
play an important role in cancer progression 
and metastasis formation (77, 78). Ca2+ 
signals control cytoskeletal organization and 
adhesion dynamics involved in cell migration and invasion (78). The relevance of these signals 
in cancer metastasis is evident from recent publications that report the differential regulation 
of Ca2+-permeable transient receptor potential (TRP) channels, as well as constituents of 
store operated Ca2+ channels, Orai1 and Stim1, in metastatic cancers and their requirement 
for (tumor-) cell migration (77).
Polarized, migrating cells exhibit a Ca2+ gradient from front to rear. High Ca2+ levels in 
the rear contribute to rear end-retraction by enhancing myosin II-based contractility and 
activation of focal adhesion destabilizing factors such as calpain and FAK (78-81). In the 
leading edge of migrating cells, local repetitive Ca2+ transients or oscillations orchestrate 
cell membrane protrusion and adhesion dynamics to establish cell polarization and direct 
cell migration towards chemical or mechanical guiding cues (78, 82, 83). Apparently, spatial 
and temporally distinct Ca2+ signals control different downstream processes. However, it 
Signaling
module
Adaptor
module
Adhesion
module
Cytoskeletal 
remodelers
Actomyosin 
cytoskeleton
Figure 4. Functional modules of cell adhesions.
Cell adhesions consist of three functional modules that 
partially overlap in molecular composition. The adhesion 
module directly binds the extracellular environment 
and perceives mechanical information. Mechanical cues 
are translated into biochemical signals by the signaling 
module to activate cytoskeletal remodelers, and are 
directly transmitted to the actomyosin cytoskeleton 
via the adaptor module to affect cellular tension. 
Reciprocally, cellular tension controls adhesion assembly 
and turnover.
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remains incompletely understood how cells can distinguish between these different types 
of Ca2+ signaling events (84).
Spatially confined Ca2+ signals occur by the combined action of influx through Ca2+-
permeable ion channels and release by intracellular Ca2+ stores, e.g. the endoplasmic 
reticulum, in response to a variety of stimuli that include growth factors, G-protein coupled 
receptor agonists, as well as mechanical cues (78). Ca2+ influx in response to mechanical 
stimuli provides a mechanism by which cells can translate mechanical information into 
local biochemical signals that control cytoskeletal remodeling and adhesion dynamics. For 
example, mechanosensitive Ca2+ channels were shown to be involved in mediating local 
Ca2+ signaling events that guide cell migration (2, 82, 85). These cation channels may either 
be intrinsically sensitive to membrane stretch or act in direct association with adhesion 
molecules and the actomyosin cytoskeleton (67-69). Alternatively, channels may be activated 
downstream of mechanosensitive G-protein coupled receptors, such as the bradykinin or 
angiotensin receptors (76, 86, 87). 
TRP family of cation channels are cellular sensors
Recent evidence points towards an important role for the TRP family of cation channels in 
mechanoregulation of adhesion dynamics and (tumor-) cell migration (Chapters 2 & 3). TRP 
channels make up a protein superfamily, implicated in a large variety of sensory processes. 
Their ion conducting properties can be modulated by different stimuli, resulting in a variety 
of cellular responses (88, 89). TRP channel family members play an essential role in the 
perception of light, temperature and taste. Furthermore, it is now widely accepted that 
the ion conducting properties of these TRP channels are crucial in the cellular response to 
osmotic changes and mechanical stress in a wide range of cells, although it remains unclear 
whether TRP channels are directly gated by mechanical stimuli (76, 90-92). 
TRP channels form large macromolecular complexes linked to the actomyosin cytoskeleton 
which may serve to localize signal transduction pathways and/or enhance the rate of signal 
transmission (75, 76, 93-95). The close association of TRP channels with the actomyosin 
cytoskeleton suggests that TRP channels might well regulate cytoskeletal dynamics by 
conducting Ca2+ in response to mechanical stimuli. Indeed, a multitude of TRP channel 
family members localize to adhesion sites to orchestrate mechanically induced cytoskeletal 
remodeling in processes such axonal outgrowth, glomerular filtration and cell migration 
(75). Moreover, defects in mechanotransduction, due to perturbed TRP channel functioning 
underlie several human pathologies including renal failure and cancer (75-77). For instance, 
the expression of a number of TRP channels is affected in cancer cells (77, 92, 96).
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TRPM7
In earlier work, we and others identified TRPM7 as regulator of adhesion dynamics. TRPM7 
is a ubiquitously expressed member of the melastatin-related subfamily of TRP channels 
(TRPM) which consists of eight members with a wide range of structural and functional 
features, ion selectivity and expression patterns (89, 97, 98). TRPM7, and its closest relative 
TRPM6, are divalent cation channels that are highly permeable for Ca2+ and Mg2+ ions 
(Box 2) (99, 100).  Similar to TRPM6, TRPM7 channel opening is inhibited by intracellular 
Mg2+ ions and Mg2+-complexed nucleotides (99, 101). Accordingly, depletion of intracellular 
Mg2+ activates TRPM6 and TRPM7. Channel opening is additionally regulated by G-protein 
coupled receptor signaling (102) or extracellular pH (103), while a number of studies have 
shown that TRPM7 ion conductance can be modulated by mechanical stimuli (82, 104-106). 
Although TRPM6 and TRPM7 were initially considered to control Mg2+ homeostasis (101, 
107), the current consensus is that TRPM7, in contrast to TRPM6, primarily orchestrates 
Ca2+-dependent cellular processes. TRPM7 Ca2+ conductance is involved in a number of 
processes including anoxic cell death, exocytosis, cell proliferation, mechanotransduction 
and cell adhesion. Moreover, mechanically-triggered TRPM7 channel opening mediates 
local Ca2+ spikes in the leading edge of migrating fibroblasts affecting the direction of cell 
migration (60, 82, 104, 108-112).
Both TRPM6 and TRPM7 are unique TRP channels in the sense that they comprise a 
C-terminal a-kinase domain (Box 2). Although poorly characterized in mammalian cells, 
the founding members of this atypical kinase family, the Dictyostelium myosin II heavy chain 
kinases, play a key role in regulating cytoskeletal tension during cell division and migration 
(Box 1) (113, 114). Initially, the TRPM6 and TRPM7 a-kinase domains were considered to 
function as sensor for intracellular Mg2+ and G-protein coupled receptor activation, to 
control channel opening (100, 115-117). However, it has now been well established that 
TRPM7 kinase activity does not affect ion conductance but instead, transmits intracellular 
signals by phosphorylation of downstream targets (60, 107, 118-120). Moreover, the kinase-
substrate interactions that have been described, depend on the presence of Ca2+ and/or 
Mg2+ (60, 119). This suggests a model where stimulation of TRPM7 leads to a local cation 
influx that allows the TRPM7 kinase to interact with substrates.
We have previously established the association between TRPM7 activation, Ca2+ influx 
and kinase-dependent cytoskeletal remodeling in a mouse neuroblastoma model (60). 
Stimulation of TRPM7 transduced cells with bradykinin, a G-protein coupled receptor 
agonist, triggers TRPM7 channel opening and a subsequent influx of extracellular Ca2+. The 
activation of TRPM7 is accompanied by kinase-dependent actomyosin redistribution and 
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invadosome formation, resembling the effect of myosin II inhibition by blebbistatin (60). 
Strikingly, TRPM7 overexpressing cells exhibit large invadosome clusters along the edges 
of 3D micro-patterned surfaces in the absence of bradykinin, suggesting that topographical 
cues are sufficient to induce TRPM7-mediated adhesion remodeling. Since TRPM7 localizes 
to adhesion sites that include focal adhesions and invadosomes (60, 109), these results 
led us to hypothesize that mechanically activated TRPM7 locally inhibits myosin II induced 
contractility to control cytoskeletal remodeling, adhesion dynamics and cell migration (60, 
61). Supporting this notion, we showed that, upon activation, TRPM7 associates with myosin 
IIA in a Ca2+- and kinase-dependent manner (60). Moreover, we identified the myosin IIA 
heavy chain as substrate for the TRPM7 kinase, similar to the closely related Dictyostelium 
myosin II heavy chain kinases (Box 1). 
Box 2. TRPM7 structure, expression and redundancy 
TRPM7, and its closest homologue TRPM6, are unique in the sense that they encode 
divalent cation channels fused to an a-kinase domain. Similar to other TRP channels, 
TRPM6 and TRPM7 possess six transmembrane domains flanked by large N- and C-terminal 
tails that reside in the cytosol. Within the N-terminal tail, four stretches of amino acids 
are present which are conserved between the different members of the TRPM subfamily 
but whose functions are poorly understood (98). Proximal to the last transmembrane 
domain in the C-terminal tail is the so called TRP box, a conserved stretch of amino acids 
present in all TRP ion channels. In addition, the C-terminal cytoplasmic domain carries 
a coiled-coil domain and at the extreme C-terminus, the a-kinase domain (135). The 
transmembrane domains organize within the plasma membrane to form the channel, of 
which the actual pore consists of a short stretch of amino acids between the 5th and 
6th transmembrane domains (A) (136). Functional channels are most likely organized as
Kinase domain
Transmembrane
domains 
TRP box
Coiled-coil domainConserved domains
in TRPM family
Pore forming 
domain
Extracellular
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Box 2. Continued
either homo- or heterotetramers which, dependent on their composition, have unique 
electrophysical properties and functions (B) (137-139). Although the exact mechanism of 
tetramerization is unknown, it has been demonstrated that several TRP channels, including 
TRPM2 and TRPM8, require the presence of the C-terminal coiled-coil domain for the 
assembly of active channels (140, 141). The TRPM6 and TRPM7 a-kinase domains are 
likely to function as a dimer (B) (142). Although a-kinases lack any significant sequence 
homology with conventional kinases, their topology is remarkably similar to other kinases 
(142, 143). 
TRPM7 is highly similar to TRPM6, displaying 50% identity at the amino acid level. 
Moreover, the kinase domains show 75% identity at the amino acid level. In spite of these 
similarities, both proteins appear to be functionally non-redundant. Knockout studies 
have shown that both TRPM6 and TRPM7 are essential during development as the loss 
of these channels leads to embryonic lethality (112, 144). While TRPM7 is ubiquitously 
expressed, TRPM6 expression is mostly limited to brain, intestine and kidneys (145). 
Moreover, overexpression of TRPM6 cannot rescue cell growth arrest due to the ablation 
of TRPM7 (139). Finally, mutations in TRPM6 cause familial hypomagnesemia with secondary 
hypocalcemia, a disease characterized by defects in renal and intestinal Ca2+ and Mg2+ 
absorption which progresses despite the expression of TRPM7 in both the kidney and 
intestine (146, 147). (Adapted from Chapter 6). 
Scope of this thesis
The complex protein-protein interactions that take place within cell adhesion sites significantly 
contribute to tumor progression and metastasis formation. Hence, proteins that regulate 
adhesion formation or turnover represent interesting therapeutic targets to limit the metastatic 
potential of cancer cells (7, 9). However, a lack of mechanistic insight into cancer-specific 
mechanisms that govern cell-matrix interactions has hampered the development of such 
treatments (121). In Chapters 2 and 3, we first discuss the interactions between TRP 
channels and the actomyosin cytoskeleton, and their roles in a variety of mechanically 
controlled cellular processes. 
In part II of this thesis we address the potential role of TRPM7 in cancer metastasis. In 
Chapter 4, we show that TRPM7 is required for breast cancer cell migration and metastasis, 
both in vitro and in vivo. Consistent with the notion that TRPM7 induces cytoskeletal relaxation, 
reduced TRPM7 expression levels confer a contractile and non-migratory phenotype onto 
invasive breast cancer cells.  Additionally, TRPM7 mRNA expression levels correlate with 
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disease progression and metastasis formation in two large breast cancer patient cohorts, 
independent from standard clinical parameters. In line with these findings, we demonstrate 
in Chapter 5 that moderate overexpression of TRPM7 transforms non-invasive mouse 
neuroblastoma cells into migratory and invasive tumor cells, accompanied by extensive 
adhesion remodeling and increased cell-matrix adhesion strength.
In part III of this thesis, we address the Ca2+- and kinase-dependent interactions between 
TRPM7 and the actomyosin cytoskeleton. After providing an in-depth review on the a-kinase 
protein family in Chapter 6, we extend on the previous observations that the TRPM7 
kinase domain is capable of phosphorylating the non-muscle myosin IIA heavy chain in 
Chapters 7 and 8. Using bioinformatics and proteomic approaches, we identified the 
TRPM7 targeted residues within the myosin IIA, IIB and IIC heavy chains, all of which 
localize to a region considered to be essential in myosin II filament assembly. Accordingly, 
phosphomimetic mutations of these residues inhibit myosin IIA filament forming properties 
and its association with actin stress fibers. In Chapter 9, we describe a mechanism by 
which the TRPM7 kinase domain may interact with its substrates. Our findings suggest a 
model where autophosphorylation of a domain upstream from the kinase domain yields 
a charge-dependent docking site for substrates such as the myosin II heavy chains. Finally, 
we describe the proteomic characterization of a large protein complex that interacts with 
TRPM7 in Chapter 10. Interestingly, most of its constituents are adhesion components 
that regulate actomyosin contractility and actin polymerization, further supporting a role 
for TRPM7 in adhesion regulation.
In Part IV of this manuscript, we integrate our findings into a working model and discuss 
the potential use of TRPM7 as diagnostic marker for disease progression and therapeutic 
target in the control of cancer metastasis (Chapter 11). 
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Abstract
Transient Receptor Potential (TRP) channels are a family of cation channels that play a 
key role in ion homeostasis and cell volume regulation. In addition, TRP channels are 
considered universal integrators of sensory information required for taste, vision, hearing, 
touch, temperature and the detection of mechanical force. Seminal investigations exploring 
the molecular mechanisms of phototransduction in Drosophila have demonstrated that 
TRP channels operate within macromolecular complexes closely associated with the 
cytoskeleton. More recent evidence shows that mammalian TRP channels similarly connect 
to the cytoskeleton to affect cytoskeletal organization and cell adhesion via ion transport-
dependent and –independent mechanisms. In this review, we discuss new insights into the 
interplay between TRP channels and the cytoskeleton and provide recent examples of such 
interactions in different physiological systems.
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Introduction
The actomyosin cytoskeleton is a large network of structural, motor and signaling proteins 
that coordinates a plethora of cellular functions including cell division, adhesion and migration. 
Proper function of the various cytoskeletal components requires the assembly of the individual 
entities into macromolecular complexes. Notably, bi-directional relationships are established 
where cytoskeletal-associated proteins affect actomyosin remodeling and contractility while 
the cytoskeleton regulates the activity of the associated protein complex. 
At the plasma membrane, integral membrane proteins are intimately connected to 
the actomyosin cytoskeleton. Integrins are the most extensively studied paradigm for the 
relationship between the cytoskeleton and transmembrane proteins. These adhesion molecules 
are physically associated with the actomyosin cytoskeleton via linker proteins such as a-actinin 
and talin to provide anchorage and structural integrity to the cell (1, 2). Upon activation, 
integrins transmit intracellular signals that regulate organization and contractility of the 
actomyosin cytoskeleton which in turn affects the architecture of cell-extracellular matrix 
(ECM) adhesion structures (3, 4). Recent investigations demonstrate that, by similarity to 
integrins, ion transport proteins including Transient Receptor Potential (TRP) channels also 
form  large macromolecular complexes linked to the actomyosin cytoskeleton (5-7). Here, 
we will focus on novel findings describing this close association between TRP channels and 
the actomyosin cytoskeleton.
Drosophila TRP channels in phototransduction
The photoresponse in the Drosophila eye involves the influx of Ca2+ ions followed by rapid 
depolarization of the photoreceptor cells. Genetic screens aimed at characterizing this 
process have led to the identification of more than 30 genes required for phototransduction 
in Drosophila (8). A spontaneous mutation in the trp locus generated a distinctive phenotype 
where illumination of photoreceptor cells led to a transient response. Ca2+ influx in trp 
mutant photoreceptors was significantly diminished and although the cells depolarized, 
recovery to baseline was accelerated and therefore referred to as ‘transient receptor 
potential’ (see review by Minke and Cook for historical perspective (9)). These findings led 
to the identification of Transient Receptor Potential (TRP), the founding member of this 
channel superfamily (10). A closely related channel, known as TRPL, is responsible for the 
small current remaining in trp flies. Deletion of both TRP and TRPL abolishes the response 
of photoreceptors to light (11).
Biochemical characterization of the signaling pathways controlling the function of TRP and 
TRPL demonstrated that several genes identified in genetic screens encode proteins that are 
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physically connected into a macromolecular complex called the signalplex (12). The central 
component of this complex is the scaffold protein ‘inactivation no afterpotential D’ (INAD), 
which contains five PDZ domains (the name ‘‘PDZ’’ derives from the first three proteins 
in which these domains were identified: PSD-95, a protein involved in signaling at the post-
synaptic density; DLG, the Drosophila discs large protein; and ZO-1, the zonula occludens 1 
protein) that mediate direct interactions with rhodopsin, TRP, TRPL, phospholipase C (PLC/
NORPA), protein kinase C (PKC/INAC) and myosin III (NINAC) (Fig. 1A). The clustering 
of signaling proteins into a single complex is thought to be necessary for proper localization 
of the components and efficient transmission and termination of signals, which is extremely 
rapid (~20 ms) in the case of phototransduction (8). These studies also revealed that TRP 
and TRPL channels are indirectly connected to the actomyosin cytoskeleton via INAD. The 
primary role of the nonconventional myosin NINAC in phototransduction is to efficiently 
terminate the photoresponse (13). Moreover, NINAC prevents the reactivation of TRP and 
TRPL channels once illumination of the photoreceptors has ceased (14). The mechanism 
responsible for the negative feedback between NINAC and TRP channels is, however, 
poorly understood. Targeting of calmodulin to rhabdomers by NINAC is necessary but not 
sufficient as a mutation in NINAC, which abrogates its association with INAD, has no effect 
on localization of calmodulin to the rhabdomers but remains inefficient in terminating the 
response to light (15-17). At this moment, it appears that the association between TRP and 
TRPL with the actomyosin cytoskeleton is sufficient to close the channels after illumination 
of photoreceptor cells has ended (15). Notably, the motor activity of NINAC is also required 
for rapid termination of the response  and thus, changes in mechanical force exerted by the 
cytoskeleton onto the signalplex may contribute to terminating phototransduction (15).
In addition to controling the gating of channels in photoreceptor cells, NINAC also 
regulates the movement of TRPL channels within the cell (18, 19). TRPL channels localize 
to the plasma membrane in the rhabdomers in dark-raised flies. However, upon exposure 
to light, TRPL channels are endocytosed and translocated to the cell body (18). Although 
this translocation event requires NINAC (19), it is unlikely that NINAC directly transports 
the vesicles from the rhabdomer to the cell body. A detailed characterization of the motor 
activity of class III myosins demonstrated that NINAC is a so-called ‘nonprocessive’ motor, 
similar to brush border myosin I, and hence, incapable of transporting vesicles (20). Instead, 
it has been suggested that secondary effects of NINAC deletion on the cytoskeleton may 
contribute to mislocalization of TRPL (19). Irrespective of the precise mechanism, these 
findings underscore the importance of the actomyosin cytoskeleton both in controlling the 
gating of TRP channels as well as in their localization.
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TRP/TRPL channels also actively reshape the actomyosin cytoskeleton in photoreceptor 
cells. Exposure to light leads to a redistribution of cortical actin away from the rhabdomer 
and into the cell body, a process that is abrogated in trp mutant flies (21). Moreover, both 
TRP and TRPL channels interact directly with Dmoesin which provides another physical 
link with the cytoskeleton (Fig. 1A) (22). ERM domain proteins (ERM is an acronym for 
ezrin, radixin and moesin, the first three proteins in which this domain was recognized) 
like Dmoesin are primarily involved in linking plasma membrane proteins to the actomyosin 
cytoskeleton (23). Notably, the interaction between the TRP channels and Dmoesin is 
highly dynamic. In dark-raised flies, Dmoesin is phosphorylated and associated with TRP and 
TRPL (22). Illumination of photoreceptors leads to a rapid dephosphorylation of Dmoesin, 
which subsequently dissociates from the channels and translocates into the cell body (22). 
Figure 1. TRP channels are 
present in macromolecular 
complexes associated with 
the actomyosin cytoskeleton.
(A) The Drosophila TRP/TRPL 
signalplex is organized around 
the mult ip le PDZ domain-
containing scaffold protein INAD 
(PDZ domains are numbered 
1-5). Note how INAD recruits 
rhodopsin, TRP/TRPL , PLC, 
PKC and NINAC (myosin III) to 
the complex. Interactions of the 
signalplex with cortical actin are 
not only mediated by NINAC 
but also involve Dmoesin, which 
connects TRP/TRPL channels to 
actin filaments. (B) Mammalian 
TRP channels such as TRPV4 or 
TRPM7 may directly interact with 
either actin filaments or myosin II.
(C) By similarity to Drosophila 
TRP/TRPL , mammalian TRP 
channels such as TRPC4 and 
TRPC5 interact with the PDZ-
containing scaffold NHERF, which 
links these channels to the actin 
cytoskeleton via ERM proteins.
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Deletion of trp prevents this light-induced translocation of Dmoesin, which is essential 
for the maintenance of the photoreceptor cells (22).  It is still unclear how TRP affects 
Dmoesin localization, or how its translocation impacts on TRP/TRPL channel activity. One 
model proposes that a phosphatase is activated by Ca2+-mediated influx through TRP which 
dephosphorylates Dmoesin and promotes the dissociation of Dmoesin and its translocation 
(22). Future work in this area will provide novel insights into the mechanisms that TRP 
channels employ to regulate cytoskeletal dynamics and vice versa.
Association of mammalian TRP channels with the cytoskeleton
The human genome encodes 27 TRP channels which have been implicated in a variety of 
sensory functions including temperature sensing, hearing, vision, smell, taste and touch as 
well as important ion transport mechanisms involved in regulating cell volume and maintaining 
ion homeostasis (24, 25). Based on homology, members of this protein superfamily have 
been further classified into 6 categories: canonical, TRPC; vanilloid, TRPV; melastatin, TRPM; 
ankyrin, TRPA; polycystin, TRPP, and mucolipin, TRPML (26). All TRP channels possess 6 
transmembrane domains that form the channel flanked by cytosolic N- and C-terminal 
tails. Within these cytosolic regions, several domains that could mediate the assembly of 
macromolecular complexes have been identified including PDZ binding motifs, coiled-coil 
domains and ankyrin repeats (26). Moreover, like their counterparts in Drosophila, several 
mammalian TRP channels interact with the actomyosin cytoskeleton. 
The association between TRP channels and the cytoskeleton can be mediated via different 
mechanisms. Since ankyrin repeats are involved in linking transmembrane proteins to the 
cytoskeleton (27), it was originally thought that TRP (TRPC, TRPV and TRPA) channels 
containing these repeats would bind directly to the cytoskeleton. However, these ankyrin 
repeats appear to be primarily involved in the homo- and heterotetramerization of the 
TRP channels, which is essential for channel function (28). Mutation or deletion of ankyrin 
repeats abolishes the assembly of several TRP channels. The available evidence suggests that 
mammalian TRP channels either directly associate with the cytoskeleton or, by similarity to 
Drosophila TRP, via scaffold proteins. For instance, TRPV4 and TRPM7 appear to associate with 
the actomyosin cytoskeleton by interacting with actin and nonmuscle myosin II, respectively 
(Fig. 1B) (6, 29). On the other hand, TRPC4 and TRPC5 interact with a PDZ domain in 
‘Na+/H+ exchanger regulatory factor’ (NHERF), which associates with the cytoskeleton via 
proteins of the ERM family  (Fig. 1C) (7). Other examples include TRPP2 and TRPP3 which 
interact with a-actinin (30, 31), while TRPC1 binds a1-syntrophin of the dystrophin-based 
cytoskeleton (32).
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Regulation of TRP channel activity by the cytoskeleton
Cell surface expression
The identification of interacting partners for TRP channels has led to important insights into 
their regulation, and it appears that the actomyosin cytoskeleton plays a prominent role in 
controlling channel activity. One mechanism by which actomyosin may affect channel function 
is by modulating the interactions between TRP channels and their regulatory proteins. For 
instance, some TRP channels localized within the plasma membrane, will associate under 
specific conditions with proteins residing in the endoplasmic reticulum and this interaction 
requires an intact actomyosin cytoskeleton (33, 34). Alternatively, the cytoskeleton can 
regulate the accumulation of channels within the plasma membrane. Depolymerization 
of actin induces the internalization of several members of the TRPC family  and inhibition 
of contractility impairs the plasma membrane localization of TRPC5 (35-37). Moreover, 
mutations that interfere with the association of TRPC4 with NHERF and ERM proteins 
prevent its delivery to the cell surface (38). In addition to regulating subcellular localization 
of TRP channels, the actomyosin cytoskeleton may also play a role in directly regulating 
channel activity, for instance during mechanotransduction.  
Mechanotransduction
The opening of several TRP channels is triggered by the application of mechanical force (39). 
However, the molecular mechanisms underlying this process are unclear, and it remains a 
challenge to classify channels as responding directly or indirectly to mechanical force (40). 
The mechanoreceptor may be the channel itself (Fig. 2A & B) but in other situations changes 
in mechanical force may be initially interpreted by other receptors such as integrins or G 
protein-coupled receptors (GPCR) (Fig. 2C & D). For instance, it was recently discovered 
that the bradykinin receptor can activate downstream signaling cascades in response to fluid 
shear and hypotonic stress independently of ligand binding (Fig. 2D), which could lead to 
the subsequent opening of TRPM7 channels (41, 42).
Different models have been developed to explain the opening of TRP channels in direct 
response to various types of mechanical force (43). Certain TRP channels involved in cell 
volume regulation are activated by osmotic shock. Since changes in osmotic pressure affect 
cell volume, forces could be transferred within the lipid bilayer to the transmembrane 
domains of TRP channels leading to the regulation of channel activity (Fig. 2A) (39). TRPC1 
is a prime example as it can be directly activated by mechanical stretch in reconstituted 
liposomes devoid of any cytoskeletal components (44). On the other hand, adherent cells 
sense mechanical forces at specialized cell-matrix adhesion sites (4). Adhesion molecules, 
42
Chapter 2
such as integrins, promote actomyosin-based contractility which could regulate the gating 
of cytoskeleton-associated TRP channels (Fig. 2C) (43). Although this hypothesis requires 
further experimentation, channels like TRPM7 are prime candidates. TRPM7 localizes to 
sites of cell-ECM adhesion where it is connected to the adjacent actomyosin cytoskeleton 
(6, 45). Moreover, TRPM7 is delivered to the cell surface and activated in response to 
mechanical forces (46-48). The accumulation of TRPM7 channels in the plasma membrane 
may help amplify the signal. Finally, TRPM7 is important for the development and maintenance 
of mechanosensitive organs (49). It will be important to determine whether channels like 
TRPM7, which associate with the actomyosin cytoskeleton, require an intact F-actin network 
in order to sense mechanical forces. 
Figure 2. Hypothetical models describing how mechanosensitive channels may respond to mechanical 
force. (A) Changes in cell volume affect tension within the lipid bilayer. Such forces could be transmitted to 
the transmembrane domains of TRP channels causing channel opening. (B) Mechanosensitive channels that 
associate with the cytoskeleton may be sensitive to changes in actomyosin-based tension, acting as a spring. (C) 
Mechanical forces are sensed at specialized cell-matrix adhesions involving a complex of integrins, cytoskeletal 
elements and TRP channels. Traction forces exerted by the ECM trigger integrin activation, accompanied by the 
recruitment and activation of adaptor and signaling molecules. Activation of this integrin signaling complex leads 
to increased actomyosin-based tension.  Thus a combination of traction forces applied externally by the ECM 
and cytoskeletal counter forces on the inside may lead to channel opening. In this particular setting, the integrin 
complex is the primary sensor. (D) Mechanical forces may initially be sensed by G protein coupled receptors 
(GPCR), as has been shown for the bradykinin receptor. Signals downstream of these receptors subsequently 
activate the channel, for instance by activation of specific kinases or PLC. Obviously, combinations of these 
different modes of activation may also take place, or serve to amplify the initial response.
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Regulation of cytoskeletal dynamics by TRP channels
Activation of TRP channels leads to remodeling of the actomyosin cytoskeleton. The 
influx of ions, primarily Ca2+, will activate a wide range of Ca2+-dependent proteins, which 
include protein kinases, phosphatases and proteases. For instance, Ca2+ influx through 
TRPC1 activates the phosphatase calcineurin, which relays the signal to slingshot (50). 
Slingshot dephosphorylates cofilin which thereby promotes actin filament severing (51). 
Alternatively, TRPM7-mediated Ca2+-influx at sites of cell adhesion activates calpains which 
cleave components of focal adhesions such as FAK (45). The ubiquitous nature of Ca2+ signaling 
pathways suggests that TRP channels can influence cell behavior in many different ways. 
Other factors likely to be important for TRP channel function are subcellular localization 
of the channel, local concentrations of Ca2+ and duration of the Ca2+ signal. 
The cytoskeleton is composed of three major filament systems known as F-actin 
microfilaments, microtubules and intermediate filaments. Not only do TRP channels associate 
with the actomyosin (microfilament) cytoskeleton but certain TRP channels also interact 
with microtubules. Of particular interest is TRPV1 which directly binds to tubulin in a 
Ca2+-dependent manner via its C-terminus (52, 53). Activation of TRPV1 leads to a rapid 
disassembly of microtubules but not of the other cytoskeletal filaments (54, 55). Moreover, 
overexpression of TRPV1 leads to the initiation and elongation of filopodia (56). Future work 
may reveal the extent of TRP channels in controlling the different cytoskeletal elements as 
well as permit a classification of microfilament-, microtubule-, and intermediate filament-
associated TRP channels.
Ion transport-dependent and -independent functions of TRP channels
Although the primary mode of action for TRP channels is through ion influx, recent findings 
suggest that these proteins may also affect cell behavior by ion transport-independent 
mechanisms. In the Drosophila eye, TRP plays an important scaffolding function whereby 
the localization of INAD and therefore, its associated proteins depends on the presence 
of TRP (Fig. 1A) (57, 58). Deletion of TRP or mutation of the INAD binding site leads to 
a mislocalization of several components of the signalplex and defects in phototransduction 
(57-59). Notably, some mammalian ion-transport proteins, such as the Na+-H+ exchanger 
NHE1 (which is not a TRP channel) also have ion transport-independent functions. It was 
shown that NHE1 binds directly to ERM proteins. Mutations which affect ERM binding but 
not ion translocation impair organization of the actomyosin cytoskeleton and the formation 
of focal adhesions as well as cell polarity (60, 61). Thus, NHE1 influences cell migration by 
coordinating the recruitment of proteins into a large macromolecular complex to the leading 
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edge of the cell. In addition to these ion-independent effects of NHE1, channel activity is 
also important for cell adhesion and migration (62).
The presence of TRP channels (eg. TRPC4-6 (5, 7)) in large macromolecular complexes 
suggests that, by similarity to NHE1,  these may also contribute to the proper architecture 
of the complex by acting as scaffolds. When these TRP channels contain domains which 
can exert enzymatic activities, these may directly affect cell behavior (24). Interestingly, the 
regulation of filopodia by TRPV1 occurs independently of channel activity (56). However, more 
studies are required to determine the mechanism underlying this phenomenon. Moreover, 
TRPM7, which encodes a TRP channel fused to an a-kinase, was shown to phosphorylate 
myosin II heavy chain accompanied by cytoskeletal relaxation. These cytoskeletal effects 
were largely kinase dependent, as a catalytically inactive mutant of TRPM7 maintained 
normal channel function but failed to induce relaxation of the actomyosin cytoskeleton (6). 
Notably, a TRPM7 kinase-dead mutant could no longer interact with actomyosin. However, 
since the interaction between the kinase and its substrate is facilitated by Ca2+-influx, it 
remains unclear whether channel activity is completely dispensable as is the case for NHE1 
(6). These studies indicate the need to further characterize the macromolecular complexes 
surrounding mammalian TRP channels, which will further help explore a role for TRP 
channels as molecular scaffolds. 
(Patho-) physiological relevance of interplay between TRP channels and the 
cytoskeleton 
The close functional association between TRP channels and the cytoskeleton is relevant to 
a number of physiological processes in mammalian cells and organ systems. Defects in the 
ability of TRP channels to interact with the cytoskeleton contribute to the pathogenesis of 
human disease. Here, we provide a few examples in which TRP channels and the cytoskeleton 
converge to regulate (patho)physiological functions. 
Hearing
To interpret the information stored in sound waves, the inner ear converts it into an electrical 
signal by activating Ca2+-influx through an unknown channel (63). Activation of the channel is 
thought to occur directly via mechanical forces. The deflection of stereocilia in response to 
sound waves will induce the opening of channels at the cell surface (64). Since the bending of 
cilia is performed by the cytoskeleton, it is not surprising that several mutations in myosins 
have been detected in patients with nonsyndromic deafness (65). Interestingly, several TRP 
channels (TRPV4, TRPA1, TRPN and TRPML3) have been proposed as candidates for the 
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mechanically-gated channel within the inner ear (63, 66). For instance, TRPV4 knockout 
mice have impaired hearing but the phenotype is milder than expected (67). More recently, 
mutations in TRPML3 which cause the mouse varitint-waddler phenotype were found to 
lead to deafness (68). However, these mutations constitutively activate the channel and Ca2+ 
overload may influence the response and viability of the cells (69, 70). Moreover, Grimm 
and colleagues  were unable to activate TRPML3 by applying mechanical force to the cells 
(70). Although the molecular composition of this channel complex awaits identification, 
the involvement of both cytoskeletal elements and mechanically-gated TRP channels in the 
perception of sound, provides an ideal model to further explore the relationship between 
the cytoskeleton and TRP channels.
Vascular endothelial cells
Endothelial cells lining the blood vessels provide a barrier, the  permeability of which is 
regulated by various factors including pro-inflammatory mediators such as thrombin and 
histamine. The integrity of the endothelial barrier is maintained by a balance between 
actomyosin contractility and cell-cell adhesions (71). Pro-inflammatory factors increase 
vascular permeability leading to vascular edema by affecting this balance. An essential event 
leading to vascular dysfunction is a rise in intracellular Ca2+ concentrations that activate 
cytoskeletal tension, actomyosin remodeling and disassembly of cell-cell interactions (71). The 
influx of Ca2+ is mediated by several TRP channels that require the actomyosin cytoskeleton 
for activation and also signal to the cytoskeleton. For instance, TRPC4 localizes to sites of 
cell-cell adhesion in pulmonary endothelial cells where it associates with protein 4.1, which 
links TRPC4 to the underlying cytoskeleton (72). Importantly, the link with the cytoskeleton 
is required for activation of TRPC4 (72). Knocking out TRPC4 in mice reduces the thrombin-
induced Ca2+-influx which was associated with a lack of actin-stress fiber formation and a 
reduction in microvascular permeability (73). Since vascular endothelial cells are also subjected 
to mechanical forces in the form of shear-stress and express several mechanosensitive 
TRP channels (71, 74), these cells provide another excellent model system to study the 
bidirectional signaling cascades between TRP channels and the actomyosin cytoskeleton. 
Kidney function
Podocytes are an integral component of the kidney glomerulus required for the ultrafiltration of 
plasma. These cells extend actin-rich foot processes which are organized into an interdigitating 
network where each neighboring foot process is connected by a multiprotein complex signal 
transduction unit called the slit diaphragm (75). The underlying actomyosin cytoskeleton 
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defines the morphology of the podocyte and organization of the actin network is required for 
proper kidney function (75). Thus, proteins involved in the dynamic regulation of the podocyte 
cytoskeleton are important components to renal (dys)function. For instance, a-actinin-4 
knockout mice die early after birth due to kidney failure while mutations in a-actinin-4 
have been associated with the pathogenesis of focal segmental glomerulosclerosis (76, 77). 
Interestingly, TRPC6 may affect function of the slit-diaphragm by inducing the remodeling 
of the actomyosin cytoskeleton. TRPC6 localizes to the glomerular slit diaphragm where it 
associates with core components such as nephrin and podocin as well as the cytoskeleton 
(78, 79). Moreover, TRPC6 overexpression leads to the reorganization of the actomyosin 
cytoskeleton in podocytes and also to proteinuria (78). Recently, activating mutations in 
TRPC6 were discovered in patients suffering from familial focal segmental glomerulosclerosis 
(79, 80). 
Another group of channels of particular interest in the kidney are the TRPP family 
members. In particular, mutations in TRPP2 underlie polycystic kidney disease (81). In 
contrast to TRPC6, TRPP2 is localized within the cilia of renal epithelial cells (82). TRPP2 
is linked to the actomyosin cytoskeleton via a-actinin and tropomyosin-1 (31, 83). TRPP2 
also associates with microtubules which increase channel activity (84). Since TRPP2 is a 
central component of the mechanosensor found in the cilia of kidney epithelial cells (82), the 
association of the channel with different cytoskeletal elements may play an integral role in 
controlling its activity. Understanding the complex relationship between TRP channels and 
the cytoskeleton may help identify the molecular mechanisms underlying kidney disease. 
Concluding remarks
Recent work has demonstrated that mammalian channels are organized into macromolecular 
complexes linked to the cytoskeleton. Since the characterization of the signalplex was essential 
to decipher the molecular mechanisms underlying phototransduction in Drosophila, defining 
the macromolecular complexes surrounding mammalian TRP channels will be pivotal to 
understanding the role of this protein superfamily in health and disease. To further explore 
the interplay between TRP channels and the cytoskeleton, several physiological systems 
such as stereocilia in the inner ear, podocytes and renal epithelial cells as well as vascular 
endothelial cells will provide excellent model systems. These studies may reveal novel 
mechanisms by which the cytoskeleton controls channel activity and clarify how TRP channels 
influence cell behavior independently of the classical ion-transport pathways. Such efforts 
will certainly contribute to our understanding of the molecular mechanisms underlying the 
pathogenesis of channelopathies.
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Abstract
The ability of cells to respond to mechanical stimulation is crucial to a variety of biological 
processes, including cell migration, axonal outgrowth, perception of pain, cardiovascular 
responses and kidney physiology. The translation of mechanical cues into cellular responses, 
a process known as mechanotransduction, typically takes place in specialized multiprotein 
structures such as cilia, cell-cell or cell-matrix adhesions. Within these structures, mechanical 
forces such as shear stress and membrane stretch activate mechanosensitive proteins, 
which set off a series of events that lead to altered cell behavior. Members of the transient 
receptor potential (TRP) family of cation channels are emerging as important players in 
mechanotransductory pathways. Localized within mechanosensory structures, they are 
activated by mechanical stimuli and trigger fast as well as sustained cytoskeletal reponses. In 
this review, we will provide an overview of how TRP channels affect cytoskeletal dynamics 
in various mechano-regulated processes. 
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Introduction
Many basic cellular functions, particularly cell proliferation, differentiation, adhesion and 
migration, are dependent on mechanical forces. As a consequence, cellular responses to 
mechanical cues are essential for proper embryonic development as well as for maintaining 
healthy organ physiology (1). The translation of mechanical cues into biochemical signals 
has been coined ‘mechanotransduction’. This process involves force transmission and the 
perception of force, followed by a distinct cellular response. Cell adhesion structures as well 
as cilia play a central role in this sequence of events (2, 3). Force transmitted through adhesion 
sites can induce conformational changes in mechanosensitive proteins, present either in 
the plasma membrane or the underlying cytoskeleton, which in turn leads to the activation 
of downstream signaling events. For instance, force-induced stretching of focal adhesion 
protein talin reveals cryptic binding sites for its interactor vinculin (4). Binding of vinculin to 
stretched talin is necessary for the growth of adhesion sites (5). Alternatively, mechanically 
activated cation channels trigger local Ca2+ signaling events to affect downstream cellular 
responses. Similar to integrin-mediated mechanisms of mechanotransduction, mechanically-
activated cation channels affect cytoskeletal organization and cell behavior. These effects 
include immediate responses, through the local regulation of cytoskeletal proteins, as well 
as more sustained effects, for instance by activation of Ca2+-sensitive transcription factors 
such as members of the nuclear factor of activated T cells (NFAT) family. Although a variety 
of different cation channels has been implicated in the perception and interpretation of 
mechanical forces (6), this review focuses on the emerging roles of transient receptor 
potential (TRP) channels as mechanosensors.
TRP channels
Members of the TRP cation family are considered important relays of mechanical signals (Table 
1). In support of this notion, TRP channels have been implicated in mechanotransduction-
related pathologies, such as progressive renal failure (7), cardiovascular diseases  (8, 9), 
hearing and balance disorders (10), neuropathic pain syndromes (11) and cancer (12, 13). TRP 
channels were first identified in Drosophila, where they were found to be essential for proper 
photoreceptor function in complex with cytoskeletal proteins (14) (for review see (15)). To 
date, 28 mammalian TRP channels have been identified (16). Based on sequence homology, 
TRP channels are subdivided into six subfamilies: canonical TRP channels (TRPC), melastatin 
TRP channels (TRPM), vanilloid TRP channels (TRPV), mucolipin TRP channels (TRPML), 
polycystin TRP channels (TRPP) and ankyrin TRP channels (TRPA). TRP channels usually 
contain six transmembrane domains, of which transmembrane domain 5 and 6 contribute 
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TRP 
channel
Mechanical 
stimulus
Biol. Process Cell type Structure Mechanism Related 
pathologies
Ref.
TRPC1 Shear stress 
- forms 
heteromeric 
channels with 
TRPV4
Cardiovascular 
homeostasis
EC NS. Cooperates with TRPV4 in 
promoting VSMC relaxation
- 147
Indirect via 
mechanically 
activated GPCR 
(AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Loss of TRPC1 prevents 
mechanical stress-induced 
pathologic cardiac 
remodeling
Cardiac 
hypertrophy
164
NS. - forms 
heteromeric 
channels with 
TRPP2
NS. Renal 
epithelial cells
Primary cilia NS. - 45, 
47 
TRPC3 Indirect via 
mechanically 
activated GPCR 
(AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT mediated 
activation of fetal gene 
expression program
Cardiac 
hypertrophy
169, 
170
TRPC4 NS. - likely to 
be activated by 
shear stress
Cardiovascular 
homeostasis
EC AJ Increasing vascular 
permeability (hypothetically 
through AJ disassembly )
- 65, 
67
TRPC6 NS. - interacts 
with TRPV4
Mechanical 
nociception 
Nociceptors NS. Essential for TRPV4-
mediated mechanical 
hyperalgesia
Mechanical 
hyperalgesia
126
Indirect via 
mechanically 
activated GPCR 
(AT1R)
Cardiovascular 
homeostasis
Cardiac 
myocytes
NS. Calcineurin/NFAT mediated 
activation of fetal gene 
expression program
Cardiac 
hypertrophy
162, 
170
Indirect via 
mechanically 
activated GPCR 
(AT1R)
Glomerular 
filtration
Podocytes Slit 
diaphragm
Dissolution of actin 
fibers  & calcineurin/NFAT 
mediated gene expression
Progressive 
kidney failure
187, 
188, 
189
TRPV1 NS. Mechanical 
nociception 
Nociceptors NS. Triggers microtubule 
disassembly
Mechanical 
hyperalgesia
125, 
132
TRPV2 Mechanical 
stretch - 
unknown 
whether direct 
or indirect
Axonal 
outgrowth
Neuronal/NS. NS. Stretch-induced axon 
outgrowth
- 103
TRPV4 NS. - forms 
heteromeric 
channels with 
TRPP2
NS. Renal 
epithelial cells
Primary cilia NS. - 44
Viscous load NS. Oviductal 
cells
Motile cilia Increase in ciliary beat 
frequency
- 34
Tracheal cells Motile cilia Increase in ciliary beat 
frequency
35
NS. NS. Keratinocytes AJ - 64
NS. - interacts 
with a2b1 
integrins and 
SRC
Mechanical 
nociception
Nociceptors NS. Triggers microtubule 
disassembly
Mechanical 
hyperalgesia
126, 
127, 
129
Shear stress Cardiovascular 
homeostasis
EC Primary cilia Promoting VSMC relaxation - 148
Mechanical 
stretch
Cardiovascular 
homeostasis
EC FA Realignment of FAs and 
stress fibers
- 152, 
154
57
Mechanoregulation of cytoskeletal dynamics by TRP channels
TRP 
channel
Mechanical 
stimulus
Biol. Process Cell type Structure Mechanism Related 
pathologies
Ref.
TRPM7 Shear stress 
- unknown 
whether direct 
or indirect
Migration Various FA Adhesion dynamics  via 
activation calpain and 
phosphorylation MHC
Cancer 57, 
87
Indirect by 
mechanically 
activated GPCR 
(BKR)
88
TRPP1/ 
TRPP2
Shear stress NS. Renal 
epithelial cells
Primary cilia NS. ADPKD 39
NS. - likely 
through 
its direct 
interaction with 
the ECM
NS. NS. FA Regulates FA dynamics by 
interacting with FAK and 
paxillin
- 58, 
59
NS. - likely to 
be activated by 
shear stress
Cardiovascular 
homeostasis
EC AJ AJ disassembly - 66
Shear stress Cardiovascular 
homeostasis
EC Primary cilia Promoting VSMC relaxation - 145, 
146
Blood pressure Cardiovascular 
homeostasis
VSMC NS. TRPP1/TRPP2 
ratio regulates SAC 
mechanosensitivity
- 158
Table 1. TRP channels are involved in mechano-regulated biological processes. ADPKD, autosomal dominant polycystic 
kidney disease; AJ, adherens junctions; AT1R, angiotensin II type 1 receptor; BKR, bradykinin receptor; EC, endothelial cells; ECM, 
extracellular matrix; FA, focal adhesions; FAK, focal adhesion kinase; MHC, myosin heavy chain; NFAT, nuclear factor of activated 
T cell; NS., not specified; SAC, stretch-activated ion channels; VSMC, vascular smooth muscle cells.
to the channel pore (17).  An exception to this rule is TRPP1 (also known as polycystin-1), which 
contains 11 transmembrane domains of which the C-terminal 6 transmembrane domains are highly 
homologous to TRP-like channel domains. In contrast to the other TRP-family members, TRPP1 
does not contain a functional channel domain and it is therefore a point of debate whether TRPP1 
is a bona fide TRP channel (18). The N- and C-terminal ends of TRP channels are cytoplasmic and 
comprise a large variety of additional functional domains, such as domains that mediate protein-
protein interactions as well as domains that exhibit a specific enzymatic activity. In addition, TRP 
cytoplasmic domains play a role in multimerization. Functional channels are formed by homo- or 
heteromerization of TRP channel subunits, usually in a tetrameric organization, and the specific 
composition of these multimeric channels determines their characteristics (17).
TRP channels play an essential role in the perception of sensory information, such as temperature 
sensing, smell and taste (19). The role of TRP channels in mechanotransduction has been appreciated 
for about a decade (20) but for most TRP channels it remains unclear whether they are directly 
gated by mechanical stress or act downstream of mechanically activated signaling cascades (21). 
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Several mechanisms that lead to TRP channel activation in response to mechanical stimulation 
have been described. First of all, channel opening can be induced by stretch-induced membrane 
tension (22). Secondly, TRP channels associated with the cytoskeleton may be opened in response 
to actomyosin-induced tension (23). Thirdly, mechanosensitive proteins in complex with TRP 
channels may affect channel opening (23). For instance, force exerted on integrin-containing 
adhesion sites will lead to increased actomyosin tension, which in turn may induce channel opening. 
Finally, mechanically activated receptors, such as the angiotensin II receptor (24) and the bradykinin 
receptor (25) can trigger TRP channel opening through the activation of second messenger 
signaling cascades (26, 27). Alternatively, force-induced stretch can increase plasma membrane 
expression of TRP channels by promoting the translocation of vesicle-stored TRP channels (28).
TRP channels form large macromolecular complexes linked to the actomyosin cytoskeleton which 
may serve to localize signal transduction pathways and/or enhance the rate of signal transmission. 
Such macromolecular complexes were first identified in Drosophila and were termed ‘signalplexes’ 
(29). In mammalian cells, proteomic analyses of TRPC5 and -6 associated molecules identified several 
binding partners involved in cytoskeletal dynamics and endocytosis, including drebrin, a-actinin 
and dynamin (30). It now seems that the interaction with the cytoskeleton within multiprotein 
complexes is a more general feature of this cation channel family (23, 31). Here, we will review 
recent literature on mechanoregulation of cytoskeletal dynamics by TRP channels, describing 
those cellular and biological processes in which TRP channel function has been well-established.
TRP channels in mechanosensing structures 
Cilia
Cilia are microtubule-based, finger-like cell protrusions that can be found on most cell types, 
although best described in epithelial cells and vascular endothelial cells (ECs). Mechanical 
stimulation of cilia elicits local Ca2+ signaling events that affect the motile properties of cilia 
and activate downstream signaling pathways (32, 33). Cilia are divided into cilia that are 
either motile or immotile. Motile cilia are essential in mediating movement of extracellular 
fluids along cell surfaces, such as the removal of mucus from the airways. The ciliary beat 
frequency (CBF), the frequency of ciliary bending which is mediated by dynein-dependent 
sliding of microtubules, and subsequent relaxation, is controlled by both the chemical and 
mechanical characteristics of the fluid (33). Mechanical stimulation of ciliated cells, for example 
by increased mucus load or viscosity, activates Ca2+ influx pathways that in turn, increase 
CBF which is sustained even after Ca2+-influx drops back to basal levels (33). Interestingly 
TRPV4 was shown to be necessary for Ca2+-dependent increases in CBF after exposure to 
increased viscous load in both hamster oviductal cells and mouse ciliated tracheal cells (34, 
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Figure 1. Mechanically triggered TRP channel activation regulates cytoskeletal dynamics. (A) Shear 
stress by fluid flow physically bends primary cilia, which leads to activation of TRP channels. Subsequent Ca2+ 
influx affects VSMC cytoskeletal dynamics by inducing the release of vasodilators such as NO and EDHF. (B 
& C) Shear stress and force applied directly to cell-matrix or cell-cell adhesions locally activate TRP channels 
through their interactions with adhesion molecules, such as integrins. TRP channel-mediated Ca2+ influx affects 
cell-matrix and cell-cell adhesion turnover by regulating cytoskeletal contractility, modulating the activity of FAK 
(cell-matrix) and activating the Ca2+ dependent protease calpain, which cleaves adhesion plaque molecules. (C & 
D) Mechanically activated G-protein coupled receptors (GPCRs), such as the angiotensin II type 1 receptor, can 
trigger TRP channel opening through activation of PLC signaling. Subsequent Ca2+ influx activates the calcineurin/
NFAT pathway, leading to changes in transcription of genes involved in cytoskeletal dynamics. 
60
Chapter 3
35). How increased Ca2+ influx results in increased CBF remains to be elucidated. However, 
it is likely that Ca2+-activated proteins regulate dynein-dependent sliding of microtubules. In 
addition, Ca2+ influx may activate kinases or phosphatases to sustain the elevation in CBF (33).
Immotile or primary cilia function in a wide range of sensory processes, including odorant 
detection, photoreception and mechanosensation (36-38). Primary cilia are sensitive to 
touch, pressure and shear stress exerted by fluid flow. Nauli and colleagues were the first 
to show that TRP channels are required for mechanosensation by primary cilia (Fig. 1A). 
Mouse kidney cells lacking functional TRPP1 or TRPP2, which localize to primary cilia, 
exhibit perturbed Ca2+ responses after stimulation by shear stress (39). TRPP1 and TRPP2 
were shown to act as a heteromeric complex involved in mechanosensing (39, 40). In this 
complex, TRPP1 may function as the mechanosensor, as the N-terminal tail of TRPP1 can be 
stretched when force is applied (41, 42), while Ca2+ influx is mediated by TRPP2. Strikingly, 
mutations in either TRPP1 or TRPP2 were found to be causal for the development of 
autosomal dominant polycystic kidney disease (ADPKD), which is characterized by renal and 
extrarenal cysts. In addition, ADPKD patients, show cardiovascular complications, such as 
hypertension and aneurysms (43). Loss of TRPV4, which also localizes to primary cilia and 
interacts with TRPP2, similarly abolishes shear stress-induced Ca2+ influx in renal epithelial 
cells (44). Additionally, TRPC1, another TRP channel localized to primary cilia, also interacts 
with TRPP2 to form heteromeric channels (45-47). This suggests that TRPP1/TRPP2, TRPC1 
and TRPV4 are part of a heteromeric mechanosensing channel in primary cilia. How the 
loss of mechanosensing in primary cilia contributes to the development of cysts remains 
unclear. It has been suggested that perception of the direction of flow is required for proper 
cell alignment and hence, tissue morphogenesis (48).
Cell adhesion structures
Integrin-containing cell-matrix adhesions, such as focal adhesions (FAs), physically and 
functionally link the extracellular matrix (ECM) to the actomyosin cytoskeleton. These 
macromolecular assemblies not only provide anchorage to the cell, but also form large 
signaling hubs that constantly probe the ECM, affecting basic cellular functions such as cell 
proliferation, survival, differentiation and motility. Similarly, cadherin-mediated cell-cell 
adhesion by adherens junctions (AJs) and desmosomes not only maintain tissue polarity and 
integrity but also steer cellular processes involved in tissue morphogenesis (49). Importantly, 
the formation, maturation and turnover of both cell-matrix and cell-cell adhesions are 
determined by the mechanical forces perceived by the structure itself (2, 3, 50, 51). 
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For instance, cells grow larger and more stable FAs on rigid substrates in comparison to more 
pliable substrates, which show irregular and highly dynamic FAs (52). In addition, increased 
substrate rigidity, sensed through FAs, enhances cytoskeletal contractility and increases 
stress fiber formation (53). Likewise, force generated by the actomyosin cytoskeleton is 
required for formation and remodeling of endothelial hormone-induced cadherin-mediated 
adhesions (54).
Local Ca2+ signaling plays an essential role in regulating cell adhesion dynamics. For 
instance, the disassembly of FAs in the rear of migrating cells is achieved by actomyosin-
based contraction, which involves phosphorylation of the myosin regulatory light-chain 
(MLC) by the Ca2+-dependent MLC kinase (55). In addition, cleavage of FA proteins such 
as talin, vinculin and FAK by the Ca2+-dependent protease calpain plays an important role 
in FA disassembly allowing the rear end of the cell to retract (55). Moreover, residency of 
focal adhesion kinase (FAK), an essential protein in FA turnover, is enhanced by Ca2+ (56).
Recently, local transient Ca2+ signals were found at the leading edge of migrating fibroblasts. 
These ‘Ca2+ flickers’ are mediated by shear stress-activated TRPM7 and are required for 
chemotactic turning of the leading edge (57). This suggests that, in addition to regulating FA 
disassembly at the rear end of cells, local Ca2+ signaling events, mediated by TRP channels, 
also affect adhesion turnover at the leading edge (57). Consistent with such a model, a 
number of different TRP channels localize to FAs and regulate FA dynamics in the response 
of ECs to shear stress or in cell migration (Fig. 1B) (see below).
TRPP1, which is frequently mutated in ADPKD, localizes to FAs and associates with FA 
components such as FAK, paxillin and vinculin (43). Interestingly, TRPP1 appears to be involved 
in regulating FA-dynamics as phosphorylation of FAK and paxillin and the formation of adhesion 
complexes are enhanced by expression of the TRPP1 C-terminus (58). Moreover, cells 
carrying a mutation in TRPP1 (an epithelial cell clone derived from an ADPKD-patient), show 
a reduction in activated FAK levels leading to larger FAs (59). Furthermore, the extracellular 
N-terminus of TRPP1 binds several ECM components, indicating force sensing by TRPP1 
is mediated via its interaction with the ECM (60). Because of the suggested formation of a 
mechanosensing complex with TRPP2 (see above) (39, 40), TRPP1 may exert its effects on 
FAs in cooperation with TRPP2. Taken together, a FA-associated TRPP1/TRPP2 complex 
may function to sense forces exerted on the extracellular matrix to affect FA dynamics and 
the cytoskeleton.
Similar to FA dynamics, Ca2+-dependent actomyosin contraction as well as Ca2+-mediated 
activation of calpain are involved in AJ disassembly (61). Interestingly, in addition to regulating 
FA turnover, several TRP channels are also implicated in regulating AJ dynamics (Fig. 1C). 
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The TRPP1/TRPP2 complex (62, 63), TRPV4 (64) and TRPC4 (65) all co-localize and co-
immunoprecipate with E-cadherin and b-catenin. In a wound-healing assay using an epithelial 
monolayer, TRPP1 overexpression induced increased reabsorption of AJ components at 
the migrating front. This resulted in induction of single cell migration, probably caused by 
TRPP1-induced AJ disassembly (66). TRPC4 is involved in Ca2+-mediated inflammation-induced 
increases in vascular permeability (67) and its localization to AJs (65) suggests it could also 
be involved in shear stress induced AJ disassembly. On the other hand, TRPV4 appears to 
be involved in Ca2+-dependent assembly of cell-cell adhesions in multilayered keratinocytes. 
This discrepancy is not well understood, but may be explained by differences in AJ barrier 
structure between mono- and multilayered cells (64).
TRP channels in mechano-regulated biological processes
Migration
Directed cell migration is not only a driving force during embryonic development, but also 
immunity and wound healing completely rely on the ability of cells to migrate towards 
chemical or mechanical gradients (68, 69). The inability of cells to migrate properly will 
lead to defects in aforementioned processes, resulting in, for instance, malformations in the 
growing embryo (70). To the converse, cancer cells may aberrantly switch on an embryonic 
migratory program, to enable metastasis from the primary tumor to distant sites. 
Cell migration is a dynamic multistep process, comprising the formation and adhesion 
of protrusions at the front of the cell, generation of traction forces and the release of cell 
adhesions at the cell rear (71). Migration efficiency critically depends on spatial and temporal 
regulation of adhesion dynamics (2) and there is increasing evidence for a role of localized 
Ca2+ signaling in this regulation (72). For instance, calcium release-activated calcium channel 
protein 1 (ORAI1) and stromal interaction molecule 1 (STIM1), channels implicated in store-
operated Ca2+ entry, were shown to be important determinants of tumor cell migration and 
metastasis (12). Similarly, the activity of a number of TRP channels has been linked to (tumor) 
cell migration. Activation of TRPV1 (73), TRPV2 (74, 75), TRPV3 (76), TRPV4 (77), TRPM7 
(57, 78) and TRPM8 (79, 80) were shown to enhance cell migration. In addition, TRPC1 
is recruited to the leading edge of EGF-induced migrating glioma cells while inhibition of 
TRPC1 leads to inhibition of chemotaxis (81). To date, at least two different TRP channels, 
TRPC1 and TRPC6, were shown to act in association with ORAI1 to mediate Ca2+ influx 
in neutrophils (82). ORAI1 was shown to mediate shear stress-induced Ca2+ transients 
that affect cytoskeletal dynamics and cell polarization during transendothelial migration of 
neutrophils (83, 84). As loss of TRPC6 in neutrophils strongly reduced chemokine-induced 
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migration (85), this may suggest that TRPC1, TRPC6 and ORAI1 cooperate in mediating 
transendothelial migration of neutrophils under shear stress. In most of these studies, 
however, TRP channels were activated in response to chemotactic factors, rather than in 
response to mechanical stimulation.
In a recent report by Wei and colleagues, shear stress was found to elicit ‘Ca2+ flickers’ at 
the leading edge of migrating fibroblasts. Knockdown of TRPM7 abolished these mechanically 
triggered local Ca2+ signaling events while cell polarization and migratory properties were 
strongly reduced. (57). Hence, TRPM7-mediated Ca2+ flickers may influence adhesion dynamics, 
for instance by activating the Ca2+-dependent protease calpain, to modulate the turnover of 
adhesion structures (86). In addition, we previously showed that TRPM7 modulates adhesion 
dynamics by affecting actomyosin-based contractility (87). How mechanical stimulation 
leads to activation of TRPM7 remains unclear. It was shown in vascular smooth muscle cells 
(VSMCs) that TRPM7 accumulates at the plasma membrane in response to shear stress which 
coincides with increased TRPM7 mediated currents (28). Shear stress-mediated activation 
of TRPM7 may also involve G-protein coupled receptors such as the bradykinin receptor, a 
known activator of TRPM7 (Fig. 1D) (87, 88). Interestingly, this ligand-operated receptor 
can also be activated by mechanical stimuli in the absence of bradykinin (25). Together, these 
results suggest that TRPM7 can be mechanically activated. To determine how TRPM7, and 
other TRP channels, exert their effects on cell migration, it will be crucial to identify the 
downstream effectors of these cation channels.
Axonal outgrowth
Axon pathfinding and elongation are essential for synapse formation and maintenance of 
neuronal communication during embryonic development and in the adult. The neuronal 
growth cone, a highly dynamic fan-shaped structure at the distal tip of the axon, is responsible 
for the interpretation of environmental cues and the subsequent remodeling of the axon. 
Lamellipodia and filopodia extend from the growth cone periphery to sample the local 
environment for guidance cues and guide axonal elongation (89). Environmentally induced 
Ca2+ signaling events modulate cytoskeletal dynamics in the growth cone and thereby steer 
growth cone turning and axon extension (90-92). The role of Ca2+-permeable TRP channels 
in axon remodeling in response to chemical cues has been extensively studied (16, 93). TRPC 
channels are required for neuronal growth cone remodeling in response to neurotrophins and 
chemoattractants such as brain derived nerve factor (BDNF), bone morphogenic proteins 
(BMP) and Netrin-1 (94, 95). For instance, TRPC1 Ca2+ conductance controls the directional 
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response of growth cones to BMP7 gradients, through the asymmetric activation of the 
actin depolymerizer ADF/cofilin (96).
In addition to chemical guidance cues, both growth cone turning and the actual axon 
elongation are subject to mechanical stimulation (97). Moreover, mechanical tension has 
been recognized as a major stimulus for axonal elongation. Traction forces on cell-matrix 
interactions within the axon growth cones, are generated by extension of the microtubule 
network and myosin driven retrograde flow of actin polymers (98-100). Additionally, axons 
are subjected to externally applied tensile forces after synapse formation, due to the increase 
in body size of the growing animal that causes stretching of the axon (101, 102).
In general, the application of mechanical stress enhances axonal elongation (97). Consistent 
with this notion, TRPV2 has been implicated in membrane stretch-evoked responses during 
axon outgrowth (103). TRPV2, which is best known as a heat activated channel (104), is 
expressed by developing motor neurons and localizes to both growth cones and axon shafts. 
It was shown that membrane stretch can induce a TRPV2-mediated Ca2+ influx to enhance 
axonal elongation. Interestingly, overexpression of a TRPV2 dominant-negative mutant strongly 
inhibited the increase in intracellular [Ca2+] in response to membrane stretch, suggesting that 
TRPV2 is essential for mechanically-induced axon elongation. Membrane stretch similarly 
induces TRPV2-mediated Ca2+ influx in smooth muscle cells (105). In both of these cases, it 
is unclear whether TRPV2 is intrinsically sensitive to mechanical stimulation or is activated 
through its interactions with the cytoskeleton (105, 106). Furthermore, how TRPV2 exerts 
its cytoskeletal effects in response to activation remains to be determined. Based on recent 
literature, TRPV2 activation possibly affects neurite outgrowth via calmodulin-mediated 
activation of LIM kinases, which regulate actin polymerization through phosphorylation and 
inactivation of the actin depolymerizing factor cofilin (107, 108). In line with this hypothesis, 
both Ca2+/calmodulin-dependent kinases (CaMKs) and LIM kinase activation were shown to 
be essential for Ca2+-induced actin filament assembly during neurite extension (108, 109).
Although mechanical stimulation of TRPV2 clearly enhances axonal elongation, the role 
of mechanically induced Ca2+ signaling events in shaping axons is less straightforward. For 
instance, Ca2+ influx, mediated by stretch activated ion channels (SACs), can also inhibit 
neurite outgrowth (50, 91, 92, 110). A potential explanation for this apparent paradox is 
that Ca2+-mediated cytoskeletal responses, as they occur during axon pathfinding, are highly 
dependent on the spatiotemporal characteristics of these Ca2+ signals (111). In support of this 
notion, the activity of CaMKs, was shown to be dependent on both amplitude and frequency 
of Ca2+ signaling events (112). In conclusion, the specific effects of mechanically regulated 
(TRP) channels on axonal outgrowth are dictated by their gating properties, subcellular 
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localization and the specific cytoskeletal assemblies associated with the channels. It will be 
a formidable challenge to fully understand how these complex signaling networks cooperate 
during axon guidance.
Nociception
The sensation of pain involves activation of ion channels by noxious stimuli such as heat 
or pressure. Ion channel activation in so-called nociceptors, specialized sensory neurons, 
triggers action potentials that transduce the pain signal from the peripheral sensory site to 
the synapse in the central nervous system (113). TRP channels, of which TRPA1 and TRPV1 
are best characterized, play an essential role in the perception and transduction of pain signals 
(nociception) (114). In addition, TRPV3, TRPV4 and TRPM8 are implicated in nociception, 
although their role has been less well studied (114). Moreover, perturbed channel function 
contributes to neuropathic pain (115). In response to continued inflammation or nerve damage, 
TRP channels can become either sensitized and consequently responsive to non-noxious 
stimuli, e.g. the sensation of a warm shower on badly sunburned skin or muscle soreness 
after exercise, or hyper-responsive to noxious stimuli, a state known as hyperalgesia.
TRPA1 may also be involved in mechanical hyperalgesia, as a TRPA1 antagonist was able 
to reduce sensitivity to mechanical hyperalgesia (116-118). TRPA1 probably induces pain 
sensation via the release of neuropeptides such as substance P and calcitonin gene-related 
peptide (119). If and how TRPA1 affects cytoskeletal dynamics is currently unknown, but it is 
clear that cytoskeletal changes can affect pain sensation. Microtubule-stabilizing anti-cancer 
drugs, such as Taxol induce severe neuropathic pain (120), while microtubule destabilizing 
agents, such as Nocodazole, reduce pain sensation (121). Both TRPV1 and TRPV4 are known 
to modulate microtubule assembly and disassembly upon activation by noxious stimuli. TRPV1 
has been recognized as a heat sensitive cation channel that is predominantly expressed by 
nociceptors (122). Interestingly, inflammatory agents, such as bradykinin and prostaglandins, 
can reduce the heat activation threshold of TRPV1 and cause thermal hyperalgesia (reviewed 
in (115)). Originally, TRPV1 was not recognized as a transducer of mechanical hyperalgesia 
as complete Freud’s adjuvant-induced mechanical hyperalgesia was similar in TRPV1-/- mice 
compared to wildtype mice (123). However, recent studies have shown an involvement 
of TRPV1 in mechanical hyperalgesia. For instance, mechanical hyperalgesia in exercised 
muscle can be suppressed by TRPV1 antogonists (124). Additionally, TRPV1 is required for 
the mechanosensitivity of mouse colon afferent fibers (125).
The mechanosensitive TRPV4 channel contributes to the perception of mechanically 
induced pain and mechanical hyperalgesia (126, 127). Mice lacking the TRPV4 gene show an 
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increase in mechanical nociceptive threshold (128). Moreover, TRPV4 is essential in Taxol-
induced mechanical hyperalgesia (126). TRPV4 is found to reside within a mechanosensing 
complex that localizes to growth cone filopodia and lamellipodia (129). In contrast to stretch 
activated Ca2+ channels, TRPV4 is not gated directly by mechanical forces, but is activated by 
mechanical stress through its interaction with integrin a2b1 and SRC tyrosine kinase (130). It 
was recently suggested that TRPC6 may cooperate in this TRPV4/integrin/SRC complex to 
mediate mechanosensory signaling, as RNAi oligos against TRPC6 blocked TRPV4-mediated 
hyperalgesia (131). 
While inactive TRPV1 and TRPV4 stabilize the microtubule network, their activation 
induces rapid disassembly of microtubules (129, 132). This is somewhat paradoxal since 
TRPV4 activity is required for the neuropathic effect of microtubule stabilizers such as 
Taxol (120, 126). Although both channels directly interact with microtubules through their 
C-terminals tails (129, 132), the precise mechanism by which TRPV1 and TRPV4 activation 
affect the microtubule network is unknown. Moreover, TRPV4 channel opening may, in turn, 
be modulated by microtubule and actin cytoskeletal integrity (128, 129). These complex 
reciprocal interactions between nociceptive TRP channels and cytoskeletal dynamics are likely 
at the root of neuropathic pain caused by inflammatory agents and microtubule stabilizing 
chemotherapeutic agents.
Cardiovascular homeostasis
During exercise, components of the cardiovascular system respond to increased metabolic 
demands of active skeletal muscles, i.e. cardiac output increases and blood flow from inactive 
organs and tissues must be redistributed to active skeletal muscles. In addition to these short-
term responses, the cardiovascular system undergoes structural adaptations in response to 
sustained alterations in metabolic demands, for instance after regular exercise. In case of 
hypertension, heart remodeling becomes pathological as a result of a chronically increased 
mechanical load (133).
The three cell types involved in the cardiovascular response to changing metabolic demands 
are 1) ECs that regulate VSMCs contraction and barrier function in response to changes in 
blood flow; 2) VSMCs that mediate vasoconstriction in response to changes in intraluminal 
pressure and 3) cardiac myocytes, striated muscle cells that generate cardiac output. These 
cellular responses are triggered by Ca2+ signaling events that translate environmental 
information, including mechanical cues, into cytoskeletal responses. Mechanosensitive TRP 
channels are therefore considered key regulators of vascular function (134, 135). Consistent 
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with this notion, perturbed TRP channel function has been associated with cardiovascular 
pathologies such as hypertension and pathologic cardiac hypertrophy (135-138).
TRP channels in endothelial cells - ECs lining the blood vessels not only function as a barrier, 
but are also regulators of angiogenesis, coagulation, inflammation and VSMC contractility. 
Since ECs are in direct contact with the circulating blood, they fulfill an essential role in 
sensing changes in blood flow. ECs induce VSMC relaxation in response to increased shear 
stress by Ca2+-dependent release of vasodilators, such as nitric oxide (NO) (139), and by 
inducing hyperpolarization of the VSMC plasma membrane. Shear stress will additionally 
trigger Ca2+-mediated EC elongation and alignment in the direction of flow to reduce the 
effect of shear stress (140-142). Initially, shear stress induces Ca2+-dependent cell elongation 
and the dissolution of cell adhesions (142, 143). Later, cells will adjust to shear stress by 
the formation of thick stress fibers and reestablishment of cell adhesions, aligned in the 
direction of flow (142, 143).
Several TRP channels regulate EC function (135, 136). TRP channels in ECs are activated 
by vasoactive agents like histamine, bradykinin as well as by mechanical cues (144). TRPP1/
TRPP2, TRPV4 and TRPC1 contribute indirectly to vasodilatation in response to changes 
in shear stress by modulating VSMC contractility (39, 145-148). Upon activation, Ca2+ influx 
induces vasodilatation by enhancing the production and release of vasodilating molecules, 
such as NO and endothelium-derived hyperpolarizing factor (EDHF). Additionally, increased 
Ca2+ influx leads to hyperpolarization of the endothelial plasma membrane through the 
activation of Ca2+-sensitive K+ channels. Connected via myoendothelial gapjunctions, the 
underlying VSMCs become hyperpolarized which affects their contractility (149). TRPV4-
/- mice show impaired vasodilatation in response to TRPV4 agonists or shear stress (148). 
TRPC1 has recently been shown to interact and cooperate with TRPV4 in mediating shear 
stress-induced Ca2+ influx (147). In addition, mechanical stimulation of the TRPP1/TRPP2 
complex in primary cilia of endothelial cells triggers the release of NO (40, 145, 146, 150, 
151). This may also in part explain the increased risk of hypertension in ADPKD patients, 
since a proper response to increased shear stress is lacking (151). These data also add 
up to the possibility that TRPP1/TRPP2, TRPC1 and TRPV4 are part of a heteromeric 
mechanosensing complex.
Stretch activated TRPV4 channels present at the basal membrane of ECs have been 
implicated in mediating endothelial elongation and realignment in response to changes in 
blood flow (152). In addition, TRPV4 may associate with b1-integrins in EC FAs since local 
mechanical stimulation of b1-integrins leads to a very rapid (~4 ms), TRPV4-mediated Ca
2+ 
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influx (130, 153). These Ca2+ signals activate the small GTPase RhoA and its target ROCK, 
resulting in the realignment of FAs and stress fibers. Thus, shear stress may generate tension 
through stress fibers on cell-matrix adhesions at the basal membrane, leading to local 
initiation of TRPV4-mediated cytoskeletal remodeling (152, 154). A similar response has 
also been observed in HUVECs, where a transient force applied directly to FA-anchored 
actin filaments resulted in activation of mechanosensitive channels near FAs and subsequent 
disassembly of FAs (155, 156). In conclusion, mechanosensitive TRP channels localized to 
EC FAs likely regulate Ca2+-dependent cytoskeletal remodeling in response shear stress.
TRP channels in vascular smooth muscle cells - VSMCs regulate vascular tone by Ca2+-dependent 
cytoskeletal relaxation or contraction. While relaxation in response to shear stress is mediated 
indirectly by ECs (see above), changes in blood pressure are perceived by VSMCs themselves 
(157). TRP channels are known to be directly involved in translating fluctuations of vascular 
wall pressure into VSMC cytoskeletal contractility, to counteract these forces (134, 136).
TRPP1 and TRPP2 in VSMCs act by modulating SACs that regulate cytoskeletal contractility. 
In contrast to their complementary activities in endothelial primary cilia (see above), TRPP1 
positively regulates SAC activation while TRPP2 overexpression inhibits SAC activation in 
response to stress. In turn, TRPP1 co-expression can reverse the inhibitory effect of TRPP2 
(158). Hence, the TRPP1/TRPP2 ratio is considered to regulate SAC sensitivity to pressure 
on the vascular wall. How does this work mechanistically? Cortical actin filaments decrease 
stretch-induced membrane tension, and thereby reduce SAC sensitivity to mechanical stimuli 
(159). Since TRPP2 directly interacts with the actin crosslinker filamin A, TRPP2 may inhibit 
mechanosensitivity of VSMCs by stabilizing actin filaments at the cell cortex. The interaction 
with TRPP1 would reverse the inhibitory effect of TRPP2 on SAC regulation, by preventing 
the interaction between TRPP2 and filamin A (158).
TRP channels in cardiac myocytes - Cardiac hypertrophy, the pathological response of the heart 
to sustained hypertension, involves a disproportionate growth of cardiac myocytes. This 
physical adaptation coincides with the re-activation of a fetal gene transcription program that 
includes a shift from the expression of a-myosin heavy chain (a-MHC) towards b-myosin 
heavy chain (b-MHC) and expression of skeletal a-actin, thereby altering the contractile 
properties of the heart (133, 160, 161). Pathological remodeling of the heart involves Ca2+-
dependent activation of the calcineurin/NFAT pathway, and since TRPC channels activate 
this pathway in cardiac myocytes, these channels are considered essential players in the 
pathogenesis of cardiac hypertrophy (162-165).
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All TRPC channels, except for TRPC2, are expressed in cardiac myocytes (166). Moreover, 
cardiac hypertrophy is associated with increased expression levels of TRPC1, -3, -5 and 
-6 (166). Cardiac TRPC channels are indirectly gated by mechanical stress through the 
activation of angiotensin II type 1 receptor (AT1R), a G-protein coupled receptor (Fig. 1D). 
Mechanically induced conformational changes in AT1R can initiate downstream signaling which 
involves PIP2 hydrolysis into DAG and IP3. The produced DAG can activate TRPC3, -6 and 
-7 (167, 168). TRPC1, -4 and -5, however, are unresponsive to DAG, but can be activated by 
G-protein coupled receptors, suggesting they might be activated downstream of IP3 signaling 
(168). Additionally, overexpression of AT1R in aortic smooth muscle cells renders TRPC6 
channel opening responsive to mechanical force (27).
Direct effects of TRPC channel activation on the cardiac myocyte cytoskeleton have 
not been described to date. However, several lines of evidence indicate that cardiac TRPC 
channels modulate transcription of cytoskeletal associated genes via the calcineurin/NFAT 
pathway. For instance, overexpression of both TRPC3 and TRPC6 results in activation of 
the calcineurin/NFAT pathway, correlating with increased skeletal a-actin and b-MHC 
expression, respectively (162, 169). Secondly, DAG-activated TRPC3 and TRPC6 were shown 
to be essential for NFAT-mediated pathological remodeling of the heart (170) while loss of 
TRPC1 expression protected mice from mechanical stress-induced cardiac hypertrophy by 
preventing calcineurin/NFAT signaling (164). Thirdly, deletion of calcineurin Ab prevented 
cardiac hypertrophy by TRPC3 overexpression (171). Finally, TRPC3 and TRPC6 are targets 
of NFAT in pathological growth and remodeling of mouse hearts (162, 169), indicating a 
regulatory feedback loop that drives cardiac hypertrophy in response to chronic pressure 
overload in the heart. 
Cardiac myocytes are constantly exposed to Ca2+ transients that initiate cardiac muscle 
contraction. It may therefore seem paradoxal that Ca2+ signaling through TRPC channels can 
lead to activation of a pathological gene transcription program via calcineurin/NFAT signaling. 
However, it is becoming evident that the spatiotemporal characteristics of mechanical stimuli 
as well as the frequency and spatial characteristics of the resultant Ca2+ signals determine 
activation of specific downstream signaling events (172).
Glomerular filtration
Podocytes, highly differentiated epithelial cells, play an essential role in ultrafiltration of 
plasma that passes through the endothelium of the glomerular capillaries. Podocytes consist 
of a cell body and actin-rich protrusions, known as foot processes, which wrap around the 
glomerular capillaries and attach to the glomerular basement membrane through focal 
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contacts. Foot processes from neighboring cells organize into a highly branched interdigitating, 
zipper-like network, bridged by multimolecular complexes that form the slit diaphragm, a 
highly specialized type of AJs. These AJs form a barrier that functions as a glomerular filter, 
allowing passage of small molecules, but inhibiting passage of large plasma proteins into the 
urinary space (173). 
Podocytes are constantly exposed to mechanical stress, generated by blood pressure in 
the glomerular capillaries, as well as shear stress resulting from fluid flow through the slit 
diaphragm and over the apical membrane of the podocyte. Ca2+-dependent remodeling of 
the actin cytoskeleton in response to mechanical load is essential to counteract these forces 
(174, 175). First of all, contractile forces generated by podocytes counteract capillary wall 
distension and prevent glomerular damage due to increased capillary pressure (176, 177). In 
addition, dynamic remodeling of focal contacts and AJs in response to increased fluid flow 
are also required to maintain the glomerular filtration barrier (173). Consistently, several 
mutations in key podocyte proteins that affect the organization and dynamic regulation of 
the highly specialized cytoskeleton in foot processes, such as nephrin, podocin, ACTN4 and 
CD2AP, contribute to loss of glomerular barrier function and consequently, progressive 
kidney failure. Gain-of-function mutations and increased expression of TRPC6 were shown 
to underlie focal and segmental glomerulosclerosis (FSGS) and progressive kidney failure 
(178-180). However, the precise mechanism by which TRPC6 affects podocyte function is 
unclear.
TRPC6 is part of the slit diaphragm multiprotein complex and associates with nephrin 
and podocin (179). Together, these proteins are suggested to function as a mechanosensing 
complex that triggers Ca2+ influx through the TRPC6 channel, in response to plasma membrane 
stretch at the insertion site of the slit diaphragm (181, 182). However, it is unclear whether 
TRPC6 in podocytes is intrinsically mechanosensitive since the stress induced activation of 
TRPC6 in podocytes depends on activation of AT1R (26, 27)(reviewed in (183). Interestingly, 
mechanical load is known to activate the angiotensin system in the kidney and induce 
protein expression of AT1R in podocytes (184). In CHO cells, however, TRPC6 could be 
activated by mechanical stress in the presence of an inhibitor phospholipase C (PLC), which 
is downstream of G-protein receptor activation (185). Hence, the requirement of G-protein 
receptor activation may be cell-type specific.
Similar to the role of TRPC channels in guiding neuronal growth cone outgrowth 
(186), Ca2+ influx through TRPC6 may regulate Ca2+-dependent cytoskeletal components. 
Although downstream targets of TRPC6-mediated Ca2+ influx remain to be identified, the 
close association of TRPC6 and the actomyosin cytoskeleton is apparent from pull-down 
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experiments, revealing a TRPC6 signalplex. This complex contains several cytoskeletal proteins 
such as actin, myosin, a-actinin and drebrin (30). Hypothetically, TRPC6 mediates its effect 
on the cytoskeleton through activation of the Ca2+-dependent phosphatase calcineurin (162). 
Increased TRPC6 channel activity results in cytoskeletal rearrangements, characterized by 
a loss of actin stress fibers (178). Interestingly, calcineurin is known to dephosphorylate 
and destabilize synaptopodin, a scaffolding protein required for stress-fiber formation (187, 
188). Thus, TRPC6-induced Ca2+ influx may render podocytes unable to respond properly 
to mechanical cues through calcineurin-mediated dissolution of actin fibers.
Additionally, TRPC6 Ca2+ influx was shown to modulate gene expression, through the 
calcineurin/NFAT pathway (162, 189, 190). Consistently, conditional activation of NFATc1 
in a murine model resulted in proteinuria and glomerulosclerosis, although transcriptional 
targets that directly affect cytoskeletal organization and slit diaphragm formation were not 
identified (189). By analogy to cardiac myocytes, angiotensin was shown to induce TRPC6 
expression in podocytes by activation of the calcineurin/NFAT pathway in a TRPC6 dependent 
manner, resulting in proteinuria in mice (191). Together these results suggest that, similar 
to the cardiovascular system, activation of the calcineurin/NFAT pathway downstream of 
TRP channel activation, acts to sustain cytoskeletal responses in glomerular foot processes.
Concluding remarks
In addition to their well-established role as sensors of heat, taste and light, TRP channels 
are considered important sensors of mechanical cues in many different organ systems. 
Consistent with this notion, perturbed TRP channel function in mechano-regulated processes 
contributes to a variety of pathologies. However, in most mechanically regulated processes, 
it remains to be established whether TRP channels act as the primary mechanosensor. 
Activation of TRP channels initiates short-term and long-term cytoskeletal adaptations to 
changes in mechanical load. Direct regulation of cytoskeletal dynamics include the activation 
of cytoskeletal remodelers, such as calpain or MLCK, or the secretion of soluble compounds, 
such as NO, that manipulate cytoskeletal organization of neighboring cells. TRP channel-
induced Ca2+ signaling may additionally regulate cytoskeletal gene expression by activation 
of Ca2+-dependent transcription factors, such as NFAT. Although transcriptional regulation 
by TRP channels has mostly been established for mechanically activated TRPC channels, it 
raises the possibility that this is a more general feature of TRP channels.
In most mechanosensory processes, the direct downstream targets of TRP channel 
signaling remain elusive. Since TRP channels generally organize into multiprotein signalplexes, 
knowing the precise composition of these cytoskeletal complexes will provide important 
72
Chapter 3
clues on how these ion channels affect cell behavior in response to mechanical cues. In 
addition, more insight is needed into what determines the spatiotemporal characteristics 
of the Ca2+ signal. These properties may be determined by heteromerization of different 
TRP channel subunits, or association with other calcium channels, such as ORAI and STIM. 
Establishing the exact roles of these mechano-complexes will improve our understanding 
of pathologies in which physical properties of the environment are altered, such as during 
cancer, atherosclerosis and hypertension.
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Abstract
TRPM7 encodes a Ca2+-permeable non-selective cation channel with kinase activity. TRPM7 
has been implicated in control of cell adhesion and migration, but whether TRPM7 activity 
contributes to cancer progression has not been established. Here we report that high levels 
of TRPM7 expression independently predict poor outcome in breast cancer patients and that 
it is functionally required for metastasis formation in a mouse xenograft model of human 
breast cancer. Mechanistic investigation revealed that TRPM7 regulated myosin II-based 
cellular tension, thereby modifying focal adhesion number, cell-cell adhesion and polarized 
cell movement. Our findings therefore suggest that TRPM7 is part of a mechanosensory 
complex adopted by cancer cells to drive metastasis formation.
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Introduction
Metastasis formation is a complicated multi-step process involving tumor cell dissemination 
from the primary tumor, matrix invasion, entry into the circulatory system, extravasation 
through capillary endothelium, and finally the outgrowth of secondary tumors in distant 
organs. Each of these events requires extensive and continuous Ca2+-dependent remodeling 
of the actomyosin cytoskeleton as well as close interactions with the cell’s surroundings, 
mediated by dynamic adhesive structures such as focal adhesions and adherens junctions. 
These specialized cell adhesion sites convey mechanical cues across the plasma membrane, 
affecting both the physical properties of their surroundings as well as intracellular cytoskeletal 
dynamics. As the formation and maturation of focal adhesions and adherens junctions is 
dependent on the applied mechanical forces, these structures are considered to function as 
mechanosensors that integrate mechanical cues from inside and outside the cell (1-5). The 
complex protein-protein interactions within these adhesion sites significantly contribute 
to tumor progression and metastasis formation. Hence, proteins that regulate adhesion 
formation or turnover represent interesting therapeutic targets to limit the metastatic 
potential of cancer cells (6).
Members of the mammalian Transient Receptor Potential (TRP) cation channel family 
are considered key players in mechanosensory signaling (7-11). TRP channels organize into 
large macromolecular complexes linked to the actomyosin cytoskeleton, which may serve 
to localize signal transduction pathways and/or enhance the rate of signal transmission (7, 
12, 13). Tethered to the cytoskeleton, their ion conducting properties can be modulated 
by different stimuli, including mechanical cues, resulting in a variety of cellular responses. In 
earlier work, we and others identified TRPM7, a Ca2+-permeable non-selective cation channel 
with kinase activity, as a regulator of actomyosin contractility, cell adhesion, and directed cell 
migration (14-16). However, a role for this bifunctional channel in cancer progression has not 
been examined. Here we show that high TRPM7 expression, at the time of diagnosis, predicts 
poor therapy outcome in a large cohort of breast cancer patients. Moreover, TRPM7 is a 
critical determinant of breast cancer cell migration in vitro and metastasis formation in vivo.
Results and discussion
TRPM7 mRNA expression levels in primary tumors are associated with breast cancer progression 
and metastasis formation, independent from standard clinical parameters
Immunohistochemistry on primary breast cancer tissue samples showed that TRPM7 
protein is expressed by epithelial cells that align mammary glands and by breast tumor 
cells. Perinuclear staining of breast carcinoma cells was observed with accentuation of the 
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nuclear membrane, with or without diffuse staining of the cytoplasm (Fig. 1A). We explored 
the prognostic value of TRPM7 mRNA levels in breast cancer, using microarray-based gene 
expression data from breast cancer specimens, obtained by resection of the primary tumor 
at diagnosis (discovery cohort; n = 368) (Table S1) (17). After dichotomization based on 
the median TRPM7 expression level, the TRPM7-high group (n = 184) was found to exhibit 
a significantly shorter recurrence-free survival as compared to the TRPM7-low group (n = 
184) (hazard ratio (HR) = 1.42, 95% CI = 1.01 to 2.01, p = 0.042) (Fig. 1B). Even stronger 
was the association of TRPM7 with distant metastasis-free survival interval (HR = 1.85, 95% 
CI = 1.22 to 2.81, p = 0.003) (Fig. 1B).
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Figure 1. TRPM7 is a strong and independent prognostic marker for breast cancer progression 
and metastasis. (A) TRPM7 protein expression in a breast tumor section (brown). Nuclei are counterstained 
with hematoxylin (blue). Top panel: scale bar = 500 mm. Bottom panel: scale bar = 100 mm. Indicated are breast 
tumor cells and stroma. (B) Kaplan-Meier analysis of recurrence-free survival (left) and distant metastasis-free 
survival (right) according to TRPM7 mRNA expression, obtained from microarray analysis on 368 breast cancer 
patients (discovery cohort). TRPM7-low: n = 184, TRPM7-high: n = 184. P-values are based on Log Rank test.
(C) Kaplan-Meier analysis of recurrence-free survival (left) and distant metastasis-free survival (right) according 
to TRPM7 mRNA expression, determined by quantitative real-time PCR measurements on 144 breast cancer 
patients (validation cohort). TRPM7-low: n = 72, TRPM7-high: n = 72. P-values are based on Log Rank test.
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Figure 2. Reduced TRPM7 expression interferes with the metastatic potential of MDA-MB-231 human 
breast cancer cells in vivo. (A) Proliferation and overall viability of control and TRPM7 knockdown MDA-
MB-231 cells, determined by MTS assays. Measurements were performed at different time points, indicated on the 
x-axis. Metabolic activity is expressed as the amount of produced Formazan, determined by photospectrometry, 
and normalized to initial metabolic activity. Data are presented as mean ± SEM of 2 independent experiments 
that were performed in triplicate. (B) Representative bioluminescence images of mice, 7 days after intravenous 
injections with MDA-MB-231 control or TRPM7 shRNA cells. (C) Quantification of bioluminescence in the lung 
region of mice, for up to 30 days after injection. Data are presented as mean ± SEM of n= 5 mice in each group. 
(D) Bioluminescence images of mice taken 30 days after injection. Photon fluxes are to the same scale. Dagger 
in C and D indicates a mouse that had to be euthanized 22 days after injection with control MDA-MB-231 
cells, due to a large tumor in the head region. Bioluminescence image in D was taken at day 21. Subsequent 
quantifications were performed on the 9 remaining mice. (E) Quantification of mean lung tumor size in mice 
injected with MDA-MB-231 control or TRPM7 shRNA cells. Error bars represent SEM for n = 3 mice in each 
group. (F) Quantification of the number of lung tumors per mouse, measured in resected lung tissue from mice 
injected with MDA-MB-231 control or TRPM7 shRNA cells. Error bars represent SEM for n= 3 in each group. 
*** P <0.001. For size distribution, see Fig. S2B. (G) Representative HE staining on lung tissue, collected 30 days 
after injection with MDA-MB-231 control or TRPM7 shRNA cells. Prominent tumors in lung tissue from mice injected 
with TRPM7 shRNA cells (bottom) are indicated by arrows. Scale bar = 1 mm.
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In three additional breast cancer cohorts (n=190, n=244 and n=216), we did not detect a 
significant association of TRPM7 with disease outcome. Discordances between microarray-
based datasets remain a serious problem, often reflecting differences in patient populations, 
probe selection, and mRNA abundance. We therefore sought for independent validation by 
performing quantitative real-time PCR (q-PCR) experiments in a highly similar, independent 
breast cancer patient cohort (validation cohort; n = 144) (Table S1). TRPM7 mRNA expression 
was associated with disease recurrence (HR = 1.88, 95% CI = 1.06 to 3.33, p = 0.029) and 
occurrence of distant metastases. Although the HR was similar as in the discovery cohort, 
the latter association did not reach statistical significance (HR = 1.84, 95% CI = 0.91 to 3.71, 
p = 0.085), possibly due to a lower number of events (Fig. 1C).
A) Recurrence free survival Univariate analysis Multivariate analysis
Parameter Category HR (95% CI) P HR (95% CI) P 
Age >50 vs ≤50 years  0.74 (0.53 to 1.03) 0.07 0.82 (0.54 to 1.24) 0.34
Histological grade 2 & 3 vs. 1 2.23 (1.37 to 3.76) <0.01 1.85 (1.10 to 3.11) 0.02
Lymph node status Positive vs. Negative 1.24 (0.93 to 1.66) 0.15 1.24 (0.79 to1.94) 0.34
Tumor size >2 cm vs ≤2 cm    1.93 (1.41 to 2.63) <0.01 1.71 (1.19 to 2.47) <0.01
Syst. Adj. Treatment Yes vs. No 1.02 (0.75 to 1.37) 0.92 0.85 (0.52 to 1.41) 0.53
Estrogen Receptor Positive vs. Negative 0.65 (0.45 to 0.93) 0.02 0.80 (0.51 to 1.26) 0.34
TRPM7 High vs Low 1.52 (1.13 to 2.03) <0.01 1.52 (1.08 to 2.12) 0.02
B) Distant metastasis free survival Univariate analysis Multivariate analysis
Parameter Category HR (95% CI) P HR (95% CI) P 
Age >50 vs ≤50 years  1.28 (0.80 to 2.05) 0.30 1.19 (0.68 to 2.08) 0.54
Histological grade 2 & 3 vs. 1 2.50 (1.34 to 4.67) <0.01 2.11 (1.12 to 4.00) 0.02
Lymph node status Positive vs. Negative 1.72 (1.21 to 2.43) <0.01 1.45 (0.86 to 2.43) 0.16
Tumor size >2 cm vs ≤2 cm    2.03 (1.40 to 2.96) <0.01 1.70 (1.10 to 2.64) 0.02
Syst. Adj. Treatment Yes vs. No 1.39 (0.95 to 2.04) 0.90 0.86 (0.47 to 1.57) 0.62
Estrogen Receptor Positive vs. Negative 0.91 (0.57 to 1.47) 0.70 0.98 (0.54 to 1.77) 0.94
TRPM7 High vs Low 1.75 (1.19 to 2.58) <0.01 1.69 (1.13 to 2.54) 0.01
Table 1. TRPM7 is a predictor of breast cancer recurrence and metastasis, independent of standard 
clinical parameters. Univariate and multivariate Cox proportional hazards modeling of factors associated with 
recurrence-free survival (A) and distant metastasis-free survival (B) in the combined discovery and validation 
cohorts (n = 512). TRPM7-low: n = 256, TRPM7-high: n = 256. HR = Hazard Ratio; CI = Confidence Interval.
89
TRPM7 is required for breast tumor cell metastasis
We next assessed the association between TRPM7 expression and standard clinical 
parameters using the combined discovery and validation cohorts (n = 512). In support of 
its association with disease progression, TRPM7 was found enriched in high grade primary 
tumors (p = 0.02) (Table S2A). Other prognostic parameters, including tumor size and 
ER-status, were not associated with TRPM7 expression levels and TRPM7 expression was 
similar between breast cancer subtypes (p = 0.28) (Table S2B & C). However, since 
the dominant prognostic feature in all microarray studies of ER-positive breast cancer is 
proliferation, we cannot exclude that TRPM7 is an indirect indicator of proliferation in the 
ER-positive subgroup of tumors.
Figure 3. TRPM7 contributes to the malignant phenotype of MDA-MB-231 breast cancer cells in 
vitro. (A) Representative phase-contrast images of control and TRPM7 shRNA MDA-MB-231 cells. Scale bar 
= 50 µm. (B) Quantification of elongated MDA-MB-231 cells, TRPM7 shRNA cells and TRPM7 shRNA cells 
made to re-express a mouse TRPM7 cDNA (rescued cells). Elongation is presented as percentage (± SEM; 4 
independent experiments, n > 400) of cells that have a length of more than twice the width. *** P < 0.001; ** P 
< 0.01. (C) Quantification of serum induced transwell migration by MDA-MB-231 cells, TRPM7 shRNA cells and 
the rescued cell line. Data, normalized to the number of control MDA-MB-231 cells, are from 5 independent 
experiments, performed in duplicate, in which the rescued cell line was included twice, and represent mean ± 
SEM. Migration was scored after 8 hours. ** P < 0.01; * P < 0.05. (D) Representative trajectories of migrating 
control (n = 10) and TRPM7 shRNA (n = 10) MDA-MB-231 cells, followed for 24 hours. (E) Quantification of 
single cell migration speed. Shown is migration speed (µm / hr, mean ± SEM) of 4 independent experiments, each 
performed in duplicate (n > 200 per cell line). ** P < 0.01.
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Univariate Cox regression analysis indicated that histological grade, tumor size and TRPM7 
expression levels are strong predictors of both disease recurrence and the occurrence of 
distant metastases (Table 1) (p < 0.01). Importantly, multivariate analysis revealed that 
TRPM7 mRNA expression is an independent prognostic marker for both disease recurrence 
(p = 0.02) and occurrence of metastases at distant sites (p = 0.01) (Table 1), after correction 
for standard clinical parameters. While future research must address to what extent TRPM7 
levels indeed have prognostic value, our results indicate a strong and independent association 
between TRPM7 expression levels and breast cancer progression.
TRPM7 knockdown interferes with the metastatic potential, but not proliferation, of invasive, 
triple-negative breast cancer cells in vivo
To establish a causal relation between TRPM7 expression levels and metastasis formation, 
shRNA-mediated knockdown was performed by lentiviral transduction of invasive, triple-
negative MDA-MB-231 breast cancer cells. Knockdown efficiency was about 80%, as 
determined both by q-PCR and by measuring TRPM7 autophosphorylation using an in vitro 
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Figure 4. Reduced TRPM7 expression 
increases cytoskeletal contractility and 
affects focal adhesion dynamics of MDA-
MB-231 cells. (A) Immunofluorescence 
staining of MDA-MB-231 cells with pTyr118 
paxillin antibodies to reveal focal adhesions, 
and Alexa-568 Phalloidin to visualize 
the actin cytoskeleton. Arrows indicate 
enrichment of filamentous actin at the cell 
cortex. Scale bar = 10 µm. (B) Quantification 
of the number of focal adhesions per cell, 
carried out by automated image analyses 
as detailed in material and methods. Data 
are mean ± SEM (n > 100 for control and 
TRPM7 knockdown cells, n = 45 for rescue 
cell line). *** P < 0.001. (C) Immunoblot 
of Triton X-100 insoluble fractions derived 
from MDA-MB-231 control, TRPM7 shRNA 
and rescued cells. Antibodies against pTyr118 
paxillin were used to determine the amount 
of tyrosine phosphorylated paxillin as a 
measure of cytoskeletal contractility and 
focal adhesion content. Antibodies against 
g-tubulin were used to control for loading. 
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Figure 5. TRPM7 knockdown 
reduces migratory properties 
a n d  i n c r e a s e s  ce l l - ce l l 
interactions of MCF7 cells. 
(A) Representative images of gap 
closure assay at time points 0, 12, 18 
and 24 hours. Scale bar = 100 µm. 
(B) Quantification of percentage 
gap remaining after 12, 18 and 24 
hours. Data are from 3 independent 
experiments, each performed in 
duplicate, and represent mean ± 
SEM. * P < 0.05, ** P < 0.01. (C) 
Representative images from MCF7 
control and TRPM7 knockdown 
cells, after 0, 2 and 4 hours of serum 
deprivation. Scale bar = 100 µm. (D) 
Immunofluorescence detection of 
E-cadherin in MCF7 cells to reveal 
adherens junctions, and Alexa-568 
Phalloidin to visualize the actin 
cytoskeleton. Arrows indicate 
enrichment of E-cadherin at cell-
cell interfaces. Scale bar = 10 µm.
kinase assay (Fig. S1A & B). A number of studies has shown that TRPM7 knockdown can 
affect cell viability and proliferation in vitro (18, 19). However, we observed that MDA-MB-231 
TRPM7 shRNA cells proliferated normally and showed no loss in cell viability (Fig. 2A & 
S2A). We next compared in vivo metastasis formation of MDA-MB-231 control and TRPM7 
shRNA cells that were made to express a luciferase reporter gene. Following injection of 
cells in the tail vein of immunodeficient Rag2-/-IL2rg-/- mice, luciferase based non-invasive 
bioluminescence imaging was used to monitor dissemination and growth of tumor cells in 
vivo. Consistent with earlier reports describing this experimental metastasis model (20), 
tumor cells were initially trapped in the lungs, probably due to size restrictions of the mouse 
lung capillaries (Fig. 2B). The progressive increase of the bioluminescent signal in mice 
injected with control cells indicates that these cells effectively developed into pulmonary 
metastases (Fig. 2C). At day 30 after injection, metastatic spread of tumor cells throughout 
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the body was observed in all of the control mice. One mouse had to be taken out of the 
experiment 22 days after injection due to a large tumor mass in the head of the animal 
(Fig. 2D). TRPM7 knockdown led to a strong reduction in bioluminescent signal intensity 
from day 7 onwards, which remained mostly restricted to the lungs (Fig. 2B & C). Similar 
results were obtained from an independent experiment in which an additional TRPM7 
knockdown cell line, derived using a second shRNA, was included (Fig. S1A & B, S2B & 
C). These observations suggest that TRPM7 knockdown impairs the initial establishment 
of tumors in the lung and dissemination to other parts of the body. Quantitative analysis 
of tumor size in hematoxyline-eosine (HE) stained lung sections confirmed that TRPM7 
knockdown did not affect proliferation (mean tumor size, control: 0.045 mm2 ± 0.0047 (n = 
474) vs. TRPM7 shRNA: 0.037 mm2 ± 0.0054 (n = 131), 3 mice per group, p = 0.29) (Fig 2E, 
G & S2D). However, TRPM7 knockdown significantly reduced the number of lung tumors 
per mouse (control: 158.33 ± 11.7 vs. TRPM7 shRNA: 43.67 ± 5.33, 3 mice per group, p < 
0.001) (Fig. 2F & G). Overall, these experiments demonstrate that a reduction of TRPM7 
protein expression effectively interferes with the metastatic potential of invasive human 
breast cancer cells in vivo.
TRPM7 knockdown impairs migratory properties of invasive, triple-negative breast cancer cells in vitro
To examine how TRPM7 may affect the ability of tumor cells to spread to distant sites, 
we studied the consequences of TRPM7 knockdown on cytoskeletal organization and cell 
behavior. Whereas control MDA-MB-231 cells exhibited a characteristic spindle shaped 
(mesenchymal) morphology with actin-rich protrusions at the leading edge, this elongated 
morphology was lost upon TRPM7 knockdown (percentage elongated control cells: 63.3% 
± 2.8% vs. TRPM7 shRNA: 30.0% ± 2.5%, n > 400, 4 independent experiments, p < 0.001) 
(Fig. 3A & B). Moreover, loss of TRPM7 expression effectively interfered with the ability 
of these cells to migrate towards a serum gradient, as determined in a transwell migration 
assay (control: 100% vs. TRPM7 shRNA: 50.56% ± 9.15%, 5 exp, p < 0.01) (Fig. 3C). By 
time-lapse microscopy we observed that TRPM7 knockdown affected cell migration speed, 
resulting in significantly shorter migration trajectories (control: 29.7 ± 2.2 µm/hr vs. TRPM7 
shRNA: 17.2 ± 1.1 µm/hr, n > 200, 4 exp, p < 0.01) (Fig. 3D & E). 
Similar results were obtained with the second TRPM7 knockdown cell line (Fig. S1A & 
B, S3). We additionally re-expressed a mouse TRPM7 cDNA into the TRPM7 knockdown 
cells, which contained one mismatch with respect to the (human-specific) shRNA. We 
confirmed by q-PCR analysis as well as by in vitro kinase assays that expression of TRPM7 was 
restored to about 70% of that in the control cells (Fig. S1C & D). Re-expression of TRPM7 
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was sufficient to rescue the elongated morphology (percentage of elongated cells: 56.2% 
± 4.7%, n = 400, 4 exp, p < 0.01), and restore the migratory properties of MDA-MB-231 
TRPM7 knockdown cells (transwell: 95.3% ± 1.2%, 2 exp., p < 0.05; single cell migration: 
25.3 ± 1.6 µm/hour, n > 200, 4 exp, p < 0.01) (Fig. 3).
Reduced TRPM7 expression levels confer a contractile phenotype onto triple-negative breast 
tumor cells and induce cell-substrate adhesion assembly
In addition to the functional changes, immunofluorescent staining of MDA-MB-231 cells 
revealed the redistribution of filamentous actin to the cell cortex and a strong increase in the 
number of focal adhesions, especially in the periphery of TRPM7 knockdown MDA-MB-231 
cells, relative to mock transduced control cells (control: 13.8 ± 0.62, TRPM7 shRNA: 29.9 
± 0.85, n > 100, p < 0.001) (Fig. 4A & B). Focal adhesions are mechanosensitive adhesion 
structures whose assembly and disassembly need to be tightly regulated by a combination of 
myosin II-based cellular tension and local Ca2+ signaling events to allow optimal cell migration 
(21-26). Increased focal adhesion assembly is generally associated with high cytoskeletal 
tension, accompanied by tyrosine phosphorylation of focal adhesion components such as 
paxillin as well as increased myosin light chain (MLC) phosphorylation (21). Indeed, the 
increase in focal adhesions observed in the TRPM7 knockdown cells was reflected by a rise 
in Tyr118-phosphorylated paxillin and Ser19-phosphorylated MLC on a western blot (Fig. 
4C & S4A). Re-expression of TRPM7 reduced focal adhesion content (18.2 ± 0.89, n = 45, 
p < 0.001), and reverted paxillin phosphorylation (Fig. 4).
ER-positive breast cancer cells exhibit reduced cell migration speed and enforced cell-cell 
adhesions upon TRPM7 knockdown
In addition to basal-like tumors, represented by the triple-negative MDA-MB-231 breast 
cancer model, a large part of the patient dataset consisted of ER-positive, luminal-type breast 
cancer patients. To validate our observations in these tumors, we knocked down TRPM7 
in non-invasive, ER-positive MCF7 human breast cancer cells (Fig. S1E). This significantly 
reduced migration of MCF7 cells in gap-closure assays (control: 11.5 ± 0.5% vs. TRPM7 
shRNA: 21.2 ± 1.7 % gap remaining after 24 hours, 3 exp, p < 0.01) (Fig. 5A & B). In these 
epithelial-like cells, TRPM7 knockdown predominantly affected cell-cell adhesion rather than 
cell-substrate adhesion. Unlike the control shRNA transduced cells, the TRPM7 knockdown 
cells were able to maintain cell-cell contacts upon serum deprivation, a condition known 
to induce scattering of epithelial cells (Fig. 5C) (27). Although increased MLC and paxillin 
phosphorylation were not observed in MCF7 TRPM7 shRNA cells (data not shown), confocal 
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Figure 6. Inhibition of cytoskeletal contractility recovers TRPM7 knockdown phenotype in both 
MDA-MB-231 and MCF7 cells. (A) Quantification of elongated MDA-MB-231 TRPM7 shRNA cells with or 
without pretreatment with 5 µM Rho-kinase inhibitor Y27632. Elongation is presented as percentage (± SEM; 
two independent experiments, n > 100) of cells that have a length of more than twice the width. * P < 0.05. (B) 
Quantification of focal adhesion content in MDA-MB-231 TRPM7 shRNA cells, with or without pretreatment for 
2 hours with 5 µM Rho-kinase inhibitor Y27632. Data are mean ± SEM (n > 100 cells per cell line). *** P < 0.001. 
(C) Immunofluorescence staining of MDA-MB-231 cells with pTyr118 paxillin antibodies to reveal focal adhesions, 
and Alexa-568 Phalloidin to visualize the actin cytoskeleton. Scale bar = 10 µm. (D) Quantification of serum-induced 
transwell migration of MDA-MB-231 control and TRPM7 shRNA cells, treated with indicated concentrations 
Y27632 Rho-kinase inhibitor. Data, normalized to the number of migrated MDA-MB-231 control cells that were 
untreated, are from three independent experiments, performed in duplicate, and represent mean ± SEM. Migration 
was scored after 8 hours. * P < 0.05. For data on GSK429286 treated cells, see Fig. S4C. (E) Quantification 
of percentage gap remaining by MCF7 control and TRPM7 shRNA cells, treated with indicated concentrations 
Y27632 Rho-kinase inhibitor. Data represent percentage gap remaining after 18 hours (mean ± SEM, 3 independent 
experiments, each performed in duplicate). ** P < 0.01, *** P < 0.0001. For data on GSK429286 treated cells, 
see Fig. S4D.
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microscopy revealed profound effects on cytoskeletal organization and cell-cell contacts 
(Fig. 5D). Similar to our observations in MDA-MB-231 cells, TRPM7 knockdown induced 
the redistribution of filamentous actin to the cell cortex. Moreover, cell-cell interactions 
appeared to be enforced in MCF7 TRPM7 shRNA cells, evident from increased cell-cell 
contact area and enrichment of E-cadherin at these interfaces. 
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Cadherin-containing cell-cell adhesions, known as adherens junctions (AJs), show functional 
and structural similarities to focal adhesions (4). Like focal adhesions, AJs are highly dynamic 
multiprotein complexes that act in close association with the actomyosin cytoskeleton to 
translate mechanical signals into cellular responses. Moreover, their formation and size are 
directly associated with myosin II-based cellular tension (5).
Pharmacological inhibition of cytoskeletal tension rescues the TRPM7 knockdown phenotype
Our results indicate that TRPM7 knockdown confers a contractile phenotype onto breast 
cancer cells and consequently, impairs their migratory and metastatic properties. Consistent 
with this notion, inhibition of myosin II-based cytoskeletal tension using the Y27632 Rho-kinase 
inhibitor (28), was sufficient to revert the phenotype of TRPM7 knockdown in MDA-MB-231 
cells to the characteristic elongated morphology of control cells (Elongated cells: 54.5% ± 
3.0%, n > 100, 2 exp, p < 0.05) (Fig. 6A), while reducing MLC- and paxillin phosphorylation, 
and the number of focal adhesions back to control levels (15.7 ± 0.26, n > 100, p < 0.001) 
(Fig. 6B & C, S4A & B). A similar effect was observed with the structurally unrelated Rho-
kinase inhibitor GSK429286 (Fig. S4A & B) (29). Strikingly, Rho-kinase inhibition restored 
serum induced transwell migration of TRPM7 knockdown cells (TRPM7 shRNA: 63.9% ± 
7.0% vs. TRPM7 shRNA + Y27632 (5 µM): 116.6% ± 17.9%, 3 exp, p < 0.05) without affecting 
MDA-MB-231 control cell migration (Fig. 6D & S4C). Likewise, gap-closure speed of MFC7 
TRPM7 shRNA cells was rescued by Rho-kinase inhibition (Fig. 6E & S4D). In contrast 
to MDA-MB-231 cells, low concentrations of Rho-kinase inhibitors already significantly 
increased gap-closure speed of MCF7 control cells. However, much higher concentrations 
of these compounds were required to maximize gap-closure speed of MCF7 TRPM7 shRNA 
cells, supporting the notion that TRPM7 knockdown increases cellular tension. 
Although our observations are not in agreement with the general notion that increases 
in Rho-ROCK signaling positively correlate with cell migration and metastasis formation (6, 
30, 31), it is well known that actomyosin contractility, adhesion dynamics, and the mechanical 
properties of the substrate, have to be tightly balanced in order to maximize migration 
velocity (23, 24, 32, 33). Hence, overassembly of either focal adhesions or adherens junctions 
in the TRPM7 knockdown cells, both a consequence of increased cytoskeletal tension, 
likely interferes with optimal cell migration (Fig. S4E). Altogether, our results indicate that 
TRPM7 is part of the mechanosensory machinery that regulates cellular tension and steers 
adhesion dynamics to allow cell migration and metastasis formation.
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Conclusions
TRP channels play a prominent role in translating mechanical forces into biochemical signals, 
although in most cases it remains to be established whether they are directly activated by 
mechanical stimulation. Activation of these proteins not only leads to changes in local Ca2+ 
concentrations but also triggers other signaling mechanisms that influence cell behavior and 
differentiation (34). Mice deficient in TRPM7 show widespread defects in early embryonic 
development, pointing at a non-redundant role for this channel-kinase in organ development 
(35). Defects in mechanotransduction, especially those that affect cellular tension, are known 
to contribute to disease progression (36, 37). Hence, we propose that TRPM7 guided cell 
adhesion and migration are normal attributes of epithelial and mesenchymal cells, required 
during organ development, but when spuriously activated in cancer cells contribute to 
metastasis formation.
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Materials and methods
TRPM7 protein expression in primary breast cancer tissue samples detected by immunohistochemistry
Formalin-fixed, paraffin embedded breast tumor tissue, derived from the tumor bank of the Department of 
Laboratory Medicine of the Radboud University Medical Centre, was probed for TRPM7 (1:400, Cayman Chemical 
Company, Ann Arbor, MI), followed by biotin conjugated donkey anti-mouse IgG and DAB, and counterstained 
with hematoxylin. 
TRPM7 expression measurements in patient samples
Our discovery cohort consisted of 368 early-stage breast cancer samples, described in a previous study (17). The 
validation cohort consisted of 144 patients with unilateral breast cancer who had undergone resection of their 
primary tumor between November 1987 and December 1997 (38). TRPM7 expression levels in tumor samples 
derived from the discovery cohort were determined by microarray analysis using Affymetrix U133B Genechips 
(Affymetrix, Santa Clara, CA). Raw data are available at the Gene Expression Omnibus repository database 
(GEO accession number: GSE6532). TRPM7 expression levels in the validation cohort were determined by 
quantitative PCR reactions on cDNA samples derived from primary tumors, using power SYBR-green reagent (Applied 
Biosystems, Carlsbad, CA) in combination with TRPM7 specific primers (forward: TAGCCTTTAGCCACTGGAC; 
reverse: GCATCTTCTCCTAGATTTGC) according to manufacturer’s recommendations. TRPM7 gene expression 
levels were normalized to the HPRT housekeeping gene (forward: GGTCCTTTTCACCAGCAAGCT; reverse: 
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TGACACTGGCAAAACAATGCA) and calculated according to the cycling threshold method (39). Statistical 
analyses were carried out using SPSS software (version 16.0; SPSS, Chicago, IL). Discovery and validation cohorts 
were dichotomized using median TRPM7 expression as cut-off. Survival curves were visualized by Kaplan-Meier 
plots, using recurrence-free and distant metastasis-free survival as endpoints, and compared using log-rank tests. 
Hazard ratios were estimated by univariate Cox regression analysis. The independent prognostic value of TRPM7 
was assessed by univariate and multivariate Cox regression analysis on combined discovery and validation cohorts. 
Generation and validation of cell lines
Human TRPM7 shRNAs (#1: 5-GCGCTTTCCTTATCCACTTAA-3; #2: 5-CAGCAGAGCCCGATATTATTT-3) 
were introduced in MDA-MB-231 (HTB-26, ATCC) and human TRPM7 shRNA#1 was introduced in MCF7 human 
breast cancer cells (HTB-22, ATCC), using the pLKO lentiviral expression vector according to manufacturer’s 
instructions (Sigma Aldrich, St. Louis, MO). A nonfunctional shRNA (5-GCTACAAGAGAAACCAAATCT-3) was 
used as negative control. Transduced cells were selected with 1 µg/ml puromycin. For bioluminescent imaging, 
control and TRPM7 knockdown MDA-MB-231 cells were co-transduced with a retroviral pLZRS luciferase 
reporter construct and selected with 0.5 mg/ml Zeocin. For rescue of TRPM7 expression levels, HA-tagged 
mouse TRPM7, containing one mismatch with respect to the human-specific shRNA (14), was introduced in MDA-
MB-231 TRPM7 shRNA cells. Transduced cells were selected with 1 mg/ml G418. TRPM7 mRNA expression levels 
were determined by quantitative RT-PCR with the additional use of mouse specific TRPM7 primers (forward: 
TAGCCTTTAGCCACTGGACC; reverse: GCATCTTCTCCTAGATTGGCAG). TRPM7 protein levels were 
determined by radioactively labeling the TRPM7 kinase domain as described previously (14).
Cell viability and proliferation measurements
The effect of TRPM7 knockdown on cell viability and proliferation was assessed by MTS assays according to 
manufacturer’s instructions (Promega, Madison, WI). Cell cycle distribution of the different cell lines was determined 
by FACS analysis on cells stained with propidium iodide. Cells were harvested and the cell pellet was incubated 
in staining solution (1 mg/ml sodium citrate, 0.1 mg/ml RNAseA, 20 µg/ml propidium iodide, and 0.1% Triton 
X-100). Cells were washed and subjected to FACS analysis. Cell cycle distribution was quantified using FlowJo 
analysis software.
Mouse xenograft experiments
All animal work was performed in accordance with protocols approved by the Animal Welfare Committee (DEC-
NKI-10.034). Immunodeficient Rag2-/-IL2rg-/- mice were used for metastasis experiments. MDA-MB-231-Luc 
control and TRPM7 knockdown cells were collected and washed with PBS. Subsequently, 0.2 ml PBS containing 
5*105 cells was injected into a tail vein. Tumor growth, was monitored by bioluminescence imaging from day 7 
onwards. Beetle luciferin (Promega, Madison, WI) was dissolved at 15 mg/ml in PBS and stored at -20°C. Animals 
were anaesthetized with 2-3% isoflurane. Luciferin solution was injected intraperitonially (0.01 ml/gram body 
weight). Light emission was measured 15 minutes later, using a cooled CCD camera (IVIS; Xenogen), coupled to 
Living Image acquisition and analysis software over an integration time of 1 min. Signal intensity was expressed 
as flux (photons / second) integrated over the lung region. Lung tissue was collected at day 30 after injection. 
Tissues were fixed in EAF (ethanol-acetic acid-formol saline fixative, 40:5:10:45 % v/v) and processed for histology. 
Paraffin sections were stained with Haematoxylin and Eosin (HE). All microscopic images were acquired using 
IP-Lab software (Scanalytics Inc., Fairfax, VA, USA) in combination with a monochrome CCD camera (Retiga SRV, 
1392 * 1040 pixels) and a RGB filter (Slikder Module; QImaging, Burnaby, BC, Canada) attached to a motorized 
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microscope (Leica DM6000, Wetzlar, Germany). Quantification of tumor size and number was carried out by 
ImageJ image analysis software.
Cell migration, -elongation and -scatter experiments
Following overnight serum starvation, cells were harvested and resuspended in DMEM containing 0.1% FBS. 
Subsequently, 50.000 cells were applied to a transwell insert with 8 µm pore size (Corning Life Sciences, Corning, 
NY), which was incubated in DMEM supplemented with 10% FBS. Cells were allowed to migrate for 8 hours at 
37 °C. Migrated cells were fixed (75% methanol and 25% acetic acid) and stained (0.25% Coomassie Blue, 45% 
methanol, 10% acetic acid in H2O). Single cell migration on vitronectin coated (500 ng/ml) culture dishes, was 
followed for 24 hours by time lapse microscopy and analyzed using ImageJ image analysis software. Cell elongation 
was determined based on length and width ratios, measured after 24 hours. A cell was considered elongated 
when the ratio length/width was larger than 2. MCF7 cell scattering on vitronectin coated (500 ng/ml) culture 
dishes was visualized by timelapse microscopy in DMEM supplemented with 0.1% FBS. Gap closure assays were 
performed according to manufacturer’s recommendations (Applied Biophysics, Troy, NY). In short, 40.000 MCF7 
cells were seeded per insert and cultured overnight. After removal of the insert, cells were allowed to migrate 
for 24 hours and migration was followed by time lapse microscopy. Where indicated, cells were incubated in the 
presence of different concentrations Y27632 (Sigma-Aldrich, St. Louis, MO) and GSK429286 (Seleckbio, Munich, 
Germany) Rho-kinase inhibitors.
Fluorescent staining of focal adhesions, E-cadherin and F-actin
Images were taken with a Leica TCS SP5 confocal (Leica Microsystems) equipped with a 63x water-immersion 
objective and LAS-AF acquisition software (Leica Microsystems). Cells were cultured overnight on vitronectin 
coated (500 ng/ml) glass coverslips in DMEM containing 0.1% FBS. Where indicated, cells were next incubated for 
2 hours in the presence of 5 µM Y27632 Rho-kinase inhibitor (Sigma-Aldrich, St. Louis, MO). Cells were fixed in 
3.7% formaldehyde, permeabilized in 0.1% Triton X-100 and stained for pTyr118 paxillin (1:100, Life Technologies, 
Carlsbad, CA), E-cadherin (1:200, BD Biosciences, Franklin Lakes, NY) and actin, using Alexa-568 conjugated 
Phalloidin (1:100, Life Technologies, Carlsbad, CA). The average number of focal adhesions per cell was quantified 
using an ImageJ analysis routine (macro). Series of paxillin images (pixel size, 0.11 x 0.11 mm2) were normalized 
with respect to intensity/contrast, background was subtracted and cell boundaries were detected by manually 
setting the appropriate threshold. The original image was subjected to a rolling-ball filter of radius 10 pixels, which 
effectively suppresses staining irregularities while retaining contrast in the focal adhesions. Further thresholding 
and the ‘Analyze Particles’ plugin (settings: particle size 30-500 pixels; circularity 0.1-1.0) were used to determine 
the number of focal adhesions. Photomicrographs of at least 60 cells were analyzed for each condition.
Detection of pSer19 myosin light chain and focal adhesion associated pTyr118 paxillin on Western blot
For detection of pSer19 myosin light chain in control and TRPM7 shRNA transduced MDA-MB-231 cells, cells 
were lysed in Laemmli buffer supplemented with 1 µM MgCl2 and 1:200 Benzoase Nuclease (Merck, Darmstadt, 
Germany), and left on ice for 30 minutes. Focal adhesion associated proteins were extracted from MDA-MB-231 
cells as described previously (40). Proteins were separated by SDS-PAGE and blotted onto a PVDF membrane. 
Blots were incubated with rabbit polyclonal anti-pTyr118 paxillin antibody (1:750, Life Technologies, Carlsbad, 
CA), or anti-pSer19 myosin light chain antibody (1:1000, Life Technologies, Carlsbad, CA) and mouse monoclonal 
g-Tubulin (1:10000, Sigma Aldrich, St. Louis, MO) antibodies, followed by HRP-conjugated secondary antibodies 
(1:5000, DAKO, Glostrup, Denmark). Proteins were detected using ECL Western blot reagent (GE Healthcare, 
Chalfont St. Giles, UK) and exposing the blots to film.
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Statistical analysis
Statistical data are expressed as mean ± standard deviation (SD) or ± standard error of the mean (SEM) as 
indicated in the text. Statistical differences were tested with two-sided, unpaired Student’s t-tests and p < 0.05 
was considered statistically significant.
References
1. Bidwell JP, Pavalko FM. Mechanosomes carry a loaded message. Science signaling. 2010;3:pe51.
2. Geiger B, Bershadsky A. Exploring the neighborhood: adhesion-coupled cell mechanosensors. Cell. 
2002;110:139-42.
3. Parsons JT, Horwitz AR, Schwartz MA. Cell adhesion: integrating cytoskeletal dynamics and cellular tension. 
Nature reviews. 2010;11:633-43.
4. Chen CS, Tan J, Tien J. Mechanotransduction at cell-matrix and cell-cell contacts. Annu Rev Biomed Eng. 
2004;6:275-302.
5. Liu Z, Tan JL, Cohen DM, Yang MT, Sniadecki NJ, Ruiz SA, et al. Mechanical tugging force regulates the size 
of cell-cell junctions. Proc Natl Acad Sci U S A. 2010;107:9944-9.
6. Paszek MJ, Zahir N, Johnson KR, Lakins JN, Rozenberg GI, Gefen A, et al. Tensional homeostasis and the 
malignant phenotype. Cancer cell. 2005;8:241-54.
7. Clark K, Middelbeek J, van Leeuwen FN. Interplay between TRP channels and the cytoskeleton in health 
and disease. European journal of cell biology. 2008;87:631-40.
8. Lin SY, Corey DP. TRP channels in mechanosensation. Current opinion in neurobiology. 2005;15:350-7.
9. Orr AW, Helmke BP, Blackman BR, Schwartz MA. Mechanisms of mechanotransduction. Developmental 
cell. 2006;10:11-20.
10. Numata T, Shimizu T, Okada Y. Direct mechano-stress sensitivity of TRPM7 channel. Cell Physiol Biochem. 
2007;19:1-8.
11. Oancea E, Wolfe JT, Clapham DE. Functional TRPM7 channels accumulate at the plasma membrane in 
response to fluid flow. Circulation research. 2006;98:245-53.
12. Clark K, Middelbeek J, Lasonder E, Dulyaninova NG, Morrice NA, Ryazanov AG, et al. TRPM7 regulates 
myosin IIA filament stability and protein localization by heavy chain phosphorylation. Journal of molecular 
biology. 2008;378:790-803.
13. Goswami C, Kuhn J, Heppenstall PA, Hucho T. Importance of non-selective cation channel TRPV4 interaction 
with cytoskeleton and their reciprocal regulations in cultured cells. PloS one. 2010;5:e11654.
14. Clark K, Langeslag M, van Leeuwen B, Ran L, Ryazanov AG, Figdor CG, et al. TRPM7, a novel regulator of 
actomyosin contractility and cell adhesion. The EMBO journal. 2006;25:290-301.
15. Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H. Calcium flickers steer cell migration. Nature. 
2009;457:901-5.
16. Su LT, Agapito MA, Li M, Simonson WT, Huttenlocher A, Habas R, et al. TRPM7 regulates cell adhesion by 
controlling the calcium-dependent protease calpain. The Journal of biological chemistry. 2006;281:11260-70.
17. Loi S, Haibe-Kains B, Desmedt C, Lallemand F, Tutt AM, Gillet C, et al. Definition of clinically distinct 
molecular subtypes in estrogen receptor-positive breast carcinomas through genomic grade. J Clin Oncol. 
2007;25:1239-46.
18. Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 
is required for breast cancer cell proliferation. American journal of physiology. 2009;297:C493-502.
19. Jiang J, Li MH, Inoue K, Chu XP, Seeds J, Xiong ZG. Transient receptor potential melastatin 7-like current 
in human head and neck carcinoma cells: role in cell proliferation. Cancer research. 2007;67:10929-38.
100
Chapter 4
20. Yang S, Zhang JJ, Huang XY. Orai1 and STIM1 are critical for breast tumor cell migration and metastasis. 
Cancer cell. 2009;15:124-34.
21. Chrzanowska-Wodnicka M, Burridge K. Rho-stimulated contractility drives the formation of stress fibers 
and focal adhesions. The Journal of cell biology. 1996;133:1403-15.
22. Giannone G, Ronde P, Gaire M, Haiech J, Takeda K. Calcium oscillations trigger focal adhesion disassembly 
in human U87 astrocytoma cells. The Journal of biological chemistry. 2002;277:26364-71.
23. Gupton SL, Waterman-Storer CM. Spatiotemporal feedback between actomyosin and focal-adhesion 
systems optimizes rapid cell migration. Cell. 2006;125:1361-74.
24. Barnhart EL, Lee KC, Keren K, Mogilner A, Theriot JA. An adhesion-dependent switch between mechanisms 
that determine motile cell shape. PLoS biology. 2011;9:e1001059.
25. Wolfenson H, Bershadsky A, Henis YI, Geiger B. Actomyosin-generated tension controls the molecular 
kinetics of focal adhesions. Journal of cell science. 2011;124:1425-32.
26. Aratyn-Schaus Y, Gardel ML. Transient frictional slip between integrin and the ECM in focal adhesions 
under myosin II tension. Curr Biol. 2010;20:1145-53.
27. Chen CL, Chan PC, Wang SH, Pan YR, Chen HC. Elevated expression of protein kinase C delta induces 
cell scattering upon serum deprivation. Journal of cell science. 2010;123:2901-13.
28. Uehata M, Ishizaki T, Satoh H, Ono T, Kawahara T, Morishita T, et al. Calcium sensitization of smooth 
muscle mediated by a Rho-associated protein kinase in hypertension. Nature. 1997;389:990-4.
29. Goodman KB, Cui H, Dowdell SE, Gaitanopoulos DE, Ivy RL, Sehon CA, et al. Development of dihydropyridone 
indazole amides as selective Rho-kinase inhibitors. J Med Chem. 2007;50:6-9.
30. Croft DR, Sahai E, Mavria G, Li S, Tsai J, Lee WM, et al. Conditional ROCK activation in vivo induces tumor 
cell dissemination and angiogenesis. Cancer research. 2004;64:8994-9001.
31. Jiang P, Enomoto A, Takahashi M. Cell biology of the movement of breast cancer cells: intracellular signalling 
and the actin cytoskeleton. Cancer letters. 2009;284:122-30.
32. DiMilla PA, Barbee K, Lauffenburger DA. Mathematical model for the effects of adhesion and mechanics 
on cell migration speed. Biophysical journal. 1991;60:15-37.
33. DiMilla PA, Stone JA, Quinn JA, Albelda SM, Lauffenburger DA. Maximal migration of human smooth muscle 
cells on fibronectin and type IV collagen occurs at an intermediate attachment strength. The Journal of cell 
biology. 1993;122:729-37.
34. Pedersen SF, Nilius B. Transient receptor potential channels in mechanosensing and cell volume regulation. 
Methods in enzymology. 2007;428:183-207.
35. Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. Deletion of Trpm7 disrupts embryonic 
development and thymopoiesis without altering Mg2+ homeostasis. Science (New York, NY. 2008;322:756-
60.
36. Clark K, Langeslag M, Figdor CG, van Leeuwen FN. Myosin II and mechanotransduction: a balancing act. 
Trends in cell biology. 2007;17:178-86.
37. Jaalouk DE, Lammerding J. Mechanotransduction gone awry. Nature reviews. 2009;10:63-73.
38. Span PN, Waanders E, Manders P, Heuvel JJ, Foekens JA, Watson MA, et al. Mammaglobin is associated with 
low-grade, steroid receptor-positive breast tumors from postmenopausal patients, and has independent 
prognostic value for relapse-free survival time. J Clin Oncol. 2004;22:691-8.
39. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 
2(-Delta Delta C(T)) Method. Methods (San Diego, Calif. 2001;25:402-8.
40. Putnam AJ, Cunningham JJ, Pillemer BB, Mooney DJ. External mechanical strain regulates membrane targeting 
of Rho GTPases by controlling microtubule assembly. American journal of physiology. 2003;284:C627-39.b
101
TRPM7 is required for breast tumor cell metastasis
Figure S1. TRPM7 expression measurements on TRPM7 knockdown MDA-MB-231 and MCF7 
cells and TRPM7 rescued cells. (A) Human TRPM7 mRNA expression in control and MDA-MB-231 TRPM7 
knockdown cells, determined by quantitative real-time PCR. TRPM7 expression in the control cells is set to 1. * 
P < 0.05. (B) Autoradiogram revealing TRPM7 autophosphorylation, indicative of TRPM7 protein levels in MDA-
MB-231 control and TRPM7 knockdown cells. Autophosphorylation of recombinant TRPM7, stably introduced in 
neuroblastoma cells (3), serves as positive control. (C) Mouse TRPM7 mRNA expression levels in MDA-MB-231 
TRPM7 knockdown cells that were made to re-express mouse TRPM7 (rescued). Mouse TRPM7 expression in 
the rescued cells is set to 1. *** P < 0.001. (D) Top panel: Autoradiogram revealing TRPM7 autophosphorylation, 
indicative for TRPM7 protein levels in MDA-MB-231 control, TRPM7 knockdown, and rescued cells. Bottom panel: 
Quantification of TRPM7 autophosphorylation by scintillation counting. Data are mean ± SEM of two independent 
experiments. ** P < 0.01. (E) Human TRPM7 mRNA expression in MCF7 control and TRPM7 knockdown cells, 
determined by quantitative real-time PCR. TRPM7 expression in the control cells is set to 1. ** P < 0.01.
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Figure S2. TRPM7 knockdown does not affect MDA-MB-231 cell proliferation but impairs metastasis 
formation in vivo. (A) Cell cycle distribution of control and TRPM7 knockdown MDA-MB-231 cells by propidium 
iodide staining and FACS analysis. Histogram shows fluorescent intensity, indicative of relative DNA content 
versus cell number. The percentage of cells in phase G1 and G2 of the cell cycle are tabulated in the inset panel. 
(B) Quantification of bioluminescence in mice treated with MDA-MB-231 control, TRPM7 shRNA or TRPM7 
shRNA#2 cells, up to 35 days after injection. Data are presented as mean ± SEM of n= 4 mice in each group. 
(C) Representative bioluminescence images of mice, 35 days after intravenous injections with MDA-MB-231 
control or TRPM7 shRNA cells. (D) Size distribution of tumors in resected long tissue from mice treated with 
MDA-MB-231 control cells or TRPM7 shRNA cells.
Figure S3. TRPM7 shRNA#2 treatment reduces malignant phenotype of MDA-MB-231 cells. 
(A) Quantification of elongated MDA-MB-231 control and TRPM7 shRNA#2 cells. Elongation is presented 
as percentage (± SEM; 3 independent experiments, n > 300) of cells that have a length of more than twice 
the width. * P < 0.05. (B) Quantification of serum induced transwell migration of MDA-MB-231 control and 
TRPM7 shRNA#2 cells. Data, normalized to the number of control MDA-MB-231 cells, are from 3 independent 
experiments, performed in duplicate and represent mean ± SEM. Migration was scored after 8 hours. ** P < 
0.01. (C) Quantification of single cell migration speed. Shown are migration speed (µm / hr, mean ± SEM) of 3 
independent experiments, each performed in duplicate (n > 150 per cell line). ** P < 0.01.
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Discovery Validation
Parameter Category No % No %
Sample size 368 144
Disease recurrence Yes 133 36.1 51 35.4
No 235 63.9 93 64.6
Distant Metastasis 
formation
Yes 95 25.8 34 23.6
No 273 74.2 110 76.4
Age ≤50 years 74 20.1 33 22.9
>50 years 294 79.9 111 77.1
Histological grade 1 76 20.7 8 5.60
2 172 46.7 47 32.6
3 70 19.0 50 34.7
Missing 50 13.6 39 27.1
Lymph node status Negative 229 62.2 62 43.1
Positive 131 35.6 69 47.9
Missing 8 2.2 13 9.0
Tumor size ≤2 cm 179 48.6 34 23.6
>2 cm 189 51.4 98 68.1
Missing 12 8.30
Syst. Adjuvant 
Treatment
Untreated 118 32.1 63 43.8
Tamoxifen 250 67.9 51 35.4
Other 0 0.0 30 20.8
Estrogen Receptor 
Status
Negative 39 10.6 45 31.3
Positive 329 67.9 99 68.8
Table S1. Patient- and tumor characteristics in 
discovery and validation cohort
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Table S2. TRPM7 expression levels and clinical parameters. (A) TRPM7 is enriched in high grade primary 
breast tumors. Patients from the combined discovery and validation cohorts (n = 512), are categorized according 
to dichotomized clinical parameters and TRPM7 expression levels. P-values are based on Fisher’s Exact test. (B 
& C) Based on ER status and gene expression analysis, we categorized the primary tumors within the discovery 
cohort (n=368) into breast cancer subtypes (luminal, basal-like and Her2/Neu-type). Her2/Neu amplification status 
was lacking for all the samples. However, the Affimatrix Genechips featured three independent probes against 
Her2/Neu. For each individual probe, tumors were ranked according to Her2/Neu expression levels. Since the 
Her2/Neu gene is reported to be amplified in ~20% of all breast cancers (1), a tumor was assigned ‘Her2/Neu 
amplified’ when Her2/Neu expression levels were in the top 20%, according to at least two out of three probes 
(probe score ≥ 2) (B). Tumors were categorized into subtypes according to the following criteria: Luminal tumors 
are predominantly estrogen receptor (ER) positive. Basal-like tumors are generally triple negative, ie. ER-negative, 
progesteron receptor (PGR) negative and exhibit normal Her2/Neu expression levels. Her2/Neu-type tumors 
are ER-negative, PGR-negative but have a positive Her2/Neu amplification status (2). PGR-status was lacking 
for the majority of the samples. However, PGR-status is strongly associated with ER-status and was therefore 
considered to be similar to ER-status in this analysis. P-values are based on Pearson’s Chi-Square test (C). 
A) TRPM7
Parameter Catagory Low High P
Age ≤ 50 years 54 53
> 50 years 202 203 1.00
Histological 
Grade
1 52 32
2&3 161 178 0.02
Lymph Node 
Status
Negative 151 140
Positive 91 109 0.17
Tumor Size ≤ 2 cm 113 100
> 2 cm 135 152 0.21
ER Status Negative 42 42
Positive 214 214 1.00
B)
Her2neu 
probe score No %
0 252 68.5
1 56 15.2
2 22 6.0
3 38 10.3
Total 368 100.0
Not Amplified (83.7%)
Amplified (16.3%)
C) TRPM7
Subtype No % Low High P
Luminal ER 
Positive
329 89.4 165 164
Basal-like 
(Triple neg.)
ER 
negative. 
normal 
Her2/Neu
26 7.1 15 11
Her2/Neu ER 
negative. 
Her2/Neu 
amplified
13 3.5 4 9
Total 368 100 184 184 0.3
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Figure S4. Rho-kinase inhibition rescues contractile and migratory phenotype of TRPM7 shRNA cells. 
(A) Immunoblots of total lysates derived from MDA-MB-231 control and TRPM7 shRNA cells that were pretreated 
for 2 hours with indicated concentrations of Y27632 (left panel) and GSK429286 (right panel) Rho-kinase inhibitors. 
Antibodies against pSer19 myosin light chain (MLC) were used to determine the amount of phosphorylated MLC as a 
measure of cytoskeletal contractility. Antibodies against g-tubulin were used to control for loading. (B) Immunoblot 
of Triton X-100 insoluble fractions derived from MDA-MB-231 TRPM7 shRNA cell lysates. Cells were pretreated for 
2 hours with the indicated concentrations of Y27632 (left panel) and GSK429286 (right panel) Rho-kinase inhibitors. 
Phosphorylated paxillin was detected with an antibody against pTyr118 paxillin. g-Tubulin served as a loading control. 
(C) Quantification of serum induced transwell migration of MDA-MB-231 control and TRPM7 shRNA cells, treated with 
indicated concentrations GSK429286 Rho-kinase inhibitor. Data, normalized to the number of migrated MDA-MB-231 
control cells that were untreated, are from 3 independent experiments, performed in duplicate, and represent mean ± 
SEM. Migration was scored after 8 hours. * P < 0.05. (D) Quantification of percentage gap remaining by MCF7 control 
and TRPM7 shRNA cells, treated with indicated concentrations GSK429286 Rho-kinase inhibitor. Data represent 
percentage gap remaining after 18 hours (mean ± SEM, 3 independent experiments, each performed in duplicate). 
* P < 0.05, ** P < 0.01, *** P < 0.0001. (E) Hypothetical model explaining how increased cytoskeletal tension in the 
TRPM7 knockdown cells, and its reduction by Rho-kinase inhibitors, may affect migration speed. Tight regulation of 
cytoskeletal tension and cell adhesion (x-axis) is required for optimal cell migration (y-axis). TRPM7 knockdown in 
MDA-MB-231 cells promotes cytoskeletal tension and consequently, impairs cell migration. Inhibition of actomyosin 
contractility by Rho-kinase inhibitors reverts these effects. Similarly, in MCF7 cells, optimal migration requires higher 
concentrations of Rho-kinase inhibitors in the TRPM7 knockdown cells relative to control cell.
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Abstract
Metastases form when tumor cells escape the primary tumor and migrate across tissue 
boundaries to colonize distant sites. This process involves extensive reorganization of the 
actomyosin cytoskeleton. We previously demonstrated that the mechanically activated 
TRPM7 channel-kinase controls cytoskeletal tension, focal adhesion dynamics and migration 
of malignant breast cancer cells and, moreover, is required for breast cancer metastasis 
formation in vivo. Consistently, TRPM7 overexpression in mouse neuroblastoma cells 
affects cytoskeletal organization and adhesion formation. Here, we addressed whether 
TRPM7-mediated cytoskeletal reorganization affects the migratory and invasive properties 
of neuroblastoma cells in vitro and in vivo. Our results indicate that TRPM7 overexpression 
promotes cell spreading and cell-substrate adhesion. Moreover, TRPM7 overexpression 
confers a migratory phenotype onto N1E-115 mouse neuroblastoma cells in vitro and strongly 
enhances their metastatic propensity in vivo. 
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Introduction
Neuroblastoma is the second-most common solid tumor in children and derives from 
precursor cells of the peripheral sympathetic nervous system. Although survival rates for 
infants and older children with localized disease have improved over the past decades, the 
prognosis of children with metastatic disease remains poor. Metastatic spread of cancer 
cells is the main cause of cancer-related mortality (1). Despite a conceptual understanding 
of the steps that comprise the metastatic cascade (dissociation, migration towards and 
transport through the vasculature, extravasation and colonization), the biological and molecular 
mechanisms that underlie these different steps remain incompletely understood.
Metastatic spread involves complex mechanical interactions between tumor cells and 
tumor microenvironment to allow efficient cell migration through a complex environment 
such as the extracellular matrix (ECM) (2). These interactions are mediated by integrin 
dependent cell adhesion complexes that link the actomyosin cytoskeleton to the ECM 
via a large variety of linker proteins, signaling molecules and actin regulatory proteins. 
Adhesion structures dynamically remodel in response to mechanical cues derived from 
the ECM and the intracellular cytoskeleton (3, 4). In addition to the well characterized 
mechanoresponsive proteins such as talin and zyxin, a role for calcium signaling by members 
of the TRP-superfamily of cation channels in mechanically induced adhesion remodeling is 
emerging (5). TRP channels are widely implicated in sensory transduction (6) and several of 
its members, including TRPM7, are known to associate with the actomyosin cytoskeleton 
and regulate its dynamics in response to environmental cues such as mechanical stress (5, 
7). The involvement of TRPM7 in controlling Ca2+-dependent remodeling of the actomyosin 
cytoskeleton, cell adhesion and cell motility has become subject of intense investigation (8-16). 
TRPM7, and its closest relative TRPM6, are unique in the sense that they harbor a 
functional C-terminal a-kinase domain, in addition to a Ca2+- and Mg2+-permeable channel 
(17-19). Using N1E-115 mouse neuroblastoma cells, we previously showed that TRPM7 
associates with the actomyosin cytoskeleton in a Ca2+- and kinase-dependent manner and 
regulates cytoskeletal organization. Moreover, TRPM7 activation induces the formation of 
invadosome-type of cell adhesions (8). Invadosomes are specialized cell-matrix adhesions that 
are implicated in (tumor-) cell invasion and capable of degrading the underlying ECM by the 
local secretion of matrix degrading proteases (20). Since TRPM7 localizes to invadosomes, 
we postulated that TRPM7 locally controls actomyosin dynamics to modify cell adhesion 
architecture (8). Consistent with this notion, Wei and colleagues showed that TRPM7-
dependent Ca2+ signaling events at the leading lamella of lung fibroblasts steer directional 
migration (11). Moreover, we showed that TRPM7 controls cytoskeletal tension and focal 
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Figure 1. TRPM7 overexpression enforces N1E-115 
cell-matrix interactions. (A) Relative TRPM7 mRNA 
expression as determined by RT-qPCR. (B) Quantification 
of cell proliferation, determined by MTS assays. Data in A, 
B are mean +/- SEM of N > 3 experiments. (C) Top panel: 
quantification of cell adhesion speed. Time is indicated on the 
X-axis. The number of adhered cells per time point, relative 
to the total number of cells, is presented on the Y-axis. Data 
are mean percentage ± SEM (Control: n = 108 cells; TRPM7: 
n = 100 cells). Bottom panel: representative images of N1E-
115 cell spreading in time. D) Representative DIC and TIRF 
images of adherent N1E-115 control N1E-115 TRPM7 cells 
loaded with CellTrackerGreen (Top panel). Adhesive surface 
of cells was quantified by normalizing TIRF area to the DIC 
area (Bottom panel). Data are mean ± SEM of 2 independent 
experiments performed in duplo (Control: n = 114 cells; 
TRPM7: n = 96 cells, ** P < 0.01, one-tailed unpaired t-test).
adhesion dynamics to allow breast cancer 
cell migration in vitro and metastasis 
formation in vivo. Taken together, these 
findings establish TRPM7 as pivotal 
player in cytoskeletal organization and 
adhesion dynamics. However, it remains 
to be established whether TRPM7 can 
be regarded as promoter of tumor 
malignancy in general. In this study, we 
set out to further investigate the role 
for TRPM7 as regulator of actomyosin 
remodeling in cell adhesion, migration 
and metastasis. We first explore how 
TRPM7 induced cytoskeletal remodeling 
and the formation of invadosomes 
contribute to the malignant phenotype 
of neuroblastoma cells in vitro. Next, we 
provide evidence showing that increased 
TRPM7 expression levels enhances the 
propensity of neuroblastoma cells to 
metastasize in vivo.
 
Results and Discussion
TRPM7 regulates neuroblastoma cell-matrix 
interactions and enhances cell motility
Stable expression of TRPM7-HA (~2 fold 
over endogenous levels, Fig. 1A) confers 
a spreading morphology onto otherwise 
contractile and poorly adhesive mouse 
N1E-115 neuroblastoma cells (8), without 
affecting cell viability and proliferation 
(Fig. 1B). Here, we assessed the effect 
of TRPM7 on N1E-115 cell adhesive 
properties, judged from the fraction of 
cells that spread in time-lapse microscopy 
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series as well as by quantifying the fraction of basal membrane area that directly adheres to 
the underlying substrate from TIRF images. TRPM7 overexpression increases the percentage 
of cells that adhere to the substrate and cell adhesion speed (Fig. 1C). Moreover, increased 
TRPM7 expression levels promote cell spreading, as was revealed by TIRF microscopy (Fig. 
1D). Overall, these results indicate that TRPM7-HA expression enhances the adhesive 
properties of N1E-115 cells.
We next set out to further characterize adhesive structures in these cells. Both the 
empty vector control cell line and TRPM7 overexpressing cells form invadopodia that stain 
positive for invadopodia markers such as cortactin (Fig. 2A) (20). As reported previously, 
TRPM7 overexpression induced the formation of large peripheral adhesion complexes in 
a subfraction  of cells. These adhesions possess features of invadosome-type structures 
known as podosomes (8). TRPM7-mediated podosome formation was promoted by either 
bradykinin, a G protein-coupled receptor agonist that was previously shown to activate 
TRPM7 (Fig 2B) (8, 21), or by substrate topological cues (Fig. 2C). 
C
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Figure 2. TRPM7 overexpression does 
not affect matrix degradation by N1E-
115 cells. (A) Invadosomes in N1E-115 
control and N1E-115 TRPM7 cells, revealed 
by overexpression of GFP-tagged cortactin. 
F-actin was visualized by using Lifeact.
(B) Peripheral invadosomes in N1E-115 TRPM7 
cells, stimulated with bradykinin (20 nm, 15 
minutes) resemble podosome-type adhesions 
with an actin-dense core (red) surrounded by 
vinculin (green). (C) Peripheral invadosomes in 
N1E-115 TRPM7 cells, visualized by Alexa-568 
Phalloidin (red) and vinculin (green), form on 
patterned substrates. Topological differences 
were generated by scratching glass coverslips 
with sandpaper. (D) Matrix degrading activity 
of invadosomes in N1E-115 control (left) and 
N1E-115 TRPM7 cells (right) plated on a thin 
layer of cross-linked Oregon Green-labeled 
gelatin (Gelatin-OG). Local matrix degradation 
is apparent form dark spots in Gelatin-OG. 
Invadosomes are visualized by staining F-actin 
with Alexa-568 Phalloidin. Scalebar = 10 µm.
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Invadosomes are thought to increase the metastatic properties of cells by mediating cell 
adhesion and localized substrate degradation to allow directional displacement through the 
ECM (20). Indeed, invadosomes in N1E-115 control and TRPM7 overexpressing cells appear 
functional in that they readily degrade fluorescently-labeled gelatin, as assessed by confocal 
microscopy (Fig. 2D). Note, however, that since central invadopodia greatly outnumber 
their peripheral counterparts, the former dominate matrix degradation. Consequently, we 
did not observe a noteworthy increase in degradative capacity upon TRPM7 overexpression 
(data not shown). While podosomes may not significantly contribute to matrix degradation, 
they are thought to increase the metastatic properties of cells by favoring adhesion and 
directional migration (20).
As cytoskeletal organization and adhesion dynamics guide malignant transformation and 
subsequent migration and metastasis of tumor cells (2), we compared migratory properties of 
N1E-115 control and TRPM7 cells by assaying migration towards a serum gradient in Boyden 
chambers. Whereas control cells remained immobile during 48 hours, TRPM7 overexpression 
increased the ability of neuroblastoma cells to cross the transwell membrane (control = 
4.1 ± 2.2 cells; TRPM7 = 336 ± 106.7 cells, p = 0.027, n = 6) (Fig. 3A). A similar effect 
was found using gelatin-coated filters (Fig. 3B). Hence, while TRPM7 does not appear to 
promote matrix degradation, the increased matrix adhesion strength observed in response 
to TRPM7 overexpression is likely to facilitate Boyden chamber migration.Figure 3 
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Figure 3. TRPM7 promotes N1E-115 cell 
migration. (A) Transwell migration of N1E-115 
control and N1E-115 TRPM7 cells. Equal numbers 
of cells were allowed to migrate towards a serum 
gradient for 48 hours. Data are mean ± SEM 
of 6 independent experiments performed in 
triplo. (B) Quantification of transwell migration 
on gelatin-coated membranes. Data are mean ± 
SEM of 3 independent experiments performed 
in triplo. * P < 0.05, two-tailed unpaired t-test 
with Welch correction.
TRPM7 promotes tumor metastasis in mice
In order to address the potential effect of TRPM7 on the malignant behavior of neuroblastoma 
cells in vivo, we intravenously injected luciferase expressing N1E-115 control and TRPM7 
overexpressing N1E-115 into Rag2-/-Il2rg-/- immunodeficient mice. Non-invasive bioluminescence 
imaging was used to monitor tumor cell dissemination and growth. Bioluminescence signals 
were observed at day 7 post-injection and progressively increased in time (Fig. 4A & B), 
showing that injected cells successfully survived, proliferated and formed metastases. In 
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good agreement with earlier reports on metastasis of neuroblastoma cells in mice (22), 
bioluminescence originated predominantly from the abdominal region. Strikingly, the abdominal 
signal in N1E-115 TRPM7 injected mice was much higher at all time points (day 7: control 
= 5.41 x 104 ± 9.92 x 103 photons/s, n = 9; TRPM7 = 9.75 x 105 ± 1.63 x 105 photons/s, n = 
9). Note that the progressive increase in bioluminescence was comparable in both groups, 
indicating that the in vivo proliferation rate of neuroblastoma cells was not affected by TRPM7 
expression levels (Fig. 4B). These data demonstrate that increased TRPM7 expression levels 
enhance metastatic spread of N1E-115 cells in vivo, consistent with our previous observations 
in breast cancer cells (16).
TRPM7 promotes metastasis to liver and bone marrow 
As the proliferation rate of N1E-115 TRPM7 cells did not differ from control cells in vitro 
and in vivo, the increased abdominal signals of mice injected with these cells suggest that 
dissemination is more widespread. Histopathological analysis showed that the dissemination 
pattern is similar in both groups, with metastases predominantly present in the liver (Fig. 
5A & B). However, image analysis of liver paraffin sections demonstrated that much more 
tumors formed in mice injected with N1E-115 TRPM7 cells (control = 9.5 ± 3.3 tumors 
per liver section; TRPM7 = 79.7 ± 13.4 tumors per liver section; p < 0.01, n = 9) (Fig. 5A 
& C). Consistent with the observation that TRPM7 does not affect proliferation in vitro, 
TRPM7 overexpression had no effect on mean tumor size (control = 0.35 ± 0.13 mm2, n = 
118 tumors; TRPM7 = 0.26 ± 0.03 mm2, n = 786 tumors; p = 0.23) (Fig. 5D & E). Hence, 
we conclude that TRPM7 enhances the metastatic potential, but not proliferation rate, of 
N1E-115 neuroblastoma cells in vivo.
In addition to the liver, bone and bone marrow metastases are commonly observed in 
neuroblastoma patients (23). We therefore isolated bone marrow content from each limb 
and analyzed luciferase activity. Limbs were considered positive when bioluminescence was 
five times above background. Strikingly, only one limb from a single N1E-115 control injected 
mouse met this criterion, whereas all mice injected with N1E-115 TRPM7 cells scored positive 
with an average of 3 infested legs per mouse (control = 1 limb in 1 out of 9 mice; TRPM7 = 
9 out of 9 mice affected with 27 out of 36 limbs scoring positive, p < 0.01) (Fig. 5F). N1E-
115 control and N1E-115 TRPM7 cells, cultured from bone marrow isolations, had retained 
viability as well as their relative TRPM7 expression levels (data not shown) and typical 
morphology (Fig. 5G). Thus, our xenograft mouse model resembles human neuroblastoma 
pathogenesis and may well serve as suitable in vivo model to elucidate how TRPM7-mediated 
cell adhesion remodeling affects metastasis formation in future experiments.
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Figure 4. TRPM7 increases the 
metastatic potential of N1E-115 
cells. (A) Representative bioluminescent 
images of mice, 7 and 20 days after 
intravenous injections with N1E-115 
control and TRPM7 overexpressing 
cells (n = 9 mice in each group). Photon 
fluxes are to the same scale (photons 
/ s). Asterix indicates an example of 
bioluminescence observed in a limb. 
(B) Quantification of bioluminescence 
in the abdominal region between day 
7 and day 21 post-injection. Data are 
mean ± SEM of n = 9 mice per group. 
Data presented are from 1 out of 4 
independent experiments that show 
highly reproducible results. 
migration by inducing cytoskeletal contractility. Here, 
we find that TRPM7 overexpression in N1E-115 mouse 
neuroblastoma cells promotes cell spreading and the 
formation of podosome-type invadosomes, both of which 
are associated with a release of cytoskeletal tension 
(20). TRPM7 localizes to cell adhesions and associates 
with the actomyosin cytoskeleton through its a-kinase 
domain (8). Resembling its homologues in Dictyostelium 
discoideum, the TRPM7 a-kinase domain may reduce 
local cytoskeletal tension by phosphorylating the myosin 
II heavy chains (19). In addition to this immediate effect 
on cytoskeletal dynamics, TRP channels mediate more 
sustained effects on the cytoskeleton by the activation 
of Ca2+-sensitive transcription factors such as the 
nuclear factor of activated T cells (NFAT) family (5, 
24-26). Future studies should address to what extent 
TRPM7 moderates immediate and sustained effects on 
cytoskeletal organization and adhesion dynamics to 
promote and tumor malignancy.
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Concluding remarks
Consistent with the observation that TRPM7 is required for breast cancer cell migration 
and metastasis formation, we here show that high TRPM7 expression levels promote 
the migratory and metastatic properties of mouse neuroblastoma cells in vitro and in 
vivo. However, the molecular mechanism by which TRPM7 brings about these changes 
remains incompletely understood. Based on the increase in focal adhesion number, we 
previously postulated that TRPM7 knockdown in breast cancer cells interferes with cell 
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Figure 5. TRPM7-induced N1E-115 metastasis in mice resembles human neuroblastoma dissemination. 
(A) Representative H&E staining on liver tissue, collected 21 days after injection with N1E-115 cells. Prominent 
tumors in the liver indicate that both N1E-115 control and TRPM7 overexpressing cells metastasize to the liver. 
(B) Histopathological analysis of mouse tissue sections, collected 21 days after injection with either N1E-115 
control or TRPM7 overexpressing cells. Mouse tissues were scored for the presence of tumor cells. Adrenal 
glands of 5 mice were scored for presence of tumor cells, whereas 9 mice were dissected for other tissues. (C) 
Quantification of the number of liver tumors per mouse, measured in resected liver tissue from mice injected 
with N1E-115 control or TRPM7 overexpressing cells. Error bars represent SEM for n= 9 in each group. ** P 
< 0.01, two-tailed unpaired t-test with Welch correction. (D) Quantification of mean liver tumor size in mice 
injected with N1E-115 control and TRPM7 overexpressing cells. Error bars represent SEM for n = 9 mice in 
each group. (E) Size distribution of tumors in liver sections emphasizes similar growth rates for both cell lines. 
(F) Percentage of mice (left panel) and limbs (right panel) with bone marrow metastases. Error bars represent 
SEM for n = 9 mice in each group. ** P < 0.01, two-tailed unpaired t-test with Welch correction. (G) N1E-115 
control and TRPM7 overexpressing cells isolated from bone marrow retained their characteristic morphology, 
as illustrated by brightfield images and actin (Alexa-568 Phalloidin) labeling.
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Ma erial and Methods
Constructs and cell lines
Cloning of full length TRPM7-HA cDNA into LZRS-neo was previously described (8). Luciferase cDNA was 
isolated from pMX-luciferase-YFP-neo and subcloned into a retroviral pLZRS-IRES-zeocin vector. N1E-115 mouse 
neuroblastoma cells stably overexpressing TRPM7-HA, empty vector control and luciferase were generated by 
retroviral transductions. Transduced cells were selected by the addition of 0.8 mg/ml G418 or 0.4 mg/ml zeocin, 
respectively. Cells were cultured in DMEM supplemented with 10% FCS and 1% penicillin-streptomycin, at 37˚C 
and 5% CO2. The effect of TRPM7 overexpression on cell viability and proliferation was assessed by MTS assays 
according to manufacturer’s instructions (Promega, Madison, WI).
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Quantitative RT-PCR
Total mRNA isolation from tranduced N1E-115 cells (Qiagen, Valencia, CA) was followed by SuperScript cDNA 
synthesis (Life Technologies, Carlsbad, CA), according to manufacturer’s protocols. TRPM7 mRNA expression levels 
in N1E-115 cells were determined by quantitative PCR reactions using power SYBR-green reagent (Applied Biosystems, 
Carlsbad, CA) in combination with mouse specific TRPM7 primers (forward: TAGCCTTTAGCCACTGGACC; 
reverse: GCATCTTCTCCTAGATTGGCAG) according to manufacturer’s recommendations. TRPM7 mRNA 
expression levels were normalized to the GAPDH-housekeeping gene (forward: gccaaggtcatccatgacaac, reverse: 
gaggggccatccacagtctt) and calculated according to the cycling threshold method (27).
Cell adhesion and spreading and transwell migration
N1E-115 control or TRPM7 overexpressing cells were seeded on culture dishes in the presense of 10% FCS. Cell 
adhesion and spreading was followed for 24 hours by time lapse microscopy and analyzed using ImageJ image 
analysis software. Cell migration was assayed in transwells. Briefly, following overnight serum starvation, cells 
were harvested and resuspended in DMEM containing 0.1% FBS. 50.000 cells were applied to a transwell insert 
with 8 µm pore size (Corning Life Sciences, Corning, NY), which was incubated in DMEM supplemented with 
10% FBS. Cells were allowed to migrate for 48 hours at 37 °C. Migrated cells were fixed (75% methanol and 25% 
acetic acid), stained (0.25% Coomassie Blue, 45% methanol, 10% acetic acid in H2O) and counted in 4 random 
fields under a light microscope. 
 
Immunofluorescence microscopy
N1E-115 control and TRPM7 overexpressing cells were seeded on glass coverslips and serum starved (0.1% FCS) 
overnight. Cells were fixed with 4% paraformaldehyde in PBS for 10 minutes at room temperature and subsequently 
permeabilized with 0.1% triton X-100 in PBS for 3 minutes. Antibodies were used to reveal the presence of vinculin 
(1:5000, Sigma-Aldrich, St. Louis, MO) and Alexa488-conjugated secondary antibodies (1:1000, Life Technologies, 
Carlsbad, CA). As no antibodies were available against Cortactin, GFP-tagged proteins were introduced into 
N1E-115 TRPM7 overexpressing cells. Transfections were carried out using Fugene HD Transfection Reagent 
(Roche Applied Science, Indianapolis, IN) according to manufacturer’s recommendations. F-actin was detected as 
indicated in figure legends. Cells were imaged using a Leica TCS SP5 confocal microscope or Zeiss Cell Observer 
wide-field microscope equipped with phase contrast optics. To determine cell adhesive surface area, cells were 
loaded with CellTracker-Green (Life Technologies, Carlsbad, CA) prior to fixation and imaged in TIRF mode.
Matrix degradation assay
Fluorescent gelatin-coated coverslips were prepared using 100/mg/ml gelatin, labeled with ATTO-633 (Sigma-
Aldrich, St. Louis, MO). PolyL lysine coated coverslips were incubated in a drop of gelatin-633, supplied with 5% 
FCS, which was subsequently cross-linked in 0.5% gluteraldehyde. Using 5 mg/ml NaBH4, free gluteralderhyde 
reactive chains were quenched. Coverslips were sterilized in 70% EtOH. 50.000 cells per coverslip were seeded 
and cultured overnight in the presence of BB94 metalloprotease inhibitor. The next day, BB94 was washed away 
and the cells were allowed to degrade matrix for 1 hour. Cell were subsequently fixed and stained as described 
above. Matrix degradation was visualized using a Leica TCS SP5 confocal microscope.
Mouse xenograft experiments
All animal work was performed in accordance with protocols approved by the Animal Welfare Committee 
(DEC-NKI-10.034). Rag2-/-Il2rg-/- immunodeficient mice, backcrossed on a Balb/c background, were used for 
metastasis experiments at 5-8 weeks old. N1E-115 mouse neuroblastoma cells were trypsinized and washed 3 
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times with PBS. Subsequently, 0.2 ml PBS containing 5*105 cells was injected into a tail vein. Tumor growth was 
monitored by bioluminescence imaging from day 7 onwards. Beetle luciferin (Promega, Fitchburg, WI, USA) 
was dissolved at 15 mg/ml in sterile PBS and stored at -20°C. Animals were anaesthetized with 2-3% isoflurane. 
Luciferin solution was injected i.p. (0.01 ml per gram body weight). Light emission was measured 15 min later, 
using a cooled CCD camera (IVIS; Xenogen), coupled to Living Image acquisition and analysis software over an 
integration time of 1 min. Signal intensity was quantified as the Flux (photons/s) measured over the abdominal 
region. Organs and tissues were collected at day 20 after injection, fixed in EAF (ethanol-acetic acid-formol saline 
fixative, 40:5:10:45 v/v) and processed routinely for histology preparations. The paraffin sections were stained 
with Haematoxylin and Eosin (H&E). For quantitative analysis of the neoplastic lesions, liver sections (9 sections 
from each liver) were stained with Haematoxylin and Eosin. Liver tumors were quantified under a microscope 
and the data were further processed by Image J.
Bone marrow isolation
Under sterile conditions, both femur and tibiae from each mouse were excised. Muscles and connective tissue 
were removed. The ends of the bones were removed and the shaft of the bones was flushed with DMEM 
supplemented with 10% FBS and 100 IU/ml penicillin-100 mg/ml streptomycin using a 25-gauge needle. Bone 
marrow suspension was centrifuged at 1400 rpm for 5 min and the cell pellet was resuspended in 1 ml of red 
cell lysisbuffer and incubated 10 min at room temperature. Subsequently, 10 ml of medium was added and cells 
were centrifuged at 1400 rpm for 5 min. Cell pellet was resuspended in 300 µl of medium and plated in a 96-well 
plate (100 µl per well). After 3 hours at 37°C, 10 µl beetle luciferin (Promega, Fitchburg, WI, USA; 15 mg/ml) 
was added per well and luminescence recorded as described for in vivo imaging. 
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Abstract
The a-kinase family represents a class of atypical protein kinases that display little sequence 
similarity to conventional protein kinases. Early studies on myosin heavy chain kinases 
(MHCKs) in Dictyostelium discoideum revealed their unusual propensity to phosphorylate 
serine and  threonine residues in the context an a-helix.  Although recent studies show 
that some members of this family can also phosphorylate residues in non-helical regions, 
the name a-kinase has remained. During evolution, the a-kinase domains combined with 
many different functional subdomains such as von Willebrand factor-like motifs (vWKa) and 
even cation channels (TRPM6 and TRPM7). As a result, these kinases are implicated in a 
large variety of cellular processes such as protein translation, Mg2+ homeostasis, intracellular 
transport, cell migration, adhesion and proliferation. Here, we review the current state 
of knowledge on different members of this kinase family and discuss the potential use of 
a-kinases as drug targets in diseases such as cancer.
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Introduction
The reversible phosphorylation of proteins catalyzed by protein kinases and phosphatases 
is one of the principle regulatory mechanisms of signal transduction. Kinase regulated 
signaling cascades control a large variety of cellular functions and physiological processes 
such as transcription, protein translation, DNA replication and repair, cell adhesion, cell 
migration as well as cell growth and proliferation. As a consequence, defects in protein 
phosphorylation are frequently associated with the pathogenesis of human diseases including 
cancer, diabetes and inflammatory disorders. Owing to their well defined catalytic properties, 
kinases represent one of the most favored groups of drug targets of the pharmaceutical 
industry. To identify novel specific kinase inhibitors and facilitate translational research into 
the use of such drugs, a detailed understanding of the regulation and function of kinases and 
their substrates is essential.
The protein kinase-like superfamily consists of a large collection of proteins sharing 
functional properties that allow them to catalyze the transfer of phosphate from ATP to a 
variety of substrates including proteins and lipids (1). The majority (90%) of protein serine/
threonine and tyrosine kinases are classified as conventional protein kinases (CPKs) since they 
possess a common architecture within the catalytic domain. The remaining protein kinases 
(about 10%), which display little sequence similarity to CPKs, are referred to as atypical 
protein kinases (APKs) and include protein kinases related to histidine kinases from bacteria, 
phosphoinositide 3-kinase related kinases and a-kinases. Phylogenic studies point out that 
both CPKs and APKs are broadly distributed in prokaryotes and eukaryotes (2). In addition, 
the ancient origin of both groups of kinases suggest that APKs developed in parallel with 
CPKs and do not simply represent modified CPKs. However, a specific subfamily of APKs 
known as a-kinases is exceptional in that it appeared recently in evolution and therefore 
displays a distribution limited to eukaryotes (2, 3). Scheeff and Bourne hypothesized that 
a-kinases developed to provide a novel signaling capacity within more complex eukaryotic 
organisms (2). Here, we highlight the research performed on a-kinases to date and their 
potential involvement in human disease. 
a-Kinases, a novel class of protein kinases
a-Kinases were first recognized as a novel class within the protein kinase superfamily by 
Ryazanov and colleagues (4) after earlier publications on the identification and characterization 
of the Dictyostelium Myosin Heavy Chain Kinase A (MHCK-A), B (MHCK-B) and C (MHCK-C) 
(5-7). Following the cloning of human, mouse, rat and Caenorhabditis Elegans eukaryotic 
Elongation Factor-2 Kinase (eEF2K, previously known as CaMKIII) (8), sequence analysis 
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revealed a surprising lack of sequence similarity to known protein kinases (4). However, 
its catalytic domain was found to be strikingly similar to that of the Dictyostelium MHCKs, 
suggesting the existence of a new class of protein kinases with a novel catalytic domain 
structure (8). The cloning of several a-kinases allowed for the rapid identification of other 
members of this kinase family in various genomes (Fig. 1) (1, 4).
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Figure 1. Phylogenetic analysis of the a-kinase family. A PSI-Blast (152) search was done, starting with 
the TRPM7 a-kinase domain and using three iterations, to detect all sequenced a-kinases. For those sequences 
that were detected with PSI-Blast, but that were not detected as having an a-kinase domain by SMART (151), 
reciprocal PSI-Blast searches were performed to ensure that they were indeed homologous a-kinases. From the 
results, species were included so that the major eukaryotic taxa with a-kinases would be represented in the tree. 
Selected sequences were then aligned using ClustalW2 (153). A phylogenetic tree was generated using PHYML 
(154) as implemented in Seaview (155). Bootstrap values of the major branches are indicated. The dashed line 
separates vertebrate from invertebrate a-kinases. Red branches indicate N-terminal a-kinases. a-Kinases with a 
typical subdomain architecture are indicated in the colors that refer to the schematic representations in Table 1.
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The a-kinase family was named after the unique mode of substrate recognition by its 
initial members, the Dictyostelium MHCKs. In contrast to the target sites of CPKs, which 
are usually located within loops, b-turns or irregular structures (9), the substrate residues 
targeted by MHCKs were found to be located within protein sequences that adopt an a-helical 
conformation (10, 11). However, recent in vitro data suggest that this is not the consensus 
as multiple a-kinases were found to target residues in non-helical regions as well (12, 13). 
Currently, a-kinases represent a family of atypical protein kinase with a unique catalytic 
domain architecture homologous to the Dictyostelium discoideum MHCKs. Determinants 
for substrate recognition remain largely unknown, although the necessity of a basic residue 
following the phosphoacceptor aminoacid has been shown previously (14). 
To date six human a-kinases have been identified. In addition to eEF2K, the human genome 
encodes a-kinase 1 (Lymphocyte Alpha-Kinase, LAK or ALPK1), a-kinase 2 (Heart Alpha-
Kinase, HAK or ALPK2) and a-kinase 3 (Muscle Alpha-Kinase, MAK or ALPK3), initially named 
after the tissue in which they were identified (4). The remaining two mammalian a-kinases, 
TRPM6 and TRPM7, represent cation channels belonging to the TRP ion channel family.
The a-kinases found in men are widely distributed among vertebrates. In contrast to the 
other human a-kinase containing proteins, eEF2K can also be found in invertebrates such as 
the metazoan Trichoplax adhaerens and in the diatom Thalassiosira pseudonana, indicating that 
eEF2K represents the oldest a-kinase within the vertebrates. According to the phylogenetic 
tree, eEF2K appears to be most closely related to the Dictyostelium discoideum MHCKs, 
especially to MHCK-B and MHCK-C, consistent with the unique N-terminal localization 
of their a-kinase domains (Fig. 1 & Table 1). The four Dictyostelium MHCKs share many 
structural and functional features which is supported by their isolated position in the phylogeny 
(7, 15-19). The closely related Dictyostelium a-kinase 1 (AK1) contains an N-terminal Arf-
GAP domain (19) and is, like the MHCKs, specifically expressed by Dictyostelium discoideum, 
indicating taxon specific gene duplications and recombination. As AK1 has not been functionally 
characterized, it is not discussed in depth. In the ciliate Tetrahymena thermophila, gene 
amplification of a-kinases is evident as its genome encodes eight very similar a-kinases with 
an N-terminal von Willebrand Factor A motif. Another striking example is the collection of 
a-kinases encoded by the genome of Entamoeba Histolytica which includes many different 
domain architectures, including proteins with SH3 and p53-like domains (20). This phylogenetic 
tree contains a number of a-kinases which are neither highlighted (Fig. 1) nor discussed in 
Table 1 as they have no typical subdomain organization and have yet to be characterized. 
Overall, we postulate that the divergent family of a-kinases arose by independent taxon 
specific gene duplications and recombination with a variety of subdomains.
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Elucidation of the crystal structure of the TRPM7 kinase domain by Yamaguchi and 
colleagues led to the striking observation that, despite a lack of sequence similarity, the 
a-kinase catalytic core has an architecture related to that of CPKs (21). CPKs and a-kinases 
share a remarkably similar N-terminal lobe that predominantly folds into a curved b-sheet 
and contains the phosphate binding loop (P-loop). The C-terminal lobe, however, might 
appear to be more divergent although in both cases it largely consists of a-helices and the 
activation loop can easily be distinguished (Fig. 2A). The interlobe cleft serves as binding 
pocket for ATP and contains well conserved key catalytic residues, such as invariant lysine- 
(K1648 in TRPM7) and aspartate- (D1767, D1777 in TRPM7), that are located in similar 
positions to position the ATP and coordinate Mg2+ ions (Fig. 2B & Fig. 3).
Although the ATP binding pockets of CPKs and a-kinases are structurally very alike, 
the nature of interactions between the kinase and base and sugar moieties of ATP differ 
significantly and may also differ within the a-kinase family itself (21). One striking difference 
is the localization of the conserved GXGXXG motif which, in CPKs, is positioned within 
the catalytic P-loop and serves to bind phosphates. Although a-kinases do contain a similar 
glycine rich motif, it is not located within the P-loop but in another loop proximal to the 
C-terminus (Fig. 3). This loop structurally resembles the activation loop in CPKs which is 
involved in peptide substrate recognition, suggesting a similar function for the glycine rich 
motif in a-kinases (21). 
The different modes of substrate recognition between a-kinases and CPKs may explain 
the distinct set of a-kinase substrates. Another major distinction between a-kinases and 
CPKs is the presence of a zinc-finger motif within the C-terminus of a-kinases (Fig. 2C 
& Fig. 3). This motif coordinates a zinc ion and is thought to play an important role in 
stabilizing the tertiary structure of the catalytic core. Indeed, mutation of the conserved 
cysteine residues (C1812, C1816 in TRPM7) abrogates kinase activity (22, 23). For an in-
depth comparison between the structures of a-kinases and CPKs, we refer the reader to 
a review by Drennan and Ryazanov (3). 
Members of the a-kinase family
Myosin heavy chain kinases in Dictyostelium
Tight regulation of myosin II induced contractility is essential for processes like cytokinesis and 
cell migration. Myosin II regulation by light chain phosphorylation has been described in many 
eukaryotic systems and is well known to regulate activity of the myosin motor domain (24). 
A role for myosin II heavy chain (MHCII) phosphorylation in regulating  myosin II activity and 
function was initially established in lower eukaryotes such as Dictyostelium and Acanthamoeba 
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(25-28). The incorporation of phosphate into the Dictyostelium myosin heavy chain, residues 
Thr1823 (11), Thr1833 and Thr2029 (10), inhibits its ability to self-assemble into bi-polar 
filaments, which is required for the generation of contractile forces (26). Mutagenesis of 
these residues into non-phosphorylatable alanines (3xAla) induces overassembly of myosin 
II proteins, severely affecting polarization, chemotaxis and cytokinesis (28, 29).
In search of protein kinases responsible for heavy chain phosphorylation in Dictyostelium, 
MHCK-A was identified in actomyosin precipitations  and shown to specifically incorporate 
phosphate into the a-helical myosin II heavy chain (15). Thereby, MHCK-A reduced the 
filament forming properties of myosin II and inhibited overall myosin II function (15, 26, 28, 
30). Cloning of MHCK-A revealed three separate domains (Table 1). A coiled-coil N-terminal 
region (~500 amino acids) is involved in the heteromerization of the kinase (31) and required 
for MHCK-A translocation to actin-rich cell regions such as the cortex. Moreover, it directly 
interacts with actin filaments in vitro which increases its kinase activity ~40-fold (32, 33). 
More recently, actin crosslinking was shown to be an additional feature of this domain (34). 
This suggests that, in addition to driving myosin II disassembly, MHKC-A may also affect the 
actin-myosin cytoskeleton by crosslinking actin filaments. The second domain represents the 
catalytic domain (Amino acids ~550-800), which showed no homology to known eukaryotic 
protein kinases (5, 6). Finally, the C-terminus contains a stretch of seven WD-repeats that 
generally coordinate multi-protein complex assemblies (35). Steimle and colleagues showed 
that the MHCK-A WD-repeat domain binds directly to the myosin heavy chain and thereby 
targets the kinase towards its substrate (36). Neither the N-terminal coiled-coil domain nor 
the WD-repeats are required for catalytic activity (6). However, these domains are essential 
in substrate phosphorylation which is strongly enhanced by autophosphorylation of the 
region that links the coiled-coil region to the catalytic core (Amino acids 500-550) (6, 37). 
Apart from MHKC-A, the Dictyostelium genome encodes three additional myosin heavy 
chain kinases, MHCK-B, MHCK-C and MHCK-D (7, 16, 38), with a catalytic domain very 
similar to that of MHCK-A. Each of these MHCK isoforms contains a C-terminal WD domain 
but in contrast to MHCK-A, MHCK-B and MHCK-C lack the large N-terminal coiled-coil 
region (Table 1). Although MHCK-D remains functionally uncharacterized to date, it does 
contain this coiled-coil region and according to sequence similarity, it appears to be the 
closest relative of MHCK-A (Fig. 1). MHCKA, B and C share many biochemical features. 
Kinase activity is regulated by autophosphorylation (17, 37, 39) and all three specifically target 
threonine residues within the MHCII in vitro, which results in myosin II filament disassembly (7, 
16-19). MHCK-A, B and C triple gene knockouts induce myosin II overassembly and severely 
affect cytokinesis, resembling the phenotypes observed when MHCII phosphorylation was 
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inhibited by substituting the targeted residues with alanine 
(3xAla) (19, 28). Overexpression of MHCK-A, B and C, 
on the other hand, also results in impaired cytokinesis by 
hyperphosphorylation of MHCII inducing myosin II filament 
disassembly (30, 39, 40). 
In spite of these similarities, the spatial regulation of 
the MHCK isoforms differs significantly, indicating specific 
functions for each isoform. Both MHCK-A localization and 
activity appear to be actin dependent (32, 41, 42). In response 
to stimulation by chemoattractants such as cAMP, MHCK-A 
is enriched in the actin-rich leading edge of the cell where it 
disassembles myosin II filaments (41). MHCK-A might thus 
provide a mechanism by which myosin II is locally inactivated, 
allowing actin based cellular protrusions such as lamellipodia 
and phagocytic cups to be formed. Hence, MHCK-A plays 
an important role in maintaining cell polarity, chemotaxis 
and cell migration (29). Both MHCK-B and C are enriched in 
the contractile ring during late cytokinesis, driving myosin II 
disassembly for efficient cell division. In addition, MHCK-C 
is enriched in the posterior region of moving cells were 
it could play a role in the disassembly of the actomyosin 
cytoskeleton and myosin II recycling required for proper cell 
body translocation (16, 17, 19, 38). Notably, in contrast to 
MHCK-A, MHCK-C distribution fully depends on myosin II 
(16, 17). Altogether, these spatial differences indicate specific 
roles for MHCK isoforms in fine tuning the Dictyostelium 
actomyosin cytoskeleton.
Table 1. Overview of a-kinases. The main characteristics of a-kinases 
and the domain architectures of these proteins. Domains were determined 
using SMART (151) and published data. The colors of these domains refer 
to colors used in Figure 1 to indicate the specific a-kinase subtypes. If 
known, substrate specificity is indicated together with the preference for 
threonines and/or serines. MHCII: Myosin II heavy chain. 
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vWFa-Kinase
vWFa-Kinase (vWKa) is one of the more recently identified a-kinases in Dictyostelium, 
carrying a kinase catalytic domain (Amino acids 398-592 in Dictyostelium) similar to the 
MHCKs. In contrast to MHCKs however, it is broadly expressed among invertebrates (Fig. 
1), it phosphorylates both threonine and serine residues (14) and has a distinct domain 
organization (Table 1). It lacks the C-terminal WD repeat domain and consequently, the 
kinase domain is located at the extreme C-terminus (Table 1). Furthermore, the protein 
contains an N-terminal vWFa motif (Amino acids 121-233 in Dictyostelium) (40). This domain 
is named after its homology to von Willebrand Factor A, a plasma glycoprotein essential for 
proper blood clotting. The vWFa domain mediates receptor-ligand binding, protein-protein 
interactions, multiprotein complex formation. Proteins containing a vWFa domain are involved 
in cell adhesion such as integrin-collagen interactions, but also in DNA repair and transcription 
(reviewed in (43). Like for the heavy chain kinases in Dictyostelium, overexpression of vWKa 
leads to multinucleation, indicative of defects in cytokinesis due to disregulation of myosin II 
function (40). Significant myosin II overassembly was observed after vWKA gene disruption, 
resembling the effect of MHCK gene disruption and introducing non-phosphorylatable 
threonine-alanine mutations into the myosin heavy chain (3xAla) (19). This is consistent with 
the notion that vWKa could be an additional myosin heavy chain kinase. However, several 
observations are in conflict with this hypothesis. First, overexpression of vWKa increased 
myosin II assembly (40). Second, vWKa is unable to phosphorylate the myosin II heavy chain 
in vitro, although it autophosphorylates and has intrinsic catalytic activity (40). Surprisingly, 
both overexpression and gene disruption of vWKa increased the myosin II protein levels 
by means of an unknown mechanism (40). Altogether, these results do indicate a role for 
vWKa in the regulation of myosin II but not by direct phosphorylation of its heavy chain. 
vWKa localizes to contractile vacuoles, organelles involved in osmoregulation, and to the 
perinuclear golgi apparatus (40). Hence, it is highly unlikely that, although varying vWKa 
expression levels affects growth kinetics, cell division and development, its function is 
restricted to the dedicated functions of the previously identified MHCKs.
 
eEF2-kinase
Eukaryotic Elongation Factor-2 Kinase (eEF2K) is a regulator of global protein synthesis. 
It phosphorylates eukaryotic Elongation Factor-2 (eEF2), a ribosome binding protein that 
catalyzes the movement of ribosomes along the mRNA during translation in most eukaryotic 
cells (44). Phosphorylation of eEF2 on threonine residues Thr56 and Thr58 decreases its affinity 
for ribosomes and inhibits the global rate of protein synthesis (45-49). As eEF2K activity is 
Ca2+ and calmodulin dependent, it was initially classified as a member of the Ca2+/calmodulin-
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dependent (CaM) protein kinase family (48, 50). However, sequence analysis revealed no 
homology to the other CaM-kinases. Instead its sequence showed remarkable homology 
to the previously described Dictyostelium MHCKs (8). Additionally, eEF2K phosphorylates 
threonines whereas the other members of the CaM-kinase family predominantly target 
serine residues (48). Of note is a publication by Jorgensen and colleagues showing that 
the targeted threonine residues are not located within an a-helix, as was determined by 
crystallography on the yeast eEF2 (12). 
eEF2K comprises three functional domains (Table 1). The catalytic domain (Amino acids 
100-350) is flanked at its N-terminus by a calmodulin binding domain (Amino acids 51-96), 
while its C-terminus contains the eEF2 binding domain (Amino acids 521-725) required for 
substrate targeting (23, 51). Importantly, catalytic activity of eEF2K requires the binding of 
calmodulin to the calmodulin binding domain.
Since protein translation consumes a large amount of energy, the cell must carefully 
balance the activity of eEF2K with its need for protein translation. Therefore, eEF2K activity 
is modulated through multisite phosphorylation by kinases downstream of mTOR and AMPK, 
the central sensors of cellular nutrients and energy levels (52-56). In the presence of sufficient 
nutrients, its kinase activity towards eEF2 is suppressed. Upon nutrient deprivation and 
hypoxia, the suppression of eEF2K is relieved which results in the phosphorylation of eEF2 
and consequently, inhibition of protein synthesis (reviewed in (55)).
eEF2K appears to be a major regulator of autophagy downstream from mTOR, which, 
besides the common degradation of organelles, serves as a cellular coping strategy to 
deal with long-term nutrient deprivation (57, 58). When cells are deprived of nutrients, 
they will consume their own cytoplasmic content to obtain the energy needed to survive 
(59, 60). During this state of metabolic stress, protein synthesis is inhibited by increased 
phosphorylation of eEF2 which terminates protein elongation (58, 61). This may be further 
enhanced by a decrease in pH due to hypoxia which dramatically increases eEFK2 activity 
(62). As a consequence, a cell becomes more resistant to metabolic stress. An increased 
eEF2K activity has been observed in many cancers and may promote cancer cell survival, 
tumor growth and metastasis, processes that require the cell to cope with hypoxia and 
nutrient deprivation (57, 58, 63). Moreover, silencing of eEF2K was shown to sensitize tumor 
cells to treatments that induce energy stress and cytotoxicity (64). 
Another link between eEF2K and cancer is the close relationship between eEF2/eEF2K 
activity during cell-cycle progression (reviewed in (65)). During G1-phase, the stage in which 
cell growth takes place, eEF2K is inactivated and consequently, eEF2 becomes active permitting 
protein synthesis. During DNA replication in the S-phase, eEF2K slowly dephosphorylates 
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to fully inhibit eEF2 at the start of the G2 and 
M phase, where proofreading and mitosis take 
place. The common explanation for this decline in 
protein synthesis is that cellular energy sources 
are to be redirected from protein synthesis to 
proofreading and the actual cell division. Various 
reports describe delayed cell cycle progression 
or a complete arrest by deregulation of eEF2 
or eEF2K (63, 66-68) which makes the eEF2/
eEF2K pathway an attractive drug target for 
cancer treatment. 
Figure 2. a-Kinases: structure and conservation. 
(A) Crystal structure of TRPM7 as determined by Yamaguchi 
et.al. (21). N-terminus (N) refers to residue G1579 in the 
human TRPM7 amino acid sequence. Please note that this 
residue corresponds to G1577 in the mouse sequence. 
Indicated are domains that resemble the N-terminal lobe 
(containing P-loop), C-terminal lobe (containing activation 
loop) and interlobe cleft of CPKs. Conserved residues within 
the a-kinase family (Fig. 3) are indicated in red. B) The well 
conserved interlobe cleft functions as ATP binding pocket. 
The ATP molecule (yellow) is positioned within the binding 
pocket by multiple residues that are well conserved within 
the a-kinase family (red). The indicated residue identities 
refer to the human TRPM7 amino acid sequence (Fig. 3). 
C) Typical zinc-finger domain within the C-terminal lobe 
of a-kinases. Residues that bind the zinc molecule (green) 
are well conserved between the a-kinase family members 
(red). The indicated residue identities refer to the human 
TRPM7 amino acid sequence (Fig. 3). 
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a-Kinase 1, 2 and 3
The vertebrate a-kinase (ALPK) 1, 2 and 3 were initially named after the tissues in which they 
were identified by Ryazanov and colleagues (4, 69); lymphocyte a-kinase, heart a-kinase and 
muscle a-kinase respectively. All three carry an a-kinase domain at their extreme C-terminus 
that is particularly well conserved between ALPK2 and ALPK3 (Table 1 & Fig. 1).
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Figure 3. Sequence alignment of Dictyostelium and human a-kinases. Dictyostelium and human a-kinase 
amino acids sequences corresponding to the human TRPM7 a-kinase domain (G1579-T1830) were aligned using 
ClustalW2 sequence alignment software (153). Names and species (D.d. for Dictyostelium discoideum and H.s. 
for Homo sapiens) are indicated on the left. Conservation of specific residues within this group of a-kinases, 
corrected for missing sequences, is indicated by shadings of blue and a barchart supporting the alignement (0: 
not conserved, 100: fully conserved). Red bars represent fully conserved residues and are indicated red in Fig. 
2. Sequences representing the P-loop and GXGXXG motif are indicated on top. The indicated residue identities 
refer to the human TRPM7 amino acid sequence. 
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ALPK1 has been implicated in epithelial cell polarity and exocytic vesicular transport 
towards the apical plasma membrane (70). ALPK1 resides on golgi-derived vesicles where 
it phosphorylates myosin IA, an apical vesicle transport motor protein that regulates the 
delivery of vesicles to the plasma-membrane (70). To our knowledge, no functional studies 
have been performed on ALPK2. Expression of ALPK3, also known as Midori (myocytic 
induction/differentiation originator) is restricted to fetal and adult heart, and adult skeletal 
muscle. Overexpression of ALPK3 enhances differentiation of murine embryonic carcinoma 
cells into cardiomyocytes. As ALPK3 localizes to the nucleus, it is thought to act as a 
transcriptional regulator implicated in early cardiac development (71).
TRPM6 and TRPM7
Transient Receptor Potential (TRP) cation channels make up a large protein superfamily. 
Members of this family function as cellular sensors responding to stimuli such as temperature, 
taste, touch, pain, osmolarity and mechanical stress (72-74). TRPM6 and TRPM7 belong to 
the melastatin-related subfamily of TRP (TRPM) channels, which represents a group of eight 
proteins displaying a wide range of structural features, expression patterns, ion selectivity, 
gating properties and functions (75). Both TRPM6 and TRPM7 are unique in the sense that 
they encode divalent cation channels fused to an a-kinase domain. As these unusual channel-
kinases have caught the attention of electrophysiologists worldwide, their channel properties 
have been studied in great detail. However, involvement of the a-kinase domain in regulating 
channel function remains subject to controversy. Before going into the proposed functions 
of the a-kinase domain within these channel-kinases, we will first discuss the regulation and 
function of their channel domains in cellular physiology. 
Like other TRP channels, TRPM6 and TRPM7 possess six transmembrane domains flanked 
by large N- and C-terminal tails that reside in the cytosol. Within the N-terminal tail, four 
stretches of amino acids are present which are conserved between the different members 
of the TRPM subfamily but whose function is poorly understood (75). Proximal to the last 
transmembrane domain in the C-terminal tail, there is the so called TRP box, a conserved 
stretch of amino acids present in all TRP ion channels. In addition, there is a coiled-coil domain 
and at the extreme C-terminus, the a-kinase domain (Table 1) (3). The transmembrane 
domains organize within the plasma membrane to form the channel with the pore formed 
by a short stretch of amino acids between the 5th and 6th transmembrane domains (76). 
Functional channels are most likely organized as either homo- or heterotetramers which 
have their unique electrophysical properties and functions (77-79). The exact mechanism of 
tetramerization is unknown. However, it has been demonstrated that several TRP channels 
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including TRPM2 and TRPM8 require the presence of the coiled-coil domain for the assembly 
of active channels (80, 81). 
TRPM7 is highly similar to TRPM6 displaying 50% identity at the amino acid level. Moreover, 
the kinase domains share 75% of their aminoacid sequence. Both channels are highly permeable 
to Mg2+ and Ca2+ (82, 83). In spite of these similarities, these proteins appear to be functionally 
non-redundant. While TRPM7 is ubiquitously expressed, TRPM6 expression is mostly limited 
to brain, intestine and kidneys (84). Knockout studies have shown that both TRPM6 and 
TRPM7 are essential in development as the loss of these channels is embryonic lethal (85, 
86). Moreover, overexpression of TRPM6 cannot rescue cell growth arrest due to the 
ablation of TRPM7 (79). Finally, mutations in TRPM6 cause familial hypomagnesemia with 
secondary hypocalcemia, a disease characterized by defects in renal and intestinal Ca2+ and 
Mg2+ absorption which progresses despite the expression of TRPM7 in both the kidney and 
intestine (87, 88).
The importance for TRPM6 in maintaining whole body Mg2+ levels, e.g. by renal Mg2+ 
reabsorbtion, is widely accepted, (82, 84, 89). The role of TRPM7 in Mg2+ homeostasis however, 
remains controversial. Various publications have implicated TRPM7 in the regulation of cellular 
Mg2+ levels (83, 90, 91). However, there is its now increasing evidence that, in contrast to 
TRPM6, the TRPM7 channel might primarily be implicated in Ca2+ signaling (86, 92, 93). Initially, 
TRPM7 was thought to mediate cellular Mg2+ homeostasis based on the growth arrest in 
TRPM7-deficient DT-40 B cells, which could be restored by culturing these cells in media 
supplemented with high Mg2+ (79, 83, 91). However, in other cell types such as retinoblastoma 
cells, defects in cell growth due to loss of TRPM7 expression could not be reverted by the 
addition of Mg2+ (92). Several investigations implicate TRPM7 in a number of other cellular 
functions including anoxic cell death, exocytosis, mechanotransduction, cell proliferation, cell 
adhesion and cell migration (93-100), processes that depend on TRPM7-mediated Ca2+ influx 
rather than involving Mg2+. Importantly, it was recently shown that TRPM7 was not essential 
for maintaining Mg2+ levels in mice TRPM7 knockout thymocytes (86). The current opinion is 
that TRPM7 regulates local intracellular Ca2+ concentrations and thereby affects the functioning 
of Ca2+ sensitive proteins in its close proximity (94, 98, 101).
Channel opening is regulated via multiple mechanisms. A unique feature of TRPM6 and TRPM7 
channels is their inhibition by intracellular Mg2+ (82, 83). Furthermore, cation conductance is 
regulated through signaling by G-protein coupled receptors such as the bradykinin receptor (102). 
Additionally, TRP channels are well-known mechanosensors. Their conducting properties are 
modulated upon application of mechanical force which result in a variety of cellular responses 
(103-105). Consistently, TRPM7 channel opening is regulated by mechanical force (94, 96, 106). 
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The role of the TRPM6 and TRPM7 a-kinase domain in mediating the influx of cations is 
still under debate. Both a-kinase domains have been suggested to function as intracellular 
Mg2+ sensors that mediate channel permeability (91, 107-110). Additionally, the RACK1 
scaffold protein inhibits Mg2+ conductance in a autophosphorylation dependent manner 
through binding of the TRPM6 kinase domain (111). Furthermore, the Repressor of Estrogen 
receptor Activity (REA) inhibits TRPM6 channel opening in a similar manner. Of interest 
is the fact that the interaction between REA and the a-kinase domain can be abolished 
by estrogens, suggesting involvement of estrogens in Mg2+ homeostasis (112). In contrast, 
phosphotransferase activity appears to be unrelated to channel opening in the case of TRPM7. 
For instance, TRPM7 channels where the entire kinase domain has been deleted remain 
sensitive to inhibition by Mg2+ and Mg2+-nucleotide complexes (91, 110). Furthermore, point 
mutations in the TRPM7 kinase domain that abolish phosphotransferase activity do not 
appear to affect TRPM7 channel gating (93) and have only a minor effect on the inhibition of 
TRPM7 channel activity by Mg2+ and Mg2+-nucleotides (113). Hence, the consensus in the field 
is that the kinase activity is not essential for opening of TRPM7 channels (114). Instead, our 
work and that of others points towards an alternative model where the opening of TRPM7 
channels affects kinase function. Since Ca2+ does not directly influence kinase activity (115), 
we propose that a local increase in Ca2+ concentration regulates the recruitment/targeting 
of TRPM7 substrates (116). 
Rather than modulating channel opening, the TRPM7 kinase domain transmits intracellular 
signals via the phosphorylation of downstream targets such as annexin 1 in a Ca2+-dependent 
manner. Annexin 1, a member of the annexin phospholipid binding family, binds Ca2+ which 
leads to a conformation change exposing the target residue to the TRPM7 kinase domain 
(117). Although annexins are known to be involved in Ca2+-dependent actin dynamics and 
membrane subdomain organization (118), the physiological relevance of the TRPM7-annexin 1 
interaction remains to be elucidated. TRPM7 function has been linked to vascular remodeling. 
Stimulation of Vascular Smooth Muscle Cells (VSMC) by the vasoactive, G-protein coupled 
receptor agonist bradykinin increases TRPM7 expression, autophosphorylation (indicative 
of kinase activity (116)), channel opening, annexin 1 activity and cell migration (119, 120). 
These findings appear to connect TRPM7 channel opening (Mg2+ and Ca2+ influx ), kinase 
activity and substrate targeting with cytoskeletal remodeling.
We recently reported the Ca2+- and kinase dependent interaction between TRPM7 and 
the actomyosin cytoskeleton (93). Very similar to the Dictyostelium myosin II heavy chain 
kinases, TRPM6 and TRPM7 are capable of phosphorylating the three mammalian a-helical 
assembly domains of the myosin II heavy chain isoforms, MHCIIA, IIB and IIC, at least in vitro 
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(13). Consequently, kinase activity may induce myosin II filament disassembly, affecting stress 
fiber formation and reducing actomyosin contractility (121, 122). Apparently, this property of 
a-kinases has been preserved during evolution. However, unlike the Dictyostelium MHCKs, 
we have shown that TRPM6 and TRPM7 can also phosphorylate the non-helical C-terminus 
of MHCIIB and MHCIIC, which suggest that residues phosphorylated by these mammalian 
a-kinases are not exclusively positioned within an a-helix (13).
Actomyosin contractility plays a central role in regulating the assembly and disassembly of 
adhesive contacts such as focal adhesion and invasive adhesions such as podosomes (123-125). 
The formation of podosomes requires a local inhibition of contractility (126). Accordingly, 
activation of TRPM7 in neuroblastoma cells results in Ca2+- and kinase dependent podosome 
formation suggesting a close link between TRPM7, cytoskeletal dynamics and cell adhesion 
(93). Consistently, Wei and colleagues showed that TRPM7 contributes to local Ca2+ flickers 
in response to mechanical stimulation, which mediate cell polarization and steer migration 
(94). In conclusion, TRPM7 appears to act as a mechanosensor that conducts Ca2+ upon 
exposure to mechanical stress which elevate local Ca2+ levels allowing Ca2+- and kinase- 
dependent cytoskeletal rearrangements to take place (93, 101).
Regulation of (a-) kinase activity
Over the years, many different mechanisms have been proposed to regulate the activity of 
CPKs. In general, kinases adopt different conformations in their inactive and active states 
(127). For several kinases, the inactive state is stabilized by intramolecular interactions 
with regulatory domains (128, 129). Transition to the active state can occur by association 
with regulatory proteins, lipids or second messengers such as cAMP (128, 130, 131), (de)
phosphorylation by upstream phosphatases and kinases (129, 132) or autophosphorylation 
(133). In addition to directly influencing the catalytic activity of the kinase, regulatory domains 
may also serve as a docking site to recruit substrates, which are subsequently phosphorylated 
by the kinase (134). 
Initial studies in understanding the molecular mechanisms controlling the catalytic activity 
of a-kinases have revealed that members of this kinase family are regulated by mechanisms 
analogous to CPKs. The regulation of eEF2K has been the most extensively studied (52-56). 
Depending on nutrient availability, eEF2K phosphorylates eEF2 leading to an inhibition of 
protein synthesis. This system is controlled by several protein kinase cascades that lead to 
the phosphorylation of eEF2K which can either inhibit or activate its catalytic activity. Two 
major kinases involved in the control of metabolic processes are mTOR and AMPK, both 
of which control eEF2K activity (53-56, 135). Under conditions of nutrient deprivation, 
eEF2K activity remains high to suppress protein translation and this occurs through the 
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phosphorylation of Ser398 by AMPK, a kinase whose activity is induced by high AMP/ATP 
ratios in the cell (54). Elevation of cAMP in cells also inhibits protein translation but this 
pathway involves the phosphorylation of eEF2K by PKA (136). In contrast to AMPK, PKA 
phosphorylates Ser499 of eEF2K leading to increased enzymatic activity (137).
Other stimuli such as stress, growth factors and mitogens must ensure the inhibition 
of eEF2K to promote protein translation. Growth factors activate a rapamycin-sensitive 
pathway involving the activation of p70S6K by mTOR and a rapamycin–resistant pathway 
where ERK1/2 activate p90RSK (138). Both p70S6K and p90RSK phosphorylate Ser366 
which correlates with a decrease in eEF2K activity and eEF2 phosphorylation in cell lysates. 
Cellular stress induces a set of protein kinase cascades including ones involving members of 
the p38 MAPK family. These signaling pathways target eEF2K leading to its phosphorylation 
on Ser359 and Ser377 (139, 140). During mitosis, CDC2 phosphorylates Ser359 of eEF2K 
(52). The phosphorylation of these residues correlates with dephosphorylation of eEF2 and 
protein translation in cells. Thus, eEF2K is a target of multiple protein kinase cascades to 
control protein synthesis under various cellular conditions. It remains unknown to what 
extent other a-kinases are also phosphorylated by protein kinases to regulate their activity.
In addition to phosphorylation, eEF2K is activated allosterically by Ca2+/calmodulin which 
binds a region directly N-terminal of the catalytic domain. The dependence of eEF2K on 
Ca2+/calmodulin for optimal catalytic activity led scientists to originally call this protein 
CaMKIII. Phosphorylation of activating residues by autophosphorylation or ‘upstream’ 
protein kinases generates an eEF2K activity that is less dependent on Ca2+/calmodulin (141). 
However, other signaling cascades modulate the binding of Ca2+/calmodulin to eEF2K to 
regulate protein synthesis. Insulin activates a rapamycin-sensitive mTOR pathway leading to 
the phosphorylation of Ser78 nearby the calmodulin binding domain (53). Phosphorylation 
of this residue inhibits the binding of Ca2+/calmodulin to eEF2K preventing its activation 
(53). Finally, Ryazanov and colleagues postulated that eEF2K is activated at pH < 7.4, also 
occurring during hypoxia and ischemia and might thus represent another route in which 
metabolic stress inhibits protein synthesis (62).
Two regulatory mechanisms appear common to several members of the a-kinase family: 1) 
autophosphorylation and 2) a requirement of additional domains beyond the catalytic core for 
efficient substrate phosphorylation. All a-kinases studied to date including MHCKs, eEF2K, 
TRPM6 and TRPM7 undergo autophosphorylation. Intriguingly, the level of autophosphorylation 
displays a wide dynamic range with stoichiometry of phosphorylation ranging from 6–30 mol 
Pi/ mol kinase (17, 36, 37). Complete autophosphorylation does not appear to be required for 
activation of MHC kinases since autophosphorylation of three sites (out of 10) is sufficient 
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to activate MHCK-A (37) and myosin II phosphorylation proceeds in parallel to MHCK-C 
autophosphorylation (17). In contrast, TRPM6 and TRPM7 only phosphorylate myosin II 
under conditions allowing complete autophosphorylation of the kinases (116). TRPM6 and 
TRPM7 autophosphorylate a Ser/Thr-rich domain flanking the N-terminus of the catalytic 
domain. Autophosphorylation is not required for catalytic activity per se but provides a 
means for the kinase to recognize protein substrates such as myosin II. Notably, MHCKs 
and eEF2K also require additional domains for substrate recognition. The C-terminus of 
eEF2K (51) and MHCK (36) bind directly to their respective substrates. Deletion of these 
regions decreases the rate of protein phosphorylation without affecting the kinetics of 
phosphorylation of a synthetic peptide (23, 31, 36, 51). 
As mentioned earlier, the crystal structure of the TRPM7 a-kinase domain has been solved 
(142). Both in solution and in crystals the kinase forms a dimer which is essential for kinase 
activity (115, 142, 143). Also the TRPM6 and TRPM7 kinase domain can heteromerize to 
form a functional kinase (143). The a-kinase domains of TRPM6 and TRPM7 dimerize where 
a short stretch of amino acids (Amino acids 1553-1562) at the C-terminus interacts with 
key catalytic residues in the opposite monomer (143). Interestingly, a monomeric TRPM7 
kinase domain can be fully activated by incubating it with a peptide corresponding to the 
activation sequence spanning amino acids 1548-1576. Thus, the activation sequence amino 
acids 1553-1562 plays a key role in controlling TRPM6 and TRPM7 catalytic activity and 
changes in conformation within this region of the kinase by posttranslational modifications 
or binding to a regulatory protein or lipid could provide an important regulatory mechanism 
to control enzymatic activity.
a-Kinases in health and disease
Protein kinases are important drug targets for the treatment of human diseases such as cancer 
as they are often the result of deregulated kinase-dependent signaling pathways (reviewed 
in (144-146)). The majority of protein kinase inhibitors bind to the ATP-binding pocket 
abolishing the access of ATP to the protein kinase. This strategy poses a major challenge 
in designing effective compounds with suitable specificity to prevent potential side-effects 
due to the blockade of other protein kinases. Since a-kinases bind to the sugar and base 
moieties of ATP using a different molecular interface than CPKs (21), it may be possible to 
take advantage of this feature to develop specific protein kinase inhibitors.
Among a-kinases, eEF2K, TRPM6 and TRPM7 have been linked to the pathogenesis of 
human disease. As we previously described, eEF2K dysfunction has been linked to cancer 
progression via its effect on eEF2 activity. Several clinically applied anti-cancer drug such 
as Doxorubicin and Ontak, inactivate eEF2 directly and thereby inhibit protein synthesis 
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and cell cycling, leading to tumor cell death (65). A few compounds have been described 
to cause cell cycle arrest by inhibition of eEF2K of which NH125 is the most potent and 
specific in vitro (147). However, its clinical value in cancer treatment has yet to be revealed.
TRPM6 has been identified as the gene mutated in patients suffering from familial 
hypomagnesemia with secondary hypocalcemia (87, 88). Unfortunately, the majority of 
genetic lesions are frameshift mutations which lead to a premature arrest of the polypeptide 
chain and disrupts both the channel and kinase activities. Furthermore, Mg2+ conductance by 
the TRPM6 channel, rather than kinase activity, appear relate to familial hypomagnesemia. 
Hence, modulation of TRPM6 protein kinase activity by pharmacological agents is unlikely 
to provide an effective treatment of this disease.
TRPM7 has been linked to ischemic brain damage (95, 148, 149). Oxygen and glucose 
deprivation in neuronal cells is reported to mediate TRPM7 channel opening via a ROS-
dependent mechanism and the resulting Ca2+ influx induces cell death. Whether this is 
due to intracellular Ca2+ overload or a positive feedback loop in which Ca2+ influx triggers 
further ROS production is not known. A role for the a-kinase domain in anoxic cell death, 
if any, has not been established. As we described previously, kinase activity of TRPM7 is 
not required for channel activation. The opposite, however, is a possibility that cannot be 
excluded. The Ca2+ influx activates downstream signaling pathways that might implicate 
the TRPM7 a-kinase domain as well. Hence, specific TRPM7 kinase inhibitors are required 
to test this hypothesis. Although clinical application of TRPM7 kinase inhibitors is unlikely 
to be beneficial in cases of ischemic brain damage, TRPM7 may be a candidate drug target 
for the treatment of cancer. As was described before, and reported in recent publications 
(100, 150), changing TRPM7 expression levels affects cancer cell proliferation. But again, 
the role of its kinase domain therein remains to be established. Of current interest is 
the role of TRPM7 in cell migration and invasion. We have previously shown that the 
TRPM7 a-kinase associates with the cytoskeleton at sites of cell-ECM adhesion where 
it regulates the level of cytoskeletal tension, e.g. by myosin heavy chain phosphorylation, 
and the formation of adhesive structures called podosomes that permit cell invasion (93). 
Knowing that TRPM7 responds to mechanical force and steers cell polarity by initiating Ca2+ 
sparks (94), indicates that TRPM7 serves as mechanosensor that senses matrix properties 
and locally steers cytoskeletal remodeling to facilitate cell invasion. As the latter appears 
to be kinase dependent, it is tempting to speculate that inhibitors of the TRPM7 kinase may 
interfere with metastasis formation. 
The development of relatively specific, small cell-permeable inhibitors of a-kinases could 
also provide important research tools to identify the physiological substrates and functions of 
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these enzymes. These compounds can be used simply and rapidly and provide a complementary 
approach of genetic methods. An immediate question these inhibitors could help resolve is 
the role of the a-kinase domain in controlling the channel activity of TRPM6 and TRPM7, a 
debate that has been raging since the discovery of these channels at the turn of the century. 
Conclusions and future perspectives
a-Kinases form a distinct family of protein kinases with a unique domain organization and 
specific substrate preference. A comprehensive search for a-kinase domains encoded by 
eukaryotic genomes has revealed a large number of novel a-kinases, many of which remain 
uncharacterized. a-Kinases show a remarkable functional diversity, which most likely arose 
by taxon specific gene duplications and recombination with other protein domains. To date, 
two members of this kinase family, eEF2K and TRPM7, have been linked to cancer growth 
and progression, while a loss of TRPM6 function contributes to familial hypomagnesia 
with secondary hypocalcemia. As the large majority of the a-kinase family remains to be 
characterized, additional roles for this intriguing set of proteins will undoubtedly be discovered.
References
1. Manning G, Whyte DB, Martinez R, Hunter T, Sudarsanam S. The protein kinase complement of the human 
genome. Science (New York, NY. 2002;298:1912-34.
2. Scheeff ED, Bourne PE. Structural evolution of the protein kinase-like superfamily. PLoS Comput Biol. 
2005;1:e49.
3. Drennan D, Ryazanov AG. Alpha-kinases: analysis of the family and comparison with conventional protein 
kinases. Prog Biophys Mol Biol. 2004;85:1-32.
4. Ryazanov AG, Pavur KS, Dorovkov MV. Alpha-kinases: a new class of protein kinases with a novel catalytic 
domain. Curr Biol. 1999;9:R43-5.
5. Futey LM, Medley QG, Cote GP, Egelhoff TT. Structural analysis of myosin heavy chain kinase A from 
Dictyostelium. Evidence for a highly divergent protein kinase domain, an amino-terminal coiled-coil domain, 
and a domain homologous to the beta-subunit of heterotrimeric G proteins. J Biol Chem. 1995;270:523-9.
6. Cote GP, Luo X, Murphy MB, Egelhoff TT. Mapping of the novel protein kinase catalytic domain of Dictyostelium 
myosin II heavy chain kinase A. J Biol Chem. 1997;272:6846-9.
7. Clancy CE, Mendoza MG, Naismith TV, Kolman MF, Egelhoff TT. Identification of a protein kinase from 
Dictyostelium with homology to the novel catalytic domain of myosin heavy chain kinase A. J Biol Chem. 
1997;272:11812-5.
8. Ryazanov AG, Ward MD, Mendola CE, Pavur KS, Dorovkov MV, Wiedmann M, et al. Identification of a new 
class of protein kinases represented by eukaryotic elongation factor-2 kinase. Proceedings of the National 
Academy of Sciences of the United States of America. 1997;94:4884-9.
9. Pinna LA, Ruzzene M. How do protein kinases recognize their substrates? Biochim Biophys Acta. 1996;1314:191-
225.
10. Vaillancourt JP, Lyons C, Cote GP. Identification of two phosphorylated threonines in the tail region of 
Dictyostelium myosin II. J Biol Chem. 1988;263:10082-7.
144
Chapter 6
11. Luck-Vielmetter D, Schleicher M, Grabatin B, Wippler J, Gerisch G. Replacement of threonine residues 
by serine and alanine in a phosphorylatable heavy chain fragment of Dictyostelium myosin II. FEBS letters. 
1990;269:239-43.
12. Jorgensen R, Ortiz PA, Carr-Schmid A, Nissen P, Kinzy TG, Andersen GR. Two crystal structures demonstrate 
large conformational changes in the eukaryotic ribosomal translocase. Nature structural biology. 2003;10:379-
85.
13. Clark K, Middelbeek J, Dorovkov MV, Figdor CG, Ryazanov AG, Lasonder E, et al. The alpha-kinases TRPM6 
and TRPM7, but not eEF-2 kinase, phosphorylate the assembly domain of myosin IIA, IIB and IIC. FEBS 
letters. 2008;582:2993-7.
14. Crawley SW, Cote GP. Determinants for substrate phosphorylation by Dictyostelium myosin II heavy chain 
kinases A and B and eukaryotic elongation factor-2 kinase. Biochim Biophys Acta. 2008;1784:908-15.
15. Cote GP, Bukiejko U. Purification and characterization of a myosin heavy chain kinase from Dictyostelium 
discoideum. J Biol Chem. 1987;262:1065-72.
16. Nagasaki A, Itoh G, Yumura S, Uyeda TQ. Novel myosin heavy chain kinase involved in disassembly of 
myosin II filaments and efficient cleavage in mitotic dictyostelium cells. Mol Biol Cell. 2002;13:4333-42.
17. Liang W, Licate L, Warrick H, Spudich J, Egelhoff T. Differential localization in cells of myosin II heavy chain 
kinases during cytokinesis and polarized migration. BMC Cell Biol. 2002;3:19.
18. Luo X, Crawley SW, Steimle PA, Egelhoff TT, Cote GP. Specific phosphorylation of threonine by the 
Dictyostelium myosin II heavy chain kinase family. J Biol Chem. 2001;276:17836-43.
19. Yumura S, Yoshida M, Betapudi V, Licate LS, Iwadate Y, Nagasaki A, et al. Multiple myosin II heavy chain kinases: 
roles in filament assembly control and proper cytokinesis in Dictyostelium. Mol Biol Cell. 2005;16:4256-66.
20. Mendoza L, Orozco E, Rodriguez MA, Garcia-Rivera G, Sanchez T, Garcia E, et al. Ehp53, an Entamoeba 
histolytica protein, ancestor of the mammalian tumour suppressor p53. Microbiology (Reading, England). 
2003;149:885-93.
21. Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J. Crystal structure of the atypical protein kinase domain 
of a TRP channel with phosphotransferase activity. Mol Cell. 2001;7:1047-57.
22. Runnels LW, Yue L, Clapham DE. TRP-PLIK, a bifunctional protein with kinase and ion channel activities. 
Science (New York, NY. 2001;291:1043-7.
23. Diggle TA, Seehra CK, Hase S, Redpath NT. Analysis of the domain structure of elongation factor-2 kinase 
by mutagenesis. FEBS letters. 1999;457:189-92.
24. Somlyo AP, Somlyo AV. Ca2+ sensitivity of smooth muscle and nonmuscle myosin II: modulated by G 
proteins, kinases, and myosin phosphatase. Physiol Rev. 2003;83:1325-58.
25. Collins JH, Korn ED. Actin activation of Ca2+-sensitive Mg2+-ATPase activity of Acanthamoeba myosin II 
is enhanced by dephosphorylation of its heavy chains. J Biol Chem. 1980;255:8011-4.
26. Kuczmarski ER, Spudich JA. Regulation of myosin self-assembly: phosphorylation of Dictyostelium heavy 
chain inhibits formation of thick filaments. Proceedings of the National Academy of Sciences of the United 
States of America. 1980;77:7292-6.
27. Kuznicki J, Albanesi JP, Cote GP, Korn ED. Supramolecular regulation of the actin-activated ATPase activity 
of filaments of Acanthamoeba Myosin II. J Biol Chem. 1983;258:6011-4.
28. Egelhoff TT, Lee RJ, Spudich JA. Dictyostelium myosin heavy chain phosphorylation sites regulate myosin 
filament assembly and localization in vivo. Cell. 1993;75:363-71.
29. Stites J, Wessels D, Uhl A, Egelhoff T, Shutt D, Soll DR. Phosphorylation of the Dictyostelium myosin II 
heavy chain is necessary for maintaining cellular polarity and suppressing turning during chemotaxis. Cell 
Motil Cytoskeleton. 1998;39:31-51.
145
The alpha-kinase family: an exceptional branch on the protein kinase tree
30. Kolman MF, Futey LM, Egelhoff TT. Dictyostelium myosin heavy chain kinase A regulates myosin localization 
during growth and development. J Cell Biol. 1996;132:101-9.
31. Kolman MF, Egelhoff TT. Dictyostelium myosin heavy chain kinase A subdomains. Coiled-coil and wd repeat 
roles in oligomerization and substrate targeting. J Biol Chem. 1997;272:16904-10.
32. Steimle PA, Licate L, Cote GP, Egelhoff TT. Lamellipodial localization of Dictyostelium myosin heavy chain 
kinase A is mediated via F-actin binding by the coiled-coil domain. FEBS letters. 2002;516:58-62.
33. Egelhoff TT, Croft D, Steimle PA. Actin-activation of myosin heavy chain kinase A in dictyostelium: A biochemical 
mechanism for the spatial regulation of myosin II filament disassembly. J Biol Chem. 2005;280:2879-87.
34. Russ M, Croft D, Ali O, Martinez R, Steimle PA. Myosin heavy-chain kinase A from Dictyostelium possesses 
a novel actin-binding domain that cross-links actin filaments. The Biochemical journal. 2006;395:373-83.
35. Neer EJ, Schmidt CJ, Nambudripad R, Smith TF. The ancient regulatory-protein family of WD-repeat 
proteins. Nature. 1994;371:297-300.
36. Steimle PA, Naismith T, Licate L, Egelhoff TT. WD repeat domains target dictyostelium myosin heavy chain 
kinases by binding directly to myosin filaments. The Journal of biological chemistry. 2001;276:6853-60.
37. Medley QG, Gariepy J, Cote GP. Dictyostelium myosin II heavy-chain kinase A is activated by 
autophosphorylation: studies with Dictyostelium myosin II and synthetic peptides. Biochemistry. 1990;29:8992-
7.
38. De la Roche MA, Smith JL, Betapudi V, Egelhoff TT, Cote GP. Signaling pathways regulating Dictyostelium 
myosin II. J Muscle Res Cell Motil. 2002;23:703-18.
39. Rico M, Egelhoff TT. Myosin heavy chain kinase B participates in the regulation of myosin assembly into the 
cytoskeleton. J Cell Biochem. 2003;88:521-32.
40. Betapudi V, Mason C, Licate L, Egelhoff TT. Identification and characterization of a novel alpha-kinase with a 
von Willebrand factor A-like motif localized to the contractile vacuole and Golgi complex in Dictyostelium 
discoideum. Mol Biol Cell. 2005;16:2248-62.
41. Steimle PA, Yumura S, Cote GP, Medley QG, Polyakov MV, Leppert B, et al. Recruitment of a myosin heavy 
chain kinase to actin-rich protrusions in Dictyostelium. Curr Biol. 2001;11:708-13.
42. Egelhoff TT, Croft D, Steimle PA. Actin activation of myosin heavy chain kinase A in Dictyostelium: a 
biochemical mechanism for the spatial regulation of myosin II filament disassembly. The Journal of biological 
chemistry. 2005;280:2879-87.
43. Whittaker CA, Hynes RO. Distribution and evolution of von Willebrand/integrin A domains: widely dispersed 
domains with roles in cell adhesion and elsewhere. Mol Biol Cell. 2002;13:3369-87.
44. Ryazanov AG, Rudkin BB, Spirin AS. Regulation of protein synthesis at the elongation stage. New insights 
into the control of gene expression in eukaryotes. FEBS letters. 1991;285:170-5.
45. Ryazanov AG, Natapov PG, Shestakova EA, Severin FF, Spirin AS. Phosphorylation of the elongation factor 
2: the fifth Ca2+/calmodulin-dependent system of protein phosphorylation. Biochimie. 1988;70:619-26.
46. Redpath NT, Price NT, Severinov KV, Proud CG. Regulation of elongation factor-2 by multisite phosphorylation. 
European journal of biochemistry / FEBS. 1993;213:689-99.
47. Carlberg U, Nilsson A, Nygard O. Functional properties of phosphorylated elongation factor 2. European 
journal of biochemistry / FEBS. 1990;191:639-45.
48. Ryazanov AG. Ca2+/calmodulin-dependent phosphorylation of elongation factor 2. FEBS letters. 1987;214:331-
4.
49. Price NT, Redpath NT, Severinov KV, Campbell DG, Russell JM, Proud CG. Identification of the phosphorylation 
sites in elongation factor-2 from rabbit reticulocytes. FEBS letters. 1991;282:253-8.
146
Chapter 6
50. Nairn AC, Bhagat B, Palfrey HC. Identification of calmodulin-dependent protein kinase III and its major Mr 
100,000 substrate in mammalian tissues. Proceedings of the National Academy of Sciences of the United 
States of America. 1985;82:7939-43.
51. Pavur KS, Petrov AN, Ryazanov AG. Mapping the functional domains of elongation factor-2 kinase. Biochemistry. 
2000;39:12216-24.
52. Smith EM, Proud CG. cdc2-cyclin B regulates eEF2 kinase activity in a cell cycle- and amino acid-dependent 
manner. The EMBO journal. 2008;27:1005-16.
53. Browne GJ, Proud CG. A novel mTOR-regulated phosphorylation site in elongation factor 2 kinase modulates 
the activity of the kinase and its binding to calmodulin. Molecular and cellular biology. 2004;24:2986-97.
54. Browne GJ, Finn SG, Proud CG. Stimulation of the AMP-activated protein kinase leads to activation of 
eukaryotic elongation factor 2 kinase and to its phosphorylation at a novel site, serine 398. J Biol Chem. 
2004;279:12220-31.
55. Proud CG. mTOR-mediated regulation of translation factors by amino acids. Biochemical and biophysical 
research communications. 2004;313:429-36.
56. Proud CG. Signalling to translation: how signal transduction pathways control the protein synthetic machinery. 
The Biochemical journal. 2007;403:217-34.
57. Wu H, Yang JM, Jin S, Zhang H, Hait WN. Elongation factor-2 kinase regulates autophagy in human glioblastoma 
cells. Cancer research. 2006;66:3015-23.
58. Hait WN, Wu H, Jin S, Yang JM. Elongation factor-2 kinase: its role in protein synthesis and autophagy. 
Autophagy. 2006;2:294-6.
59. Meijer AJ, Codogno P. Regulation and role of autophagy in mammalian cells. The international journal of 
biochemistry & cell biology. 2004;36:2445-62.
60. Levine B, Kroemer G. Autophagy in the pathogenesis of disease. Cell. 2008;132:27-42.
61. Chen Y, Matsushita M, Nairn AC, Damuni Z, Cai D, Frerichs KU, et al. Mechanisms for increased levels of 
phosphorylation of elongation factor-2 during hibernation in ground squirrels. Biochemistry. 2001;40:11565-
70.
62. Dorovkov MV, Pavur KS, Petrov AN, Ryazanov AG. Regulation of elongation factor-2 kinase by pH. 
Biochemistry. 2002;41:13444-50.
63. Parmer TG, Ward MD, Yurkow EJ, Vyas VH, Kearney TJ, Hait WN. Activity and regulation by growth 
factors of calmodulin-dependent protein kinase III (elongation factor 2-kinase) in human breast cancer. 
British journal of cancer. 1999;79:59-64.
64. Wu H, Zhu H, Liu DX, Niu TK, Ren X, Patel R, et al. Silencing of elongation factor-2 kinase potentiates the 
effect of 2-deoxy-D-glucose against human glioma cells through blunting of autophagy. Cancer research. 
2009;69:2453-60.
65. White-Gilbertson S, Kurtz DT, Voelkel-Johnson C. The role of protein synthesis in cell cycling and cancer. 
Molecular oncology. 2009.
66. White SJ, Kasman LM, Kelly MM, Lu P, Spruill L, McDermott PJ, et al. Doxorubicin generates a proapoptotic 
phenotype by phosphorylation of elongation factor 2. Free radical biology & medicine. 2007;43:1313-21.
67. Nakamura J, Aoyagi S, Nanchi I, Nakatsuka S, Hirata E, Shibata S, et al. Overexpression of eukaryotic 
elongation factor eEF2 in gastrointestinal cancers and its involvement in G2/M progression in the cell cycle. 
International journal of oncology. 2009;34:1181-9.
68. Abdelmajid H, Leclerc-David C, Moreau M, Guerrier P, Ryazanov A. Release from the metaphase I block 
in invertebrate oocytes: possible involvement of Ca2+/calmodulin-dependent kinase III. The International 
journal of developmental biology. 1993;37:279-90.
147
The alpha-kinase family: an exceptional branch on the protein kinase tree
69. Ryazanov AG. Elongation factor-2 kinase and its newly discovered relatives. FEBS letters. 2002;514:26-9.
70. Heine M, Cramm-Behrens CI, Ansari A, Chu HP, Ryazanov AG, Naim HY, et al. Alpha-kinase 1, a new 
component in apical protein transport. J Biol Chem. 2005;280:25637-43.
71. Hosoda T, Monzen K, Hiroi Y, Oka T, Takimoto E, Yazaki Y, et al. A novel myocyte-specific gene Midori 
promotes the differentiation of P19CL6 cells into cardiomyocytes. J Biol Chem. 2001;276:35978-89.
72. Clapham DE. TRP channels as cellular sensors. Nature. 2003;426:517-24.
73. Corey DP. New TRP channels in hearing and mechanosensation. Neuron. 2003;39:585-8.
74. Ramsey IS, Delling M, Clapham DE. An introduction to TRP channels. Annu Rev Physiol. 2006;68:619-47.
75. Perraud AL, Knowles HM, Schmitz C. Novel aspects of signaling and ion-homeostasis regulation in 
immunocytes. The TRPM ion channels and their potential role in modulating the immune response. Mol 
Immunol. 2004;41:657-73.
76. Owsianik G, Talavera K, Voets T, Nilius B. Permeation and selectivity of TRP channels. Annu Rev Physiol. 
2006;68:685-717.
77. Chubanov V, Waldegger S, Mederos YSM, Vitzthum H, Sassen MC, Seyberth HW, et al. Disruption of 
TRPM6/TRPM7 complex formation by a mutation in the TRPM6 gene causes hypomagnesemia with 
secondary hypocalcemia. Proceedings of the National Academy of Sciences of the United States of America. 
2004;101:2894-9.
78. Li M, Jiang J, Yue L. Functional characterization of homo- and heteromeric channel kinases TRPM6 and 
TRPM7. J Gen Physiol. 2006;127:525-37.
79. Schmitz C, Dorovkov MV, Zhao X, Davenport BJ, Ryazanov AG, Perraud AL. The channel kinases TRPM6 
and TRPM7 are functionally nonredundant. The Journal of biological chemistry. 2005;280:37763-71.
80. Mei ZZ, Xia R, Beech DJ, Jiang LH. Intracellular Coiled-coil Domain Engaged in Subunit Interaction and 
Assembly of Melastatin-related Transient Receptor Potential Channel 2. The Journal of biological chemistry. 
2006;281:38748-56.
81. Erler I, Al-Ansary DM, Wissenbach U, Wagner TF, Flockerzi V, Niemeyer BA. Trafficking and Assembly of 
the Cold-sensitive TRPM8 Channel. The Journal of biological chemistry. 2006;281:38396-404.
82. Voets T, Nilius B, Hoefs S, van der Kemp AW, Droogmans G, Bindels RJ, et al. TRPM6 forms the Mg2+ 
influx channel involved in intestinal and renal Mg2+ absorption. J Biol Chem. 2004;279:19-25.
83. Nadler MJ, Hermosura MC, Inabe K, Perraud AL, Zhu Q, Stokes AJ, et al. LTRPC7 is a Mg.ATP-regulated 
divalent cation channel required for cell viability. Nature. 2001;411:590-5.
84. Fonfria E, Murdock PR, Cusdin FS, Benham CD, Kelsell RE, McNulty S. Tissue distribution profiles of the 
human TRPM cation channel family. J Recept Signal Transduct Res. 2006;26:159-78.
85. Walder RY, Yang B, Stokes JB, Kirby PA, Cao X, Shi P, et al. Mice defective in Trpm6 show embryonic 
mortality and neural tube defects. Human molecular genetics. 2009.
86. Jin J, Desai BN, Navarro B, Donovan A, Andrews NC, Clapham DE. Deletion of Trpm7 disrupts embryonic 
development and thymopoiesis without altering Mg2+ homeostasis. Science (New York, NY. 2008;322:756-
60.
87. Schlingmann KP, Weber S, Peters M, Niemann Nejsum L, Vitzthum H, Klingel K, et al. Hypomagnesemia 
with secondary hypocalcemia is caused by mutations in TRPM6, a new member of the TRPM gene family. 
Nat Genet. 2002;31:166-70.
88. Walder RY, Landau D, Meyer P, Shalev H, Tsolia M, Borochowitz Z, et al. Mutation of TRPM6 causes familial 
hypomagnesemia with secondary hypocalcemia. Nat Genet. 2002;31:171-4.
89. Chubanov V, Gudermann T, Schlingmann KP. Essential role for TRPM6 in epithelial magnesium transport 
and body magnesium homeostasis. Pflugers Arch. 2005;451:228-34.
148
Chapter 6
90. Paravicini TM, Yogi A, Mazur A, Touyz RM. Dysregulation of vascular TRPM7 and annexin-1 is associated 
with endothelial dysfunction in inherited hypomagnesemia. Hypertension. 2009;53:423-9.
91. Schmitz C, Perraud AL, Johnson CO, Inabe K, Smith MK, Penner R, et al. Regulation of vertebrate cellular 
Mg2+ homeostasis by TRPM7. Cell. 2003;114:191-200.
92. Hanano T, Hara Y, Shi J, Morita H, Umebayashi C, Mori E, et al. Involvement of TRPM7 in cell growth as a 
spontaneously activated Ca2+ entry pathway in human retinoblastoma cells. J Pharmacol Sci. 2004;95:403-
19.
93. Clark K, Langeslag M, van Leeuwen B, Ran L, Ryazanov AG, Figdor CG, et al. TRPM7, a novel regulator of 
actomyosin contractility and cell adhesion. The EMBO journal. 2006;25:290-301.
94. Wei C, Wang X, Chen M, Ouyang K, Song LS, Cheng H. Calcium flickers steer cell migration. Nature. 
2009;457:901-5.
95. Aarts M, Iihara K, Wei WL, Xiong ZG, Arundine M, Cerwinski W, et al. A key role for TRPM7 channels in 
anoxic neuronal death. Cell. 2003;115:863-77.
96. Numata T, Shimizu T, Okada Y. TRPM7 is a stretch- and swelling-activated cation channel involved in volume 
regulation in human epithelial cells. American journal of physiology. 2007;292:C460-7.
97. Oancea E, Wolfe JT, Clapham DE. Functional TRPM7 channels accumulate at the plasma membrane in 
response to fluid flow. Circ Res. 2006;98:245-53.
98. Su LT, Agapito MA, Li M, Simonson WT, Huttenlocher A, Habas R, et al. TRPM7 regulates cell adhesion by 
controlling the calcium-dependent protease calpain. J Biol Chem. 2006;281:11260-70.
99. Krapivinsky G, Mochida S, Krapivinsky L, Cibulsky SM, Clapham DE. The TRPM7 ion channel functions in 
cholinergic synaptic vesicles and affects transmitter release. Neuron. 2006;52:485-96.
100. Jiang J, Li MH, Inoue K, Chu XP, Seeds J, Xiong ZG. Transient receptor potential melastatin 7-like current 
in human head and neck carcinoma cells: role in cell proliferation. Cancer research. 2007;67:10929-38.
101. Clark K, Langeslag M, Figdor CG, van Leeuwen FN. Myosin II and mechanotransduction: a balancing act. 
Trends in cell biology. 2007;17:178-86.
102. Langeslag M, Clark K, Moolenaar WH, van Leeuwen FN, Jalink K. Activation of TRPM7 Channels by 
Phospholipase C-coupled Receptor Agonists. J Biol Chem. 2007;282:232-9.
103. Chachisvilis M, Zhang YL, Frangos JA. G protein-coupled receptors sense fluid shear stress in endothelial 
cells. Proceedings of the National Academy of Sciences of the United States of America. 2006;103:15463-8.
104. Clark K, Middelbeek J, van Leeuwen FN. Interplay between TRP channels and the cytoskeleton in health 
and disease. European journal of cell biology. 2008;87:631-40.
105. Orr AW, Helmke BP, Blackman BR, Schwartz MA. Mechanisms of mechanotransduction. Dev Cell. 2006;10:11-
20.
106. Numata T, Shimizu T, Okada Y. Direct Mechano-Stress Sensitivity of TRPM7 Channel. Cell Physiol Biochem. 
2007;19:1-8.
107. Cao G, Hoenderop JG, Bindels RJ. Insight into the molecular regulation of the epithelial magnesium channel 
TRPM6. Current opinion in nephrology and hypertension. 2008;17:373-8.
108. Runnels LW, Yue L, Clapham DE. The TRPM7 channel is inactivated by PIP(2) hydrolysis. Nat Cell Biol. 
2002;4:329-36.
109. Takezawa R, Schmitz C, Demeuse P, Scharenberg AM, Penner R, Fleig A. Receptor-mediated regulation of 
the TRPM7 channel through its endogenous protein kinase domain. Proceedings of the National Academy 
of Sciences of the United States of America. 2004;101:6009-14.
110. Demeuse P, Penner R, Fleig A. TRPM7 channel is regulated by magnesium nucleotides via its kinase domain. 
J Gen Physiol. 2006;127:421-34.
149
The alpha-kinase family: an exceptional branch on the protein kinase tree
111. Cao G, Thebault S, van der Wijst J, van der Kemp A, Lasonder E, Bindels RJ, et al. RACK1 inhibits TRPM6 
activity via phosphorylation of the fused alpha-kinase domain. Curr Biol. 2008;18:168-76.
112. Cao G, van der Wijst J, van der Kemp A, van Zeeland F, Bindels RJ, Hoenderop JG. Regulation of the 
epithelial Mg2+ channel TRPM6 by estrogen and the associated repressor protein of estrogen receptor 
activity (REA). J Biol Chem. 2009;284:14788-95.
113. Matsushita M, Kozak JA, Shimizu Y, McLachlin DT, Yamaguchi H, Wei FY, et al. Channel function is dissociated 
from the intrinsic kinase activity and autophosphorylation of TRPM7/CHAK1. The Journal of biological 
chemistry. 2005.
114. Penner R, Fleig A. The Mg2+ and Mg(2+)-nucleotide-regulated channel-kinase TRPM7. Handb Exp Pharmacol. 
2007;179:313-28.
115. Ryazanova LV, Dorovkov MV, Ansari A, Ryazanov AG. Characterization of the protein kinase activity of 
TRPM7/ChaK1, a protein kinase fused to TRP ion channel. The Journal of biological chemistry. 2004;279:3708-
16.
116. Clark K, Middelbeek J, Morrice NA, Figdor CG, Lasonder E, van Leeuwen FN. Massive autophosphorylation 
of the Ser/Thr-rich domain controls protein kinase activity of TRPM6 and TRPM7. PloS one. 2008;3:e1876.
117. Dorovkov MV, Ryazanov AG. Phosphorylation of annexin I by TRPM7 channel-kinase. The Journal of 
biological chemistry. 2004;279:50643-6.
118. Gerke V, Creutz CE, Moss SE. Annexins: linking Ca2+ signalling to membrane dynamics. Nature reviews. 
2005;6:449-61.
119. Callera GE, He Y, Yogi A, Montezano AC, Paravicini T, Yao G, et al. Regulation of the novel Mg2+ transporter 
transient receptor potential melastatin 7 (TRPM7) cation channel by bradykinin in vascular smooth muscle 
cells. Journal of hypertension. 2009;27:155-66.
120. Touyz RM. Transient receptor potential melastatin 6 and 7 channels, magnesium transport, and vascular 
biology: implications in hypertension. Am J Physiol Heart Circ Physiol. 2008;294:H1103-18.
121. Clark K, Middelbeek J, Lasonder E, Dulyaninova NG, Morrice NA, Ryazanov AG, et al. TRPM7 regulates 
myosin IIA filament stability and protein localization by heavy chain phosphorylation. Journal of molecular 
biology. 2008;378:790-803.
122. Ronen D, Ravid S. Myosin II Tailpiece Determines Its Paracrystal Structure, Filament Assembly Properties, 
and Cellular Localization. J Biol Chem. 2009;284:24948-57.
123. Bershadsky AD, Ballestrem C, Carramusa L, Zilberman Y, Gilquin B, Khochbin S, et al. Assembly and 
mechanosensory function of focal adhesions: experiments and models. Eur J Cell Biol. 2006;85:165-73.
124. Geiger B, Bershadsky A. Exploring the neighborhood: adhesion-coupled cell mechanosensors. Cell. 
2002;110:139-42.
125. Gimona M, Buccione R. Adhesions that mediate invasion. The international journal of biochemistry & cell 
biology. 2006;38:1875-92.
126. Burgstaller G, Gimona M. Actin cytoskeleton remodelling via local inhibition of contractility at discrete 
microdomains. J Cell Sci. 2004;117:223-31.
127. Huse M, Kuriyan J. The conformational plasticity of protein kinases. Cell. 2002;109:275-82.
128. Bokoch GM. Biology of the p21-activated kinases. Annu Rev Biochem. 2003;72:743-81.
129. Roskoski R, Jr. Src protein-tyrosine kinase structure and regulation. Biochemical and biophysical research 
communications. 2004;324:1155-64.
130. Du K, Tsichlis PN. Regulation of the Akt kinase by interacting proteins. Oncogene. 2005;24:7401-9.
131. Van Etten RA. c-Abl regulation: a tail of two lipids. Curr Biol. 2003;13:R608-10.
132. Qi M, Elion EA. MAP kinase pathways. J Cell Sci. 2005;118:3569-72.
150
Chapter 6
133. Hubbard SR. Protein tyrosine kinases: autoregulation and small-molecule inhibition. Curr Opin Struct Biol. 
2002;12:735-41.
134. Zhu G, Liu Y, Shaw S. Protein kinase specificity. A strategic collaboration between kinase peptide specificity 
and substrate recruitment. Cell Cycle. 2005;4:52-6.
135. Horman S, Browne G, Krause U, Patel J, Vertommen D, Bertrand L, et al. Activation of AMP-activated 
protein kinase leads to the phosphorylation of elongation factor 2 and an inhibition of protein synthesis. 
Curr Biol. 2002;12:1419-23.
136. Hovland R, Eikhom TS, Proud CG, Cressey LI, Lanotte M, Doskeland SO, et al. cAMP inhibits translation 
by inducing Ca2+/calmodulin-independent elongation factor 2 kinase activity in IPC-81 cells. FEBS letters. 
1999;444:97-101.
137. Diggle TA, Subkhankulova T, Lilley KS, Shikotra N, Willis AE, Redpath NT. Phosphorylation of elongation 
factor-2 kinase on serine 499 by cAMP-dependent protein kinase induces Ca2+/calmodulin-independent 
activity. The Biochemical journal. 2001;353:621-6.
138. Wang X, Li W, Williams M, Terada N, Alessi DR, Proud CG. Regulation of elongation factor 2 kinase by 
p90(RSK1) and p70 S6 kinase. The EMBO journal. 2001;20:4370-9.
139. Knebel A, Morrice N, Cohen P. A novel method to identify protein kinase substrates: eEF2 kinase is 
phosphorylated and inhibited by SAPK4/p38delta. The EMBO journal. 2001;20:4360-9.
140. Knebel A, Haydon CE, Morrice N, Cohen P. Stress-induced regulation of eukaryotic elongation factor 2 
kinase by SB 203580-sensitive and -insensitive pathways. The Biochemical journal. 2002;367:525-32.
141. Redpath NT, Proud CG. Cyclic AMP-dependent protein kinase phosphorylates rabbit reticulocyte elongation 
factor-2 kinase and induces calcium-independent activity. The Biochemical journal. 1993;293 ( Pt 1):31-4.
142. Yamaguchi H, Matsushita M, Nairn AC, Kuriyan J. Crystal structure of the atypical protein kinase domain 
of a TRP channel with phosphotransferase activity. Mol Cell. 2001;7:1047-57.
143. Crawley SW, Cote GP. Identification of dimer interactions required for the catalytic activity of the TRPM7 
alpha-kinase domain. The Biochemical journal. 2009;420:115-22.
144. Noble ME, Endicott JA, Johnson LN. Protein kinase inhibitors: insights into drug design from structure. 
Science (New York, NY. 2004;303:1800-5.
145. Fabbro D, Garcia-Echeverria C. Targeting protein kinases in cancer therapy. Current opinion in drug 
discovery & development. 2002;5:701-12.
146. Johnson LN. Protein kinase inhibitors: contributions from structure to clinical compounds. Quarterly 
reviews of biophysics. 2009;42:1-40.
147. Arora S, Yang JM, Kinzy TG, Utsumi R, Okamoto T, Kitayama T, et al. Identification and characterization 
of an inhibitor of eukaryotic elongation factor 2 kinase against human cancer cell lines. Cancer research. 
2003;63:6894-9.
148. Sun HS, Jackson MF, Martin LJ, Jansen K, Teves L, Cui H, et al. Suppression of hippocampal TRPM7 protein 
prevents delayed neuronal death in brain ischemia. Nature neuroscience. 2009.
149. Wei WL, Sun HS, Olah ME, Sun X, Czerwinska E, Czerwinski W, et al. TRPM7 channels in hippocampal 
neurons detect levels of extracellular divalent cations. Proceedings of the National Academy of Sciences 
of the United States of America. 2007;104:16323-8.
150. Guilbert A, Gautier M, Dhennin-Duthille I, Haren N, Sevestre H, Ouadid-Ahidouch H. Evidence that TRPM7 
is required for breast cancer cell proliferation. American journal of physiology. 2009;297:C493-502.
151. Letunic I, Copley RR, Schmidt S, Ciccarelli FD, Doerks T, Schultz J, et al. SMART 4.0: towards genomic data 
integration. Nucleic acids research. 2004;32:D142-4.
151
The alpha-kinase family: an exceptional branch on the protein kinase tree
152. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, Miller W, et al. Gapped BLAST and PSI-BLAST: a 
new generation of protein database search programs. Nucleic acids research. 1997;25:3389-402.
153. Larkin MA, Blackshields G, Brown NP, Chenna R, McGettigan PA, McWilliam H, et al. Clustal W and Clustal 
X version 2.0. Bioinformatics (Oxford, England). 2007;23:2947-8.
154. Guindon S, Gascuel O. A simple, fast, and accurate algorithm to estimate large phylogenies by maximum 
likelihood. Systematic biology. 2003;52:696-704.
155. Galtier N, Gouy M, Gautier C. SEAVIEW and PHYLO_WIN: two graphic tools for sequence alignment and 
molecular phylogeny. Comput Appl Biosci. 1996;12:543-8.
 

Chapter 7
trpm7 regulates myosin iia filament 
stability and protein loCalization by 
heavy Chain phosphorylation
Kristopher Clark, Jeroen Middelbeek, Edwin Lasonder, Natalya G. Dulyaninova, Nick A. 
Morrice, Alexey G. Ryazanov, Anne R. Bresnick, Carl G. Figdor, Frank N. van Leeuwen
Journal of Molecular Biology, 2008 May 9;378(4):790-803
154
Abstract
Deregulation of myosin II-based contractility contributes to the pathogenesis of human 
diseases such as cancer, which underscores the necessity for tight spatial and temporal 
control of myosin II activity. Recently, we demonstrated that activation of the mammalian 
a-kinase TRPM7 inhibits myosin II-based contractility in a Ca2+- and kinase-dependent manner. 
However, the molecular mechanism is poorly defined. Here, we demonstrate that TRPM7 
phosphorylates the COOH-termini of both mouse and human myosin IIA heavy chains, 
the COOH-terminus being a region that is critical for filament stability. Phosphorylated 
residues were mapped to Thr1800, Ser1803 and Ser1808. Mutation of these residues to 
alanine and that to aspartic acid lead to an increase and a decrease, respectively, in myosin IIA 
incorporation into the actomyosin cytoskeleton and accordingly affect subcellular localization. 
In conclusion, our data demonstrate that TRPM7 regulates myosin IIA filament stability and 
localization by phosphorylating a short stretch of amino acids within the a-helical tail of 
the myosin IIA heavy chain.
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Introduction
The actomyosin cytoskeleton plays a vital role in maintaining the structural integrity of 
cells and in producing the force necessary to accomplish basic cellular functions such as 
cytokinesis and migration (1-3). Myosins are a diverse superfamily of actin-based motor 
proteins that convert chemical energy into mechanical force (4). In muscle and non-muscle 
cells, myosin II is the major motor protein driving cell contraction. Notably, the level of 
myosin II-based cytoskeletal tension generated inside the cell must be carefully controlled 
during cell behavior (5-7). Deregulation of pathways controlling myosin II activity contributes 
to the pathogenesis of several human diseases including cancer (8). 
Myosin II is a hexameric protein composed of two heavy chains, two essential light chains 
and two regulatory light chains (9). To accomplish its cellular function, myosin II assembles 
into bipolar filaments through electrostatic interactions between the a-helical rod domain 
of its heavy chains (10). The motor domains on each end of a bipolar filament pull together 
oppositely oriented actin filaments to generate cortical tension. Three non-muscle myosin 
II isoforms have been identified in mammalian cells, these are termed non-muscle myosin 
IIA, IIB and IIC. These three isoforms have overlapping functions since defects due to the 
knockdown of a single non-muscle myosin II isoform can be rescued by overexpressing the 
other isoforms (11). However, accumulating evidence suggests that the different myosin II 
isoforms also have non-redundant roles. Several studies have identified differences in mRNA 
expression, protein localization, enzymatic properties of the motor domain, and binding 
partners between the three myosin II isoforms (12-20). Accordingly, mouse knockouts for 
non-muscle myosin IIA and IIB show distinct phenotypes (21, 22).
In mammalian cells, phosphorylation of the regulatory light chains is the predominant 
mechanism regulating myosin II activity (3, 23). Phosphorylation of the regulatory light 
chains stabilizes myosin II filaments, strengthens the actin-myosin association and activates 
the ATPase activity of the motor domain leading to an increase in actomyosin contractility. 
However, strong experimental evidence exists for additional regulatory mechanisms including 
myosin II heavy chain (MHCII) phosphorylation (24-27).
Recently, we identified a novel signaling pathway downstream of the bradykinin receptor 
that regulates myosin II-based contractility in non-muscle cells (28, 29). Bradykinin stimulation 
of neuroblastoma cells activates TRPM7, promoting its association with myosin IIA in a 
Ca2+- and kinase-dependent manner, which leads to actomyosin relaxation and remodeling 
of cell adhesion structures. Since TRPM7 is related to Dictyostelium a-kinases, which control 
the assembly and localization of myosin II by phosphorylating its heavy chain (30-33), we 
proposed that TRPM7 may use a similar mechanism to inhibit myosin II-based contractility 
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in mammalian cells. Indeed, we found that TRPM7 can phosphorylate associated myosin IIA 
(28), however, it is unclear if and how myosin IIA phosphorylation contributes to TRPM7-
mediated cytoskeletal relaxation. Therefore, we investigated whether TRPM7 may affect 
actomyosin relaxation by directly phosphorylating MHCIIA to regulate filament stability.
Results
TRPM7 phosphorylates the region required for assembly of myosin IIA filaments
Previously, we demonstrated that TRPM7 phosphorylates the mouse MHCIIA (28). To assess 
the consequences of this phosphorylation event on myosin IIA function, we set out to map 
the residues phosphorylated by TRPM7 within the MHCIIA. The assembly of non-muscle 
myosin II isoforms requires the extreme COOH terminus which is the only positively charged 
region (34, 35). Therefore, this region is predicted to be highly affected by phosphorylation, 
a hypothesis supported by the fact that other regulatory proteins, including kinases, target 
this region (20, 25). Therefore, we investigated whether TRPM7 could phosphorylate the 
extreme COOH-terminus of the coiled-coil domain of the MHCIIA. To this end, different 
regions of the mouse MHCIIA were expressed as glutathione S-transferase (GST) fusion 
proteins (Fig. 1) and tested for their ability to be phosphorylated by TRPM7 in in vitro kinase 
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Figure 1. Fragments of the MHCIIA that served as substrate 
in TRPM7 kinase reactions. A schematic diagram of the MHCIIA is 
depicted with the coiled-coil domain spanning from amino acid 1091 to 
1924. The MHCIIA ends with a short nonhelical tail piece (Amino acids 
1924-1960). For each myosin IIA fragment, the first and last amino acids 
are indicated on either side of the line. Above the line is the total number 
of threonine and serine residues within each fragment. 
assays (Fig. 2). Wild-type 
(WT) but not kinase-dead 
(KD) TRPM7 phosphorylated 
the COOH-terminus (Amino 
acids 1795-1960) and different 
fragments derived from this 
region of mouse myosin IIA, 
including both helical and 
non-helical components. In 
contrast , TRPM7 did not 
phosphorylate other fragments 
that were derived from areas 
located further towards the 
N-terminus of the MHCIIA. 
These results demonstrate 
that TRPM7 phosphorylates 
the positively charged COOH-
terminus of the MHCIIA.
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TRPM7 phosphorylates mouse and human myosin IIA
Certain kinases, such as calmodulin-dependent protein kinase II, specifically phosphorylate 
the mouse MHCIIA but not the human MHCIIA (36). The differences appear to arise due 
to a lack of sequence conservation within the non-helical tail. We therefore determined 
whether TRPM7 could also phosphorylate the COOH-terminus of human MHCIIA (Fig. 
3). In vitro kinase assays showed that TRPM7 efficiently phosphorylates the COOH-termini 
of both mouse and human MHCIIA. Phosphorylation of MHCIIA was detectable within 1 
min and increased progressively until it reached a maximum at about 10 min (Fig. 4). One 
notable difference was observed between mouse and human myosin IIA. While TRPM7 
could phosphorylate the non-helical tail of mouse MHCIIA, TRPM7 did not phosphorylate 
this region within the human homologue. Thus, our results show that TRPM7, in contrast 
to calmodulin-dependent protein kinase II, phosphorylates the coiled-coil domain of both 
mouse and human MHCIIA.
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Figure 2. TRPM7 phosphorylates the COOH-
terminus of mouse MHCIIA. Different regions 
of the coiled-coil domain of mouse MHCIIA were 
expressed as GST-fusion proteins. The purified 
recombinant proteins were incubated with WT 
or KD TRPM7 in the presence of [g-32P]ATP. The 
products of the kinase reaction were separated by 
SDS-PAGE and the gel was stained with coomassie 
brilliant blue (Bottom panel). Phosphorylated 
proteins were detected by autoradiography (Top 
panel). 
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Figure 3. TRPM7 phosphorylates the a-helical 
tail but not the non-helical tail of human 
MHCIIA.  
The COOH-termini and nonhelical tails of mouse 
and human MHCIIA were purified as GST-fusion 
proteins and incubated with WT or KD TRPM7 in the 
presence of [g-32P]ATP. The proteins were separated 
by SDS-PAGE and visualized by staining the gel with 
coomassie blue (Bottom panel). Phosphorylated 
proteins were detected by autoradiography (Top 
panel). 
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Figure 5. Mapping of phosphorylation sites in MHCIIA. (A) Identification of Ser1803 by Edman degradation 
sequencing of 32P-labeled peptides. GST-MHCIIA COOH-terminus was incubated with TRPM7 in the presence of 
[g-32P]ATP and subjected to SDS-PAGE. The phosphorylated GST-MHCIIA fusion protein was excised from the 
gel, digested with trypsin and the peptide mixture was separated by HPLC on a C18 column. The phosphopeptides 
were sequenced by Edman sequencing with 32P-radioactivity being measured after each cycle of degradation. 
The phosphorylated residue was assigned by a combination of solid-phase Edman sequencing and MALDI-TOF. 
(B) Identification of phosphorylation sites by LC-MS/MS. Phosphorylated GST-MHCIIA COOH-terminus was 
digested with trypsin and peptides were separated on a nanoLC C18 column, which was connected inline with a 
high mass accuracy LTQ-FT mass spectrometer. Representative MS2 and MS3 spectra of a peptide phosphorylated 
at position Ser1808 is depicted. (m/z observed of parent ion was 637.8227, mass accuracy 0.82 ppm, +2 charge 
state; NL indicates neutral loss of H3PO4 which triggers acquisition of MS
3 spectrum). (C) Summary table of the 
phosphorylation site results by LC-MS/MS. 
0 1´ 2´ 3´ 5´ 10´ 15´ 30´Time (min)
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pGST-MHCIIA
GST-MHCIIA
32P ATP
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Figure 4. Kinetics of MHCIIA phosphorylation 
by TRPM7. Purified TRPM7 was mixed with 2 mg of 
GST-myosin IIA and the reaction was initiated by the 
addition of 0.1 mM ATP containing 5 mCi of [g-32P]
ATP. The reaction proceeded at 30oC for the indicated 
times after which 20 mM EDTA was added to stop the 
kinase reaction. Proteins were resolved on a 10% SDS-
PAGE gel and detected by coomassie staining (Bottom 
panel). Phosphorylated TRPM7 and GST-MHCIIA were 
revealed by autoradiography (Top and middle panels).
159
TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation
Coomassie
32P ATP
32P ATP
GS
T
W
T
S1
80
3A
T1
80
0A
/S
18
03
A
S1
80
3A
/S
18
08
A
S1
80
3A
/T1
81
0A
T1
80
0A
/S
18
03
A/
S1
80
8A
GST-hMHCIIA
GST
pGST-hMHCIIA
pTRPM7
GS
T
W
T
S1
80
3A
T1
80
0A
/S
18
03
A
S1
80
3A
/S
18
08
A
S1
80
3A
/T1
81
0A
R
el
at
iv
e 
P
ho
sp
ho
ry
la
tio
n
0
0.5
1.0
A
B
C
W
T
S1
80
3A
T1
93
1A
S1
80
3A
/T1
93
1A
Coomassie
32P ATP
32P ATP
GST-mMHCII
pGST-mMHCII
pTRPM7
W
T
S1
80
3A
T1
93
1A
S1
80
3A
/T1
93
1A
R
el
at
iv
e 
P
ho
sp
ho
ry
la
tio
n
0
0.5
1.0
T1
80
0A
/S
18
03
A/
S1
80
8A
D
Coomassie
32P ATP
32P ATP
GS
T
W
T
S1
80
3A
T1
80
0A
/S
18
03
A
S1
80
3A
/S
18
08
A
S1
80
3A
/T1
81
0A
T1
80
0A
/S
18
03
A/
S1
80
8A
GST-hMHCIIA
GST
pGST-hMHCIIA
pTRPM7
GS
T
W
T
S1
80
3A
T1
80
0A
/S
18
03
A
S1
80
3A
/S
18
08
A
S1
80
3A
/T1
81
0A
R
el
at
iv
e 
P
ho
sp
ho
ry
la
tio
n
0
0.5
1.0
A
B
C
W
T
S1
80
3A
T1
93
1A
S1
80
3A
/T1
93
1A
Coomassie
32P ATP
32P ATP
GST-mMHCII
pGST-mMHCII
pTRPM7
W
T
S1
80
3A
T1
93
1A
S1
80
3A
/T1
93
1A
R
el
at
iv
e 
P
ho
sp
ho
ry
la
tio
n
0
0.5
1.0
T1
80
0A
/S
18
03
A/
S1
80
8A
D
Figure 6. Ser1803 is the major phosphorylation site in the COOH-termini of the coiled-coil domains 
of both human and mouse MHCIIA. (A) Mutations of Thr1800, Ser1803 and Ser1808 in human MHCIIA 
reduce phosphorylation to background levels. The phosphorylated residues mapped in GST-hMHCIIA COOH were 
mutated to alanine individually or in combination. Since substrate recognition by a-kinases may be influenced by the 
secondary structure, Thr1810, which was not identified by mass spectrometry nor predicted to be phosphorylated, 
was also mutated as a negative control. GST-human MHCIIA proteins were incubated with TRPM7 in the presence 
of [g-32P]ATP and subjected to SDS-PAGE. Equal loading of the GST-fusion proteins was verified by coomassie 
staining (Top panel) and phosphorylated proteins were detected by autoradiography. The phosphorylation of the 
different GST-human MHCIIA proteins by TRPM7 is depicted in the middle panel. The presence of equal levels 
of kinase activity in each sample was determined by monitoring TRPM7 autophosphorylation (Bottom panel). 
(B) Quantification of the degree of phosphorylation of the different GST-human MHCIIA fusion proteins by 
TRPM7 using phosphoimager analysis. The level of 32P incorporation into the WT GST-human MHCIIA fusion 
protein was set to 1, and phosphorylation of all other proteins is reported relative to this value. (C) Ser1803 
is the major phosphorylation site in the helical region of mouse MHCIIA. GST-mouse MHCIIA was mutated 
at positions Ser1803 and Thr1931 either individually or in combination. Phosphorylation of these GST-mouse 
MHCIIA mutants by TRPM7 was compared with WT GST-mouse MHCIIA by in vitro kinase assay as described 
in (B). (D) Phosphorylation of different mouse MHCIIA proteins was quantified as described in (B) 
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TRPM7 phosphorylates Thr1800, Ser1803 and Ser1808 in human MHCIIA
A multidisciplinary approach involving bioinformatics and proteomics was used to map 
the phosphorylation sites in the human MHCIIA. Recently, an algorithm was developed to 
predict residues phosphorylated by TRPM7 in its substrates (details of the algorithm will be 
published elsewhere,  A. Ryazanov et.al., unpublished 
results). This algorithm calculated that Ser1803 
was the residue with the highest probability to be 
phosphorylated by TRPM7. The phosphorylation 
sites in the MHCIIA were mapped using two 
distinct approaches to further substantiate these 
predictions. Initially, 32P-labeled tryptic peptides 
from TRPM7-phosphorylated human MHCIIA 
were separated by reversed-phase HPLC. These 
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peptides eluted off the column into 3 fractions at 33%, 43% and 54% v/v acetonitrile (data not 
shown). When peptides from the major peak (54%) were subjected to solid-phase sequencing, 
a burst of 32P release was observed after the 12th cycle of Edman degradation (Fig. 5A). The 
molecular mass of the peptide (1822.79) as determined by MALDI-TOF mass spectrometry 
was identical with that expected for the tryptic phosphopeptide comprising the last 3 
residues of GST fused to residues 1795-1806 of MHCIIA and phosphorylated at Ser1803. All 
the other fractions also contained peptides phosphorylated at Ser1803. However, mutation 
of Ser1803 to alanine reduced the incorporation of phosphate by only 70% compared with 
WT, suggesting the presence of additional phosphorylation sites within the MHCIIA (Fig. 
6). We therefore further analyzed tryptic and GluC digests of phosphorylated MHCIIA by 
high mass accuracy mass spectrometry using a LTQ-FT mass spectrometer. Several mono-
phosphorylated peptides were detected using the LTQ-FT in nano liquid chromatography 
tandem mass spectrometry (LC-MS/MS) by the loss of H3PO4 during MS/MS and MS/MS 
spectral analysis of these peptides determined that in addition to Ser1803, Thr1800 and 
Ser1808 are also phosphorylated by TRPM7 (Fig. 5B & C). Mutational analysis demonstrated 
that all three residues contribute to the overall phosphorylation of myosin IIA with Ser1803 
being the major phosphorylation site (Fig. 6A & B). The reduction in phosphorylation is 
not due to changes in MHCIIA structure since mutation of an irrelevant residue (Thr1810) 
had no effect on the efficiency of MHCIIA phosphorylation.
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
5          15         25         35         45         55     
mMyoIIA QEMESAVKSK YKASIAALEA KIAQLEEQLD NETKERQAAS KQVRRTEKKL KDVLLQVEDE 
hMyoIIA QEMEGTVKSK YKASITALEA KIAQLEEQLD NETKERQAAC KQVRRTEKKL KDVLLQVDDE 
hMyoIIB QELEGAVKSK FKATISALEA KIGQLEEQLE QEAKERAAAN KLVRRTEKKL KEIFMQVEDE 
hMyoIIC GEEDAGARAR HKMTIAALES KLAQAEEQLE QETRERILSG KLVRRAEKRL KEVVLQVEEE 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....| 
65         75         85         95        105        115     
mMyoIIA RRNAEQFKDQ ADKASTRLKQ LKRQLEEAEE EAQRANASRR KLQRELEDAT ETADAMNREV
hMyoIIA RRNAEQYKDQ ADKASTRLKQ LKRQLEEAEE EAQRANASRR KLQRELEDAT ETADAMNREV 
hMyoIIB RRHADQYKEQ MEKANARMKQ LKRQLEEAEE EATRANASRR KLQRELDDAT EANEGLSREV 
hMyoIIC RRVADQLRDQ LEKGNLRVKQ LKRQLEEAEE EASRAQAGRR RLQRELEDVT ESAESMNREV 
....|....| ....|....| ....|....| ....|....| ....|....| ....|....
125        135        145        155        165        175   
mMyoIIA SSLKNKLRRG -DLPFVVT-- -RRIVRKGTG --DCSDEEVD GKADGADAKA AE--
hMyoIIA SSLKNKLRRG -DLPFVVP-- -RRMARKGAG --DGSDEEVD GKADGAEAKP AE--
hMyoIIB STLKNRLRRG GPISFSSSRS GRRQLHLEGA SLELSDDDTE SKTSDVNETQ PPQSE
hMyoIIC TTLRNRLRRG -PLTFTTRTV -RQVFRLEEG --VASDEEAE EAQPGSGPSP EPEGSPPAHP Q
Figure 7. Conservation of phosphorylation sites between mouse, and human myosin II. Alignment of 
the mouse MHCIIA and human MHCIIA, IIB and IIC COOH-termini. The phosphorylation sites are underlined 
and conserved amino acids are shown in bold. Note that two of three residues in the conserved stretch of 
amino acids within the coiled-coil domain of human MHCIIA were verified in mouse MHCIIA by LC-MS/MS . 
Alignment with human MHCIIB and C reveals that the major phosphorylated residue in human MHCIIA, Ser1803, 
is conserved in MHCIIB but not in IIC, whereas Ser1808 in mouse and human MHCIIA is conserved in both 
human MHCIIB and IIC.
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To address the differences in phosphorylation between mouse and human MHCIIA, we 
also analyzed mouse MHCIIA using LC-MS/MS. We detected several phosphopeptides and 
mapped the phosphorylation sites to Ser1799, Ser1803 and Thr1931. Notably, Thr1931 
is present in the non-helical tail of mouse MHCIIA but not human MHCIIA (Fig. 7), which 
explains the differences observed in in vitro kinase assays (Fig. 3). Mutations of Ser1803 and 
Thr1931 led to a significant reduction in 32P incorporation demonstrating that these two 
residues are the major phosphorylation sites in mouse MHCIIA (Fig. 6C & D). Alignment 
of the COOH-termini of MHCIIA, MHCIIB and MHCIIC shows that Ser1803 is conserved 
in myosin IIB whereas Ser1808 is conserved in all three myosin II isoforms (Fig. 7). We 
conclude that TRPM7 phosphorylates a conserved stretch of amino acids in the coiled-coil 
domain of non-muscle myosin II isoforms. 
myosin IIA rods midpoint (mM)
WT 176.5 +/- 3.3
3xA 173.4 4.0
3xD 153.9 2.7
+/-
+/-
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B
Figure 8. Mutation of phosphorylation sites 
to aspartic acid affects MHCIIA filament 
stability. (A) The assembly of WT and mutant 
rods was monitored using a standard sedimentation 
assay. The solid lines represent the best fit to the 
Hill equation. (B) Midpoint measurement for WT 
and mutant MHCIIA rods. Data are reported as the 
mean ± SEM for 2 to 3 independent experiments.
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Figure 9. Mutation of phosphorylation sites to 
aspartate increases Triton solubility of MHCIIA. 
YFP-MHCIIA constructs were transiently transfected 
into COS7 cells. The cells were fractionated into a Triton 
soluble and insoluble fractions. Equal amounts of these 
fractions were separated by SDS-PAGE and immunoblotted. 
Exogenous myosin IIA was detected using anti-GFP 
antibodies followed by IRDye800-coupled anti-mouse IgG 
secondary antibodies. Fluorescence was measured using 
an Odyssey infrared imaging system. (A) A representative 
Western blot depicting the presence of YFP-MHCIIA 
mutants in the different fractions. (B) Quantification of the 
degree of solubility of each YFP-MHCIIA fusion protein. The 
data are presented as the percentage of soluble MHCIIA 
protein (mean ± SEM, n=5). * P < 0.05.
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Mutation of phosphorylation sites affects filament stability and protein localization
To investigate the consequences of phosphorylation on MHCIIA filament assembly, we 
generated MHCIIA rod constructs with the phosphorylation sites (Thr1800, Ser1803 and 
Ser1808) mutated to alanine or aspartic acid. The WT and mutant MHCIIA rods were 
assembled into filaments at different NaCl concentrations and the degree of solubility 
was measured. MHCIIA rods containing phosphomimetic aspartic acid mutations showed 
increased solubility at physiological salt concentrations in comparison with WT MHCIIA 
and the alanine mutant (Fig. 8A). At 150 mM NaCl, 50% of the 3xD mutant remains in the 
supernatant whereas only 25% of the WT MHCIIA as well as 3xA mutant is soluble. The 
differences in MHCIIA assembly between WT and 3xD rods are further demonstrated by 
the midpoint values (Fig. 8B).
The same mutations were introduced into a YFP-tagged MHCIIA construct to study the 
effect of these phosphorylation sites on myosin IIA stability in vivo. In addition, the last 170 
amino acids of the COOH-terminus in YFP-MHCIIA (DC170) were deleted to serve as a 
positive control for myosin IIA filament disassembly (34). Subsequently, these constructs 
were expressed in COS7 cells because they predominantly express MHCIIB and no MHCIIA. 
Western blotting showed that all constructs were expressed to similar levels in COS7 
cells. However, biochemical fractionation of the cells revealed significant differences in the 
degree of filament assembly between the various MHCIIA mutants (Fig. 9). The majority 
of WT YFP-MHCIIA assembles into the actomyosin cytoskeleton whereas deletion of the 
last 170 amino acids prevents this assembly. Notably, mutations of the phosphorylation sites 
to alanine (3xA) and aspartate (3xD) led to a decrease and an increase in YFP-MHCIIA 
solubility, respectively (Fig. 9B). These findings identify Thr1800, Ser1803 and Ser1808 as 
novel regulatory sites of myosin IIA filament assembly.
Based on the results of our biochemical experiments, we hypothesized that the various 
YFP-MHCIIA proteins have different distribution patterns in COS7 cells. Indeed, we observed 
that WT YFP-MHCIIA co-localized with the cortical F-actin cytoskeleton whereas the 
DC170 mutant was homogenously distributed throughout the cytosol (Fig. 10A). Although 
the 3xA YFP-MHCIIA mutant also localized with the cortical F-actin cytoskeleton, the 3xD 
MHCIIA protein formed disorganized fibrillar assemblies within the cell body that failed to 
incorporate into cytoskeletal structures. In order to quantify differences observed between 
these myosin IIA tail mutants, we monitored the extent of cortical localization (cortical 
index), as was described earlier to determine subcellular localization of myosin IIB (26). 
Measurement of the cortical index confirmed the distribution of the various YFP-MHCIIA 
recombinant proteins, with both 3xD and DC170 mutants showing reduced cortical localization 
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in comparison with WT myosin IIA and the 3xA mutant. These differences most probably 
reflect a differential ability of these mutants to incorporate into functional actyomyosin 
assemblies (Fig. 10B). It should be noted that the distribution patterns of WT and mutant 
YFP-MHCIIA are consistent with filament stability observed in vitro. Notably, the ability of 
the 3xD MHCIIA mutant to self-assemble into disorganized fibrillar structures is represented 
by its relative insolubility in Triton X-100 in comparison with the deletion mutant DC170, 
but its inability to associate with cytoskeletal structures leads to an increase in solubility in 
comparison with WT MHCIIA. Thus, the different assays to monitor assembly of myosin 
IIA filaments both in vitro and in vivo are in good agreement. Phosphomimetic mutations lead 
to proteins that require lower NaCl concentrations to disrupt filaments in vitro, are more 
soluble in Triton X-100 and show lower cortical indices compared with WT MHCIIA in vivo. 
In contrast, mutations that prevent phosphorylation have the opposite effect. We therefore 
conclude that phosphorylation of Thr1800, Ser1803 and Ser1808 leads to a redistribution 
of the MHCIIA filaments in cells away from the cortex and prevents their incorporation 
into cytoskeletal structures. 
Discussion
In this study, we addressed the molecular mechanism by which TRPM7 directly affects the 
activity of non-muscle myosin IIA. We demonstrate that TRPM7 phosphorylates Thr1800, 
Ser1803 and Ser1808 in the coiled-coil domain of the MHCIIA and that phosphomimetic 
mutations introduced at these sites lead to the disassembly of myosin IIA filaments when 
expressed in cells. To the best of our knowledge, this study and another recent investigation 
(37) are the first to show that phosphorylation of the MHCIIA affects filament assembly in 
vivo. Moreover, our results indicate a conservation of function between Dictyostelium and 
mammalian a-kinases.
We have chosen to investigate the effect of TRPM7 on the non-muscle myosin IIA isoform 
rather than the myosin IIB or IIC isoforms for several reasons. First, both TRPM7 and myosin 
IIA are ubiquitously expressed whereas myosin IIB and IIC have a more restricted expression 
pattern (12, 38, 39). For instance, both TRPM7 and myosin IIA are widely expressed in 
hematopoeitic cells whereas myosin IIB and IIC are absent. Secondly, previous work has 
shown that TRPM7 associates with the non-muscle myosin IIA isoform in a Ca2+- and 
kinase-dependent manner leading to actomyosin relaxation (28). Third, non-muscle myosin 
IIA regulates cell adhesion in neuronal cells. Knockdown of myosin IIA but not myosin IIB 
leads to the disruption of focal adhesions formed in neuronal cells (40). Recently, we have 
shown that activation of TRPM7 leads to remodeling of adhesion structures in neuronal cells 
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and that this phenotype can be mimicked 
by pharmacological inhibition of myosin II 
(28). Taken together, these results suggest 
that TRPM7 may be influencing myosin IIA 
function. However, we did observe that 
several phosphorylation sites (Ser1803, 
Ser1808) are conserved in myosin IIB and 
myosin IIC. Therefore, we are currently 
addressing the potential role of TRPM7 in 
regulating myosin IIB and IIC.
TRPM7 associates with the actomyosin 
cytoskeleton where it phosphorylates the 
MHCIIA but not the associated myosin light 
chain (Fig. S1). Here, we extend on these 
findings by demonstrating that TRPM7 
phosphorylates the extreme COOH-
terminus of the MHCIIA. Interestingly, this 
region of the MHCIIA is critical for filament 
assembly (34), and this can be regarded 
as an important regulatory domain. Net 
charge analysis of the MHCIIA shows that 
the region phosphorylated by TRPM7 lies 
within the only positively charged area of 
the coiled-coil domain (data not shown). 
This region was recently found to be critical 
to myosin IIB filament assembly (35), and 
based on its charge, we predict that it will 
be highly responsive to phosphorylation. 
Accordingly, a number of protein kinases 
including protein kinase C (PKC) and 
casein kinase 2 (CK2) have been found to 
phosphorylate this region of the helical 
tail, leading to a decrease in the critical 
salt concentration required to solubilize 
MHCIIA filaments in vitro (25). Moreover, 
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Figure 10. Relocalization of YFP-MHCIIA 3xD 
mutant away from the cortex. (A) Representative 
images of COS7 cells expressing myosin IIA mutants. 
YFP-MHCIIA constructs were transiently expressed in 
COS7 cells. Subsequently, the actin cytoskeleton was 
stained using Texas Red-conjugated phalloidin and cellular 
localization of YFP-MHCIIA and F-actin was visualized by 
fluorescence microscopy. (B) Cortical index measurement 
of the myosin IIA mutants. The cortical index for 10 
representative cells was measured as previously described. 
Data is presented as mean ± SEM. * p < 0.001.
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point mutations that alter the charge composition of the MHCIIA tail affect myosin IIA 
filament assembly leading to human disease (41). Finally, other regulatory proteins, such as 
S100A4, also target this area of the MHCIIA (20). Thus, TRPM7 specifically phosphorylates 
the region important for the regulation of myosin IIA filament formation.
Our experiments identify Thr1800, Ser1803 and Ser1808 as novel residues important for 
regulating myosin IIA assembly. These three TRPM7 phosphorylation sites are concentrated 
in a short stretch of amino acids rather than being scattered throughout the COOH-terminus 
of the MHCIIA, demonstrating that the kinase reactions are highly specific. Moreover, the 
conservation of these residues across species and among non-muscle myosin II isoforms 
provides further evidence that they represent important regulatory sites. Based on this 
conservation, we propose that Ser1803 and Ser1808 are expected to be the most important 
regulatory sites. Accordingly, we found that mutating Ser1803 was already sufficient to affect 
the subcellular localization and Triton X-100 solubility of MHCIIA (Fig. S2 & S3).
Although the differences in solubility between WT and mutant MHCIIA are relatively 
modest, they are highly reproducible. Importantly, mutation to alanine and that to aspartic 
acid produce opposite effects on MHCIIA filament stability, which strengthens the notion that 
these residues regulate filament forming properties. A possible explanation for the relatively 
small differences between the various recombinant MHCIIA proteins is that the mutations, 
in particular mutations to aspartic acid (3xD), may not fully mimic the phosphorylated state. 
Recently, Dulyaninova et.al. could not recapitulate the phenotype of CKII-phosphorylated 
myosin IIA by mutation of the CKII target residues to aspartic acid (37). Thus, our aspartic 
acid mutants may give an underestimation of the effects of TRPM7-mediated phosphorylation 
on myosin IIA filament stability. Although most point mutations in the MHCIIA produce 
relatively modest effects on salt-assembly characteristics, these mutations can have a large 
impact on cell behavior and the pathogenesis of human disease. Several (point) mutations 
that cause myosin IIA-related diseases have been identified in myosin IIA (42, 43). These 
single amino acid substitutions are found mainly in the coiled-coil domain. While most of 
these mutations produce minor effects on MHCIIA solubility, they do effectively interfere 
with organization of the monomers into filaments (41). Thus, we cannot exclude that TRPM7-
mediated phosphorylation of mammalian non-muscle MHCIIA has a greater impact on the 
organization of the filaments in vivo than measured by its solubility in vitro. Accordingly, the 
small increase in solubility of MHCIIA indicates that the majority of the 3xD mutant retains 
some kind of filamentous organization. This phenotype is reminiscent of that described by 
Dulyaninova et.al. (37) who found that the S1934D mutant still associates with endogenous 
MHCIIA. Nevertheless, we clearly demonstrate a distinct subcellular distribution of the 
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recombinant MHCIIA proteins in line with previous reports (26, 44). Our findings and those 
of others indicate that future work is necessary to understand exactly how phosphorylation 
affects the organization and turnover of myosin II filaments in vivo. 
The importance of heavy chain phosphorylation to myosin IIA filament stability remains 
controversial. Initial studies reported that myosin IIA filament assembly was predominantly 
regulated by S100A4 binding whereas myosin IIB was regulated by heavy chain phosphorylation 
(45, 46). More recently, it was demonstrated that phosphorylation of the MHCIIA by CK2 and 
PKC isoforms leads to filament disassembly in vitro (25). Moreover, phosphorylation of the 
PKC site in MHCIIA correlates with exocytosis, suggesting a role for MHCIIA phosphorylation 
in regulated secretion (47). Our results clearly demonstrate that phosphorylation of the 
MHCIIA affects filament assembly in vivo. Mutation of TRPM7 phosphorylation sites to aspartic 
acid in MHCIIA reduces the incorporation of myosin IIA into the actomyosin cytoskeleton, 
leading to a relocalization of the protein away from the cortex. While myosin IIA and IIB 
are both regulated by heavy chain phosphorylation, important differences exist between 
the two isoforms. For instance, PKC phosphorylates myosin IIA in the coiled-coil domain 
whereas it phosphorylates myosin IIB in the nonhelical tail (45, 48). Moreover, different 
signaling pathways control the assembly of each myosin II isoform as the kinetics of MHCIIA 
and IIB phosphorylation upon agonist stimulation of mammalian cells differ and separate 
members of the PKC family specifically phosphorylate myosin IIA and IIB (26, 27, 46). We 
conclude that both myosin IIA and IIB are regulated by heavy chain phosphorylation in vivo 
but that specific signaling pathways control the assembly of these different myosin II isoforms.
To date, we have observed no global change in MHCIIA phosphorylation in response to 
TRPM7 activation (Fig. S4). This result is not surprising since myosin IIA is constitutively 
phosphorylated on multiple sites making it difficult to detect changes in 32P incorporation of 
a single site. In fact, detecting the phosphorylation of a particular site on myosin II generally 
requires the mutation of several residues that are phosphorylated by other kinases (27). 
Moreover, the TRPM7 kinase is low in abundance relative to other kinases. Based on the 
low expression levels, we do not believe that TRPM7 is responsible for the global regulation 
of myosin IIA dynamics in mammalian cells and that additional mechanisms are in place for 
this purpose. Instead, we propose that it affects myosin IIA locally. Accordingly, TRPM7 is 
enriched in cell adhesion structures including podosomes (28, 49). Activation of TRPM7 may 
generate a local relaxation of the actomyosin cytoskeleton in close proximity to adhesion 
structures leading to a remodeling of focal adhesions and podosomes (28). Our current 
efforts are aimed at defining the cellular context in which phosphorylation of Thr1800, 
Ser1803 and Ser1808 by TRPM7 has its strongest effects.
167
TRPM7 regulates myosin IIA filament stability and protein localization by heavy chain phosphorylation
Both TRPM7 and PKC phosphorylate the MHCIIA a-helical tail. Since TRPM7 and PKC are 
activated by PLC-mediated PIP2 hydrolysis (29, 50), it is possible that both kinases synergize 
to regulate myosin IIA filament formation. Notably, both activation of TRPM7 and PKC lead to 
the remodeling of adhesion structures and de novo formation of podosomes, which requires 
an inhibition of myosin II activity (28, 51). It will therefore be interesting to investigate how 
the different kinase pathways cooperate to provide temporal and spatial regulation of myosin 
II filament stability and localization in cells. The development of phospho-specific antibodies 
against the TRPM7, PKC and CK2 sites will be essential to address this issue. Ultimately, 
antibodies that allow in situ detection of phospho-MHCIIA will provide further insight into 
the dynamics of the actomyosin cytoskeleton in mammalian cells. 
In conclusion, we demonstrate that TRPM7 regulates myosin IIA filament stability and 
protein localization by phosphorylating the heavy chain. Moreover, our results identify novel 
residues, Thr1800, Ser1803 and Ser1808, that regulate myosin IIA filament assembly in vivo. 
Future experiments will be aimed at understanding the spatial and temporal organization 
of signaling networks controlling MHCIIA phosphorylation in mammalian cells.
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Materials and Methods
Constructs
The retroviral vector encoding the HA-tagged WT and KD TRPM7 kinase domain (HA-TRPM7-C; amino acids 
1158-1864) was previously described (28). Mouse MHCIIA fragments (Fig. 1) were amplified by RT-PCR using 
RNA isolated from N1E-115 cells and cloned in frame in pGEX-1N using BamHI and EcoRI sites. Human MHCIIA 
fragments fused to GST were generated as described for mouse MHCIIA constructs but the cDNA was amplified 
by PCR using the pTRE-GFP-MHCIIA construct (kind gift of Robert Adelstein, NIH, Bethesda, USA) as template. 
The vector pTRE-GFP-MHCIIA contains a TET-responsive element (34), which allows the inducible expression 
of GFP-MHCIIA in mammalian cells, however in our hands, expression in different cell lines was inefficient. 
Therefore, MHCIIA was excised using HindIII and SpeI sites and cloned into pEYFP-C3, which contains a CMV 
promoter. To generate DC170 mutant, YFP-MHCIIA was digested with AflII and SpeI, Klenow filled and ligated. 
The construct encoding myosin IIA rod in the pET28a vector was previously described (20). All point mutations 
were introduced by site-directed mutagenesis using the QuikChange mutagenesis kit (Stratagene). All constructs 
were verified by DNA sequencing.
Cell culture
RBL-2H3 and COS7 cells were cultured in DMEM medium with 10% FCS. Stable RBL-2H3 cell lines expressing 
WT and KD HA-TRPM7-C were generated by retroviral transduction (52). Cells were selected by the addition 
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of 0.8 mg/ml G418 to the media and the selection was complete within 7 days. For transient protein expression, 
COS7 cells were transfected using either the DEAE-detran method or Fugene 6 (Roche) according to the 
manufacturer’s protocol. 
GST-fusion protein purification
GST-fusion proteins were induced in BL21 DE3 E. Coli by the addition of 200 mM IPTG and incubating the culture 
at 37oC for 3 h. Bacteria were washed and subsequently resuspended in ice-cold GST-lysis buffer (50 mM Tris 
pH 7.5, 300 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM DTT, 1% Triton X-100 and protease inhibitors). 
To degrade the cell wall, bacteria were incubated on ice for 15 min in the presence of lysozyme (100 mg/ml). The 
bacteria were lysed by sonication and insoluble material was removed by centrifugation. The GST-fusion proteins 
were isolated by incubating the supernatant with glutathione-sepharose beads for 2 h at 4oC. The beads were 
washed in GST-lysis buffer and GST-fusion proteins were eluted in elution buffer (100 mM Tris pH 8.0, 300 mM 
NaCl, 20 mM reduced glutathione, and 1 mM DTT). Protein concentration was measured using the Bradford 
assay. For long-term storage, proteins were frozen in the presence of 10% glycerol at –80oC.
In vitro kinase assays
WT and KD HA-TRPM7-C were purified from mammalian cells by immunoprecipitation. Cells were lysed in ice-
cold RIPA buffer (50 mM Tris pH 7.5, 150 mM NaCl, 0.5% sodium deoxycholate, 0.1% SDS, 1% Triton X-100 and 
protease inhibitors). Debris was removed by centrifugation and TRPM7 kinase was isolated by immunoprecipitation 
using anti-HA antibodies (12CA5) coupled to protein G-Sepharose. TRPM7 immune-complexes were washed 
and resuspended in IVK buffer (50 mM Hepes pH 7.0, 4 mM MnCl2, 2 mM DTT) with 2 mg of GST-fusion proteins. 
The kinase reactions were initiated by adding ATP (100 mM cold ATP plus 5 mCi [g-32P]ATP) and incubating at 
30oC for 30 min. Kinase reactions were stopped by the addition of Laemmli buffer containing 40 mM EDTA. 
Samples were boiled, separated by SDS-PAGE and phosphorylated proteins were detected by autoradiography. 
Quantification was performed by phosphoimager analysis.
EDMAN sequencing and MALDI-TOF MS 
Residues phosphorylated by TRPM7 in MHCIIA were determined by a combination of solid-phase Edman sequencing 
and mass spectrometry (MS). Mapping of phosphorylation sites by Edman degradation sequencing and MS analysis 
of 32P-labeled peptides were performed as previously described (53).
Phosphopeptide analysis by LC-MS/MS
Tryptic and GluC digests of phosphorylated myosin IIA were purified and desalted using C18 STAGE tips (54) before 
analysis by MS. Peptide identification experiments were performed using a nano HPLC Agilent 1100 nanoflow 
system connected online to a 7-Tesla linear ion trap Ion Cyclotron Resonance Fourier Transform (LTQ-FT) mass 
spectrometer (Thermo Fisher, Bremen, Germany). Peptides were separated on a 15 cm 100 µm ID PicoTip columns 
(New Objective, Woburn, MA, USA) packed with 3 µm Reprosil C18 beads (Dr. Maisch GmbH, Ammerbuch, 
Germany) using a 90 min gradient from 10% buffer B to 40% buffer B (buffer B contains 80% acetonitrile in 0.5% 
acetic acid) with a flow-rate of 300 nl/min. Peptides eluting from the column tip were electro-sprayed directly 
into the mass spectrometer with a spray voltage of 2.1 kV. Data acquisition with the LTQ-FT was performed in 
a data-dependent mode to automatically switch between MS, MS2, and neutral-loss-dependent MS3 acquisitions. 
Briefly, full-scan MS spectra of intact peptides (m/z 350–2000) with an automated gain control accumulation target 
value of 106 ions were acquired in the Fourier transform ion cyclotron resonance (FT ICR) cell with a resolution of 
50.000. The four most abundant ions were sequentially isolated and fragmented in the linear ion trap by applying 
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collisionally induced dissociation using an accumulation target value of 10.000 (capillary temperature, 100°C; 
normalized collision energy, 30%). A dynamic exclusion of ions previously sequenced within 180 s was applied. 
All unassigned charge states and singly charged ions were excluded from sequencing. A minimum of 50 counts 
was required for MS2 selection. Data-dependent neutral loss scanning of phosphoric acid groups was enabled 
for each MS2 spectrum among the three most intense fragment ions. RAW spectrum files were converted into 
a Mascot generic peak list by DTA Supercharger (http://msquant.sourceforge.net). Accurate parent masses of 
MS3 spectra were automatically generated by DTA Supercharger from the full FT MS scan. Peptides and proteins 
were identified using the Mascot (Matrix Science) search engine version 2.0 to search a local version of the 
human International Protein Index (IPI) database version 3.05 supplemented with the sequences of GST-myosin 
IIA fusion proteins. The settings for MASCOT searches were 10 ppm tolerance for the parental peptide and 0.5 
Da for fragmentation spectra, a fixed carbamidomethyl modification for cysteines, variable modifications for 
oxidation of methionine, deamidation for glutamine and asparagine and phosphorylation for serine, threonine and 
tyrosine. Verification and site mapping of phosphorylated peptides were perfomed using the Posttranslational 
modification scoring algorithm of MSQuant, according to the procedure of Olsen et.al. for phosphopeptides 
(55). As a final verification step, peptides containing phosphorylation sites occurring only once or twice were 
verified by manual inspection of the MS2 and MS3 spectra.
Myosin IIA filament assembly
WT and mutant myosin IIA rods were purified as previously described (20). The assembly properties of the 
myosin IIA rods were characterized in the presence of magnesium as described by Dulyaninova et.al. (25). The 
solubility data were plotted as a function of NaCl concentration and fit to the Hill equation in order to compare 
the midpoint of the curves for WT and mutant rods. 
Cytoskeletal extraction
COS7 cells were transiently transfected with YFP-MHCIIA constructs 24 h prior to the experiment. Cells were 
washed twice with ice-cold PBS and lysed in cytoskeletal extraction buffer (50 mM Tris pH 7.5, 50 mM NaCl, 5 mM 
MgCl2, 1% Triton X-100, 1 mM PMSF, 2 mg/ml aprotinin and 2 mg/ml leupeptin) for 10 min on ice. The lysates were 
centrifuged for 10 min at 16000 g to remove any insoluble material. Laemmli buffer was added to the supernatant. 
To solubilize the triton insoluble fraction, the purified cytoskeletons were first washed twice with cytoskeletal 
extraction buffer and proteins were solubilized in Laemmli buffer. The proteins were separated by SDS-PAGE on 
a 6% gel and transferred to nitrocellulose. YFP-MHCIIA proteins were detected using anti-GFP (1:1000; Roche) 
antibodies followed by IRDye 800CW-conjugated anti-mouse IgG (1:5000; Westburg). The fluorescence intensity 
of each band was quantified using the Odyssey Infrared Imaging System (LI-COR Biosciences). 
Microscopy
COS7 cells were seeded on glass coverslips and transfected with YFP-MHCIIA constructs. On the following 
day, cells were fixed in 3.7% formaldehyde/PBS for 10 min, permeabilized with 0.1% Triton X-100/PBS for 3 min 
and blocked in 3% BSA/PBS. To detect F-actin, cells were incubated with Texas Red-labelled phalloidin (1:200; 
Molecular Probes) for 45 min. Cells were washed 3 times with PBS between each step. Cells were viewed using 
a Leica-DMRA microscope with a 63X, 1.32 NA oil immersion lens. Cortical index was measured as previously 
described (26).
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Statistical analysis
Quantitative data are presented as the mean ± SEM. Statistical significance of differences between experimental 
groups was assessed with Student's t test. Differences in means were considered significant if p < 0.05.
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Figure S1. Myosin light chain (MLC) is not phosphorylated 
by TRPM7. To show that TRPM7 phosphorylation is restricted 
to the myosin heavy chain, HA-tagged full length MHCIIA 
was immunoprecipated from transfected COS7 cells. Co-
immunoprecipitation of the myosin light chain (MLC) was confirmed 
by Western blotting using aMLC antibodies (ICN) (Left panel). 
The immunoprecipitated proteins were subsequently incubated 
with purified HA-TRPM7, together with [g-32P] ATP and separated 
by SDS-PAGE on a 15% gel. 32P incorporation was detected by 
autoradiography (Right panel).
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Figure S3. Localization of YFP-
MHCIIA mutants in HELA cells. 
YFP-MHCIIA constructs were transfected 
into HELA cells using Fugene 6 (Roche). 
24 hours later, the actin cytoskeleton 
was stained using Texas red-conjugated 
phalloidin and cellular localization of 
YFP-MHCIIA and F-actin was visualized 
by fluorescence microscopy.
Figure S4. Overexpression of TRPM7 
does not affect the degree of MHCIIA 
phosphorylation in mammalian cells. 
N1E-115 cells were retrovirally transduced 
to generate empty vector control cells 
or N1E-115 TRPM7-HA cells. Cells were 
labeled overnight with 32P04 (or 
35SMet/
Cys) in phosphate-free (or Met/Cys 
free) DMEM. Labeled cells were either 
untreated or stimulated for 5 minutes with bradykinin (to increase 
TRPM7 kinase activity) prior to lysis in RIPA buffer. Lysates were 
cleared by centrifugation and subjected to immunoprecipitation 
using anti-MHCIIA antibodies. To control for the amount of 
myosin IIA present in N1E-115 TRPM7 vs empty vector controls, 
cells were labeled in parallel with 35S Met/Cys and subjected to 
immunoprecipitation. Samples were separated by SDS-PAGE and 
gels were fixed and dried prior to exposure to film. We did not 
observe significant differences in myosin IIA phosphorylation 
either in response to bradykinin or between control or TRPM7 
expressing cells.
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Figure S2. Mutation of Ser1803 to aspartate increases 
the solubility of MHCIIA. Constructs encoding WT, 1xD 
(Ser1803Asp) and 3xD YFP-MHCIIA recombinant proteins 
were transiently transfected into COS7 cells. The proteins were 
separated into Triton X-100 soluble and insoluble fractions. YFP-
MHCIIA was detected in each fraction by immunoblotting using 
anti-GFP antibodies followed by IRDye800-coupled anti-mouse 
IgG secondary antibodies. Fluorescence was measured using 
the Odyssey detection system. The data is represented as the 
percentage of soluble MHCIIA protein (mean ± SEM, n=5). * P 
< 0.05.
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Abstract
TRPM6 and TRPM7 encode channel-kinases. While these channels share electrophysiological 
properties and cellular functions, TRPM6 and TRPM7 are non-redundant genes raising the 
possibility that the kinases have distinct substrates. Here, we demonstrate that TRPM6 
and TRPM7 phosphorylate the assembly domain of themyosin IIA, IIB and IIC heavy chains 
on identical residues. Whereas phosphorylation of the myosin IIA heavy chain is restricted 
to the coiled-coil domain, TRPM6 and TRPM7 also phosphorylate the non-helical tails of 
the myosin IIB and IIC heavy chains. TRPM7 does not phosphorylate eukaryotic elongation 
factor-2 (eEF-2) and the myosin II heavy chain is a poor substrate for eEF-2 kinase. In 
conclusion, TRPM6 and TRPM7 share exogenous substrates among themselves but not 
with functionally distant a-kinases.
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Introduction
TRPM6 and TRPM7 are bifunctional proteins encoding a TRP cation channel fused to an 
a-kinase and represent the only two proteins in the mammalian genome with this particular 
architecture. A critical issue in understanding the biological function of TRPM6 and TRPM7 
is to identify the substrates for each kinase.
Within the mammalian a-kinase family, TRPM6 and TRPM7 are most closely related to 
each other. In addition to similarity in primary structure, TRPM6 and TRPM7 have comparable 
electrophysiological properties as well as cellular functions. Physiological Mg2+ and Mg2+-
nucleotide concentrations inhibit TRPM6 and TRPM7 channels (1, 2) and these channels 
play a key role in Mg2+ homeostasis (3-5). However, TRPM6 and TRPM7 also have unique 
roles in human biology. Overexpression of TRPM6 cannot rescue cell growth arrest due to 
ablation of TRPM7 (6) and the disease familial hypomagnesemia with secondary hypocalcemia, 
which is caused by mutations of TRPM6, progresses despite the expression of TRPM7 in 
both the intestine and kidney (3, 4). Thus, TRPM6 and TRPM7 have unique functions even 
though they share many structural and electrophysiological features. Are these functional 
differences related to a distinct set of substrates for each kinase?
In contrast to channel function, little is known about the substrates for TRPM6 and TRPM7 
kinases. To date, no exogenous substrates have been identified for TRPM6, whereas TRPM7 
phosphorylates annexin I and myosin IIA heavy chain (MHCIIA) (7-9). In addition to MHCIIA, 
mammalian cells also express MHCIIB and IIC. These three non-muscle MHCII isoforms 
are well conserved throughout the entire protein and share certain cellular functions but 
there is increasing evidence for non-redundant roles for each isoform (10). Whether TRPM7 
phosphorylates the heavy chains of all three myosin II isoforms remains unknown. Therefore, 
we compared the substrate specificity of TRPM6, TRPM7 and a functionally distant a-kinase, 
eEF-2 kinase, by assessing the phosphorylation of non-muscle MHCIIA, IIB and IIC. 
Results
TRPM7 phosphorylates the COOH extremity of the MHCIIA (9). To examine whether 
TRPM7 also phosphorylates MHCIIB and IIC, regions homologous to MHCIIA were purified 
as GST-fusion proteins (Fig. 1A). Incubation of these proteins with TRPM7 led to the 
phosphorylation of all three MHCII isoforms (Fig. 1B). Like MHCIIA, the phosphorylation 
sites in the MHCIIB and IIC are located within the COOH terminus since upstream regions 
of the coiled-coil domain were not phosphorylated by TRPM7. However after a 30 min 
reaction, 32P incorporation by TRPM7 into MHCIIB and IIC was approximately 10-fold 
greater than for MHCIIA (Fig. 1C). 
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Figure 1. Phosphorylation of myosin IIA, IIB and IIC heavy chains by TRPM7. (A) A schematic diagram 
of the r gions of myosin IIA, IIB and IIC heavy chains (MHCII) expressed as GST-fusion proteins. The start and end 
amino acid is indicated on either side of the line. Above the line is the total number of threonine and serine residues 
within the fragment. (B) TRPM7 phosphorylates the COOH termini of myosin IIA, IIB and IIC heavy chains. Top, 
coomassie blue stained gel; middle, autoradiogram of GST-MHCII; bottom, autoradiogram of autophosphorylated 
TRPM7. (C) Quantification of MHCII p osphorylation by TRPM7. The level of 32P incorporation after a 30 min 
incubation with TRPM7 is reported relative to the degree of MHCIIA phosphorylation which was set to 1. (D) 
Deletion of the non-helical tail from the COOH termini of MHCIIB and IIC reduces their phosphorylation to 
levels observed in MHCIIA. Top, coomassie blue stained gel; middle, autoradiogram of GST-MHCII; bottom, 
autoradiogram of autophosphorylated TRPM7.
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Sequence alignment of the myosin II isoforms revealed that the helical tail is highly conserved 
between all three isoforms but the non-helical tail differs significantly in length and sequence 
(Fig. 2B). The non-helical tails of MHCIIB and IIC contain a short stretch of amino acids rich 
in serines and threonines that is absent in the MHCIIA isoform. We therefore generated 
GST-fusion proteins where the helical and nonhelical tails were separated from one another. 
The MHCIIB and IIC non-helical tails were phosphorylated by TRPM7 whereas the MHCIIA 
nonhelical tail was not phosphorylated (Fig. 1D). Moreover, removal of the non-helical tail 
from the COOH terminus of MHCIIB and IIC reduced the levels of phosphorylation to those 
observed in MHCIIA (Fig. 1D). Thus, differential phosphorylation of the nonhelical tail by 
TRPM7 accounts for the differences in phosphorylation of the MHCII isoforms. 
TRPM7 phosphorylates mainly serines in MHCIIA and IIB but threonines in MHCIIC (data 
not shown). We mapped the phosphorylation sites in all three non-muscle isoforms by mass 
spectrometry (Fig. 2 & Table S1). TRPM7 phosphorylates Thr1800, Ser1803 and Ser1808 
in the coiled-coil domain of MHCIIA. This part of the heavy chain is also phosphorylated 
in MHCIIB and IIC. In contrast to Ser1803, which is only conserved in myosin IIB (S1812), 
Ser1808 is conserved and phosphorylated in both MHCIIB (T1817) and IIC (T1833). In 
addition to the coiled-coil domain, TRPM7 phosphorylates numerous serines in the MHCIIB 
and threonines in the MHCIIC non-helical tails. LC-MS/MS analysis determined with high 
probability that multiple residues in both MHCIIB and IIC are phosphorylated by TRPM7 
in this region. 
Like TRPM7, TRPM6 phosphorylates the COOH terminus of the different MHCII isoforms 
(Fig. 3A) with a 10-fold greater incorporation of 32P in MHCIIB and IIC. Again, this difference 
is due to the phosphorylation of the non-helical tails of MHCIIB and IIC by TRPM6 (data 
not shown). Our LC-MS/MS experiments indicated that TRPM6 phosphorylates the same 
sites as TRPM7 in the different MHCII isoforms (data not shown). Moreover, mutation of 
the phosphosites Thr1800, Ser1803 and Ser1808 to alanine reduced the phosphorylation 
of MHCIIA by TRPM6 and TRPM7 to background levels (Fig. 3B). Finally, we found that 
TRPM7 cannot phosphorylate eEF-2 and conversely, eEF-2 kinase poorly phosphorylates 
non-muscle MHCII isoforms, showing that these distantly related members of the a-kinase 
family each phosphorylate specific substrates in vitro (Fig. 4).
Discussion
An important conclusion from our investigation is that TRPM6 and TRPM7 share exogenous 
substrates with themselves but not with a-kinases having distantly related functions such 
as eEF-2 kinase. We demonstrated that TRPM6 and TRPM7 phosphorylate the different 
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MHCII isoforms on identical residues. Moreover, TRPM7 failed to phosphorylate eEF-2 and 
eEF-2 kinase only weakly phosphorylated MHCII. While the differences between TRPM7 
and eEF-2 kinase are consistent with a recent study on peptide substrate specificity of 
a-kinases (11), our results contrast with another study by Schmitz et.al. who concluded that 
TRPM6 and TRPM7 have different substrate specificities since TRPM6 cross-phosphorylates 
TRPM7 but not vice versa (6). Our studies differ in two important ways: 1) we examined the 
phosphorylation of unrelated exogenous substrates, whereas Schmitz et.al. investigated the 
level of cross-phosphorylation by both kinases (6) and 2) we measured the incorporation 
of 32P into our substrates while Schmitz et.al. used a pan phospho-threonine antibody to 
detect phosphorylation (6). TRPM6 and TRPM7 undergo massive autophosphorylation of 
the Ser/Thr-rich domain predominantly on serine residues (6, 12, 13). Therefore, the use 
of the pan-phosphothreonine antibody may not provide an accurate account of the extent 
of cross-phosphorylation by the kinases. Our data clearly demonstrate that TRPM6 and 
TRPM7 share substrate specificity when it comes to phosphorylating exogenous substrates. 
Although TRPM6 and TRPM7 phosphorylate all three nonmuscle MHCII isoforms, we 
observed important differences between substrates. Most notably, both TRPM6 and TRPM7 
phosphorylate the nonhelical tail of MHCIIB and IIC but not that of MHCIIA. The presence of 
additional phosphoacceptor sites in this region of MHCIIB and IIC led to a 10-fold increase in 
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Figure 2. Mapping of TRPM7 
phosphorylation sites in 
myosin IIA, IIB and IIC heavy 
chains by nanoLC-MS/MS. 
(A) A representative MS2 and 
MS3 spectra for a myosin IIB 
peptide phosphorylated on Ser-
1935. (m/z observed of parent 
ion was 537.7342, mass accuracy 
0.38 ppm, +2 charge state; NL 
indicates neutral loss of H3PO4 
which triggers acquisition of MS3 
spectrum). The b+-ion series is 
indicated in red whereas the y+-
ion series is blue. (B) Alignment 
of the COOH termini of myosin 
IIA, IIB and IIC heavy chains. 
The helical tail is in normal font 
and the non-helical tail in italic. 
Residues phosphorylated by 
TRPM7 are in bold and underlined. 
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32P incorporation in comparison to MHCIIA 
under the kinase reaction conditions used 
in this investigation (single time-point and 
substrate concentration). We would like 
to emphasize that these results do not 
necessarily mean that MHCIIB and IIC are 
better substrates for TRPM6 and TRPM7 
than MHCIIA, as the phosphorylation 
occurs on different residues and important 
regulatory components present in 
mammalian cells may be absent from 
the in vitro kinase reactions. Additional 
experiments will be required to establish 
the circumstances under which TRPM6 and 
TRPM7 phosphorylate the different MHCII 
isoforms in mammalian cells. 
The phosphorylation of the non-helical 
tails of MHCIIB and IIC by TRPM6 and 
TRPM7 was unexpected since a-kinases 
are thought to preferentially phosphorylate 
amino acids in the context of an a-helix, a 
distinguishing feature of this atypical protein 
kinase family (14). However, characterization 
of a peptide library demonstrated 
that TRPM6 and TRPM7 preferentially 
phosphorylate peptides with a consensus 
sequence that adopts an a-helix structure 
under specific solvent conditions. Taking 
this information into consideration, an 
algorithm was designed to predict TRPM6 
and TRPM7 phosphorylation sites in its 
substrates (Ryazanov et.al., manuscript 
in preparation). This algorithm accurately 
predicted the phosphorylation of the 
MHCIIB and IIC non-helical tails. Currently, 
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Figure 3. Myosin II phosphorylation by TRPM6. 
(A) TRPM6 phosphorylates the COOH terminus of 
the myosin IIA, IIB and IIC heavy chains. (B) TRPM6 
phosphorylates the same residues in the myosin IIA heavy 
chain as TRPM7. Thr1800, Ser1803 and Ser1808 were 
mutated to alanine to generate GST-MHCIIA COOH 
3xA (Amino acids 1795-1960). 
Figure 4. Preferential phosphorylation of the 
myosin II heavy chain by TRPM7 and eEF-2 by eEF-
2 kinase. Kinase reactions consisted of TRPM7-cat and 
eEF-2 kinase with either GST-myosin IIB COOH or eEF-2. 
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we are investigating the possibility that the TRPM6 and TRPM7 kinase domains assist in the 
shaping of these peptides into a-helices for subsequent phosphorylation.
Elucidation of the pathways that control myosin II function is critical to our understanding 
of the pathogenesis of human diseases involving defects in mechanobiology (10). Recently, 
we demonstrated that TRPM7 promotes actomyosin relaxation in mammalian cells by 
phosphorylating MHCIIA (8, 9). Here, we further extend on these findings by showing that 
TRPM6 and TRPM7 phosphorylate the assembly domain of all three non-muscle MHCII 
isoforms. Both channel-kinases phosphorylate the same stretch of amino acids in the helical 
domain of all three MHCII isoforms. We recently demonstrated that this region regulates 
the assembly of MHCIIA filaments (9). In addition to the helical domain, TRPM6 and TRPM7 
phosphorylate a cluster of serines and threonines in the MHCIIB and IIC non-helical tails, 
respectively. This stretch of serine residues in MHCIIB is phosphorylated in vivo by PKCζ 
in response to EGF stimulation and is a critical determinant in regulating filament assembly 
and protein localization to the cortical cytoskeleton (15). This raises the intriguing possibility 
that TRPM6 and TRPM7 may synergize with PKCζ to regulate myosin IIB filament stability. 
In conclusion, our results are consistent with a role for TRPM6 and TRPM7 in regulating 
actomyosin contractility by phosphorylating MHCIIA, IIB and IIC. Establishing the cellular 
context in which TRPM6 and TRPM7 control the activity of these different myosin II isoforms 
and its link to magnesium homeostasis remain challenges for future research. 
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Materials and methods
Constructs
Cloning of wild-type (WT) and kinase-dead (KD) HA-TRPM7-C and WT HA-TRPM6-C in pcDNA3, eEF-2 kinase 
in pGEX-2T and the TRPM7 kinase domain (TRPM7-cat) in pMAL-p2x were previously described (12, 13, 16). 
GST-MHCIIA, IIB and IIC constructs (Fig. 1A) were generated by inserting PCR products into the BamHI-EcoRI 
sites in the pGEX-1N vector. All constructs were verified by DNA sequencing.
Cell culture
HEK293 cells were cultured in DMEM medium with 10% FCS. Cells were transfected using lipofectamine (Roche). 
Purification of recombinant proteins
GST-myosin II proteins were expressed in E. Coli and purified by affinity chromatography on a glutathione-sepharose 
column using standard methods. HA-TRPM6-C and HA-TRPM7-C kinases were purified from mammalian cells 
by immunoprecipitation (13). TRPM7-cat, eEF-2 kinase and eEF-2 were purified as previously described (12, 16). 
The identity and integrity of the recombinant proteins were verified by mass spectrometry. 
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In vitro kinase assays
TRPM6 and TRPM7 kinases (20 ng) were dissolved in 50 ml  IVK buffer (50 mM HEPES pH 7.0, 4 mM MnCl2, 2 
mM DTT) with 2 mg of GST-fusion protein. Kinase reactions were initiated by adding 0.1 mM ATP in combination 
with 5 mCi of [g-32P]ATP and allowed to proceed for 30 min at 30oC. Activity of eEF-2K was assayed as previously 
described (16). The reactions were stopped by adding Laemmli buffer containing 40 mM EDTA and subjected to 
SDS-PAGE. Phosphorylated proteins were detected by autoradiography and quantified  by phosphorimager analysis. 
Mass spectrometry
Peptide identification experiments were performed using a nano HPLC Agilent 1100 nano flow system connected 
online to a 7-Tesla linear ion trap Ion Cyclotron Resonance Fourier Transform mass spectrometer (Thermo 
Fisher, Bremen, Germany). Verification and site mapping of phosphorylated peptides was perfomed using the 
Post Translational Modification algorithm implemented in MSQuant according to the procedure of Olsen and 
coworkers (17). Phosphopeptides were identified with a 99%-significance threshold when the sum of the Mascot 
and PTM score was higher than 28 (17). The delta PTM score, the difference between the highest and second 
highest PTM score, was set to be larger than 8.0 to exclusively report peptides with a mapped phosphorylation 
site. As a final verification step, peptides containing phosphorylation sites occurring only once or twice were 
verified by manual inspection of the MS2 and MS3 spectra.
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Abstract
TRPM6 and TRPM7 are bifunctional proteins expressing a TRP channel fused to an atypical 
a-kinase domain. While the gating properties of TRPM6 and TRPM7 channels have been 
studied in detail, little is known about the mechanisms regulating kinase activity. Recently, we 
found that TRPM7 associates with its substrate myosin II via a kinase-dependent mechanism 
suggesting a role for autophosphorylation in substrate recognition. Here, we demonstrate 
that the cytosolic C-terminus of TRPM7 undergoes massive autophosphorylation (32 ± 4 
mol/mol), which strongly increases the rate of substrate phosphorylation. Phosphomapping 
by mass spectrometry indicates that the majority of autophosphorylation sites (37 out of 
46) map to a Ser/Thr-rich region immediately N-terminal of the catalytic domain. Deletion 
of this region prevents substrate phosphorylation without affecting intrinsic catalytic activity 
suggesting that the Ser/Thr-rich domain contributes to substrate recognition. Surprisingly, 
the TRPM6-kinase is regulated by an analogous mechanism despite a lack of sequence 
conservation with the TRPM7 Ser/Thr-rich domain. In conclusion, our findings support 
a model where massive autophosphorylation outside the catalytic domain of TRPM6 and 
TRPM7 may facilitate kinase-substrate interactions  leading to enhanced phosphorylation 
of those substrates.
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Introduction
The channel-kinases TRPM6 and TRPM7 are bifunctional proteins consisting of a TRP cation 
channel fused to a kinase and represent the only two proteins in the mammalian genome with 
this particular architecture (1, 2). A critical issue in understanding these intriguing proteins 
is to identify the molecular mechanisms controlling the activation of the channel as well as 
kinase activity and establish the functional link between these two domains. 
Within only a few years, major advances have been made in our understanding of the role 
and regulation of TRPM6 and TRPM7 channels. Genetic and electrophysiological studies 
have identified a major role for TRPM6 and TRPM7 in Mg2+ homeostasis. Both TRPM6 and 
TRPM7 channels permeate divalent cations including Mg2+ (3-5). Mutations in TRPM6 cause 
the disease familial hypomagnesemia with secondary hypocalcemia (6, 7) whereas ablation 
of TRPM7 in DT-40B cells leads to growth arrest as the cells become hypomagnesic (8). 
Importantly, these phenotypes can be rescued by supplementing the patient’s diet or growth 
media with Mg2+ (6-8). However, recent evidence suggests additional cellular roles for TRPM6 
and TRPM7. For instance, TRPM7 has been implicated in various cellular functions, many of 
which are dependent on Ca2+-influx, including cell proliferation, anoxic cell death, exocytosis, 
mechanotransduction, actomyosin contractility and cell adhesion (3, 8-15). 
The principal feature of TRPM6 and TRPM7 channels, which distinguishes them from other 
TRP channels, is their sensitivity to physiological Mg2+ and Mg2+-nucleotide concentrations 
(3, 5, 16). These channels are activated upon depletion of Mg2+ ions in cells and native 
TRPM7-like currents have been called magnesium inhibited cation (MIC) or magnesium-
nucleotide regulated metal ion (MagNuM) currents (3, 17). This property suggested a role 
for the kinase in regulating the gating of these channels. However, it has become evident that 
catalytic activity is not required for TRPM7 channel opening although the kinase domain may 
govern the set point for Mg2+ sensitivity (8, 18, 19). We and others have found that TRPM7 
channels are also regulated by receptor-mediated signaling (20-22). While the function and 
regulation of TRPM6 and TRPM7 channels have been extensively studied, little is known 
about the molecular mechanisms activating their kinase moieties.
TRPM6 and TRPM7 are members of a novel family of atypical protein kinases called 
a-kinases (23, 24). These kinases display little sequence similarity with conventional protein 
kinases (CPK). Moreover, a-kinases can be further distinguished from CPK by their substrate 
specificity. While CPK phosphorylate amino acids found in irregular structures as well 
as turns and loops (25), a-kinases are thought to predominantly phosphorylate residues 
present in a-helices (26). Despite these differences, the topology of the a-kinase domain 
is very similar to that of CPK (27). 
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Like CPK, TRPM6 and TRPM7 undergo autophosphorylation (18, 28, 29) but the 
functional consequences for catalytic activity are unknown. Recently, we demonstrated 
that the interaction between TRPM7 and the actomyosin cytoskeleton is dependent on 
kinase activity, suggesting a role for autophosphorylation in the recognition of its substrates 
including myosin II (10). Therefore, we further investigated the role of autophosphorylation 
in regulating the activity of the mammalian a-kinases TRPM6 and TRPM7.
Results
TRPM7 undergoes massive autophosphorylation of its C-terminus
To test the role of autophosphorylation in modulating the kinase activity of TRPM7, the 
cytosolic C-terminal tail of TRPM7 (TRPM7-C-long; amino acids 1158-1864; Fig. 1) was 
purified from mammalian cells and subjected to in vitro kinase assays. Remarkably, incubation 
of TRPM7 with ATP in vitro led to the incorporation of 32 ± 4 mol of phosphate per mol 
of kinase which was accompanied by a dramatic shift in electrophoretic mobility on SDS-
PAGE gels (Fig. 2A). The non-phosphorylated protein, which migrates at around 80 kDa, 
shows an apparent molecular mass of 120 kDa after in vitro kinase assays. The change in 
electrophoretic mobility is due to autophosphorylation because incubation of a catalytically 
TRPM6-C-Long
TRPM6
TRPChannel KinaseS/T-rich
1 2022
TRPM7
TRPM7-C-Long
TRPM7-C-Short18651548
18651158
20221134
1 1865
TRPChannel KinaseS/T-rich
Figure 1. Schematic diagram depicting the constructs of TRPM6 and TRPM7 used in the current 
investigation. TRPM6 and TRPM7 encode both a channel (black) and an a-kinase domain (grey). The typical 
TRP domain (stripes) is present directly C-terminal to the last transmembrane domain and a Ser/Thr-rich region 
(checkered) is present immediately N-terminal of the kinase domain. In addition to the full-length protein, 
the entire cytosolic C-terminal tail but excluding the TRP domain of TRPM6 and TRPM7 (TRPM6-C-long and 
TRPM7-C-long) as well as the isolated kinase domain of TRPM7 (TRPM7-C-short) were expressed as HA-tagged 
recombinant proteins in mammalian cells. Mouse and human TRPM7 sequences found in the NCBI database differ 
by a single amino acid. Since we used human TRPM7 in this study, we have corrected all positions to correspond 
to the human sequence and therefore Ser1511 and Ser1567 become Ser1512 and Ser1568, respectively.
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inactive mutant with ATP had no effect on the migratory behavior of TRPM7-C-long. The 
kinetics of TRPM7-C-long autophosphorylation demonstrates that this process is very rapid. 
Autophosphorylation was detectable within 10 sec and reached completion within 2-5 min (Fig. 
2B, see also Fig. 4). Moreover, autophosphorylation of TRPM7-C-long proceeds via multiple 
intermediate phosphorylation states as depicted by the gradual change in electrophoretic 
mobility of TRPM7. These results demonstrate that TRPM7 massively phosphorylates its 
cytosolic C-terminal tail via a multi-step process.
The change in electrophoretic mobility of TRPM7 correlates with its ability to phosphorylate 
exogenous substrates
The degree of TRPM7 autophosphorylation depends on ATP concentration (Fig. 3). Titration 
of ATP demonstrated that TRPM7-C-long undergoes complete autophosphorylation at 
concentrations ranging between 10 and 500 µM when using Mn2+ as cofactor. Notably, the 
phosphorylation of myosin II was optimal at those ATP concentrations that led to complete 
autophosphorylation of TRPM7-C-long (Fig. 3A). Even at very high [g-32P]ATP specific 
activities, phosphorylation of myosin II was not observed when ATP concentrations were 
below a certain threshold (10 µM) (Fig. 3B). In contrast, TRPM7-C-long autophosphorylation 
was easily detected at these low ATP concentrations (Fig. 3B). When comparing the 
kinetics of kinase versus substrate phosphorylation, we observed that the onset of myosin 
II phosphorylation occurs when TRPM7 autophosphorylation is complete (Fig. 4). Again, 
TRPM7-C-long autophosphorylation reached maximum after about 5 min. In contrast, 
myosin II phosphorylation was only measurable after 5 min and increased throughout the 
experiment, which was stopped at the 30 min mark. These results indicate that TRPM7 
autophosphorylation facilitates the subsequent phosphorylation of exogenous substrates. 
TRPM7 autophosphorylation accentuates the kinetics of substrate phosphorylation
To show that autophosphorylation regulates TRPM7 kinase activity towards its substrates, we 
compared the rate of myosin II phosphorylation by TRPM7-C-long before and after treatment 
with ATP (Fig. 5). In this classical experimental design, it is predicted that the phosphorylated 
kinase will phosphorylate its substrates more rapidly than the nonphosphorylated kinase 
if autophosphorylation is a key event in activating the protein kinase. The reason for 
the difference in kinetics is that the kinase pre-treated with ATP will be able to directly 
phosphorylate its substrates whereas the nonphosphorylated kinase will first need to undergo 
autophosphorylation. Here, we show that pre-treatment of TRPM7-C-long with ATP led to 
a significant increase in the kinetics of myosin II phosphorylation (Fig. 5A & B). Suddenly, 
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Figure 3. Onset of substrate
phosphorylation occurs after completion of TRPM7 
autophosphorylation. (A) Ef fect of reducing ATP 
concentration on TRPM7 autophosphorylation and myosin 
II phosphorylation. TRPM7-C-long was incubated with GST-
myosin IIA in the presence of varying MnATP concentrations 
for 30 min at 30oC. The specific activity of ATP was maintained 
constant for all samples. The proteins were separated by SDS-
PAGE, stained with coomassie brilliant blue (bottom panel) and 
phosphorylated proteins were detected by autoradiography (top 
panel). (B) Myosin II phosphorylation correlates with TRPM7 
autophosphorylation even at exceedingly high specific activities. 
The experiment was performed as described in A, except that 
the specific activity of the ATP solution was varied to detect 
myosin II phosphorylation at low ATP concentrations. All samples 
contained 5 µCi of [g-32P]-ATP supplemented with the indicated 
concentrations of cold ATP. 
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Figure 4. TRPM7 autophosphorylation precedes 
phosphorylation of substrates. TRPM7-C-long was 
incubated with GST-myosin IIB in the presence of Mn[g-32P]-
ATP for the indicated times. The proteins were separated by 
SDS-PAGE, revealed by coommassie staining (bottom panel) 
and phosphorylated proteins were detected by autoradiography 
(top panel). 
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Figure 2. TRPM7 undergoes extensive
autophosphorylation of the C-terminus via a sequential 
series of phosphorylation events. (A) Autophosphorylation 
of TRPM7 dramatically reduces its electrophoretic mobility. 
WT and KD TRPM7-C-long were incubated in the absence or 
presence of MnATP for 30 min and detected using anti-HA (Top 
panel) and anti-pThr antibodies (Bottom panel). (B) Kinetics 
of TRPM7 autophosphorylation. TRPM7-C-long was incubated 
with MnATP for the indicated times. Proteins were detected by 
immunoblotting using anti-HA antibodies. 
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phosphorylation of myosin II was detectable within 10 sec and increased steadily in the first 
5 min, which is a time scale where no to little myosin II phosphorylation was detected if 
TRPM7-C-long was not previously incubated with ATP. TRPM7 requires approximately 5 min 
to complete autophosphorylation (Fig. 4) and after this time point, myosin II phosphorylation 
will proceed at the same rate in both samples explaining the detection of significant myosin 
II phosphorylation at later time points. In contrast, phosphorylation-kinetics of the artificial 
substrate MBP were not affected by prior treatment of TRPM7 with ATP as previously 
described (Fig. 5C & D) (29). These results demonstrate that TRPM7 autophosphorylation 
facilitates kinase activity towards exogeneous substrates such as myosin II without affecting 
intrinsic catalytic activity.
Time (s) 0 10 20 40 60 30
0
90
0
18
00
0 10 20 40 60 30
0
90
0
18
00
pMHCII
MHCII Coomassie
32P ATP
Pre-incubation -ATP +ATP
Time (s)
pMBP
MBP Coomassie
32P ATP
0 30 60 12
0
30
0
60
0
18
00
0 30 60 12
0
30
0
60
0
18
00
Pre-incubation -ATP +ATP
A
C
0 300
600
900
Time (s)
1200
1500
1800
2100
-ATP
+ATP
10
1
0.1
0.01
0.001
R
el
. P
ho
sp
h.
D
B
10
1
0.1
0.01
0.001R
el
. P
ho
sp
h.
0.0001
-ATP
+ATP
Time (s)
1500
0 500
1000
2000
Figure 5. Autophosphorylation of TRPM7 accelerates susbtrate phosphorylation without affecting 
catalytic activity. (A) Kinetics of myosin II phosphorylation by TRPM7 prior to and after autophosphorylation. 
TRPM7-C-long was incubated in the absence (-ATP) or presence (+ATP) of cold MnATP to generate non-
phosphorylated and completely autophosphorylated TRPM7. ATP was subsequently removed by washing the kinase 
with in vitro kinase buffer lacking ATP. Kinase reactions were initiated by adding Mn[g-32P]-ATP and GST-myosin 
IIB and allowed to proceed at 30oC for the indicated times. Proteins were resolved by SDS-PAGE and visualized 
by coomassie staining (Bottom panel). Phosphorylated myosin II (Top panel) was detected by autoradiography. 
Note that the kinase pre-incubated in buffer without ATP (-ATP) must first complete autophosphorylation (5 
min), apparent from the reduced electrophoretic mobility shift of TRPM7 (Refer to Fig. 4), to acquire the ability 
to phosphorylate its substrates. (B) Quantification of myosin II phosphorylation by TRPM7 pre-incubated in 
absence (-ATP) or presence (+ATP) of ATP. 32P incorporation was measured by phosphorimaging analysis. The 
phosphorylation levels measured for myosin incubated for 30 min with TRPM7 that was pre-incubated with 
ATP was set to 1 and all other values are reported relative to that sample. (C) TRPM7 autophosphorylation 
does not affect catalytic activity. Experiment was performed as described in A but using MBP as substrate. (D) 
Quantification of MBP phosphorylation by TRPM7 pre-incubated in absence (-ATP) or presence (+ATP) of ATP. 
Data was derived as described in B. 
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Massive autophosphorylation of the Ser/Thr-rich domain (Amino acids 1380-1548) controls 
substrate phosphorylation
To address the mechanism by which autophosphorylation affects TRPM7 kinase activity, 
we first mapped the phosphorylation sites by nano liquid chromatography tandem mass 
spectrometry (LC-MS/MS) using a LTQ-FT mass spectrometer according to a recent algorithm 
for post-translational modification scoring from Olsen and colleagues (30). To discriminate 
between the residues phosphorylated by exogenous kinases and TRPM7 itself, a catalytically 
inactive mutant of TRPM7-C-long was also analyzed in these experiments. Our data identify 
49 phosphorylation sites of which 3 were also found in the kinase-dead (KD) mutant (Fig. 
6 & Table S1). Thus we have identified 46 TRPM7 autophosphorylation sites and 3 sites 
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Figure 6. Identif ication of 
phosphorylated residues in 
TRPM7 by LC-MS/MS.
WT and KD TRPM7-C-long were 
incubated in the presence of MnATP 
for 0 or 30 min. Tryptic peptides 
were analyzed using LTQ-FT mass 
spectrometer. (A) Representative 
MS2 and MS3 spectra for a TRPM7 
peptide phosphorylated on Ser-
1614. (m/z observed of parent ion 
was 823.3848, mass accuracy 1.85 
ppm, +2 charge state; NL indicates 
neutral loss of H3PO4 which triggers 
acquisition of MS3 spectrum). The 
b+-ion series is indicated in red 
whereas the y+-ion series is in 
blue. S* refers to dehydroserine. 
(B)  Diagr am dep ic t ing the 
phosphorylated residues identified 
in WT (red) and KD (blue) TRPM7-
C-long incubated in presence (right) 
or absence (left) of ATP.
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targeted by other protein kinases. Moreover, many of the novel TRPM7 autophosphorylation 
sites are phosphorylated in vivo demonstrating the physiological relevance of the identified 
sites (Fig. 6B). It should be noted however that these sites are probably substoichiometrically 
phosphorylated in vivo and further phosphorylated when TRPM7 is incubated with ATP in 
vitro. Although autophosphorylation sites are present throughout the entire C-terminal tail, 
the majority of these sites are concentrated in the Ser/Thr-rich region directly adjacent to 
the catalytic domain (Amino acids 1380-1585). We therefore hypothesized that this region 
could be an important regulatory domain. 
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Figure 7. Deletion of the Ser/Thr-rich domain in TRPM7 reduces substrate phosphorylation. 
(A) Autophosphorylation of TRPM7-C-short only leads to a minor change in electrophoretic mobility on SDS-PAGE 
gels. TRPM7-C-short and TRPM7-C-long were incubated in the absence or presence of MnATP for 30 min at 30oC 
and subjected to immunoblotting using anti-HA antibodies. (B) TRPM7-C-short phosphorylates myosin II less 
efficiently than TRPM7-C-long. (i) TRPM7-C-short and TRPM7-C-long were incubated with GST-myosin IIB in the 
presence of Mn[g-32P]-ATP. The proteins were separated by SDS-PAGE, revealed by coommassie staining (middle 
panel) and phosphorylated proteins were detected by autoradiography (Left panel). (ii) Equal amounts of each 
kinase was verified by Western blotting (Right panel). (C) Quantification of myosin II phosphorylation by TRPM7-
C-short and TRPM7-C-long. 32P incorporation was measured by phosphorimaging analysis. The phosphorylation 
levels measured for myosin II incubated with TRPM7-C-long was set to 1 and values obtained for TRPM7-C-
short are reported relative to that value. (D) Deletion of residues 1158-1548 does not affect catalytic activity. (i) 
TRPM7-C-long and TRPM7-C-short WT and KD were incubated with MH1 peptide in presence of Mn[g-32P]-ATP. 
The level of phosphorylation was measured by scintillation counting. Background activity as determined using 
the KD mutant was subtracted from the WT TRPM7 samples and catalytic activity was reported relative to 
that of TRPM7-C-long, which was set to 1. (ii) Equal amounts of each kinase were verified by Western blotting. 
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We investigated the contribution of this Ser/Thr-rich domain to TRPM7 kinase activity 
by generating a construct (TRPM7-C-short) containing only the catalytic domain plus 
a small extension (40 amino acids) that is required for dimerization. TRPM7-C-short 
autophosphorylated itself leading to the incorporation of approximately 4 times less phosphate 
than TRPM7-C-long. However in contrast to TRPM7-C-long, the electrophoretic mobility of 
TRPM7-C-short did not change significantly (Fig. 7A). Strikingly, phosphorylation of myosin 
II by TRPM7 was greatly reduced when the regulatory domain was deleted (Fig. 7B & Fig. 
S1). The level of myosin II phosphorylation was only 5% of the levels achieved when using 
TRPM7-C-long in in vitro kinase reactions (Fig. 7C) despite TRPM7-C-short having similar 
catalytic activity in comparison to TRPM7-C-long (Fig. 7D). Removal of a more upstream 
region (Amino acids 1158 to 1380) led to a kinase that underwent extensive electrophoretic 
mobility shift and could phosphorylate myosin II to similar degree as the TRPM7-C-long 
kinase (unpublished data). Thus, the autophosphorylation sites concentrated in the Ser/Thr-
rich domain are responsible for the electrophoretic mobility shift and required for efficient 
phosphorylation of substrates but dispensable for catalytic activity. 
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Figure 8. Regulation of TRPM6 by 
autophosphorylation. (A) TRPM6 and 
TRPM7 display no sequence homology in 
the region spanning between the TRP box 
and the kinase domain. Alignment of amino 
acid sequences of TRPM6 and TRPM7 using 
Blast-2-Blast from NCBI. The gap is a result 
of low sequence similarity between the 
two proteins in the indicated region. (B) 
Autophosphorylation of TRPM6 leads to a 
dramatic shift in electrophoretic mobility 
on SDS-PAGE gels. TRPM6-C-long and 
TRPM7-C-long were incubated in the absence or presence of MnATP, resolved by SDS-PAGE and subsequently 
detected using anti-HA antibodies. (C) TRPM6 autophosphorylation precedes myosin II phosphorylation. TRPM6-
C-long was incubated with GST-myosin IIB in the presence of Mn[g-32P]-ATP for the indicated times. The proteins 
were separated by SDS-PAGE, revealed by coommassie staining (bottom panel) and phosphorylated proteins 
were detected by autoradiography (top panel). (D) Accelerated kinetics of myosin II phosphorylation after pre-
incubation of TRPM6 with ATP. TRPM6-C-long was incubated in the absence or presence of MnATP to generate 
non-phosphorylated and completely autophosphorylated TRPM6. To initiate the phosphorylation of myosin 
II, in vitro kinase buffer containing Mn[g-32P]-ATP and GST-myosin IIB was added. The reaction was allowed to 
proceed at 30oC and stopped by adding Laemmli buffer after the indicated times. Proteins were resolved by 
SDS-PAGE, visualized by coomassie staining (bottom panel) and phosphorylated proteins were detected by 
autoradiography (top panel).
195
Massive autophosphorylation of the Ser/Thr-rich domain controls protein kinase activity of TRPM6 & TRPM7
Despite a lack of sequence conservation, TRPM6 is also regulated by autophosphorylation of the 
Ser/Thr-rich domain
Alignment of the TRPM6 and TRPM7 sequences reveals that the protein is highly conserved 
throughout the molecule except in the region between the TRP and kinase domains of the 
C-terminal tail (Fig. 8A). Since this region regulates substrate recognition by TRPM7, we 
investigated whether it has a similar role in controlling TRPM6 kinase activity. Incubation of 
TRPM6-C-long with ATP led to a noticeable shift in electrophoretic mobility on SDS-PAGE 
gels (Fig. 8B). The kinetics of autophosphorylation of TRPM6-C-long also preceeded the 
phosphorylation of myosin II (Fig. 8C). Moreover, pre-incubation of TRPM6-C-long with 
ATP increased the rate of myosin II phosphorylation indicating that TRPM6 is activated by 
autophosphorylation (Fig. 8D). Despite the lack of sequence homology between TRPM6 and 
TRPM7, autophosphorylation also occurs in the region immediately upstream of the kinase 
(data not shown). Accordingly, this domain is serine and threonine-rich in both kinases. We 
conclude that although the regulatory domains of TRPM6 and TRPM7 show little similarity 
at the amino acid level, these sequences are essential for substrate phosphorylation by 
both kinases. 
Discussion
TRPM6 and TRPM7 play a key role in Mg2+-homeostasis (6-8). In addition, TRPM7 has been 
implicated in other cellular processes including exocytosis, actomyosin contractility and 
cell adhesion (11). The role of TRPM6 and TRPM7 kinase activity during these processes is 
largely unknown but experimental evidence has clearly demonstrated that it is dispensable 
for channel activation (18, 19). Instead, the catalytic activity of TRPM6 and TRPM7 kinases 
is most likely required for the phosphorylation of downstream targets such as annexin I and 
myosin II (10, 31). Our work now demonstrates a vital role for autophosphorylation of the 
Ser/Thr-rich domain in controlling the protein kinase activity of TRPM6 and TRPM7 towards 
their substrates. This investigation provides the first account of a mode of activation for the 
mammalian a-kinases TRPM6 and TRPM7 which will help refine current models and develop 
new ones as to how TRPM6 and TRPM7 function during health and disease. 
How does autophosphorylation of the Ser/Thr-rich region affect the protein kinase 
activity of TRPM6 and TRPM7? Our data clearly demonstrate that in the absence of 
autophosphorylation or the Ser/Thr-rich domain, the phosphorylation of protein substrates 
by TRPM6 and TRPM7 is inefficient despite the kinase having full enzymatic activity. Thus, 
autophosphorylation of the Ser/Thr-rich region does not enhance enzymatic activity but 
provides access of the catalytic domain to the substrate. The simplest mechanistic explanation 
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for this process is that substrate recognition occurs through a direct interaction between 
the hyperphosphorylated Ser/Thr-rich region and substrate. Unfortunately, the high salt 
conditions required to maintain myosin II filaments in a non-aggregated state in vitro, do not 
allow us to study direct interactions between hyperphosphorylated TRPM7 and myosin II. 
However, in support of this model, we have demonstrated that several residues in the Ser/
Thr-rich domain are phosphorylated in vivo and that the association of TRPM7 with myosin 
II in mammalian cells requires kinase activity (10). Alternatively, hyperphosphorylation of the 
Ser/Thr-rich region is predicted to cause dramatic changes in the 3D structure of TRPM6 
and TRPM7, which may promote a conformation more apt for the phosphorylation of protein 
substrates. Current efforts are aimed at understanding the molecular mechanisms by which 
hyperphosphorylation of the Ser/Thr-rich domain elevates substrate phosphorylation.
Although TRPM6 and TRPM7 are highly homologous proteins (50% identity; 64% similarity), 
remarkably the Ser/Thr-rich domain is poorly conserved at the amino acid level. Yet TRPM6 
also requires massive autophosphorylation of the Ser/Thr-rich region for efficient substrate 
phosphorylation. From these results, we conclude that the build-up of negative charge 
in response to hyperphosphorylation is the defining property rather than the primary 
structure of the protein. In an attempt to further examine this notion, we varied the salt 
concentration in the kinase reactions. It is predicted that if the negative charge is an important 
characteristic of the hyperphosphorylated kinase then counteracting this charge by adding 
sodium ions should interfere with protein phosphorylation. Indeed, we noticed that the 
addition of salt inhibited the ability of TRPM7-C-long to phosphorylate myosin II but it had 
no effect on autophosphorylation (Fig. S2A & B). The differences in the degree of TRPM7-
mediated phosphorylation of itself and myosin II in presence of salt is not due to different 
modes of catalysis (intra- vs. intermolecular) since intermolecular autophosphorylation of 
TRPM7 appears to be independent of salt or the presence of the regulatory domain (Fig. 
S2C). These data further strengthen the notion that the role of hyperphosphorylation 
of the Ser/Thr-rich region is to allow access of the catalytic domain to the substrate and 
moreover, that this process requires the build-up of negative charge. Notably, the region of 
the coiled-coil domain of myosin II that is phosphorylated by TRPM7 is positively charged. 
Thus, we speculate that electrostatic interactions between the hyperphosphorylated Ser/
Thr-rich domain and myosin II are established to enhance substrate phosphorylation or 
provide substrate specificity in vivo. Although we cannot exclude other effects of salt within 
the kinase reactions such as effects on substrate rather than kinase, this salt dependency 
should be further explored to assess the role of massive autophosphorylation in regulating 
the kinase activity of TRPM6 and TRPM7 towards their substrates. 
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One of the most surprising results of this investigation is the unprecedented number 
of autophosphorylation sites in TRPM6 and TRPM7. By LC-MS/MS, we identified 46 
residues phosphorylated in wild-type (WT) but not in a catalytically inactive mutant of 
TRPM7 demonstrating that phosphorylation the result of autophosphorylation. Moreover, 
hyperphosphorylation of TRPM7 appears to be a physiologically relevant process since 20 
sites were phosphorylated in vivo. Our phosphomapping experiments are consistent with 
the level of phosphate incorporation into the kinase where 32 ± 4 mol of phosphate is 
incorporated per mol of TRPM7. Moreover, we identified previously reported sites of TRPM7 
autophosphorylation including Thr1482, Ser1512 and Ser1568 (18, 32)1. The authenticity of 
the phosphorylation sites is further demonstrated by the ratio of phosphorylated serine and 
threonine residues and their distribution within TRPM7. Phosphoamino acid analysis of TRPM7 
determined that phosphate is incorporated 70% into serines and 30% into threonines (28, 
32). Accordingly, we identify 31 serine and 15 threonine residues that are phosphorylated 
by TRPM7. Moreover, these residues (37 out of 46) are predominantly located in the Ser/
Thr-rich domain, which is directly adjacent to the catalytic domain. Deletion of this region 
leads to a corresponding 4-fold decrease in phosphate incorporation into TRPM7. Others 
have also found this region of TRPM6 and TRPM7 to be strongly autophosphorylated (18, 
28). In conclusion, our data convincingly show the presence and identification of multiple 
TRPM6/TRPM7 autophosphorylation sites.
A major challenge is to identify residues essential for TRPM6 and TRPM7 kinase activity. 
By deletion mapping, we have determined that the Ser/Thr-rich region between residues 
1380 and 1548, which contains the greatest density of autophosphorylation sites, is required 
for the electrophoretic mobility shift and efficient phosphorylation of substrates. However, 
we have yet to identify any priming event that would modulate the extent of TRPM7 
autophosphorylation, which is consistent with a model where a build-up of negative charge 
is required for substrate phosphorylation. Mutation of different residues to alanine (Ser1512, 
Ser1568, Thr1686, Ser1694, Ser1780) either individually or in combination did not suffice 
to affect TRPM7 autophosphorylation or activity towards myosin II (Fig. S3). Previously, 
Matsushita and colleagues reported that Ser1512 and Ser1568 are the major sites of TRPM7 
autophosphorylation (18). Mutation of these residues to alanine led to a 90% decrease in 
phosphate incorporation during in vitro kinase assays. This discrepancy with our study may 
reflect differences in expression systems. We have opted to purify TRPM7 directly from 
mammalian cells whereas Matsushita et.al. (18) produced TRPM7 in bacteria. 
1Mouse and human TRPM7 sequences found in the NCBI database differ by a single amino acid. Since we used 
human TRPM7 in this study, we have corrected all positions to correspond to the human sequence and therefore 
Ser1511 and Ser1567 become Ser1512 and Ser1568, respectively.
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A major problem with the purification of recombinant proteins from prokaryotic cells is 
the reproducibility of the specific activity of the enzyme. Unfortunately, Matsushita and co-
workers (18) did not provide evidence that catalytic activity of the TRPM7 S1512A/S1568A 
double mutant was intact by measuring the phosphorylation of a peptide substrate such as 
MBP, which was previously shown to be independent of autophosphorylation (29), nor did 
they confirm that mutation of Ser1512 and Ser1568 was sufficient to abolish the incorporation 
of 32P into TRPM7 in mammalian cells. In contrast, we have found many autophosphorylation 
sites of TRPM7 basally phosphorylated in mammalian cells and in combination with our in 
vitro analysis of TRPM7 mutants, it seems unlikely that the TRPM7 S1512A/S1568A mutant 
would have significantly reduced incorporation of phosphate in living cells. Although our 
study raises doubts about the contribution of Ser1512 and Ser1568 to the capacity of TRPM7 
to undergo autophosphorylation in mammalian cells, it is plausible that an unknown factor in 
mammalian cells may predispose TRPM7 to undergo massive autophosphorylation, despite 
the mutation of Ser1512 and Ser1568 to alanine. This factor could be an associated protein or 
phosphorylation by upstream protein kinases. Indeed, we have found 3 phosphorylation sites 
in a catalytically inactive mutant of TRPM7, demonstrating the presence of protein kinases 
capable of phosphorylating TRPM7. These sites are unlikely to be phosphorylated in bacterially-
produced TRPM7 and therefore, may regulate the extent of TRPM7 autophosphorylation. 
Clearly, further studies are required to address the discrepancies between our study and 
that of Matsushita and colleagues. 
The molecular mechanism regulating the protein kinase activity of TRPM6 and TRPM7 
shows similarities but also important differences with that of other a-kinases. The Dictyostelium 
myosin heavy chain kinases (MHCK) A, B and C are all activated by autophosphorylation 
(33-35). The level of autophosphorylation displays a wide dynamic range with stoichiometry 
of phosphorylation ranging from 6–20 mol Pi/ mol kinase (33, 34, 36). However, complete 
autophosphorylation does not appear to be required for activation of MHC kinases since 
autophosphorylation of 3 sites (out of 10) is sufficient to activate MHCKA (33) and myosin 
II phosphorylation proceeds in parallel to MHCKC autophosphorylation (34). In contrast, 
TRPM6 and TRPM7 only phosphorylate myosin II under conditions allowing complete 
autophosphorylation of the kinases. Interestingly, eukaryotic elongation factor-2 (eEF-2) 
kinase and MHCK, like TRPM7, require the presence of additional regulatory domains for 
efficient substrate phosphorylation. In contrast to TRPM6 and TRPM7 however, the regulatory 
domains in eEF-2 kinase and MHCK are not subject to autophosphorylation (36-38). Similar 
to deletion of the Ser/Thr-rich domain of TRPM6 and TRPM7, removal of the regulatory 
domains in eEF2 kinase and MHCK decreases the rate of substrate phosphorylation without 
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affecting the kinetics of phosphorylation of a synthetic peptide (36-39). We therefore speculate 
that the Ser/Thr-rich domain has a similar function to the regulatory domains found in other 
a-kinases which play a key role in substrate recognition and that autophosphorylation of this 
region provides an additional level of regulation of TRPM6 and TRPM7 protein kinase activity.
In conclusion, we have identified a novel mechanism regulating the activity of the mammalian 
a-kinases TRPM6 and TRPM7. Based on the experimental evidence, we propose that 
massive autophosphorylation of the Ser/Thr-rich domain in TRPM6 and TRPM7 provides 
an electrostatic interface for the recruitment of substrates which greatly enhances their 
phosphorylation. Therefore, the protein kinase activity of TRPM6 and TRPM7 may impinge 
on their cellular functions by controlling the recruitment of substrates in vivo through 
hyperphosphorylation of the Ser/Thr-rich domain. Future experiments should be aimed at 
revealing the structural changes that occur in TRPM6 and TRPM7 after autophosphorylation 
and understanding how these contribute to phosphorylation of substrates. 
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Materials and methods
Constructs
To generate the different expression vectors encoding human TRPM6 and TRPM7 kinase variants (Fig. 1), 
cDNA was amplified by PCR using primers containing an HA-tag at the 5’-end and inserted into pcDNA3 as a 
BamHI-NotI fragment. Point mutations were introduced into TRPM7 by site-directed mutagenesis using the 
Quikchange mutagenesis kit (Stratagene). Human myosin IIA (aa 1795-1960) and IIB (aa 1802-1977) heavy chain 
tails were amplified by PCR and inserted into the BamHI-EcoRI sites in frame with GST in the pGEX-1N vector. 
All constructs were verified by DNA sequencing.
Cell culture
HEK293 cells were cultured in DMEM medium with 10% FCS. Cells were transfected using Lipofectamine 2000 
(Invitrogen) according to the manufacturer’s recommendations. 
Purification of GST-myosin II and protein kinases
GST-myosin IIA and GST-myosin IIB were expressed in E. Coli and purified by affinity chromatography on a 
glutathione-sepharose column using standard methods. TRPM6 and TRPM7 kinases (Fig 1) were purified from 
mammalian cells by immunoprecipitation. Cells were lysed in RIPA buffer and the kinases were immunoprecipitated 
using anti-HA antibodies (12CA5) coupled to protein G-sepharose.
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In vitro kinase assays
Immunecomplexes containing 20 ng of kinase were washed and resuspended in IVK buffer (50 mM HEPES 
pH 7.0, 4 mM MnCl2, 2 mM DTT) with or without substrate. For protein substrates, 2 µg of GST-myosin IIA, 
GST-myosin IIB or myelin basic protein (MBP) were added to the reaction whereas the peptide substrate MH1 
(RKKFGESEKTKTKEFL) was present at a concentration of 100 µM. The kinase reactions were initiated by adding 
MnATP and were incubated at 30oC for the indicated times. Kinase reactions containing recombinant proteins as 
substrates were stopped by the addition of Laemmli buffer containing 40 mM EDTA and subjected to SDS-PAGE. 
Proteins were detected by immunoblotting using anti-HA (3F10, Roche) or anti-phosphothreonine antibodies 
(Cell Signalling Technology) or by autoradiography. Quantification was performed by phosphorimager analysis. 
Peptide substrates were spotted on p81 cellulose paper and quantified by scintillation counting.
Mass Spectrometry
Phosphoproteins were separated by SDS-PAGE, stained with colloidal coomassie blue and digested in-gel with 
trypsin using standard protocols. Peptide identification experiments were performed using a nano HPLC Agilent 
1100 nano flow system connected online to a 7-Tesla linear ion trap Ion Cyclotron Resonance Fourier Transform 
(LTQ-FT) mass spectrometer (Thermo Fisher, Bremen, Germany). Verification and site mapping of phosphorylated 
peptides was perfomed according to the procedure of Olsen and coworkers (30). Phosphopeptides were identified 
with a 99%-significance threshold when the sum of the Mascot and PTM score was higher than 28 (30). The delta 
PTM score, the difference between the highest and second highest PTM score, was set to be larger than 6.5 to 
exclusively report peptides with a mapped phosphorylation site. Moreover, only phosphopeptides occurring 
more than once were included in the results.  
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Table S1. TRPM7 phosphopeptides detected in WT and KD TRPM7-C-long by LC-MS/MS.  Please, 
refer to http://www.plosone.org/article/info%3Adoi%2F10.1371%2Fjournal.pone.0001876#s5
Figure S1. Autophosphorylation and substrate phosphorylation 
by TRPM7-C-short is not due to a contaminating protein kinase 
Wild-type (WT) and kinase-dead (KD) TRPM7-C-short were incubated 
with GST-myosin IIB in presence of Mn[g-32P]-ATP. Proteins were 
separated by SDS-PAGE and detected by coomassie staining (Middle 
panel). Phosphorylated proteins were revealed by autoradiography (Top 
panel). Equal amounts of WT and KD TRPM7-C-short was verified by 
Western blotting (Bottom panel).
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Figure S2. High ionic strength inhibits 
substrate phosphorylation by TRPM7 
without affecting catalytic activity.
(A) Effect of salt on TRPM7 and myosin 
II phosphorylation. TRPM7-C-long was 
incubated with GST-myosin IIB and Mn[g-32P]-
ATP in the absence or presence of 250 mM 
NaCl for 30 min at 30ºC. The proteins were separated by SDS-PAGE, stained 
with coomassie brilliant blue (bottom panel) and phosphorylated proteins were 
detected by autoradiography (top panel). (B) Quantification of TRPM7 and myosin 
II phosphorylation levels in absence and presence of salt. 32P incorporation was 
measured by phosphorimaging analysis. The phosphorylation levels measured for 
the sample containing no salt was set to 1 for each protein and values obtained 
in presence of salt are reported relative to this value. (C) Intermolecular 
autophosphorylation of TRPM7 is independent of salt. Lysates of mammalian 
cells expressing WT TRPM7-C-short were added to those of cells expressing 
KD TRPM7-C-long. The proteins were co-purified by immunoprecipitation using 
anti-HA antibodies. The beads were incubated with Mn[g-32P]-ATP for 30 min at 
30ºC in presence of 0 and 250 mM NaCl. Proteins were separated by SDS-PAGE 
and phosphorylated proteins were detected by autoradiography. 
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Figure S3. Mutation of Ser1512, Ser1568, Thr1686, Ser1694 or Ser1780 to alanine has no effect on 
TRPM7 autophosphorylation or substrate phosphorylation. TRPM7-C-long constructs containing the 
point mutations S1512A, S1568A, T1686A, S1694A or S1780A and the double mutants S1512A/S1568A and T1686A/
S1780A were immunoprecipitated from mammalian cells and subjected to in vitro kinase assays. (A) Electrophoretic 
mobility shift. After incubation in absence or presence of ATP, proteins were subjected to immunoblotting using 
anti-HA antibodies. (B) Phosphorylation of myosin II is unaffected by the different point mutations. TRPM7-C-
long was incubated with GST-myosin IIB in presence of Mn[g-32P]-ATP. Proteins were separated by SDS-PAGE 
and detected by coomassie staining (Middle panel). Phosphorylated proteins were revealed by autoradiography 
(Top panel). Equal amounts of WT and mutant TRPM7 kinase was verified by Western blotting (Bottom panel).
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Abstract
Metastases form when tumor cells escape the primary tumor and cross tissue boundaries 
to colonize distant sites. This process involves extensive reorganization of the actomyosin 
cytoskeleton and dynamic interactions with the tumor microenvironment. We previously 
demonstrated that expression levels of the channel-kinase TRPM7 are closely associated with 
the migratory and metastatic properties of tumor cells in vitro and in vivo, accompanied by 
extensive cytoskeletal reorganization and adhesion remodeling. Here, we set out to further 
characterize the interactions between TRPM7 and the actomyosin cytoskeleton. Using a 
proteomics approach, we show that TRPM7 is part of a large complex of proteins, many of 
which function in cytoskeletal organization, cell protrusion formation and adhesion dynamics. 
Expression of a subset of these TRPM7 interacting proteins strongly correlates with disease 
progression in a cohort of 88 neuroblastoma patients as well as in an independent validation 
cohort. Thus, TRPM7 is part of a large cytoskeletal complex that controls the metastatic 
potential of tumor cells by regulating actomyosin dynamics and cell-matrix interactions
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Introduction
Tumor cell migration and tissue invasion critically depend on the physical interactions between 
the tumor cell and its surroundings. Cell matrix adhesions link the extracellular matrix (ECM) 
to the cytoskeleton and convey mechanical cues across the plasma membrane to control 
cell motility and intracellular signaling. Reciprocally, their formation and maturation are 
controlled by the mechanical properties of the underlying substrate as well as local cytoskeletal 
tension. Hence, cell adhesion structures are considered to function as mechanosensors 
(1, 2). Members of the mammalian TRP channel family, including TRPM7, play a central 
role in mechanosensory signaling (3-8). Tethered to the cytoskeleton and ECM, their Ca2+ 
conducting properties are modulated upon application of mechanical force, resulting in a 
variety of cellular responses including cytoskeletal reorganization and adhesion remodeling 
(3, 9). Indeed, we previously postulated that TRPM7, a Ca2+-permeable cation channel fused 
to a C-terminal kinase domain, controls adhesion dynamics and tumor cell migration in 
vitro. Consistent with this notion, high TRPM7 expression levels strongly associate with the 
malignant behavior of neuroblastoma and breast tumor cells in vivo (Chapter 5 & (10, 11)). 
Although little is known about the molecular mechanism by which TRPM7 regulates adhesion 
formation and tumor cell motility, we previously established that TRPM7 regulates cellular 
tension through Ca2+- and kinase-dependent interactions with the actomyosin cytoskeleton 
(11-13). Based on the presence of TRPM7 in adhesion structures and because TRPM7 can be 
activated by mechanical stress, this cation channel may act as a mechanosensor that locally 
guides adhesion dynamics in response to mechanical cues (6-8, 11, 14). 
There is growing evidence that mammalian TRP channels form large macromolecular 
complexes linked to the actomyosin cytoskeleton (3, 9). Organization of TRP channels into 
large multiprotein complexes may serve to localize signal transduction pathways and/or 
enhance the rate of signal transmission. By performing mass-spectrometry on TRPM7 immune 
complexes, obtained from N1E-115 neuroblastoma cells made to overexpress TRPM7, we set 
out to address whether TRPM7 acts in complex with other proteins to control cytoskeletal 
dynamics. We show that TRPM7 is part of a large cytoskeletal protein complex involved in cell 
protrusion dynamics and adhesion formation. By combining a comprehensive literature study 
with microarray-based gene expression analysis, we demonstrate that ~55% of the TRPM7 
interactors are associated with cancer progression and metastasis formation. Moreover, a 
number of these components accurately predicts neuroblastoma metastasis formation in 
two independent neuroblastoma patient cohorts. Together, these results provide further 
insight into the close interactions between TRPM7 and the actomyosin cytoskeleton and 
indicate a regulatory role for the ‘TRPM7 interactome’ in cancer progression and metastasis.
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Results
TRPM7 associates with a cytoskeletal complex that localizes to invadosomes
Proteins in complex with TRPM7 were identified using a proteomic approach (Fig. 1A). The 
TRPM7 complex was purified by immunoprecipitation from mouse N1E-115 neuroblastoma 
cells which moderately overexpress TRPM7-HA. Associated proteins were resolved by SDS-
PAGE. Silver staining of the gels revealed several proteins that were uniquely present in the 
TRPM7 fraction (Fig. 1B). All proteins present in the control and TRPM7 immunoprecipitations 
were identified by nano liquid chromatography tandem mass spectrometry (LC-MS/MS) 
and proteins were considered enriched when iBAQ ratio between the TRPM7 fraction and 
control fraction was greater than 10. This analysis led to the identification of 251 proteins 
of which 64 were found specifically enriched in the TRPM7 fraction (Table 1 & S1). 
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TRPM7-HA overexpressing cells
1D SDS-PAGE (6-12% PAA)
Silver stain gel
Cut gel into 24 pieces
In-gel digest with trypsin
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Reverse database search
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Figure 1. TRPM7 associates with components of the actomyosin cytoskeleton. (A) Flow chart for 
proteomic analysis of the TRPM7 complex. (B) Detection of TRPM7 associated proteins by silver staining of SDS-
PAGE gels. HA-tagged TRPM7 was isolated by immunoprecipitation using anti-HA monoclonal antibodies (12CA5) 
from N1E-115 control and TRPM7-transduced cells. Proteins were separated by SDS-PAGE on 6% (top) and 12% 
(bottom) gels and subjected to silver staining. Proteins which co-immunoprecipitate with TRPM7, are indicated. 
(C). TRPM7-HA immunoprecipitates (IP) are enriched for cytoskeletal proteins. GO analysis was performed 
on the set of proteins enriched in TRPM7 IP (iBAQ > 10) and proteins identified in control IP. GO enrichment, 
relative to the mouse whole genome, was determined for both IPs. GO terms in categories ‘biological process’, 
‘molecular function’ and ‘cell component’, that were most significantly enriched in the TRPM7 IP, are indicated. The 
fraction of proteins within the IPs, annotated to these terms, are presented in a bar chart. Statistical significance 
between control and TRPM7 IP content was determined by a fisher exact test. *** P < 0.0001.
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116 kDa U5 small nuclear ribonucleoprotein component
14-3-3 protein sigma
AT-rich interactive domain-containing protein 1A
ELAV-like protein 3
Histone H3.2
Importin-7
Importin-9
Prelamin-A/C
Probable ATP-dependent RNA helicase DDX5
Protein transport protein Sec16B
Sarcoplasmic/endoplasmic reticulum calcium ATPase 2
Transcription intermediary factor 1-beta
Ubiquitin carboxyl-terminal hydrolase 15
Voltage-dependent anion-selective channel protein 1
EFTUD2
SFN
ARID1A
ELAVL3
HIST1H3E
IPO7
IPO9
LMNA
DDX5
SEC16B
ATP2a2
TRIM28
USP15
VDAC1
20624
55948
93760
15571
319151
233726
226432
16905
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89867
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Actin, cytoplasmic 1
Actin, cytoplasmic 2
Actin-related protein 2
Actin-related protein 2/3 complex subunit 1A
Actin-related protein 2/3 complex subunit 1B
Actin-related protein 2/3 complex subunit 2
Actin-related protein 2/3 complex subunit 3
Actin-related protein 2/3 complex subunit 4
Actin-related protein 2/3 complex subunit 5
Actin-related protein 2/3 complex subunit 5-like protein
Cofilin-1
Drebrin
F-actin-capping protein subunit alpha-1
F-actin-capping protein subunit alpha-2
F-actin-capping protein subunit beta
Gelsolin
Tropomodulin-2
Tropomodulin-3
Tropomyosin alpha-1 chain
Tropomyosin alpha-3 chain, isoform 1 & 2
Tropomyosin alpha-4 chain
ACTB
ACTG1
ACTR2
ARPC1A
ARPC1B
ARPC2
ARPC3
ARPC4
ARPC5
ARPC5L
CFL1
DBN1
CAPZA1
CAPZA2
CAPZB
GSN
TMOD2
TMOD3
TPM1
TPM3
TPM4
11461
11465
66713
56443
11867
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56378
68089
67771
74192
12631
56320
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227753
50876
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81873
1072
1627
829
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2934
29767
29766
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Mouse Human
Category Gene ID Invadosome
Myosin-9 (NMHC IIA) MYH9 17886 4627
novel
novel
Myosin-14 (NMHC IIC) MYH14 71960 79784 novel
Myosin-10 (NMHC IIB) MYH10 77579 4628 novel
MYO5A 17918 4644 novel
novel
CA
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
1
1
1
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
Table 1. Overview of TRPM7 interactome components and their association with invadosomes 
and cancer progression. All 64 TRPM7 interactors (iBAQ score > 10) are categorized by general biological 
function. Components are indicated by protein name, gene symbol and gene ID (for mouse and human). Known 
(+) and novel invadosome components are indicated, as well as established associations with cancer progression 
(CA), as was determined by literature search. 1 = associated with neuroblastoma progression.
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Proteins were classified according to Gene Ontology (GO) annotation for molecular function, 
cell component and biological process. A distribution of GO terms between the control 
and TRPM7 fractions showed that proteins involved in the organization and biogenesis of 
the actomyosin cytoskeleton were specifically enriched in TRPM7 immunoprecipitates 
(Fig. 1C). This set of proteins includes conventional myosin II and several non-conventional 
myosins (myosins I, V and VI) as well as proteins regulating actin dynamics such as the Arp2/3 
Figure 2. TRPM7 specifically interacts with a cytoskeletal complex that localizes to invadosomes. 
(A) The interactions between TRPM7 and the actomyosin cytoskeleton are specific. Protein complexes were 
immunoprecipitated from N1E-115 control and TRPM7 overexpressing cells, using anti-HA antibodies (12CA5). 
Proteins present in immunoprecipitations (IP, left) and total lysates (TL, right) were detected by Western blot. 
Known invadosome components are indicated in red. (B) By using confocal microscopy, novel podosome components 
were identified in N1E-115 cells that stably overexpress TRPM7. If available, antibody staining was performed 
(myosin IIA, IIB and IIC, drebrin, p116Rip and a-actinin4). Alternatively, protein localization was evaluated by 
expression of GPP- or myc-tagged proteins (myosin V and SIPA1-L1). Actin was visualized by Alexa-568 Phalloidin 
labeling, to indicate invadosome cores (red). All the tested TRPM7 interactors (green) localized to peripheral 
invadosomes. Scale bars = 5 mm.
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Cohort: NB-88 Cohort: Oberthuer-251
Gene OS RFS MFS KM-arm OS RFS KM-arm
MYO5A 1,23E-9 1,60E-5 3,45E-8 low 3,21E-8 4,35E-9 low
TMOD2 6,17E-9 7,67E-5 5,50E-6 low 1,17E-4 9,92E-5 low
EFTUD2 2,16E-6 1,29E-3 9,08E-4 high - - -
TRIM28 3,02E-5 4,99E-3 3,06E-3 high 1,30E-19 2,61E-11 high
KIDINS220 3,21E-4 3,35E-2 n.s. low - - -
ACTR2 3,51E-4 1,80E-3 5,30E-3 low - - -
IPO7 5,42E-4 6,96E-4 n.s. high n.s. 1,22E-2 high
TAX1BP1 2,53E-3 1,76E-2 5,53E-3 low 1,44E-13 1,31E-6 low
TPM3 4,57E-3 n.s 2,58E-2 high n.s. n.s. n.s.
ALDOA 1,68E-2 n.s n.s. high 6,92E-3 1,09E-2 high
CALM1 3,03E-2 3,94E-2 n.s. low - - -
CFL1 4,18E-2 n.s n.s. high - - -
ANXA2 n.s. 2,93E-2 n.s. low - - -
TPM4 n.s. 4,03E-2 1,45E-2 high - - -
ACTN4 n.s. n.s. 9,20E-3 high - - -
MYH9 n.s. n.s 1,80E-2 high n.s. 1,33E-2 low
ACTB n.s. n.s. 2,81E-2 high - - -
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Figure 3. Expression levels of TRPM7 interactome components correlate with disease outcome in 
two independent neuroblastoma patient cohorts. (A) Overview of TRPM7 interactome components that 
correlate with overall survival (OS), relapse-free survival (RFS) and bone/bone marrow metastasis free survival 
(MFS) in the NB-88 (left) and Oberthuer-251 cohorts (right). Genes that significantly correlate with OS and/or 
RFS in both cohorts are underlined. P-values are corrected for multiple testing (bonferoni and false discovery 
rate). n.s. = not significant; - = gene not present on array; KM-arm ‘low’ means that low expression correlates 
with poor outcome, ‘high’ means that high expression predicts poor outcome in the Kaplan-Meier analysis. P 
< 0.05 was considered significant. (B) Kaplan-Meier analysis of overall survival according to mRNA expression 
levels of TRPM7 interactome genes that are associated with OS and RFS in both NB-88 and Oberthuer-251 
cohorts. Low expression of MYO5A, TAX1BP1 and TMOD2, and high expression of and TRIM28 strongly correlate 
with poor disease outcome. P-values are based on log-rank test and corrected for multiple testing (bonferoni).
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complex, F-actin capping proteins, drebrin, tropomyosins, tropomodulins, gelsolin and cofilin 
(Table 1). Moreover, a group of structural proteins involved in regulating cell adhesion and 
migration, including a-actinin4 and plectin, was also present (Table 1). We confirmed by 
immunoprecipitation and Western blotting that these interactions were specific, as abundant 
actin-binding proteins such as a-actinin1, talin, cortactin and vinculin, were not detected in 
TRPM7 immunoprecipitations (Fig. 2A).
We previously showed that TRPM7 is enriched in peripheral podosome-type adhesions 
(invadosomes), where it may aid in the assembly of such structures (11). In agreement with 
this assumption, a significant number of TRPM7 interactors are known constituents of either 
the invadosome core, such as F-actin, F-actin capping proteins, Arp2/3, gelsolin, cofilin, or 
the ring, such as nonmuscle myosin IIA and tropomyosin (Table 1) (15-17). Moreover, the 
‘TRPM7 interactome’ comprises previously unknown invadosome components, including 
drebrin, myosin IIB and IIC, myosin V, a-actinin4 and SIPA1-L1/SPAR1 (Fig. 2B). Together, 
these findings underline the specificity of our proteomics approach and suggest that, as a 
functional complex, the TRPM7 interactome may control the dynamics of cell adhesions 
such as invadosomes.
Components of the ‘TRPM7 interactome’ associate with human neuroblastoma metastasis
An extensive literature survey demonstrated that expression of many of the TRPM7 
interactome components (~55%) have been associated with disease outcome in various 
cancers, although only a minority of these have thus far been implicated in neuroblastoma 
progression (~5%) (Table 1). We therefore tested to what extent components of the TRPM7 
interactome may predict outcome in human neuroblastoma, using a large neuroblastoma 
gene expression dataset (18). This set (NB-88) contains expression profiles of 88 primary 
tumor biopsies, along with clinical information on overall survival, relapse-free survival and 
metastasis to bone and bone marrow. Probes for all validated components of the TRPM7 
interactome, with the exception of myosin IIC (MYH14), were present on this microarray. For 
TRPM7, our analysis revealed no significant correlation (not shown), but expression levels of 
a substantial number of interactome components (17 out of 64) correlate significantly with 
overall survival (12 genes), relapse-free survival (11 genes) and/or metastasis-free survival (11 
genes) after correction for multiple testing (Fig. 3A, left panel). It is interesting to note that 
the correlation of myosin Va (MYO5A) and tropomodulin 2 (TMOD2) with disease outcome 
is exceptionally high (Fig. 3B). We validated these positive hits in an independent cohort 
of 251 neuroblastoma patients (Oberthuer-251) (19). Probes for 8 of the 17 genes were 
present in the Oberthuer-251 set. Out of 8, 7 correlate significantly with overall survival 
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and/or relapse-free survival and, except for myosin IIA (MYH9), confirm the associations 
found in the NB-88 cohort (Fig. 3A, right panel). Again, MYO5A and TMOD2, together 
with TRIM28 and TAX1BP1, were amongst the genes that correlated most significantly with 
disease outcome (Table S2). Overall, these observations suggest that TRPM7 is part of a 
cytoskeletal complex that drives neuroblastoma metastasis formation.
Discussion
A detailed understanding of the TRPM7-associated cytoskeletal complex is important to 
our understanding of how this channel-kinase drives tumor metastasis. Proteomic analysis 
of TRPM7 immunoprecipitations revealed that TRPM7 is part of a large macromolecular 
complex involved in the dynamic regulation of the actomyosin cytoskeleton and cell adhesion. 
The interactions between TRPM7 and the actomyosin cytoskeleton appear to be highly 
specific. First of all, none of the interactors were found in significant quantities in control 
immunoprecipitations. Moreover, actin-binding proteins such as a-actinin1, cortactin, talin 
and vinculin, which are abundantly expressed in these cells and thus likely contaminants 
in immunoprecipitations, were not detected either by mass spectrometry or Western 
blotting. Finally, the detection of myosin IIA, IIB and IIC heavy chain, known substrates 
of the TRPM7 a-kinase domain (11-13), served as a positive control for our proteomics 
approach. Our findings are consistent with the notion that TRP channels commonly function 
in macromolecular complexes associated with the cytoskeleton (3, 9). Like TRP channels in 
Drosophila photoreceptors (20), TRPM7 may function to anchor and maintain the integrity of 
the complex. Additionally, TRPM7 kinase activity and ion conductance potentially modulate 
the activity of cytoskeletal interactors. 
We previously observed that activation of TRPM7 promotes the formation of large 
peripheral adhesion structures, resembling podosome-type invadosomes. Invadosomes are 
highly dynamic, protrusive adhesion structures that are capable of degrading the underlying 
matrix to permit cell invasion (15, 17). In addition to the many known invadosome components, 
including TRPM7 (11), we show by confocal microscopy that the TRPM7 interactome also 
comprises novel invadosome components. These findings are in line with a role for TRPM7 
and its cytoskeletal interactors in the formation of invadosomes and cell adhesions in 
general. Consistent with the fact that invadosomes are actin-based protrusive structures, 
many of the TRPM7 interactors were shown to regulate the dynamic formation of cell 
protrusions such as filopodia, neuronal growth cones, dendritic spines and podocytes (9, 
21, 22). For instance, the TRPM7 interactome component calmodulin is a calcium sensor 
that can activate the serine/threonine phosphatase calcineurin (23). Calcineurin regulates 
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cytoskeletal organization and neurite extension by activation of the phosphatase slingshot 
and its substrate cofillin, both of which are present in the TRPM7 interactome (24, 25). The 
vesicle carrier myosin Va links long distance microtubule-based cargo transport to short 
distance actin-based transport and is crucial for filopodia and neurite extension (26-28). 
Tropomodulin 2, in turn, is an actin-regulatory protein with capping activity that regulates 
actin filament elongation (29). Many other TRPM7 interacting proteins, such as myosin VI 
(30), drebrin (31-33), and SIPA1-L1/SPAR1 (34), have been similarly implicated in the regulation 
of cytoskeletal remodeling and cell protrusion formation. 
Molenaar and colleagues recently showed by whole-genome sequence analysis of 88 
neuroblastomas with different stages, that defects in genes encoding cytoskeletal regulators 
of neuritogenesis or growth cone guidance, strongly correlate with aggressive, high-stage 
tumors (35). Although TRPM7 expression did not significantly correlate with clinical parameters 
in the NB-88 cohort, and the custom array of the Oberthuer-251 cohort did not contain 
probes for TRPM7, we find that expression of a substantial part of TRPM7 associated proteins 
does correlate with neuroblastoma disease progression. In particular, the transcriptional 
regulator TRIM28 and the cytoskeleton-associated genes MYO5A, TAX1BP1 and TMOD2 
strongly correlate with disease outcome in the two independent neuroblastoma cohorts. 
In contrast to myosin Va and tropomodulin 2, transcription intermediary factor 1-beta 
(TRIM28) and Tax1-binding protein 1 (TAX1BP1) have not been directly associated with 
neurite extension or cell protrusion formation in general. TAX1BP1 interferes with NFκB 
signalling, as a part of the A20 ubiquitin-editing complex (36). However, in association with 
myosin VI, TAX1BP1 contributes to vesicle transport, plasma membrane dynamics and 
actin filament formation, processes that are essential for cell protrusion (36). The functional 
implications of the interaction between TRPM7 and TRIM28, a transcriptional co-regulator 
that localizes to the nucleus (37), remain elusive. Although we have not yet established the 
presence of TRIM28 in cell protrusions and adhesion sites, we speculate that the association 
of transcriptional regulators with actin-based adhesion complexes, such as the TRPM7 
interactome, provides a mechanism by which physical cues from the cellular environment 
affect gene expression to mediate sustained effects on cytoskeletal organization. 
A role for the 'TRPM7 interactome' in mediating tumor cell dissemination is further 
supported by recent literature that implicate the majority of TRPM7 interactome constituents, 
including TRPM7 (10), in progression and metastasis of various malignancies (Table 1). For 
instance, TMOD2 is included as prognostic marker in a 55-gene expression signature that 
identifies subgroups within clinically indistinguishable high-risk metastatic neuroblastomas 
(38). Consistently, the differential expression of TRIM28, calcineurin and myosin Va expression 
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have recently been linked to metastasis formation (37, 39-41). Together our findings suggest 
that TRPM7 associates with an actin-based machinery involved in cell protrusion formation, 
that is adopted by tumor cells to invade the extracellular matrix and disseminate to other 
organs.
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Material and Methods
Constructs and cell lines
Full length TRPM7 cDNA, cloned into LZRS-neo, was previously described (11). The recombinant protein contains 
an HA-tag at the C-terminus. Stable N1E-115 cells moderately overexpressing TRPM7-HA and empty vector 
control. Transduced cells were selected by the addition of 0.8 mg/ml G418. Mouse N1E-115 neuroblastoma cells 
were cultured in DMEM supplemented with 10% FCS and 1% penicillin-streptomycin.
Immunoprecipitation
N1E-115 control and TRPM7-transduced cells were washed twice in ice-cold PBS and subsequently, lysed on 
ice for 30 min in MyoII lysis buffer (50 mM Tris pH 7.5, 300 mM NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 0.5 mM 
DTT, 1% Triton X-100 and protease inhibitors). The lysate was cleared by centrifugation for 10 min at 16000 g. 
HA-tagged proteins were immunoprecipitated by incubating the supernatant with proteinG-sepharose beads 
that were blocked with 0.5 %w/v BSA and precoupled with 12CA5 antibodies. The samples were incubated on 
an end-over-end rotor for 3 h at 4 °C. Subsequently, the immunocomplexes were washed in MyoII lysis buffer 
and solubilized in Laemmli buffer. 
Mass Spectrometry
1. Nano LC-MS/MS measurements 
Proteins were separated by SDS-PAGE on 6% and 12% polyacrylamide gels and subsequently, detected by silver 
staining. Gels were sliced into pieces and digested with trypsin overnight at 37 °C. Peptide mass spectrometric 
experiments were performed using a nano-HPLC Agilent 1100 system connected to a 7-Tesla linear quadruple 
ion trap-Ion Cyclotron Resonance Fourier transform (LTQFT) mass spectrometer (Thermo Fisher). Peptides 
were separated on 15 cm 100 µm ID PicoTip (New Objective) columns packed with 3 µm Reprosil C18 beads (Dr. 
Maisch GmbH) using a 45 min gradient from 10% buffer B to 35% buffer B (80% acetonitrile in 0.5% acetic acid). 
Peptides eluting from the column tip were electrosprayed directly into the mass spectrometer with a spray voltage 
of 2.1 kV. Peptide selection and fragmentation was set by the Xcalibur 1.4 data acquisition software (Thermo 
Electron). The mass spectrometer was operated in the data-dependent mode to sequence the four most intense 
ions per duty cycle. Briefly, full-scan MS spectra of intact peptides (m/z 350–1500) with an automated gain control 
accumulation target value of 106 ions were acquired in the Fourier transform ion cyclotron resonance (FT ICR) 
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cell with a resolution of 50000. The four most abundant ions were sequentially isolated and fragmented in the 
linear ion trap by applying collisionally induced dissociation using an accumulation target value of 20000 (capillary 
temperature, 150°C; normalized collision energy, 30%). A dynamic exclusion of ions previously sequenced within 
180 s was applied. All unassigned charge states were excluded from sequencing. A minimum of 500 counts was 
required for MS2 selection. 
2. Proteome data analysis
Mass spectrometry data were analyzed with the protein identification and quantification algorithms embedded 
in the MaxQuant /Andromeda software (42). Raw spectrum files were converted into peak lists for the top 6 
peaks per 100 Da window. Peptides and proteins were identified by searching the peak lists against the mouse IPI 
database (version 3.88) supplemented with frequently observed contaminants and concatenated with reversed 
copies of all entries. Andromeda (43) search parameters for protein identification specified a mass tolerance 
of 6 ppm for the parental peptide and 0.5 Da fragmentation spectra and a trypsin specificity allowing up to 3 
miscleaved sites. Carboxyamidomethylation of cysteines was specified as a fixed modification, and oxidation of 
methionine were set as variable modifications. The required minimal peptide length was set at 6 amino acids. 
We accepted peptides and proteins with a false discovery rate (FDR) better than 0.01. Label-free quantification 
was performed by MaxQuant with iBAQ values reflecting protein abundance (44).
3. Functional annotation of identified proteins 
Validated peptides of all samples combined were remapped to mouse IPI database version 3.88 to remove protein 
redundancy between different samples using an in-house Perl script. Priority of redundant IPI entries was given 
to Swiss prot, TREMBL, and REFSEQ entries respectively for maximising Gene Ontology (GO) annotation of 
identified proteins. External contaminating proteins (keratins, trypsin) were excluded for further analysis. Entrez 
gene identifiers were obtained using the Gene Conversion ID tool of DAVID (http://david.abcc.ncifcrf.gov/). 
Proteins in TRPM7 and control immuniprecipitations were quantified by intensity-based absolute quantification 
(iBAQ) (44), and normalized with median expression values. Proteins were considered enriched in the TRPM7 
immunoprecipitate when the ratio between normalized iBAQ score in TRPM7 and control immunoprecipitates 
was larger than 10. Subsequent GO annotation analysis was performed using the DAVID functional annotation 
tool. First, GO-term enrichment in both TRPM7 and control immunoprecipitates, relative to the mouse whole 
genome, was determined. Next, the number of proteins in TRPM7 and control immunoprecipitates, functionally 
annotated to the most significantly enriched terms in the categories ‘molecular function’, ‘biological process’ and 
‘cellular function’, were compared. Statistical significance was calculated using the fisher exact test and corrected 
for multiple testing (FDR).
Microscopy
N1E-115/TRPM7 cells were seeded on glass coverslips and serum starved (0.1% FCS) overnight prior to stimulation 
with 200nM bradykinin for 15 min. Cells were fixed with 4% paraformaldehyde in PBS for 10 minutes at room 
temperature and subsequently permeabilized with 0.1% triton X-100 in PBS for 3 minutes. Antibodies were 
used to reveal the presence of anti-myosin IIA (1:100; BTI), anti-myosin IIB (1:100), anti-myosin IIC (1:100), anti-
drebrin (1:100), anti-p116Rip (1:200), anti-a-actinin4 (1:200) and alexa488-conjugated secondary antibodies (1:1000; 
Molecular Probes). As no antibodies were available against myosin V and SIPA1-L1, GFP- and Myc-tagged proteins, 
respectively, were introduced into N1E-115/TRPM7 cells. Transfections were carried out using Fugene HD 
Transfection Reagent (Roche Applied Science) according to manufacturer’s protocol. F-actin was detected using 
Aleaxa-568 phalloidin (1:100; Molecular Probes). Cells were viewed using a Leica TCS SP5 confocal microscope. 
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Western blotting
Proteins were separated by SDS-PAGE and transferred to nitrocellulose. Subsequently, proteins were detected 
by immunoblotting using anti-a-actinin1 (1:1000; Sigma), anti-cortactin (1:500; (45)), anti-talin (1:500; Sigma), anti-
vinculin (1:2000; Sigma), anti-myosin IIA (1:1000; Sigma), anti-myosin IIB (1:1000; Sigma), anti-myosin IIC (1:1000; 
(46), anti-drebrin (1:1000, Progene), anti-p116Rip (1:2000, (47)) and anti-a-actinin4 (1:500, K. Cho), followed by 
HRP-conjugated secondary antibodies (1:5000; Dako). Antibody-reactive bands were visualized by treating the 
blots with ECL (Amersham) followed by autoradiography.
Microarray-based patient dataset analysis
Both the discovery cohort (NB-88) and validation cohort (Oberthuer-251) have been previously described and 
microarray based expression data are publically available) (19, 35). Statistical analyses were performed using R2, 
an Affymetrix analysis and visualization platform, developed at the department of Human Genetics, Academic 
Medical Center in the University of Amsterdam (http://r2.amc.nl). For each gene that was analyzed, discovery and 
validation cohorts were dichotomized based on an optimal cut-off value. The optimal threshold was determined 
as follows: (i) patient samples were sorted, based on normalized expression of the gene of interest; (ii) for all 
possible thresholds, significance of the correlation with disease outcome (overall survival, recurrence free survival 
or bone/bonemarrow metastasis free survival) was calculated using the log-rank test; (iii) the best performing 
threshold is used as cut-off value to dichotomize the cohort. To correct for multiple testing, p-values were 
Bonferoni corrected. Survival curves were visualized by Kaplan-Meier plots, using overall survival as endpoints, 
and compared using log-rank tests. 
Literature survey
Association of TRPM7 interactome components with cancer progression was evaluated by an online Pubmed 
search, using Gene ID and cancer, tumor or metastasis as search terms, followed by hand screening of titles, 
abstracts and full text articles. Genes were considered cancer-associated when shown to correlate with patient 
outcome in microarray-based gene expression profiles or when differential expression in tumor cell models 
affects tumorigenesis in vitro or in vivo.
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Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
tropomyosin 3, gamma isoform 1 TPM3 1 21 0 231900 nd
tropomyosin 1, alpha TPM1 1 15 0 116350 nd
myosin, heavy polypeptide 11, smooth muscle MYH11 1 22 0 10740 nd
DEAD (Asp-Glu-Ala-Asp) box polypeptide 5 DDX5 1 5 0 9929 nd
lamin A LMNA 0 2 0 0 TRPM7 
actin related protein 2/3 complex, subunit 5-like ARPC5L 0 2 0 80199 TRPM7
capping protein (actin filament) muscle Z-line, alpha 2 CAPZA2 0 8 0 584280 TRPM7
gelsolin GSN 0 2 0 1240 TRPM7
stratifin SFN 0 2 0 6472 TRPM7
actinin alpha 4 ACTN4 0 12 0 18076 TRPM7
tropomodulin 3 TMOD3 0 6 0 38515 TRPM7
voltage-dependent anion channel 1 VDAC1 0 2 0 3936 TRPM7
actin related protein 2/3 complex, subunit 3 ARPC3 0 4 0 274150 TRPM7
actin related protein 2/3 complex, subunit 1B ARPC1B 0 4 0 48984 TRPM7
actin related protein 2/3 complex, subunit 1A ARPC1A 0 4 0 55220 TRPM7
importin 9 IPO9 0 10 0 30143 TRPM7
myosin, light polypeptide 3 MYL3 0 2 0 709080 TRPM7
drebrin 1 DBN1 0 17 0 262900 TRPM7
actin related protein 2/3 complex, subunit 4 ARPC4 0 5 0 423610 TRPM7
ubiquitin specific peptidase 15 USP15 0 2 0 628 TRPM7
ARP2 actin-related protein 2 homolog (yeast) ACTR2 0 8 0 207850 TRPM7
junction plakoglobin JUP 0 4 0 5492 TRPM7
transient receptor potential cation channel, subfamily M, member 7 TRPM7 0 9 0 4968 TRPM7
tripartite motif-containing 28 TRIM28 0 2 0 2197 TRPM7
Tax1 binding protein 1 TAX1BP1 0 2 0 956 TRPM7
myosin IE MYO1E 0 15 0 17124 TRPM7
importin 7 IPO7 0 2 0 1586 TRPM7
ATPase, Ca++ transporting, cardiac muscle, slow twitch 2 ATP2a2 0 4 0 3093 TRPM7
actin related protein 2/3 complex, subunit 5 ARPC5 0 2 0 40802 TRPM7
tropomodulin 2 TMOD2 0 2 0 10069 TRPM7
myosin phosphatase Rho interacting protein MPRIP 0 8 0 2900 TRPM7
protein phosphatase 1, regulatory subunit 9B PPP1R9B 0 5 0 8071 TRPM7
tropomyosin 4 TPM4 0 9 0 191370 TRPM7
signal-induced proliferation-associated 1 like 1 SIPA1L1 0 4 0 685 TRPM7
myosin VI MYO6 0 8 0 5218 TRPM7
Table S1. Proteins identified in control and TRPM7 immunoprecipitations by LC-MS/MS.
Supplementary data
221
The TRPM7 interactome defines a cytoskeletal complex involved in neuroblastoma metastasis
Table S1. Proteins identified in control and TRPM7 immunoprecipitations by LC-MS/MS.
Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
SEC16 homolog B (S. cerevisiae) SEC16B 0 2 0 651 TRPM7
calmodulin 1 CALM1 0 2 0 21928 TRPM7
annexin A2 ANXA2 0 2 0 2835 TRPM7
myosin IC MYO1C 0 37 0 274780 TRPM7
plectin 1 PLEC 0 11 0 526 TRPM7
slingshot homolog 2 (Drosophila) SSH2 0 7 0 3779 TRPM7
elongation factor Tu GTP binding domain containing 2 EFTUD2 0 2 0 1102 TRPM7
capping protein (actin filament) muscle Z-line, alpha 1 CAPZA1 0 7 0 341240 TRPM7
actin related protein 2/3 complex, subunit 2 ARPC2 0 10 0 305890 TRPM7
LIM domain and actin binding 1 LIMA1 0 8 0 21672 TRPM7
pericentriolar material 1 PCM1 0 2 0 128 TRPM7
aldolase A, fructose-bisphosphate ALDOA 0 2 0 1795 TRPM7
LIM and calponin homology domains 1 LIMCH1 0 13 0 24971 TRPM7
myosin, heavy polypeptide 14 MYH14 0 71 0 134470 TRPM7
AT rich interactive domain 1A (SWI-like) ARID1A 0 2 0 861 TRPM7
cofilin 1, non-muscle CFL1 0 3 0 21929 TRPM7
myosin, light polypeptide 6 MYL6 1 9 2724 6376800 2340,56
tropomyosin 3, gamma isoform 2 TPM3 1 21 757 1575800 2082,85
myosin, heavy polypeptide 9, non-muscle MYH9 3 131 4971 6689900 1345,68
myosin, heavy polypeptide 10, non-muscle MYH10 1 107 1259 1407800 1118,00
myosin, light chain 12A, regulatory, non-sarcomeric MYL12a 2 9 15613 6227500 398,87
capping protein (actin filament) muscle Z-line, beta CAPZB 1 12 777 301410 387,91
myosin IB MYO1B 1 45 1615 285350 176,63
myosin VA MYO5A 1 86 2663 450660 169,24
actin, gamma, cytoplasmic 1 ACTG1 10 21 39237 4320100 110,10
actin, beta ACTB 13 25 254900 20963000 82,24
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 3 ELAVL3 5 2 44637 931190 20,86
desmoplakin DSP 3 15 151 2677 17,77
histone cluster 1, H3e HIST1H3E 2 4 28719 319860 11,14
kinase D-interacting substrate 220 KIDINS220 2 7 140 1459 10,41
ubiquitin C UBC 1 4 2745 22582 8,23
histone cluster 1, H1b HIST1H1B 1 2 4006 20073 5,01
cullin 2 CUL2 3 11 4637 21759 4,69
histone cluster 1, H4k HIST1H4K 5 8 696209 3251600 4,67
heterogeneous nuclear ribonucleoprotein U-like 1 HNRNPUL1 21 33 224939 985770 4,38
damage specific DNA binding protein 1 DDB1 13 21 11419 45034 3,94
heterogeneous nuclear ribonucleoprotein U-like 2 HNRNPUL2 3 10 5090 19707 3,87
interleukin enhancer binding factor 3 ILF3 4 8 3342 12278 3,67
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Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
heat shock protein 90, beta (Grp94), member 1 HSP90B1 1 2 1208 3974 3,29
UPF1 regulator of nonsense transcripts homolog (yeast) UPF1 2 4 444 1389 3,13
RNA binding motif protein 14 RBM14 14 19 183701 547350 2,98
SEC16 homolog A (S. cerevisiae) SEC16A 41 72 100492 298870 2,97
histone cluster 1, H2bp HIST1H2BP 4 5 377946 1122200 2,97
Histone cluster 3, H2a HIST3H2A 4 4 469604 1335500 2,84
mab-21-like 2 (C. elegans) MAB21L2 6 1 40544 113330 2,80
ribosomal protein L22 RPL22 3 3 47005 126580 2,69
heterogeneous nuclear ribonucleoprotein U HNRNPU 23 26 321915 850970 2,64
transformed mouse 3T3 cell double minute 1 MDM1 1 2 866 2260 2,61
lysozyme 1 Lyz1 2 2 16104 40373 2,51
ribosomal protein S14 RPS14 1 2 11714 27069 2,31
NHP2 non-histone chromosome protein 2-like 1 (S. cerevisiae) NHP2L1 2 2 13006 28757 2,21
heat shock protein 8 HSPA8 24 29 514047 1136400 2,21
ribosomal protein S5 RPS5 2 3 32525 69986 2,15
heat shock protein 90, alpha (cytosolic), class A member 1 HSP90AA1 2 3 5205 10897 2,09
ribosomal protein L9 RPL9 2 3 20538 42162 2,05
heat shock protein 9    HSPA9 32 40 3354449 6640000 1,98
Sec24 related gene family, member C (S. cerevisiae)     SEC24C 1 3 1020 1950 1,91
eukaryotic translation initiation factor 2C, 3  EIF2C3 13 13 6549 12368 1,89
ribosomal protein S7 rps7 1 2 33989 63091 1,86
ribosomal protein L24 rpl24 3 3 13966 24772 1,77
A kinase (PRKA) anchor protein 8        AKAP8 16 19 462648 811980 1,76
clathrin, heavy polypeptide (Hc)        CLTC 2 2 381 657 1,72
proteasome (prosome, macropain) 26S subunit, non-ATPase, 2 PSMD2 7 13 31671 53361 1,68
proteasome (prosome, macropain) 26S subunit, non-ATPase, 1      PSMD1 17 23 63900 107040 1,68
ribosomal protein L12 rpl12 4 4 48240 80103 1,66
ribosomal protein L18     RPL18 2 1 10488 17294 1,65
ribosomal protein L27 Rpl27 2 2 23992 38291 1,60
Ewing sarcoma breakpoint region 1  EWSR1 7 7 337523 531430 1,57
ribosomal protein S6; RPS6 3 3 22594 35320 1,56
ribosomal protein S15A RPS15A 3 4 23063 35953 1,56
heat shock protein 5    HSPA5 16 18 114589 171850 1,50
poly(A) binding protein, cytoplasmic 1  PABPC1 12 17 83539 124960 1,50
trypsin 10      Try10 2 2 2057889 3054700 1,48
trinucleotide repeat containing 6b      TNRC6B 41 38 89422 129720 1,45
PRP39 pre-mRNA processing factor 39 homolog (yeast) prpf39 8 12 108977 156160 1,43
transcription elongation factor B (SIII) Tceb2 4 6 81191 113920 1,40
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Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
fusion, derived from t(12;16) malignant liposarcoma (human)     fus 11 12 4649543 6321400 1,36
phospholipase C, beta 3 plcb3 7 8 12316 16685 1,35
ribosomal protein L11 rpl11 2 2 65765 88563 1,35
ribosomal protein S16       rps16 3 4 83571 105880 1,27
ribosomal protein S19 rps19 6 7 44200 55656 1,26
GrpE-like 1, mitochondrial      GRPEL1 2 2 7391 9261 1,25
ribosomal protein S26 RPS26 1 2 63983 79394 1,24
ribosomal protein S24 RPS24 2 2 39040 47789 1,22
RIKEN cDNA 0610009D07 gene      0610009D07Rik 2 2 17968 21727 1,21
ribosomal protein S13 rps13 4 3 29920 35307 1,18
ribosomal protein L23 rpl23 3 3 79792 93794 1,18
trinucleotide repeat containing 6a      TNRC6A 19 16 21640 25272 1,17
KH-type splicing regulatory protein     khsrp 1 3 3930 4561 1,16
heterogeneous nuclear ribonucleoprotein A/B     Hnrnpab 14 13 5388355 5951200 1,10
keratin 77      KRT77 7 8 643693 710870 1,10
DEAH (Asp-Glu-Ala-His) box polypeptide 9        dhx9 37 38 339198 373080 1,10
ribosomal protein L31 rpl31 1 2 40588 44574 1,10
DEAD (Asp-Glu-Ala-Asp) box polypeptide 1        DDX1 3 5 6194 6774 1,09
eukaryotic translation initiation factor 2C, 2  EIF2C2 28 33 379942 415190 1,09
nucleolin       ncl 1 3 655 700 1,07
eukaryotic translation initiation factor 2C, 1  EIF2C1 13 12 5931 6287 1,06
TAF15 RNA polymerase II, TATA box binding protein (TBP)-associated factor taf15 5 8 171123 180380 1,05
ribosomal protein S12 rps12 3 3 103338 108490 1,05
fructosamine 3 kinase related protein   FN3KRP 2 2 7666 7601 0,99
DEAD/H (Asp-Glu-Ala-Asp/His) box polypeptide 3, X-linked        DDX3X 18 21 261719 259510 0,99
ribosomal protein L6  rpl6 6 4 61130 59700 0,98
ATP synthase, H+ transporting, mitochondrial 
F1 complex, gamma polypeptide 1    
Atp5c1 1 1 2299 2228 0,97
transcription elongation factor B (SIII) TCEB1 4 4 110478 106320 0,96
leucine zipper-EF-hand containing transmembrane protein 1       LETM1 27 32 1834168 1760300 0,96
ribosomal protein L18A  RpL18A 3 2 9524 8952 0,94
similar to Immunogloblin heavy chain LOC630320 5 4 3128713 2886300 0,92
ubiquitination factor E4A, UFD2 homolog (S. cerevisiae) ube4a 6 6 7157 6538 0,91
kelch domain containing 10      KLHDC10 9 5 141410 128930 0,91
NHP2 ribonucleoprotein homolog (yeast)  NHP2 3 3 860952 777490 0,90
ribosomal protein L30 RpL30 3 2 151085 131880 0,87
small nuclear ribonucleoprotein D3      snrpd3 2 2 62940 54441 0,86
ribosomal protein, large, P0        rplP0 8 5 163827 140220 0,86
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symbol control TRPM7 control TRPM7 ratio
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily c, member 1
SMARCC1 5 3 4012 3392 0,85
ribosomal protein S9 rps9 4 3 24414 19905 0,82
immunoglobulin light chain variable region      Gm10883 6 6 708988 571590 0,81
heterogeneous nuclear ribonucleoprotein C       Hnrnpc 8 4 175279 140370 0,80
immunoglobulin heavy chain 3 (serum IgG2b) Igh-3 11 10 1671778 1323500 0,79
ribosomal protein S10 rps10 3 2 44611 34171 0,77
poly(A) binding protein, cytoplasmic 4 PABPC4 6 5 2529 1932 0,76
ribosomal protein SA;  rpsA 6 4 153072 114700 0,75
ribosomal protein L7 RPL7 9 6 73446 53889 0,73
programmed cell death 6 pdcd6 7 6 133491 97116 0,73
ribosomal protein, large P2 Rplp2 4 4 344104 247270 0,72
guanine nucleotide binding protein (G protein), beta polypeptide 2 like 1 GNB2L1 12 9 116923 83800 0,72
Ribosomal protein L7a Rpl7a 6 5 69504 48136 0,69
peroxiredoxin 2 PRDX2 2 1 4623 3177 0,69
SWI/SNF related, matrix associated, actin dependent 
regulator of chromatin, subfamily a, member 4       
SMARCA4 17 13 14103 9443 0,67
ribosomal protein S25 RPS25 3 2 88709 57869 0,65
ribosomal protein S3    rps3 16 12 219556 142780 0,65
heterogeneous nuclear ribonucleoprotein D       HNRNPD 16 13 4284943 2716000 0,63
ribosomal protein S17 rps17 2 2 54573 33807 0,62
proteasome (prosome, macropain) 26S subunit, non-ATPase, 6      PSMD6 11 9 94322 55368 0,59
peroxiredoxin 1; predicted gene 7204    PRDX1 3 1 5000 2839 0,57
ribosomal protein L14 rpl14 2 1 9477 5380 0,57
c-myc binding protein   MYCBP 2 2 54128 30666 0,57
ribosomal protein S3A rps3a 7 6 53948 30022 0,56
proteasome (prosome, macropain) 26S subunit, non-ATPase, 14     PSMD14 3 2 84612 45749 0,54
RNA binding motif protein, X chromosome retrogene       Rbmxrt 7 4 230816 122970 0,53
heterogeneous nuclear ribonucleoprotein A1 HNRNPA1 13 11 1327316 706940 0,53
heterogeneous nuclear ribonucleoprotein A3 Hnrnpa3 16 15 3399028 1781300 0,52
ribosomal protein L26 RPL26 2 2 17284 8958 0,52
immunoglobulin kappa chain variable 8 (V8)-19   Igk-V8-19 2 2 612588 312200 0,51
heterogeneous nuclear ribonucleoprotein D-like  HNRPDL 14 10 522185 264850 0,51
coiled-coil domain containing 106       CCDC106 13 8 204443 102890 0,50
trinucleotide repeat containing 6C      TNRC6C 19 12 20579 10237 0,50
splicing factor, arginine/serine-rich 7 sfrs7 4 2 24819 12152 0,49
eukaryotic translation elongation factor 1 alpha 1     EEF1A1 5 3 30645 14976 0,49
proteasome (prosome, macropain) 26S subunit, non-ATPase, 7      psmd7 5 3 80296 37787 0,47
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Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
proteasome (prosome, macropain) 26S subunit, ATPase, 6  Psmc6 14 10 333431 156730 0,47
proteasome (prosome, macropain) 26S subunit, non-ATPase, 11       Psmd11 17 11 162930 76508 0,47
SEC13 homolog (S. cerevisiae)   sec13 7 4 801791 372040 0,46
immunoglobulin kappa chain variable V19 - 17   Igk-V19-17 4 3 1853849 859510 0,46
protease (prosome, macropain) 26S subunit, ATPase 5     PSMC5 17 13 525755 240680 0,46
eukaryotic translation initiation factor 3, subunit J EIF3J 23 22 20682333 9047500 0,44
heterogeneous nuclear ribonucleoprotein A2/B1    HNRNPA2B1 20 18 13826058 6006900 0,43
La ribonucleoprotein domain family, member 1    LARP1 2 1 594 255 0,43
adhesion regulating molecule 1 Adrm1 2 1 23221 9933 0,43
ribosomal protein S18 rps18 4 2 25261 10246 0,41
TAR DNA binding protein   TARDBP 7 5 260722 104990 0,40
proteasome (prosome, macropain) 26S subunit, ATPase 2   PSMC2 21 10 231704 88876 0,38
ribosomal protein L27a RPL27A 2 1 18198 6145 0,34
protein phosphatase 4, catalytic subunit        PPP4C 2 1 5761 1944 0,34
succinate dehydrogenase complex, subunit A, flavoprotein (Fp)   SDHA 1 2 3078 1012 0,33
ribosomal protein S2 rps2 6 2 49903 16134 0,32
Tia1 cytotoxic granule-associated RNA binding protein-like 1    Tial1 14 9 2755875 869660 0,32
PCI domain containing 2 PCID2 2 1 9149 2853 0,31
cytotoxic granule-associated RNA binding protein 1      Tia1 10 7 341450 106410 0,31
lactate dehydrogenase A LdhA 8 4 17407 5412 0,31
proteasome (prosome, macropain) 26S subunit, non-ATPase, 8      PSMD8 6 3 102862 31273 0,30
heterogeneous nuclear ribonucleoprotein H3      Hnrnph3 8 7 846352 251190 0,30
heterogeneous nuclear ribonucleoprotein A0      HNRNPA0 8 5 2116383 626160 0,30
WD repeat domain 51A    poc1a 17 8 527338 151290 0,29
hnRNP-associated with lethal yellow RALY 5 2 49676 13381 0,27
heterogeneous nuclear ribonucleoprotein F  HNRNPF 7 3 143671 34959 0,24
mitochondrial ribosomal protein S23 MRPS23 3 1 10151 2100 0,21
microtubule-associated protein 1B       Mtap1b 4 1 1680 344 0,20
ribosomal protein L3; predicted gene 5851 RPL3 3 1 22678 4266 0,19
protein phosphatase 4, regulatory subunit 1 Ppp4r1 3 2 3825 668 0,17
Sjogren syndrome antigen B      ssb 6 1 55799 9472 0,17
interleukin enhancer binding factor 2   ilf2 8 4 166793 28030 0,17
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 4      ELAVL4 10 4 160257 26165 0,16
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 1      ELAVL1 5 3 35316 5734 0,16
small nuclear ribonucleoprotein polypeptide A snrpa 6 1 64448 9087 0,14
Era (G-protein)-like 1 (E. coli)        ERAL1 8 1 31512 4242 0,13
Trk-fused gene  TFG 10 5 1248227 167940 0,13
proteasome (prosome, macropain) 26S subunit, non-ATPase, 13     PSMD13 10 3 163461 10304 0,06
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Protein name Gene Peptides iBAQ
symbol control TRPM7 control TRPM7 ratio
DAZ associated protein 1        DAZAP1 4 1 93022 5491 0,06
tRNA selenocysteine 1 associated protein 1      Trnau1ap 6 3 165356 9486 0,06
proteasome (prosome, macropain) 26S subunit, ATPase 3   psmc3 9 1 52991 2241 0,04
ribosomal protein S4, X-linked   rps4x 11 1 64270 2472 0,04
proteasome (prosome, macropain) 26S subunit, ATPase, 4  psmc4 9 0 115806 0 control
GAR1 ribonucleoprotein homolog (yeast)  Gar1 3 0 8268 0 control
superkiller viralicidic activity 2-like 2 (S. cerevisiae)       SKIV2L2 2 1 1373 0 control
splicing factor 1       Sf1 2 0 6540 0 control
ribosomal protein S11 rps11 2 1 4198 0 control
small nuclear ribonucleoprotein D2 snrpd2 2 0 17953 0 control
mediator of cell motility 1; similar to Memo1 protein   memo1 2 0 2020 0 control
SWI/SNF related, matrix associated, actin dependent
regulator of chromatin, subfamily b, member 1       
SMARCB1 4 0 39551 0 control
ribosomal protein L8 rpl8 3 0 42551 0 control
small nuclear ribonucleoprotein polypeptide A’  snrpa1 5 0 8102 0 control
heterogeneous nuclear ribonucleoprotein H1      Hnrnph1 5 2 9259 0 control
kelch-like 22 (Drosophila)      Klhl22 2 1 5079 0 control
clathrin, light polypeptide (Lcb)       Cltb 2 0 4163 0 control
S-adenosylhomocysteine hydrolase     ahcY 3 0 3385 0 control
death associated protein 3      DAP3 4 0 27799 0 control
eukaryotic translation elongation factor 1 beta 2       Eef1b2 2 0 12065 0 control
actin-like 6A   actl6a 4 0 5708 0 control
cold shock domain protein A     csdA 2 0 23699 0 control
mitochondrial ribosomal protein S9      MRPS9 3 0 10099 0 control
ELAV (embryonic lethal, abnormal vision, Drosophila)-like 2 (Hu antigen B)      ELAVL2 9 3 23580 0 control 
phosphoglycerate mutase family member 5 pgam5 3 2 8210 0 control
D4, zinc and double PHD fingers family 2        dpf2 4 0 17942 0 control
splicing factor, arginine/serine-rich 1 (ASF/SF2) SFRS1 2 0 1306 0 control
tubulin, beta 2B        tubb2b 1 1 0 1411 nd
Table S1. Proteins identified in control and TRPM7 immunoprecipitations by LC-MS/MS. Overview of peptide annotations in 
control and TRPM7 immunoprecipitations. Indicated are protein name, gene symbol, number of peptides and the normalized IBAQ score 
in either the control or TRPM7 IPs, and IBAQ ratio . Note that for tropomodulin 3 gamma isoform 1, tropomyosin 1 alpha, myosin 11 and 
DEAD box polypeptide 5, IBAQ scores were not determined. However, based on their abundance in the TRPM7 IP and absence in the 
control IP, these proteins were considered enriched in the TRPM7 fraction. 
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Table S1. Proteins identified in control and TRPM7 immunoprecipitations by LC-MS/MS. 
IP, these proteins were considered enriched in the TRPM7 fraction. 
Cohort: Oberthuer-251
Gene OS RFS KM-arm
TRIM28 1,30E-19 2,61E-11 high
GSN 6,17E-17 7,06E-9 low
TAX1BP1 1,44E-13 1,31E-6 low
JUP 4,00E-9 3,45E-9 low
MYO5A 3,21E-8 4,35E-9 low
MYL6 4,16E-7 6,29E-5 low
ELAVL3 5,66E-7 5,26E-6 low
ARPC5 2,38E-6 1,43E-2 high
ARID1A 5,28E-6 3,98E-2 low
DSP 1,00E-4 n.s. low
TMOD2 1,17E-4 9,92E-5 low
PCM1 2,52E-4 1,30E-3 high
CAPZB 8,56E-4 n.s. low
MYO6 2,61E-3 1,10E-2 low
ALDOA 6,92E-3 1,09E-2 high
DDX5 1,09E-2 n.s. high
ACTG1 1,83E-2 n.s. high
LMNA 2,42E-2 n.s. low
SIPA1L1 3,84E-2 2,26E-3 low
CAPZA1 n.s. 1,12E-3 high
PPP1R9B n.s. 3,17E-3 low
SFN n.s. 1,07E-2 low
IPO7 n.s. 1,22E-2 high
MYH9 n.s. 1,33E-2 low
TPM1 n.s. 3,81E-2 high
Table S2. TRPM7 interactome components correlate 
with poor prognosis in a second, independent 
neuroblastoma patient cohort. Overview of all TRPM7 
interactome components that correlate with OS or RFS 
in the Oberthuer-251 cohort. P-values are corrected 
for multiple testing (bonferoni and false discovery rate). 
Genes that significantly correlate with OS and/or RFS in 
the NB-88 cohort are underlined. n.s. = not significant; 
KM-arm ‘low’ means that low expression correlates with 
poor outcome, ‘high’ means that high expression predicts 
poor outcome in the Kaplan-Meier analysis. P < 0.05 was 
considered significant. 
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Introduction
Tumor progression and metastasis formation are affected by a variety of intracellular and 
extracellular cues, including genetic alterations and growth factor stimulation. We have only 
recently began to appreciate the essential contribution of the mechanical characteristics of the 
tumor microenvironment to cancer metastasis (1-5). The mechanical crosstalk between the 
cell and its surroundings is mediated by cell adhesion structures. These structures integrate 
mechanical information from both inside and outside the cell and control extracellular 
matrix (ECM) remodeling and intracellular cytoskeletal dynamics accordingly (3, 6, 7). Since 
the complex protein-protein interactions that take place at cell adhesion sites significantly 
contribute to malignant cell behavior, they are potential therapeutic targets to limit the 
metastatic capacity of cancer cells. However, a lack of insight into cancer-specific mechanisms 
that govern mechanosensitive cell-cell and cell-matrix interactions has hampered the 
development of such treatments (Chapter 1).
Cell adhesions are intrinsically sensitive to mechanical stimuli. For instance, multiple 
adhesion components undergo conformational changes upon the application of mechanical 
load. These unfolding responses expose cryptic phosphorylation or protein-binding sites 
that trigger a variety of signaling events, leading to cytoskeletal reorganization and adhesion 
remodeling (8-10). In addition to well-characterized mechanosensitive adhesion constituents 
such as talin and zyxin, recent evidence indicates a role for mechanically gated ion channels 
in cell adhesion regulation (9, 11-13). Members of the mammalian TRP cation channel family, 
including TRPM7, play a central role in mechanosensory signaling (9, 13-18). Tethered to the 
cytoskeleton and ECM, their ion-conducting properties are modulated upon application of 
mechanical force. In turn, TRP channels modulate cytoskeletal organization and adhesion 
dynamics (Chapter 2 & 3). Despite an increasing number of publications that associate TRP 
channel expression with cancer progression, how TRP channels contribute to the malignant 
behavior of tumor cells remains largely unknown (19, 20).
TRPM7, a Ca2+ permeable TRP channel which comprises a C-terminal a-kinase domain, 
directly associates with the actomyosin cytoskeleton and regulates adhesion dynamics in 
response to a variety of stimuli, including mechanical stress (16-18, 21, 22). In this dissertation, 
we have examined how TRPM7 regulates cytoskeletal dynamics and adhesion remodeling. 
In addition, we have established a role for TRPM7 in guiding tumor metastasis formation 
using a combination of in vitro and in vivo approaches.
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TRPM7 is required for tumor cell motility and metastasis formation
TRPM7 promotes neuroblastoma- and breast cancer metastasis in vivo
Using two different tumor cell models, human MDA-MB-231 breast cancer cells and 
mouse N1E-115 neuroblastoma cells, we addressed if and how TRPM7 contributes to the 
malignant behavior of tumor cells in vivo. Following intravenous injection, we compared the 
metastatic potential of wild type and TRPM7 knockdown MDA-MB-231 cells in Rag2-/-Il2rg-/- 
immunodeficient mice (Chapter 4). We observed by luciferase-based bioluminescence imaging 
that reduced expression of TRPM7 significantly impairs metastasis formation by these highly 
invasive cells. Using the reverse approach, we show in Chapter 5 that TRPM7 overexpression 
significantly enhances the metastatic potential of N1E-115 mouse neuroblastoma cells following 
mouse tail vein injection. In support of these results, we find that TRPM7 expression levels 
are positively correlated with disease progression and metastasis formation in two separate 
breast cancer patient cohorts, independent of standard clinical parameters. Overall, our 
data indicate that high TRPM7 expression levels associate with cancer malignancy. When 
considering malignant transformation of tumor cells as the inappropriate activation of an 
embryonic developmental program (Chapter 1), it is interesting to note that TRPM7 was 
shown to be essential for embryogenesis and tissue morphogenesis (23-25).
TRPM7 does not affect tumor cell proliferation
TRPM7 is required for cell viability and proliferation (26-32), controls Fas-induced apoptosis 
(23) and mediates anoxic neuronal cell death (33). Consistently, TRPM7 may contribute to 
tumor malignancy by promoting tumor cell proliferation (34-37). However, we find that TRPM7 
expression levels are not associated with tumor size in breast cancer patients. Moreover, 
manipulation of TRPM7 expression levels neither in neuroblastoma cells nor breast cancer 
cells, affects cell viability and proliferation in vitro or in vivo. Whereas our observations are 
based on cell lines that were stably transduced to either overexpress TRPM7 or reduce TRPM7 
expression, others manipulated TRPM7 protein levels by transient expression of siRNA oligos. 
In our hands, transient knockdown as well as overexpression of TRPM7 induces cell death within 
48 hours after transfection (data not shown). Apparently, manipulating TRPM7 protein levels in 
transient assays negatively affects cell survival. In agreement with this assumption, exposure to 
high concentrations of TRPM7 channel blockers reduces cell viability (34, 38, 39), while gene 
silencing revealed that TRPM7 is required for early embryogenesis and organogenesis (25). 
Along the same line of reasoning, we propose that by generating stable TRPM7 overexpression 
and knockdown cells lines, we have modulated TRPM7 expression levels within a range 
compatible with normal cell viability and proliferation. 
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TRPM7 does not promote the matrix degrading properties of tumor cells
(Tumor-) cells exhibit specialized adhesion structures, invadopodia and podosomes, that 
degrade the underlying matrix to allow tissue invasion (Chapter 1). In addition to invadopodia 
that are expressed by wild-type N1E-115 mouse neuroblastoma cells, TRPM7 overexpression 
promotes the formation of large peripheral podosomes while leaving invadopodia unaffected 
(Chapter 5). We hypothesized that TRPM7 overexpression induces tumor cell metastasis 
by facilitating matrix degradation. The data presented in Chapter 5, however, indicate that 
TRPM7-induced podosomes only marginally contribute to the matrix degrading properties 
of mouse neuroblastoma cells when compared to endogenously expressed invadopodia. 
This is consistent with the current view that podosomes degrade the underlying matrix in a 
shallow manner to allow tissue remodeling by non-malignant cells, whereas invadopodia are 
deployed by invasive tumor cells to invade the surrounding tissue (40). Of note, similar to 
N1E-115 cells, invadopodia expressed by highly invasive MDA-MB-231 cells are not affected by 
TRPM7 expression levels (data not shown). Hence, it seems unlikely that TRPM7 contributes 
to tumor metastasis formation by enhancing the matrix degrading capacity of tumor cells.
TRPM7 controls adhesion dynamics to optimize cell migration
In addition to matrix degradation, tumor cell invasion and metastasis strongly depend on 
directional migration. We show that moderate overexpression of TRPM7 confers a migratory 
phenotype onto otherwise immotile mouse N1E-115 neuroblastoma cells. In addition to the 
adhesive properties of N1E-115 TRPM7 cells, transwell migration may be facilitated by TRPM7-
induced podosomes that stabilize cell membrane protrusions (Chapter 5 & (21, 40, 41)). 
TRPM7 knockdown, in turn, coincides with focal adhesion overassembly in mesenchymal-like 
MDA-MB-231 cells and enforcement of cell-cell adherens junctions in epithelial-like MCF7 
cells (Chapter 4). Consistent with the notion that cell migration critically depends on the 
tightly coordinated remodeling of cell adhesions (Chapter 1), reduced TRPM7 expression 
impairs the migratory properties of both human breast cancer cell lines. Hence, in agreement 
with previous findings that implicate TRPM7 in cell migration (18, 30, 31, 42-46), we show that 
TRPM7 expression levels strongly associate with the migratory properties of tumor cells.
TRPM7 regulates cytoskeletal tension
Formation and turnover of podosomes, focal adhesions and adherens junctions are known to 
be controlled by cellular tension (Chapter 1). Whereas podosome formation is promoted by 
cytoskeletal relaxation (21, 40, 47, 48), the formation of focal adhesions and adherens junctions 
is promoted by increased cytoskeletal tension (49, 50). Similar to TRPM7 overexpression, 
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treatment of N1E-115 neuroblastoma cells with blebbistatin, an inhibitor of myosin II motor 
activity, induced podosome formation (21). Moreover, inhibition of myosin II motor activity 
reduces the formation of focal adhesions and adherens junctions in TRPM7 knockdown breast 
cancer cells (Chapter 4). Strikingly, treatment of TRPM7 knockdown breast cancer cells 
with myosin II inhibitors fully restored their migratory properties. Since TRPM7 localizes to 
adhesion sites (21, 51), we propose that TRPM7 locally controls the delicate and reciprocal 
crosstalk between cell-adhesion strength and actomyosin contractility to allow cell migration 
(Fig. 1) (52-54). 
Interplay between TRPM7 channel and kinase domains steer cytoskeletal 
dynamics
TRP channels generally operate within multiprotein complexes that serve to localize signal 
transduction and/or enhance the rate of signal transmission. To date, many TRP channels are 
shown to control cellular processes in close association with the actomyosin cytoskeleton 
(Chapter 2 & 3). Consistently, we find that TRPM7 is part of a large cytoskeletal protein 
complex of which many components are involved in adhesion regulation and cell protrusion 
formation (Chapter 10). It is not well understood how TRPM7 controls cytoskeletal 
proteins in its proximity, although this most likely involves a combination of conducting 
cations and kinase activity.  
TRPM7 cation channel
Mg2+ conductance by TRPM7 is thought to be essential for migration of osteoblasts, endothelial 
cells, and pancreatic cancer cells (30, 31, 46). Moreover, TRPM7 knockdown in mouse 
embryonic fibroblasts induces cytoskeletal contractility and impairs polarized cell movements, 
which is rescued by expression of the SLC41A2 Mg2+  transporter (42). Unfortunately, these 
reports provide little insight in how Mg2+ influx through TRPM7 may regulate cytoskeletal 
proteins. Although Mg2+ is considered essential for (tumor-) cell viability and proliferation, 
little is known about the role of Mg2+ in cancer progression and how Mg2+ may regulate cell 
motility (42, 55, 56). Mg2+ is a cofactor of many enzymes that participate in cell metabolism and 
protein synthesis. Since targeted deletion of TRPM7 impaired T-lymphocyte differentiation 
without altering cellular Mg2+ concentrations (24), the authors suggested that TRPM7 triggers 
Mg2+ signaling events that act locally to control cellular processes (57). However, due to 
high free intracellular Mg2+ levels (~1 mM), we argue that Mg2+ ions are not likely to act as 
local messengers that guide cell adhesion dynamics. 
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In contrast to Mg2+, local Ca2+ signaling is well 
known to play a prominent role in cytoskeletal 
regulation, adhesion dynamics and cancer metastasis 
(Chapter 1). Ca2+  signals induce adhesion 
disassembly to control cell protrusion formation 
and cell polarization (58-60), and are essential for 
cell migration in various model systems. For instance, 
Yang and colleagues noted an absolute requirement 
for Orai1/Stim1-mediated Ca2+ entry for MDA-
MB-231 focal adhesion turnover, cell migration and 
in vivo metastasis formation (61). Along the same line, 
TRPM7 is suggested to control cell polarization and 
migration by mediating local Ca2+ flickers in the cell 
periphery (18, 43-45, 60). Acting in close proximity 
to cell adhesion sites, these Ca2+ signals can activate 
m-calpain, a Ca2+-dependent protease (18, 51). Since 
m-calpain cleaves adhesion components such as 
paxillin, talin and vinculin, TRPM7-mediated Ca2+ 
signals are proposed to induce cell adhesion turnover 
to steer cell polarization and migration (Fig. 2) (18, 
Figure 1. TRPM7 modulates the
reciprocal interactions between cell-
substrate adhesions and the actomyosin 
cytoskeleton. Hypothetical model in which 
TRPM7 acts as mechanosensor in the vicinity 
of adhesion sites. In response to the physical 
properties of the ECM, TRPM7 modulates 
cytoskeletal tension to trigger adhesion 
remodeling.
Cytoskeletal
contractility
Adhesion
dynamics
Cell-substrate
interactions
51, 62). Despite the observation that moderate TRPM7 overexpression significantly induces 
Ca2+ flicker probability in N1E-115 cells, we have not been able to localize these signaling 
events specifically to cell adhesion structures (data not shown). Hence, it remains to be 
established whether TRPM7-mediated Ca2+ signals act locally to affect cell adhesion dynamics. 
a-Kinase domain
TRPM7 directly associates with the actomyosin cytoskeleton and controls adhesion dynamics in 
a kinase-dependent manner, suggesting that TRPM7 potentially controls actomyosin dynamics 
by phosphorylation of cytoskeletal components (21). The founding members of the atypical 
a-kinase family, the Dictyostelium myosin heavy chain kinases, are well established players 
in cytoskeletal regulation, cell division and migration. They coordinate filament forming 
properties of myosin II motor proteins by phosphorylating the a-helical tails of myosin II 
heavy chains (MHCII) to reduce myosin II filament assembly and consequently, cytoskeletal 
tension (63-65). Although well conserved, much less is known about the role of a-kinases in 
vertebrates (Chapter 6). We previously showed that TRPM7 phosphorylates mouse MHCIIA 
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in vitro (21). In Chapter 7, we demonstrate that TRPM7-mediated MHCIIA phosphorylation 
interferes with myosin IIA filament forming properties and cellular distribution in vitro, 
resembling a-kinase function in Dictyostelium. In addition, we show in Chapter 8 that the 
a-kinase domain of TRPM7 targets the assembly domains of non-muscle myosin IIB and IIC 
as well (Chapter 8). Unlike the Dictyostelium a-kinases, which specifically target residues 
within an a-helical context, TRPM7 also targets the non-helical tails of MHCIIB and IIC 
(Chapter 8). This tail piece was recently found to dictate isoform-specific filament forming 
properties and cellular functions. In addition to different expression levels and cellular 
localization, phosphorylation of this region by TRPM7 is likely to have isoform-specific 
functional consequences in vivo (66-72). Although it remains a challenge to demonstrate that 
TRPM7 phosphorylates MHCII in vivo, our findings indicate that TRPM7 regulates cytoskeletal 
tension by inhibition of myosin II-mediated contractility (Fig. 2) (21, 51). 
Ca2+
Mg2+
Ca2+
Ca2+
Ca2+
Mg2+
Mg2+
Mg2+
Ca2+
Ca2+
Ca2+
Mg2+
?
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Phosphorylation
Cell-matrix adhesion Myosin II F-actin
Figure 2. TRPM7 modifies adhesion sites in a Ca2+ and kinase dependent manner. (1) Actomyosin 
cytoskeletal tension promotes and stabilizes the formation of cell adhesion sites. (2) Activation of TRPM7, for 
instance by mechanical stimulation, leads to the local influx of Mg2+ and Ca2+ ions through the channel domain and 
autophosphorylation of the TRPM7 a-kinase. (3) Although Mg2+ is required for catalytic activity of TRPM7, little is 
known about its role in cytoskeletal regulation. Local rises in Ca2+ concentrations activate Ca2+-dependent adhesion 
remodelers such as calpain. Calpain, in turn, induces adhesion disassembly by the proteolytic cleavage of adhesion 
components. Autophosphorylation of the kinase domain generates a charge-dependent docking site that allows 
TRPM7 to associate with the actomyosin cytoskeleton. In the presence of Mg2+ and Ca2+, TRPM7 phosphorylates 
its substrates, including myosin II. The resultant release of cytoskeletal tension reduces cell adhesion assembly.
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The ability to phosphorylate MHCII is not restricted to TRPM7. Consistent with a high 
degree of similarity at the amino acid level, TRPM7 and its closest relative TRPM6 share many 
structural and functional features (Chapter 1, box 2). Accordingly, we find that the TRPM6 
a-kinase domain phosphorylates MHCIIA, IIB and IIC. Two conventional protein kinases, 
casein kinase 2 (CK2) and protein kinase C (PKC) also phosphorylate MHCIIA and MHCIIB 
and control the cellular distribution of myosin motor proteins in vertebrates (73-75). For 
instance, mutation of the CK2-targeted residue to inhibit MHCIIA phosphorylation leads 
to increased myosin IIA filament assembly and focal adhesion formation (74, 76). Similar to 
the effect of TRPM7 knockdown, inhibited CK2-mediated MHCIIA phosphorylation impairs 
MDA-MB-231 breast cancer cell migration (76). Although these observations underscore 
the importance of MHCII phosphorylation in regulating migration of mammalian cells, it 
will remain a challenge to resolve how these different kinases act synergistically to spatially 
and temporally control myosin II assembly. 
Similar to other members of the a-kinase family and many conventional protein kinases, 
we show in Chapter 9 that substrate phosphorylation by TRPM7 is strongly enhanced 
upon autophosphorylation. A unique feature is that the TRPM7 autophosphorylation sites 
are predominantly located within a Ser/Thr-rich domain located N-terminally to the actual 
catalytic domain. Since autophosphorylation is not required for catalytic activity per sé, these 
findings suggest a model where massive autophosphorylation outside the catalytic domain 
generates an electrostatic interface for substrates such as myosin II (Fig. 2). Although many 
other cytoskeletal proteins associate with TRPM7 (Chapter 10), we have no evidence 
that TRPM7 phosphorylates cytoskeletal interactors other than myosin II motor proteins. 
It is, however, tempting to speculate that upon autophosphorylation of its kinase domain, 
TRPM7 acts as molecular scaffold that provides a docking site for cytoskeletal proteins and 
adhesion components.  
 
Crosstalk between TRPM7 channel and kinase domain
TRPM7 cation conductance and kinase activity may affect distinct cellular processes by 
targeting different cytoskeletal components. Nonetheless, it is very likely that the channel 
and the a-kinase domain of TRPM7 are functionally linked. The kinase domain was initially 
thought to control TRPM7 channel opening (77, 78). Recent literature, however, indicates 
that phosphotransferase activity of the TRPM7 kinase is not required for opening of the 
channel (21, 26, 79, 80). Instead, Clapham and colleagues proposed that the TRPM7 kinase 
domain merely modulates channel opening since caspase-mediated cleavage of the kinase 
domain promotes cation influx (23, 26). Vice versa, as Ca2+ is essential for the association 
239
General discussion & future perspectives
of TRPM7 kinase with its substrates, channel opening is considered to modulate substrate 
phosphorylation (Fig. 2) (21, 26, 81, 82). Future experiments, using channel-dead and kinase-
dead mutants, or TRPM7 channels blockers such as Waixenicin and NS8593 (34, 39), should 
resolve how the distinct functional domains of TRPM7 contribute to cell adhesion remodeling 
and cell migration. 
Regulation of TRPM7 in cancer cells
In this dissertation, we have provided ample evidence supporting a role for TRPM7 in the 
regulation of cytoskeletal tension, adhesion dynamics and cancer metastasis. However, it 
remains elusive how TRPM7 expression levels and activity are regulated in tumor cells. 
Although mechanosensitive properties of TRPM7 are only starting to be addressed, recent 
studies indicate that TRPM7-mediated Ca2+ conductance increases upon the application 
of membrane stretch and fluid flow (16-18, 22). While Wei and colleagues reported that 
TRPM7-mediated local Ca2+ increases control focal adhesion dynamics and polarized cell 
migration (18), we show here that TRPM7-induced podosomes develop specifically on the 
edges of 3D micro-patterned surfaces (Chapter 5). Hence, we postulate that TRPM7 
triggers adhesion remodeling in response to mechanical cues, although it remains to be 
established whether TRPM7 is directly gated by mechanical stress or acts downstream of 
mechanically activated signaling pathways. 
Mechanical stimuli might directly activate TRPM7 through its association with the actomyosin 
cytoskeleton and adhesion components (Chapter 2 & 10). Additionally, TRPM7 is subject 
to regulation by G-protein coupled receptor agonists such as bradykinin and angiotensin (21, 
44, 83, 84). Since their receptors trigger downstream signaling in response to mechanical 
stimuli, this could provide an indirect mechanism by which TRPM7 is regulated by the physical 
properties of its surroundings (Chapter 3 & (85, 86)). In addition to its presence within 
the plasma membrane, TRPM7 resides in vesicles (17, 87). Force-induced membrane stretch 
triggers the rapid translocation of vesicle-stored TRPM7 channels to the plasma membrane 
(17). Overall, these findings support a model in which TRPM7 directs movement of tumor 
cells along mechanical cues, so-called durotaxis. 
In addition to activation by mechanical cues, TRPM7 plasma membrane localization and 
channel opening are promoted by growth factor stimulation and, possibly, by other tumor 
specific factors. For instance, TRPM7 is activated at the plasma membrane by epidermal 
growth factor (EGF) and platelet derived growth factor (PDGF). As TRPM7 is required 
for the EGF and PDGF-mediated effects on cell migration, TRPM7 may guide migration 
towards chemical cues (18, 31, 45). Additionally, TRPM7 is activated by reactive oxygen 
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species (ROS) and acidification, characteristic features of the pro-metastatic hypoxic and 
inflammatory tumor microenvironment (33, 88-90). Since cation influx through TRPM7 is 
enhanced by low (intra-) cellular Mg2+ concentrations (32, 91), Prevarskaya recently proposed 
that Mg2+ depletion in hypoxic tumors could trigger downstream signaling by TRPM7 and 
consequently, promote tumor cell metastasis (20). However, the effects of hypoxia on 
intracellular Mg2+ levels and the role of Mg2+ in cancer progression are complex and remain 
subject to controversy (56, 92). 
Little is known about how expression of TRPM7 is regulated. The few reports that 
address TRPM7 expression regulation indicate that TRPM7-activating compounds also affect 
TRPM7 expression levels (31, 45, 83, 93-95). Although more direct evidence is lacking, this 
may imply the existence of a positive feedback loop by which TRPM7 activation modulates 
its own expression levels. 
Future directions & concluding remarks
TRPM7 and 3D migration
We extensively studied the effect of TRPM7 knockdown on mesenchymal migration of 
breast cancer cells on 2D substrates. Within a 3D environment, however, cells continuously 
adopt different migratory strategies to overcome physical constraints by the surrounding 
matrix (5, 96). Although this plasticity is controlled by cytoskeletal tension and adhesion 
dynamics, we have no formal proof that TRPM7-promoted tumor cell metastasis in vivo is 
due to an effect on cell motility or tissue invasion. For instance, we cannot rule out that 
TRPM7 affects tumor cell survival in the circulation following tail vein injections, despite 
our in vitro observations that indicate the contrary (Chapter 4 & 5). To study how TRPM7 
controls cell migration in a 3D environment and if TRPM7 expression levels affect viability 
of circulating tumor cells, we are currently setting up an intravital imaging approach where 
cell survival and liver metastasis formation can be followed by multiphoton microscopy in 
living mice, after injection of tumor cells into the portal vein (97). 
TRPM7 as regulator of cytoskeletal gene expression
There is mounting evidence that the mechanical properties of the tumor microenvironment 
not only promote tumor metastasis formation by altering cytoskeletal protein function, but 
also enhance malignant cell behavior by affecting (cytoskeletal-) gene expression. In addition 
to mechanical activation of YAP/TAZ and MKL1 transcription factors (98-100), force-induced 
Ca2+ conductance by TRP channels modulates gene transcription by activating the Ca2+-
dependent transcription factor NFAT (Chapter 3). TRPM7, however, may target additional 
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transcriptional regulators. For instance, Clapham and colleagues previously demonstrated 
in mouse thymocytes that a genetic loss of TRPM7 strongly impairs STAT3 transcriptional 
regulation and EMT-like processes that are controlled by STAT3 (24). Of interest is also the 
cancer-associated TRIM28 transcriptional co-regulator which we identified as component of 
the TRPM7 protein complex. Finally, by regulating cytoskeletal tension, TRPM7 may control 
nuclear translocation of the tension-regulated transcription factors YAP/TAZ or MKL1. 
We are currently performing microarray analysis on our different cell models to determine 
how TRPM7 expression affects (cytoskeletal-) gene transcription and what transcriptional 
pathways could be involved.
TRPM7 mRNA expression as prognostic tool
The strong correlation between TRPM7 expression levels in primary breast tumors and 
disease progression, independent of other clinical parameters such as tumor size and molecular 
subtypes, suggests that TRPM7 may serve as prognostic marker at time of diagnosis. Despite 
this promising observation, it remains to be seen whether TRPM7 will be a useful marker of 
tumor progression. We did not find a significant correlation between TRPM7 expression and 
tumor progression in three additional breast cancer patients cohorts, nor in a neuroblastoma 
patient dataset (Chapters 4 & 10). Moreover, it is unlikely that progression of a heterogeneous 
disease, such as breast cancer, can be adequately predicted by altered mRNA expression 
levels of a single gene. To further stratify patients into risk groups, current efforts in the 
field of cancer research are aimed at the identification of genetic profiles that are based on 
differential gene expression regulation or co-occurrence of genetic alterations in tumors 
(101-103). Since TRPM7 interacts with many cytoskeletal proteins that associate with cancer 
progression at the transcriptional level (Chapter 10), we can now begin to assemble a 
metastatic gene signature that, in contrast to existing profiles, represents a network of 
structurally and functionally interacting proteins.
TRPM7 as a therapeutic target?
TRP channels are generally considered as attractive drug targets. However, to date no specific 
TRP channel inhibitors have entered the clinic (104). For TRPM7, two potent channel blockers 
have been recently identified, WaixenicinA and NS8593. Although prolonged incubation with 
WaixenicinA and NS8593 impaired cell proliferation (34, 38, 39), lower concentrations of 
NS8593 reduced cell motility without affecting cell viability (39). Further characterization 
of these novel TRPM7 specific channel blockers may lead to the development of nontoxic 
drugs that can be used to selectively interfere with TRPM7 activity in cancer cells. The 
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presence of an a-kinase domain, a feature unique for TRPM6 and TRPM7, offers additional 
targeting possibilities that have yet to be exploited.
Due to redundancy in strategies for cell migration and invasion, attempts to limit the 
metastatic potential of cancers by targeting individual components of the invasive machinery, 
such as matrix degrading enzymes and integrins, have been unsuccessful (5, 105). Future 
efforts should therefore aim at the characterization of common cellular machineries that 
mediate tumor cell metastasis. Our observations indicate that the ‘TRPM7 interactome’ 
could represent such a machinery. The TRPM7 interactome contains actin regulatory proteins 
and myosin motor proteins that guide the formation of cell protrusions such as filopodia, 
invadosomes and dendritic spines (106-110). Strikingly, defects in genes that regulate these 
processes were recently identified as key tumor-driving events in neuroblastoma and pancreatic 
cancer (111, 112). In agreement, expression of a substantial number of the TRPM7 interactome 
components was significantly correlated with overall survival in a large neuroblastoma patient 
dataset (Chapter 10). In line with recent literature, we propose that TRPM7 is part of a 
cytoskeletal complex that guides cell protrusion formation and is adopted by tumor cells 
to invade surrounding tissues (111, 112). Hence, functional characterization of this complex 
may, in addition to improving risk stratification, also help identify those (actin regulatory) 
signaling cascades that can be selectively targeted to treat patients with metastasic disease 
at diagnosis. 
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Invasie en metastasering, het verspreiden van kankercellen vanuit de primaire tumor 
naar andere organen, is de belangrijkste oorzaak van overlijden ten gevolge van kanker. 
Dit kwaadaardige gedrag van tumorcellen wordt in belangrijke mate veroorzaakt door 
een verandering in de manier waarop de cel zijn omgeving waarneemt en vervolgens op 
deze informatie reageert. Zogenaamde cel adhesie structuren stellen de cel in staat om 
de mechanische eigenschappen van zijn omgeving te interpreteren. Daarnaast zorgt een 
uiterst zorgvuldig gereguleerde cyclus van adhesievorming en -afbraak voor een efficiënte 
voortbeweging van de cel. Het is recent duidelijk geworden dat de eiwit-eiwit interacties 
die plaatsvinden in cel adhesies bijdragen aan het maligne karakter van tumorcellen. De 
hierbij betrokken eiwitten en signalering routes worden dan ook beschouwd als potentieel 
interessante therapeutische doelwitten. 
Ionkanalen, waaronder die van de TRP familie, spelen een belangrijke rol in de wijze 
waarop cellen mechanische informatie uit de directe omgeving interpreteren. Activatie van 
deze eiwitten, bijvoorbeeld door mechanische stimulatie, veroorzaakt een verandering 
in de geleiding van ionen zoals Ca2+, met een verscheidenheid aan cellulaire reacties tot 
gevolg. Omdat TRP kanalen vaak geassocieerd zijn met het actomyosine cytoskelet, wordt 
verondersteld dat deze kanalen betrokken zijn bij de regulatie van het cytoskelet. Uit onze 
eerdere studies is gebleken dat TRPM7, een TRP kanaal met een C-terminaal kinase domein, 
zich bevindt in adhesie structuren en een belangrijke rol speelt bij de vorming hiervan. 
Omdat TRPM7 onder andere kan worden geactiveerd door mechanische stimuli en direct 
associeert met het actomyosine cytoskelet, is onze hypothese dat TRPM7 de organisatie van 
het cytoskelet en de vorming van adhesie structuren reguleert door mechanische stimuli 
uit de directe omgeving waar te nemen en hierop te reageren. In dit proefschrift is de 
betrokkenheid van TRPM7 bij tumorcel migratie en metastasering onderzocht. Daarnaast 
zijn de onderliggende interacties tussen TRPM7 en het actomyosine cytoskelet nauwkeurig 
bestudeerd. 
Deel 1 van dit proefschrift, bestaande uit de hoofdstukken 1, 2 en 3, geeft een 
algemene inleiding over tumorcel metastasering, TRP kanalen en hun interacties met het 
actomyosine cytoskelet.  In twee review artikelen (hoofdstukken 2 en 3) wordt een actueel 
overzicht gegeven van de rol die TRP kanalen spelen bij de regulatie van het cytoskelet, cel 
adhesie structuren en cel migratie, zowel tijdens normale fysiologische processen als onder 
pathologische omstandigheden.
Deel 2 van dit proefschrift beschrijft de rol van TRPM7 bij het maligne gedrag van tumor 
cellen. Zo wordt in hoofdstuk 4 aangetoond dat TRPM7 essentieel is voor migratie en 
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metastasering van borstkanker cellen, zowel in vitro als in vivo. Het verlies van TRPM7 
expressie leidt tot cytoskelet contractie en beperkt de migratie van borstkanker cellen. Deze 
waarnemingen worden verder ondersteund door de positieve associatie tussen TRPM7 mRNA 
expressie in primair tumor materiaal van borstkanker patiënten en de kans op metastasering. 
In hoofdstuk 5 wordt aangetoond dat verhoogde TRPM7 expressie ook in neuroblastoma 
cellen aanleiding geeft tot invasief gedrag in vitro en de vorming van metastasen in vivo. 
Deel 3 van dit proefschrift gaat gedetailleerd in op de Ca2+- en kinase afhankelijke interacties 
tussen TRPM7 en het actomyosine cytoskelet. Hoofdstuk 6 verschaft een uitgebreid overzicht 
van onze huidige kennis over de familie van a-kinases, tot welke TRPM7 behoort. Eerder 
onderzoek door onze groep heeft aangetoond dat TRPM7 activatie cytoskelet relaxatie 
induceert door middel van directe, Ca2+- en kinase afhankelijke interacties met myosine II 
motor eiwitten. Actief myosine II bestaat uit bipolaire filamenten die cellulaire trekkracht 
genereren door associatie met en het vervolgens samentrekken van tegengesteld georiënteerde 
actine filamenten. Hoofdstukken 7 en 8 beschrijven dat TRPM7 de carboxy-terminus van 
de zware keten van het myosine II eiwit fosforyleert. Fosforylatie van dit domein leidt tot het 
uiteenvallen van de bipolaire myosine II filamenten en het verlies van cytoskelet contractie. 
Hoofdstuk 9 gaat dieper in op het mechanisme waarmee het TRPM7 kinase domein associeert 
met zijn substraten, in het bijzonder myosine II. Onze bevindingen ondersteunen een model 
waarin een regio, amino-terminaal van het feitelijke kinase domein, wordt gefosforyleerd 
door het kinase domein zelf, waarmee een elektrostatische interactie plaats ontstaat voor 
substraten zoals myosine II. Om de relatie tussen TRPM7 en het actomyosine cytoskelet 
beter te kunnen begrijpen, is de aan TRPM7 gebonden actomyosine fractie onderworpen 
aan een gedetailleerde proteoom analyse, zoals staat beschreven in hoofdstuk 10. Hiermee 
is aangetoond dat TRPM7 deel uit maakt van een groot cytoskelet complex waarvan vele 
componenten zijn betrokken bij de vorming van cel adhesie structuren en cel protrusies. 
Bovendien correleert de mRNA expressie van een aantal van deze eiwitten, zoals myosine 
Va en tropomodulin 2, in primair tumor weefsel zeer sterk met neuroblastoma progressie 
en metastasering in patiënten op het moment van diagnose. 
In hoofdstuk 11 (deel 4) van dit manuscript worden al deze bevindingen geintegreerd 
in een model en de eventuele klinische toepasbaarheid van TRPM7 en zijn interactoren als 
prognostische markers of als doelwit voor therapie bediscussieerd.
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Dankwoord
Liefste,
In alle dankwoorden die ik tot dusver las, word jij als laatste bedankt. Voor mij ben jij het  
allerbelangrijkst en daarom open ik dit dankwoord met een ode aan jou.
‘Ah! Voortreffelijk calcium of magnesium kanaal met alpha-kinase domein. Ik weet nog steeds 
niet waar je bent en wat je doet. Maar het belangrijkste eiwit, dat ben jij, want zonder jou was dit 
manuscript nooit tot stand gekomen.’ 
Of
‘Ah! Voortreffelijk vrouwmens. ‘s Avonds ben jij in staat mijn hoofd uit te schakelen en bestaat er 
een leven zonder TRPM7.  Maar ‘s ochtends ben ik je dankbaar dat je me weer ons bed uit schopt, 
want zonder jou was dit manuscript nooit tot stand gekomen.’
Beste collega,
Mijn onbegrip over je toewijding aan andere eiwitten dan TRPM7 schuif ik nooit onder 
stoelen of banken. Ik hekel de regeltjes die je opstelt en vloek hartgrondig wanneer jij het  
laatste restje methanol gebruikt zonder een nieuwe fles te bestellen. Je hebt me beschuldigd 
van veelwijverij, vindt dat ik mijn zooi nooit opruim, en denkt dat mijn dieet bestaat uit niets 
anders dan tosti’s. Ik beschouw onze relatie dan ook als liefdevol en vol wederzijds respect. 
Beste vriend, vriendin, ouder en broer, 
Sartre stelt dat de mens geen opgelegd doel heeft en dat alleen hijzelf de verantwoording 
draagt voor zijn bestaan. Vanwege het onontkomelijke oordeel van zijn medemens is hij, helaas, 
nooit volledig vrij om zichzelf te vormen. De mens lijdt onder het besef dat hij zijn leven ook 
anders had kunnen invullen maar nooit een kans zal krijgen het te verwezenlijken...L’enfer, 
c’est les autres. 
Maar hé, Sartre beschreef de hel  lang voordat jij en ik werden geboren. Ook al zijn onze 
vrijheden beperkt, met jou is mijn hel een zeer plezierige en ik zou geen andere willen. 
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Beste lezer, 
Het zit er op! Het schrijven van dit dankwoord voelt alsof ik een levenswerk afsluit. Dat 
klinkt ridicuul, maar mijn hoofd werd de afgelopen jaren voor een heel groot gedeelte in 
beslag genomen door TRPM7. Het is voor een belangrijk deel aan jullie, mijn begeleiders 
en directe collega’s, te danken dat zes jaar puzzelen tot dit manuscript hebben geleid. Many 
thanks voor jullie enthousiasme en begeleiding. Naast dat jullie me de benodigde praktische 
vaardigheden en theoretische kennis hebben bijgebracht, vond ik het fantastisch om samen 
te kunnen sparren over het ‘verschrikkelijke’ bestaan van de wetenschapper. 
Pama en familie, vriendjes en vriendinnetjes, het is natuurlijk helemaal niet verschrikkelijk 
om onderzoeker te zijn. Ik mag jullie er dan ook graag over vertellen. Dank dat jullie altijd 
vol interesse luisteren naar mijn avonturen op het lab, al kan ik me prima voorstellen dat 
niet alles daarvan blijft hangen. Dat maakt ook niet uit. Als jullie maar één ding onthouden, 
en dat is dat ik onderzoek doe naar TRPM7, het belangrijkste eiwit ter wereld.
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Curriculum Vitae
Jeroen Almer Johannes Middelbeek werd op 12 december 1981 geboren te Goirle. Na het 
behalen van zijn VWO diploma aan het Maaslandcollege in Oss, startte hij in 2000 met de studie 
Biomedische Wetenschappen aan het UMC St. Radboud te Nijmegen. Tijdens deze studie 
liep hij stage op het Laboratorium  Hematologie van de afdeling Laboratoriumgeneeskunde 
(dr. JM. Beekman en dr. H. Dolstra) en op het Tumor Immunologie Laboratorium (dr. K. 
Clark en dr. FN. van Leeuwen) van het UMC St. Radboud in Nijmegen. Na het behalen 
van zijn master diploma in 2007, startte hij als junior onderzoeker op het Laboratium voor 
Kinderoncologie van het UMC St. Radboud in Nijmegen. Hier voerde hij, onder leiding van 
dr. FN. van Leeuwen, prof. dr. B. Wieringa, prof. dr. PM. Hoogerbrugge, en dr. Kees Jalink 
(Nederlands Kanker Instituut, Amsterdam), het onderzoek uit dat in dit proefschrift is 
beschreven. Gedurende deze periode heeft hij vier studenten begeleid, won hij de prijs voor 
beste poster (NCMLS PhD retreat, 2008), beste presentatie (RUCO science day, 2011), 
en werd hij genomineerd voor de Tom Voûte Young Investigator Award. Tevens was hij 
actief als lid van de NCMLS PhD commissie en werd hij gekozen tot lid van de UMC raad. 
Vanaf medio 2012 geeft hij als post-doc vervolg aan het onderzoek dat in dit proefschrift 
is gepresenteerd.
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